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1.1 Asymmetric catalysis 
 
1.1.1. Catalysis 
“A catalyst accelerates a chemical reaction without affecting the position of the equilibrium.” 
This still valid definition of a catalyst was coined by Wilhelm Ostwald, who already in 1895 
realized catalysis as an ubiquitous phenomenon.
[1]
 
Catalysts have always had a significant impact on the industrial development and it is 
estimated that ~90% of all chemically obtained industrial goods came in contact with catalysts 
at least once during their production.
[2]
 By altering the activation energy of a given reaction, 
catalysts change the kinetic parameters of chemical processes (figure 1.1). Therefore, 
catalysts can accelerate or initiate a chemical reaction which will otherwise require long 
reaction times or will never occur in the absence of a catalyst. Hence, catalysis has a 
significant impact on our society. Based on the development of suitable catalysts, many 
important industrial processes were introduced, for example, the Haber-Bosch process used 
for the synthesis of ammonia from its elements, serving as a starting point for important 
components of fertilizers, medicaments, dyes, explosives or resins.
[3]
 
 
 
Figure 1.1: Simplified depiction of the mode of action of a catalyst. 
 
1.1.2 Enantioselectivity 
Another important research area affecting many different neighboring fields deals with the 
selective introduction of chirality into molecules.
[4]
 Chirality is defined as: “the geometric 
property of a rigid object (or spatial arrangement of points or atoms) of being non-
superposable on its mirror image; such an object has no symmetry elements of the second 
INTRODUCTION  CHAPTER 1 
 
4 
kind (a mirror plane, σ = S1, a centre of inversion, i = S2, a rotation-reflection axis, S2n). One 
of a pair of molecular entities which are mirror images of each other and non-superposable,” 
are termed enantiomers.
[5]
 The most frequent origin of chirality is based on a carbon atom 
bearing four different substituents. In an achiral environment the enantiomers have the same 
physical properties. However, when they are exposed to a chiral environment, such as 
biological systems, a significantly different behavior of two enantiomers can be observed. For 
example, they can smell or taste differently or they can have a contrary biological effect, like 
in the case of penicillamine where the (R)-enantiomer is highly toxic but the (S)-enantiomer is 
used for the treatment of heavy-metal poisoning or rheumatoid arthritis (figure 1.2).
[6]
  
 
 
Figure 1.2: Penicillamine: the pair of enantiomers and their different effects in the human body. 
 
Therefore, most of the chiral active pharmaceutical ingredients that are introduced on the 
market nowadays are pure enantiomers.
[7]
 To allow for the production of enantiomerically 
pure substances different approaches exist. 
One possibility is to start from molecules which are available from the chiral pool, using these 
substances to generate chiral molecules of higher complexity. Common chiral starting 
materials include amino acids, monosaccharides or hydroxy acids.
[8]
 Therefore, the molecular 
diversity which can be easily accessed is restricted and furthermore, in the majority of the 
cases, only one enantiomer is available while the other enantiomer is extremely expensive.  
An alternative approach is the application of chiral auxiliaries, which are covalently bound to 
the substrate. This strategy allows for a substrate-controlled diastereoselective synthesis. 
However, the use of usually expensive, stoichiometric amounts of auxiliaries and the 
necessity to split off this part of the molecule in the end of the synthesis are a clear 
drawback.
[9]
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Among all possible methods to obtain the desired enantiomerically pure compounds, 
asymmetric catalysis represent the best option in many cases.
[10]
 The successive development 
of different chiral catalysts over the last years allowed for the application of many different 
synthetic transformations with high enantioselectivity and efficiency. 
 
1.2 Asymmetric hydrogenation  
 
Among many different catalysts that have been developed for asymmetric transformations so 
far, transition metal-based complexes containing a chiral ligand transferring its chiral 
information in the course of the reaction to the substrate are the most common ones. In this 
context, transition metal-catalyzed asymmetric hydrogenation is one of the most established 
transformations. Furthermore, based on important attributes such as perfect atom economy, 
mild reaction conditions, low catalyst loadings, high conversions and high enantioselectivities 
which have been achieved for many asymmetric hydrogenations, this reaction is one of the 
most commonly applied in industry and academia.
[11]
 In particular complexes based on 
ruthenium or rhodium have emerged as efficient catalysts and have found broad application in 
many industrial processes. The impact of these catalysts was recognized by awarding Ryoji 
Noyori and William S. Knowles the Nobel Prize in 2001 for their work “on chirally catalyzed 
hydrogenation reactions” .[12] 
The progress of asymmetric hydrogenation is driven largely by the invention of new ligands 
and a larger number of chiral phosphine ligands are known which induce high 
enantioselectivity in rhodium- and ruthenium-catalyzed hydrogenations. A concept often 
recurring in the development of more efficient catalysts was the introduction of C2-symmetric 
bidentate ligands. For such ligands the number of undesired, competing diastereoselective 
transition states, lowering the selectivity of the reactions, can be reduced compared to C1-
symmetric bidentate ligands. Furthermore, the relatively easy access to C2-symmetric ligands 
by employing dimerization strategies of chiral monomeric units, the reduced complexity of 
NMR analysis for mechanistic investigations and the rationalization for the enantioselective 
outcome of reactions, were strong arguments in favor of this concept.
[13]
 A survey of chiral 
ligands reveals that many broadly applied ligands posses C2 symmetry (figure 1.3). 
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Figure 1.3: Selection of ligands possessing C2 symmetry. 
 
However, in the early 1990s, Achiwa and co-workers conducted a study aiming at the 
improvement of well-established P,P-ligands for the Rh-catalyzed hydrogenation of C=C 
bonds with adjacent coordinating groups.
[14]
 The mechanism of the hydrogenation of 
dehydroamino acid derivatives had already been elucidated at this time. On the basis of the 
catalytic cycle they postulated the “Respective Control Concept” recognizing that in the 
crucial steps of the reaction, the two phosphines exhibit a different spatial orientation. Hence, 
these two phosphines play different roles in the catalytic cycle. The phosphine in cis-
orientation to the C=C bond reveals significantly more steric interaction with the olefin and 
therefore is primarily responsible for the enantiomeric outcome of the reaction. The phosphine 
in trans-position to the C=C bond is better suited for electronic interaction with the substrate 
and hence mainly affects the reaction rate (figure 1.4). 
 
Figure 1.4: Intermediate in the Rh-catalyzed asymmetric hydrogenation used to explain the “Respective Control 
Concept” by Achiwa and co-workers. 
 
Based on this concept, Achiwa and co-workers successfully demonstrated that by the right 
choice of the phosphine unit the results in the hydrogenation of dimethyl itaconate (1.1) can 
be improved (table 1.1). Using a non-C2-symmetric BPPM derived ligand (1.3) both reactivity 
and selectivity of the reaction significantly increased to the optimal combination (entry 3). 
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Table 1.1: Asymmetric hydrogenation of dimethyl itaconate using ligand with different phosphines. 
 
Entry Pcis Ptrans 
Catalyst loading 
[mol%] 
Conv. [%] Ee [%] 
1 PPh2 PPh2 0.1 36 5 
2 P(p-Me2NPh)2 PPh2 0.1 55 68 
3 PPh2 P(p-Me2NPh)2 0.1 >99 93 
 
Although these results emphasize the potential advantages of electronically and sterically 
unsymmetrical ligands, this approach does not guarantee an improved catalyst performance. If 
isomeric complexes are formed, in which the two phosphine groups have switched positions, 
all efforts to optimize the coordinating groups individually can be pointless. However, in the 
absence of such complications the catalyst performance can be impressive as in the case of the 
industrial production of (S)-metolachlor.
[15]
 Applying the C1-symmetric Xyliphos ligand (1.6), 
the catalyst reached more than 10
6
 turnovers and 10
5
 turnovers per hour (scheme 1.1). 
 
 
Scheme 1.1: Asymmetric hydrogenation as key step in the production of (S)-metolachlor. 
 
1.3 Synthesis and further development of chiral ligands enabling 
the hydrogenation of C=C bonds by iridium-based catalysts 
 
The range of prochiral olefins that can be hydrogenated with high enantiomeric excess is still 
limited using both rhodium- and ruthenium-based catalysts. Such complexes require the 
presence of a coordinating functional group adjacent to the C=C bond. For this reason 
dehydro-amino acid derivatives or allylic alcohols are frequently found as suitable substrates 
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for these catalysts. On the other hand olefins lacking coordinating groups normally show poor 
results as substrates for rhodium- or ruthenium-catalyzed asymmetric hydrogenations. 
One key step to significantly broaden the substrate scope for asymmetric hydrogenation was 
the development of mixed N,P ligands. Such ligands represent an even more effective way of 
desymmetrization, based on the different electronic nature of P and N atoms. These bidentate 
ligands contain a “soft” P-ligand with π-acceptor properties and a “hard” N-ligand with 
mainly σ-donator character (figure 1.5).  
 
 
Figure 1.5: Desymmetrization by different coordinating heteroatoms. 
 
The first ligands of this type were phosphinooxazoline ligands (PHOX) and were introduced 
in 1993 in three independent publications from the laboratories of Helmchen, Pfaltz and 
Williams.
[16]
 PHOX ligands were successfully used for asymmetric palladium-catalyzed 
allylic substitution and later on for many different reactions.
[17]
 In 1998 the potential of this 
ligand class for the asymmetric hydrogenation of unfunctionalized olefins was demonstrated. 
Inspired by Crabtree’s catalyst (1.7),[18] which showed high reactivity in the hydrogenation of 
unfunctionalized C=C bonds, Ir complexes derived from PHOX ligands such as 1.8 were 
tested in the asymmetric hydrogenation of olefins and found to give encouraging results 
(scheme 1.2, A and B).
[19]
  
 
 
Scheme 1.2: PHOX-based iridium complex as catalyst in the hydrogenation of unfunctionalized olefins. 
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By 
1
H NMR experiments conducted at low temperature it was possible to demonstrate that 
out of the four possible stereoisomers formed upon oxidative addition of dihydrogen, 
exclusively one stereoisomer was obtained due to electronic and steric differentiation (scheme 
1.3, A).
[20]
 Most recently it was even possible to characterize dihydride intermediates with a 
coordinated alkene, representing the resting state of the catalyst (scheme 1.3, B).
[21]
 These 
findings show that the electronic discrimination of the N,P ligand results in the oxidative 
addition of hydrogen exclusively trans to the Ir–N bond, which is electronically favored.[22] 
This orientation of the hydrides leaves a free coordinating side trans to the Ir–P bond and 
therefore, in agreement with computational studies,
[23]
 also determines the coordination of the 
substrate in trans position to the phosphorous atom.  
 
 
Scheme 1.3: Selective formation of specific iridium dihydride species due to electronic and steric differentiation. 
 
But not only the electronic nature of the catalyst proved to have a crucial effect on the 
performance of such complexes, a major influence had also to be ascribed to the counterion of 
these complexes. The first results obtained with iridium complexes derived from chiral PHOX 
ligands showed encouraging results in the hydrogenation of trans-methyl stilbene derivative 
1.10. Applying 50 bar hydrogen pressure, the product 1.13 was obtained in up to 91% ee and 
>99% conversion (scheme 1.2, B).
[19]
 However, lower catalyst loadings than 4 mol% resulted 
in decreased conversion. Kinetic studies conducted showed an initial high turnover frequency 
of 7200 h
–1
 and full conversion was achieved within less than 1 min.
[24]
 Apparently, 
deactivation seemed to be a serious problem for these catalysts. Investigations aimed at 
solving this issue revealed the formation of the inactive trinuclear iridium hydride cluster 1.12 
(scheme 1.4),
[25]
 in analogy to the deactivation products observed for Crabtree’s catalyst.[26] 
All attempts to regenerate the catalytic active species from trimer 1.12 failed.
[25]
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Scheme 1.4: Formation of trinuclear iridium hydride species as main deactivation pathway of catalysts. 
 
Efforts to increase conversion by variation of reaction parameters such as solvent, 
concentration or hydrogen pressure were unsuccessful. The solution to this problem was as 
simple as surprising. The exchange of the counterion from PF6 to tetrakis[3,5-
bis(trifluoromethyl)phenyl]borate (BArF) showed significantly increased conversion. 
Applying the PF6 and the BArF salt of the identical PHOX-derived iridium complexes in the 
hydrogenation the trans-methyl stilbene derivative 1.10 resulted in more than 10 times higher 
conversion in the case of the BArF salt (table 1.2). 
 
Table 1.2: Enantioselective hydrogenation of trans-methyl stilbene derivative 1.10 with PHOX-based iridium 
catalyst bearing different counterions. 
 
Entry Counterion Catalyst loading [mol%] Conv. [%] Ee [%] 
1 PF6 4.0 78 75 
2 BArF 0.3 >99 70 
 
The reason for such behavior is not obvious but comparative kinetic experiments conducted 
with iridium complexes bearing different counterions provided a plausible answer to this 
question.
[27]
 Catalysts with PF6 as counterion showed first order rate dependence on the olefin 
concentration whereas for catalysts containing BArF as counterion the rate was close to zero 
order.  
The observed difference may be explained by the stronger coordination ability of the PF6 
counterion or the formation of a tighter ion pair compared to BArF, that therefore slows down 
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the coordination of the olefin to the metal center of the catalyst. As result the addition of the 
olefin to the metal center becomes rate-determining. In contrast, the bulky and very weakly 
coordinating BArF does not hamper olefin coordination, which means that the metal center 
remains “saturated” with substrate. Taking in account that the structure of the trinuclear 
cluster is responsible for catalyst deactivation, the lower reactivity of PF6 salts with the olefin 
should favor the formation of such trinuclear clusters starting from an iridium hydride species 
with a vacant coordination site. In addition to the higher conversion obtained with BArF-based 
iridium complexes, the exchange of the counterion resulted in catalysts that were significantly 
easier to handle. In fact, these complexes are stable against moisture and oxygen and therefore 
can be easily handled in air, whereas PF6-based complexes required handling under inert gas 
atmosphere. Furthermore, it is possibile to purify iridium-BArF complexes by column 
chromatography on silica gel if necessary which facilitates the purification of catalysts 
significantly. 
After these first reports the number of chiral N,P ligand complexes for the asymmetric 
hydrogenation of C=C bonds continuously increased. Because of the limited mechanistic 
insights at this time the synthesis of new ligand classes relied on empirical approaches. 
Therefore, most of the ligands applied in the iridium catalyst asymmetric hydrogenation were 
found by chance, intuition or systematic screening. To facilitate the finding of new efficient 
catalysts by systematic screening, ligands revealing a high modular structure emerged as 
desirable targets. One of such modular ligand structures, is derived from the amino acids 
serine or threonine.
[28]
 In contrast to the first PHOX ligands, a phosphinite is attached to the 
stereogenic center of the catalyst, being part of the six-membered chelate ring. Overall this 
ligand class contains four structural elements, which can be modified in a four step reaction 
sequence, employing different carboxylic acid derivatives, chlorophosphines and Grignard 
reagents (scheme 1.5). 
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Scheme 1.5: Modular synthesis of SerPHOX and ThrePHOX ligands. 
 
The high modularity of this ligand structure allowed for the preparation of a diverse library of 
chiral iridium complexes. The effectiveness of this approach was nicely demonstrated using 
the three olefins 1.18, 1.19 and 1.20, representing different isomers at the C=C bond, which 
provide after hydrogenation the same product. In this case, a different catalyst performed best 
for each substrate and high enantiomeric excesses between 94 and >99% were obtained 
(scheme 1.6). The fact that these catalysts showed high selectivity in the hydrogenation of 
many different substrates such as 1.21, 1.22 and 1.23 highlights the importance of the 
modular approach for catalyst synthesis and helped to further broaden the substrate scope 
compared to the previously discussed PHOX-based iridium complexes.
[28b, 29]
 
 
 
Scheme 1.6: Different ThrePHOX-based iridium catalysts achieving high selectivity in the hydrogenation of 
different substrates. 
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Although reasonably high enantioselectivity for substrate 1.20 (92% ee) was obtained using 
iridium catalyst 1.17, in general terminal olefins remained challenging substrates in terms of 
enantioselectivity compared to trisubstituted ones. The difficulty arises from the fact that 
these substrates contain only two substituents, and these are responsible for the discrimination 
between the two enantiofaces of the C=C bond. Furthermore, terminal olefins with α 
hydrogen atoms next to the double bond are known to undergo a competitive isomerization 
under hydrogenation conditions to the thermodynamically more stable trisubstituted 
isomers.
[30]
 However, the hydrogenation of the corresponding trisubstituted isomers can result 
in the product with opposite configuration. In order to overcome these issues, Andersson and 
co-workers prepared a library containing 96 different phosphite-oxazoline ligands. By 
systematic variation of different residues on the ligand scaffold of catalyst 1.24, axial chiral 
biarylphosphites were found to be highly beneficial in the hydrogenation of 1,1 disubstituted 
alkenes.
[30-31]
 These ligands allowed for the hydrogenation of a wide range of different 1,1 
disubstituted alkenes containing one aromatic substituent on the C=C bond (scheme 1.7, A). 
Unfunctionalized terminal olefins were hydrogenated with up to >99% ee. In addition, the 
presence of neighboring groups such as hydroxyl, acetate, silane or heteroaryls were tolerated 
as well and ees between 91 and 99% were obtained. Furthermore, catalyst 1.25 showed good 
to excellent results in the hydrogenation of sterically and electronically diverse terminal biaryl 
alkenes. For example, the terminal olefin consisting of a phenyl and a ortho-tolyl substituent 
on the double bond was reduced with up to >99% ee. In the case of electronically different 
aryl substituents like para-trifluoromethylphenyl and a para-methoxyphenyl a promising 
result (65% ee) was obtained (scheme 1.7, B). 
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Scheme 1.7: Hydrogenation of terminal olefins with oxazoline-based catalyst bearing an axial chiral 
biarylphosphite moiety. Full conversion was observed for all entries. 
 
All previously introduced complexes emerged as efficient catalysts for the hydrogenation of 
trisubstituted and terminal olefins. However, they all performed poorly in the hydrogenation 
of tetrasubstituted olefins. Such a limitation can be explained by the increased steric demand 
of tetrasubstituted olefins compared to trisubstituted ones. Tetrasubstituted alkenes have been 
successfully hydrogenated by Buchwald and co-workers using chiral zirconocene complexes. 
However, long reaction times, high pressure and high catalysts loadings are drawbacks of 
these systems.
[32]
 Encouraging results for tetrasubstituted alkenes were observed by the 
application of the easily accessible phosphanyl oxazoline ligands, first reported by Spritz and 
Helmchen for allylic substitution reactions.
[16a]
 The corresponding iridium complexes 
achieved high enantioselectivities and high conversion for tetrasubstituted substrates that 
possess at least one methyl substituent (scheme 1.8).
[33]
 For more sterically demanding 
substrates also these catalyst showed reduced reactivity. A reasonable explanation for the 
higher reactivity of phosphanyl oxazoline-derived iridium complexes might originate from the 
formation of a 5-membered chelate ring with the metal center rather than a 6-membered 
chelate ring which is typical of the previously discussed complexes. A smaller chelate ring 
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between the ligand and the metal center results in a smaller bite angle and a subsequent easier 
access of the substrate to the metal. 
 
 
 
Scheme 1.8: Phosphanyl oxazoline-derived iridium catalysts in the hydrogenation of tetrasubstituted 
unfunctionalized olefins. (The BArF counterions and the COD-ligand were omitted for clarity). 
 
In contrast to the previously discussed iridium complexes, reports on ligands forming larger 
chelate rings constantly increased in the last years and the resulting catalysts showed 
promising results in the hydrogenation of different substrate classes. Especially worth 
mentioning are the SIPHOX-based iridium catalysts developed Zhou and co-workers, bearing 
an extremely rigid axially chiral spirobiindane backbone. These catalysts showed remarkable 
selectivities in the hydrogenation of a wide variety of different unsaturated carboxylic acids. 
Furthermore, the applied reaction conditions with methanol as solvent and a base as additive 
were quite unique for iridium-based catalysts. Normally asymmetric hydrogenation with 
iridium-based catalysts are performed in weakly coordinating solvent such as CH2Cl2 or 
toluene.
[34]
 Coordinating solvents or additives, such as methanol or triethylamine are known 
to significantly reduce catalyst reactivity.
[35]
 Nevertheless, the substrate scope of the 
SIPHOX-based catalysts is remarkably broad in the presence of a coordinating solvent and a 
base (scheme 1.9), as unsaturated heterocyclic acids,
[36]
 α-aryloxy and α-alkoxy α,β-
unsaturated carboxylic acids,
[37]
 β,γ-unsaturated carboxylic acids[38] or terminal double bonds 
with a carboxylic acid in the β-position were successfully hydrogenated.[39] In all these 
examples the coordination of the carboxylate to the metal center proved to have a crucial 
effect on the catalyst reactivity. Unfunctionalized olefins or the analogous carboxylic esters 
showed no reactivity in the hydrogenation with these catalysts. 
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Scheme 1.9: Iridium SIPHOX-based catalyst in the asymmetric hydrogenation of α,β-unsaturated carboxylic 
acids. 
 
As demonstrated by the previous two examples the size of the chelate ring can have a 
significant influence on the catalyst performance. So far the focus was set on N,P ligands 
which are not the only ligand class successfully used in the iridium-catalyzed asymmetric 
hydrogenation. Another class originally developed by Burgess and co-workers are C,N 
ligands. In this case the phosphorous unit is replaced by a N-heterocyclic carbene.
[40]
 This 
exchange resulted in iridium complexes with different electronic properties on the metal 
center, which turned out to be highly advantageous for acid-labile substrate. During the course 
of the reaction different iridium hydride species are formed, containing hydrides with 
different acidity. DFT calculations of putative Ir(V)-hydride intermediates in the catalytic 
cycle predicted that iridium N,P ligand complexes can form hydrides being up to 7.6 pka units 
more acidic than the corresponding C,N intermediates (scheme 1.10, A).
[41]
 These calculations 
were supported by experimental observations. For example the enol ether 1.38 was converted 
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selectively to the desired product 1.39 in the presence of the C,N ligand-based iridium 
complex 1.40,
[42]
 whereas N,P ligand-based iridium complex 1.37 resulted in the formation of 
a complex reaction mixture (scheme 1.10, B).
[43]
 Also other substrates containing acid-labile 
groups such as TMS-ethers or tert-butyl carboxylic esters were hydrogenated with superior 
results using C,N instead of N,P ligand-based iridium catalysts.
[44]
 
 
 
Scheme 1.10: Iridium C,N ligand-based complexes as superior catalysts for substrates containing acid-labile 
groups. 
 
1.4 Mechanistic studies and deviation of a model for the 
enantioselective step 
 
Despite the vast amount of literature on iridium-catalyzed asymmetric hydrogenations and the 
remarkable progress on ligand development over the last years, the mechanism of this 
transformation is not completely understood so far. Current mechanistic proposals by 
Andersson and co-workers and Burgess and co-workers are almost entirely based on DFT 
calculations which support a catalytic cycle starting from iridium(III) intermediates (scheme 
1.11, B).
[45]
 On the other hand experiments conducted by Chen and Dietiker, based on 
electrospray ionization tandem mass spectrometry, suggest an Ir
I
/Ir
III
 cycle,
[46]
 analogous to 
the well-established mechanism for rhodium-catalyzed hydrogenation (scheme 1.11 A).
[47]
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Nevertheless, these experiments which were conducted in the gas phase do not rule out a 
Ir
III
/Ir
VI 
cycle
 
in solution.
[46]
 Recent experimental studies, where a [Ir
III
(H)2(alkene)(L)]
+
 
intermediate was obtained and characterized at low temperature (for details see scheme 1.3), 
showed that additional H2 is required to enable hydrogen addition to the alkene upon 
warming.
[21]
 These experimental data support an Ir
III
/Ir
V
 cycle via an 
[Ir
III
(H)2(alkene)(H2)(L)]
+ 
intermediate, as originally proposed by Andersson and co-workers. 
 
 
Scheme 1.11: Different catalytic cycles proposed for iridium-catalyzed asymmetric hydrogenation. 
 
So far mechanistic considerations had only limited influence on the design and development 
of new catalysts and were mainly used to explain results after the fact. Given the high 
fluxionality, multifaceted aggregation behavior of iridium hydride complexes and high 
reactivity of different iridium hydride species, it will remain a significant challenge if not an 
impossible task to rationally design new ligands. Furthermore, it cannot be ruled out that the 
mechanism differs depending on the reaction conditions, the catalyst or on the substrates used. 
For example, substrates with an additional coordinating group should disfavor coordination of 
a second hydrogen molecule that would be essential for the formation of an Ir(V)-intermediate. 
Perhaps under certain reaction conditions different pathways could operate in parallel. 
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Regardless of the full mechanistic picture, the essential part of enantioselective reactions is 
the enantiodiscriminating step. Based on DFT calculations, Brandt and Andersson proposed a 
qualitative model that predicts the enantiofacial selectivity of iridium-based catalysts.
[48]
 As 
depicted in scheme 1.12, the ligand forms a chiral pocket around the metal center. One part of 
the ligand, as for example in scheme 1.12, B, the phenyl group, points out of the plane, and 
sterically interacts with the substrate, which is bound trans to the P atoms. This steric 
interaction favors a coordination geometry, in which the smallest substituent of the C=C bond, 
the H atom, is positioned in the hindered quadrant. The substituents at the phosphorus atom 
cannot generate direct steric interaction with the substrate, due to the long distance. However, 
the residues on the phosphorous atom can still influence the enantioselectivity by electronic 
effects as well as steric effects by interaction with axial ligands and the backbone of the 
ligand, as depicted in scheme 1.12, B.  
This model can be used to predict the absolute configuration of the product for a wide range 
of hydrogenations, by the identification of the hindered quadrant and placing the least 
sterically demanding substituent of the substrate in this position to minimize steric repulsion. 
In this case, the substrate is bound with the enantioface resulting in the formation of the 
experimentally observed product. However, this model has to be used with caution. In 
substrates with a strongly polarized C=C bond such as α,β-unsaturated carboxylic esters, 
electronic effects can override steric interactions resulting in a break-down of the model.
[49]
 
 
 
 
Scheme 1.12: Andersson’s quadrant model developed to rationalize the enantioselectivity. 
 
In addition, this model predicts how the substrate interacts with the catalyst and therefore 
enables a semi-rational approach to improve ligands. Taking into account that mainly one part 
of the ligand is involved in steric repulsion with the substrate, this group should significantly 
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affect the outcome of the reaction. A large substituent should result in a more congested 
environment around the metal center of the catalyst and therefore form a tighter chiral pocket. 
On the other hand, if this group is too sterically demanding, reduced reactivity and 
enantioselectivity should be observed. In chapter 2 experiments confirming these predictions 
are presented. 
Another bidentate ligand structure, for which this model was successful used for optimization, 
is shown in scheme 1.13. In this work O,P ligands based on a proline scaffold were applied to 
the asymmetric hydrogenation of functionalized and unfunctionalized olefins. These ligands 
were developed starting with a broad automated screening of various metal-ligand 
combinations, which revealed for Tomioka’s ligand[50] (1.41) 68% ee in the hydrogenation of 
(E)-1,2-diphenylprop-1-ene.
[51]
 This ligand can be easily obtained starting from proline and 
forms a seven-membered chelate ring with the metal center. In line with the model shown in 
scheme 1.12 for systematic variation of the residues (R
2
), higher ee values were obtained by 
increasing the size of the amide or urea group. For example in the hydrogenation of ethyl (E)-
3-phenylbut-2-enoate (1.22) the enantiomeric excess was raised from 33% up to 98%, by 
increasing the steric bulk of the ligand. Moreover, also for many other substrates, catalysts 
containing a sterically more demanding R
2
 group showed high ee values (scheme 1.13). 
 
 
Scheme 1.13: Proline-based iridium complexes as catalysts in the hydrogenation of different substrates. 
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1.5 Conclusion 
 
Since the first successful report in 1998, the iridium-catalyzed asymmetric hydrogenation of 
alkenes emerged as a method to introduce new stereogenic centers to a broad variety of 
different functionalized and unfunctionalized prochiral olefins in a highly selective manner. 
The key factor to success was the application of hetero-bidentate ligands with two 
coordinating atoms exhibiting different electronic properties. Initially ligand development was 
conducted empirically by systematic screening of highly modular ligand scaffolds. The 
modularity of new ligands emerged as an important feature to achieve high 
enantioselectivities for a wide range of derivatives of a certain substrate classes, because 
minor changes in the substrate can significantly affect the selectivity of the reaction.  
Although progress has been made in the mechanistic understanding of the Ir catalysis, much 
further work will be necessary to reach the level allowing truly rational catalyst design based 
on mechanistic considerations. Moreover, despite the large number of Ir catalysts developed 
so far, there are still important substrate classes such as dienes or heterocylic compounds for 
which generally applicable hydrogenation catalysts are lacking. The goal of this thesis was to 
develop new catalysts and improved hydrogenation for challenging substrate classes that so 
far had given unsatisfactory results. 
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2.1 Introduction  
 
As discussed in the previous chapter, the continuous development of known catalysts and 
ligands can lead to significantly improved results in the asymmetric hydrogenation of 
unfunctionalized olefins. One class of iridium-based catalysts which was not discussed in the 
first chapter is the one based on bicyclic pyridine-phosphinite ligands. These complexes are 
among the most successfully applied catalysts in the hydrogenation of unfunctionalized 
olefins.
[52]
 They resemble chiral versions of Crabtree’s catalyst,[18] as they consist of a 
pyridine moiety which is bridged by a cyclic aliphatic backbone to a phosphinite unit, forming 
a six-membered chelate ring with the metal center. Remarkable selectivity was observed in 
the hydrogenation of different functionalized and unfunctionalized olefins and also for 
complex intermediates in key steps of several total syntheses (Figure 2.1).
[29b, 53]
 Therefore, 
these iridium-based complexes belong to the small group of catalysts which showed their 
applicability to a broad substrate range.  
Several systematic variations have been investigated to optimize the ligand structure of these 
catalysts on different positions. Five-, six- and seven-membered aliphatic rings were 
employed in the backbone of the catalyst. Different phosphinite groups, with phenyl, ortho-
tolyl, furyl, cyclohexyl and tert-butyl residues were tested as well as phosphines and amino 
phosphines. Furthermore, the influence of different substituents at the 2-position of the 
pyridine moiety was investigated. A methyl and a phenyl group showed a significant 
influence on the selectivity compared to a hydrogen atom at this position. It should be 
mentioned, that larger groups such as a tert-butyl group were also applied, but they are not 
tolerated in this position, probably because strong steric hinderance inhibited coordination to 
the metal center.
[52, 54]
 Out of several different combinations, two catalysts were identified to 
perform better overall: Catalyst 2.1, bearing a di-tert-butyl phosphinite, a five-membered ring 
in the backbone, and a phenyl group at the 2-position of the pyridine, and catalyst 2.2, 
containing a di-ortho-tolyl-phosphinte, an aliphatic six-membered ring in the backbone and 
also a phenyl group on the pyridine. Among other examples, these catalysts have been 
successfully applied in the hydrogenation of the vitamin E precursor, γ-tocotrienyl acetate, 
which allowed for the hydrogenation of three double bonds and the introduction of two 
stereogenic centers in one step. In the case of catalyst 2.2 >98% of the natural (R,R,R)-isomer 
of γ-tocopheryl acetate was obtained.[53c] 
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Figure 2.1: Different selected substrate classes and intermediates in total synthesis successfully hydrogenated by 
the use of the most efficient catalysts of this series 2.1 and 2.2. 
 
However, there is still room for improvement, which could lead to a further broadening of the 
substrate scope. Based on the already discussed model for the enantioselectivity-determining 
step developed by Andersson and co-workers, it can be presumed that the aryl moiety of this 
catalyst should have a significant influence on the enantioselectivity of the hydrogenation 
(figure 2.2, A). Therefore, the idea was to introduce sterically demanding aryl groups at the 2-
position of the pyridine moiety, which should generate a more congested environment around 
the metal center of the catalyst (figure 2.2, B). In addition, it is known for iridium complexes 
that they can undergo an insertion into an adjacent aromatic C–H bond, which was found to 
be a facile process for 2-phenylpyridines.
[55]
 Such behavior was also observed by Dr. Andreas 
Schumacher who was able to isolate the C–H inserted Ir(III)-complex 2.3 formed from its 
COD precatalyst in the absence of a substrate under hydrogen atmosphere (figure 2.2, C). 
Therefore, an introduction of a substituent in ortho-position should block a potential C–H 
activation, or sterically more demanding substituents in meta-position could favor an 
orientation which might impede the C–H insertion. This project was started by Dr. David 
Woodmansee in the course of his PhD thesis in which the influence of mesityl, 2-naphtyl and 
9-antracenyl groups was tested. Based on the preliminary success obtained with the new 
catalysts, it was decided to further investigate this part of the ligand. 
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Figure 2.2: Andersson’s model for the enantioselectivity-determining step, A; The different aryl groups tested at 
the 2-position of the pyridine moiety, B; C–H inserted Ir(III)-complex obtained in the absence of a substrate 
under hydrogen atmosphere.  
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2.2 Catalyst Synthesis 
 
The original synthesis of the catalysts bearing a phenyl group was in the meanwhile 
intensively investigated and thus can be achieved efficiently. However, the phenyl group is 
introduced in the very first step of the synthesis by a Mannich reaction using acetophenone 
(2.5) and therefore this route is not practical for the fast synthesis of different aryl derivatives 
(scheme 2.1). 
 
Scheme 2.1: Optimized synthesis of the pyridine-based iridium complexes. a: Mannich reaction; b: substitution; 
c: condensation; d: N-oxide formation; e: Boekelheide reaction followed by saponification f: enzymatic kinetic 
resolution g: phosphinite formation followed by complexation. 
 
Therefore, an alternative route was elaborated with the goal to establish a flexible synthesis 
allowing for the derivatization of the ligand at a late stage of the synthesis. Shortly after the 
initial publication on the pyridine complexes bearing a phenyl substituent, Zhou and co-
workers reported a route to nearly the same complexes that utilized a Suzuki–Miyaura cross-
coupling to introduce the aromatic group on 2-chloropyridines at a late stage of the ligand 
synthesis.
[56]
 Hence, the synthesis to the 2-chloro pyridyl alcohols 2.32 and 2.33 was achieved 
based on literature known procedures in overall 5% yield for 2-chloro-4-methyl-6,7-dihydro-
5H-cyclopenta[b]pyridin-7-ol (2.32) and 11% yield for 2-chloro-5,6,7,8-tetrahydroquinolin-8-
ol (2.33) (for details see experimental part).
[57]
 As key step of the synthesis, the 
functionalization in the benzylic position was achieved by a Boekelheide rearrangement,
[58]
 
followed by saponification (scheme 2.2). These steps could be adopted from the original 
synthetic sequence.  
PYRIDYL PHOSPHINITE-BASED CATALYST  CHAPTER 2 
 
29 
 
Scheme 2.2: Retrosynthesis of the racemic 2-chloro pyridyl alcohols 2.32 and 2.33. 
 
With the racemic 2-chloropyridyl alcohols 2.32 and 2.33 in hand two different strategies were 
envisioned. The first using an early Suzuki cross coupling followed by enzymatic kinetic 
resolution of the different derivatives of the racemic pyridyl alcohols (scheme 2.3, A), 
whereas the second employs a enzymatic kinetic resolution on the stage of the racemic 2-
chloro-pyridylaclohols, followed by TBS protection and Suzuki cross-coupling. The 
deprotection of the silyl ethers afforded the enantiopure pyridyl alcohols, which can be 
directly converted into the corresponding N,P ligand complexes (scheme 2.3, B). The first 
route is more labor intensive and will be not discussed in this chapter.
[59]
 The second route 
proved to be significantly more efficient. This approach is two steps shorter and, even more 
importantly, the kinetic resolution representing the most laborious step of the hole synthesis 
can be performed before the derivatization step. The second route will be discussed in detail 
in this chapter. Data obtained previously, based on the 4,5-di-tert-butyl-4-methoxyphenyl, the 
3,4,5 tri-methoxyphenyl and the 3,5-difluoromethylphenyl substituents, are provided to allow 
a complete discussion of this project.
[59]
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Scheme 2.3: Different strategies applied to access the enantiopure pyridyl alcohols. 
 
The enzymatic kinetic resolution applied for the first synthesized pyridine-based complexes 
bearing a phenyl group at the 2-position of the pyridine moiety, was investigated Dr. Matthias 
Maywald,
[60]
 based on the work of Uenishi and co-workers.
[61]
 This method allowed for the 
synthesis of highly enantioenriched pyridyl alcohols in multigram scale. This protocol could 
be adopted for the resolution of racemic 2-chloro-substituted pyridyl alcohols 2.32 and 2.33 
and achieved also in this case good selectivity (scheme 2.4). To achieve high enantiomeric 
excess for at least one enantiomer, the reaction progress was monitored by analytical HPLC 
and stopped after the complete consumption of the (R)-alcohols (R)-2.32 or (R)-2.33. This 
approach provided the enantiomerically pure (S)-alcohols (S)-2.32 or (S)-2.33 in >99.9% ee. 
The mixture of the enantiopure alcohol and the enantioenriched acetates turned out to be 
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extremely difficult to separate. Therefore the free alcohol was TBS-protected, in order to 
facilitate the separation by column chromatography. The enantiomeric excess of the (R)-
acetate (R)-2.34 or (R)-2.35 reached still useful values for recrystallizations. 
However, subjecting the free pyridyl alcohols to the Suzuki–Miyaura cross-coupling only 
traces of product were obtained, as reported by Dr. D. Woodmansee 
[54a]
 This might be 
explained by strong coordination of the pyridyl alcohols via a five-membered chelate ring to 
palladium. Hence, the TBS-protection is essential for the cross-coupling and did not represent 
an additional step needed only to allow the purification of the product (82% and 94% ee). 
 
Scheme 2.4: Enzymatic kinetic resolution applied for the separation of the enantiomers. 
 
In the Suzuki–Miyaura cross-coupling excellent yields from 83% to 99% for a range of 
different aryl boronic esters were obtained (table 2.1). Only for the sterically demanding [1,1'-
biphenyl]-2-ylboronic acid a moderate yield of 36% was obtained (entry 10). The introduction 
of the 2,6-difluorophenyl moiety failed under these reaction conditions and only 
dehydroborylated product was isolated. 
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Table 2.1: Preparation of the aryl derivatives by Suzuki–Miyaura cross-coupling. 
 
Entry Silyl ether 
Boronic 
acid/ester  
Product label Yield [%] 
1 
 
A 2.38 88 
2 B 2.39 95 
3 C 2.40 86 
4 
 
A 2.41 97 
5 B 2.42 91 
6 
 
D (S)-2.42 60 
7 F (S)-2.43 99 
8 G (S)-2.44 -- 
9 
 
D (S)-2.45 83 
10 E (S)-2.46 36 
 
Such dehydroborylations are frequently observed for electron deficient boronic acids and can 
be avoided by using palladium XPhos-based catalyst 2.49, which was reported to be very 
efficient for the coupling of boronic acids such as 2.47.
[62]
 Applying this catalyst the cross-
coupling was achieved with 94% and 95% yield (scheme 2.5). 
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Scheme 2.5: Synthesis of the enantiopure pyridyl alcohols with a 2,6-difluoro substitution pattern on the aryl 
moiety. 
 
After having installed the desired aryl moieties, the silyl ethers were cleaved to provide the 
pyridyl alcohols in good to excellent yields with no exception (table 2.2). 
 
Table 2.2: Deprotection of the enantiopure silyl ether derivatives to afford the corresponding pyridyl alcohols. 
 
Entry n R R
1
 Product label Yield [%] 
1 1 H A (S)-2.50 98 
2 2 H A (S)-2.51 83 
3 1 CH3 B (S)-2.52 92 
4 2 H B (S)-2.53 65 
5 1 CH3 D (S)-2.54 88 
6 2 H D (S)-2.55 80 
7 2 H E (S)-2.56 77 
8 1 CH3 F (S)-2.57 86 
9 1 CH3 G (S)-2.58 99 
10 2 H G (S)-2.59 85 
 
With the enantiopure pyridyl alcohols in hand, the phosphinite formation followed by 
subsequent complexation was the next and last step in the sequence (table 2.3). The 
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introduction of the aryl phosphinites was achieved using DMAP in combination with the 
corresponding diarylphosphinechloride. The obtained phosphinites were filtered over a plug 
of aluminum oxide and were directly converted in the presence of [Ir(COD)Cl]2 and NaBArF 
to the desired iridium complexes.
[54b]
 However, this protocol is not applicable for the 
synthesis of di-tert-butyl phosphinites, which were obtained from pyridyl alcohols in the 
presence of KH in DMF and di-tert-butyl phosphinechloride. Again, the obtained 
phosphinites were directly converted to the corresponding iridium-complexes in the presence 
of [Ir(COD)Cl]2 and NaBArF.  
The iridium complexes containing a diarylphosphinite residue were obtained in the majority 
of the cases in good yields. However, some pyridyl alcohols could not be converted into their 
corresponding iridium complexes. In the case of the aryl moieties B and C this might be 
explained by C–H activation which was observed to be a significant problem also for 
phosphine or amino phosphine-based catalysts of this type.
[54, 59]
 Also the introduction of the 
sterically demanding di-tert-butyl phosphinites proved to be challenging in certain cases, 
indicated by the low yield obtained or irremovable impurities. However, twelve new catalysts 
were obtained, which were investigated in the hydrogenation of model substrates. 
 
Table 2.3: Formation of the iridium complexes.
 
Entry Method n R R
1
 
Yield 
[%] 
Compound 
label 
Remark 
1 I, Ph 1 CH3 A 29 (S)-2.60  
2 I, o-Tol 1 CH3 A 73 (S)-2.61  
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3 I, o-Tol 2  A 68 (S)-2.62  
4 II, t-Bu 1 CH3 A 51 (R)-2.63  
5 I, Ph 1 CH3 B --   
6 I, o-Tol 1 CH3 B --   
3 I, o-Tol 2  B --   
7 II, t-Bu 1 CH3 B --   
8 I, Ph 1 CH3 C --   
9 I, o-Tol 1 CH3 C --   
10 II, t-Bu 1 CH3 C 29% (S)-2.64 
5% impurity based on 
31
P 
NMR 
11 I, o-Tol 1 CH3 D 76 (S)-2.65  
12 I, o-Tol 2 H D 72 (S)-2.66  
13 II, t-Bu 1 CH3 D 10  
17% impurity based on 
31
P 
NMR 
14 I, o-Tol 2 H E 65 (S)-2.67  
15 II, t-Bu 2 H E --   
16 I, o-Tol 1 CH3 F 49 (S)-2.68  
17 II, t-Bu 1 CH3 F 10 (S)-2.69  
18 I, o-Tol 1 CH3 G --  
Loss of BArF (2
nd
 column on 
Alox) 
19 II, t-Bu 2 H G 56 (S)-2.70  
20 I, o-Tol 1 CH3 G 54 (S)-2.71  
21 II, t-Bu 2 H G 40 (S)-2.72  
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2.3 Hydrogenation Results 
 
The new pyridyl phosphinite-based iridium complexes with sterically demanding aryl 
substituents were evaluated in the asymmetric hydrogenation of different model substrates. 
The set of these substrates includes different substituent patters around the double bond, 
geometric isomers, a terminal double bond and double bonds embedded in a cyclic ring. 
Furthermore, different α,β-unsaturated, functionalized olefins such as an allyl alcohol, 
different unsaturated carboxylic esters and ketones, plus a ketimine were investigated (figure 
2.3). In addition, the obtained results were compared with the best results achieved by the use 
of the original iridium complexes with a phenyl group at the 2-position of the pyridine moiety. 
In a few cases the results obtained by Dr. D. Woodmansee in the course of his PhD work are 
reported to allow for a complete overview over the results obtained with these catalysts with a 
sterically more demanding aryl substituent. 
 
Figure 2.3: Different model substrates tested in the hydrogenation applying the newly synthesized catalysts.  
 
(E)-α-Methylstilbene (S1) is one of the test substrates used to evaluated the performance of 
new catalysts and excellent enantioselectivity and full conversion have been previously 
achieved with many different catalyst classes. Although, it is rather simple to achieve good 
results for this substrate, its use allows for a first estimation of the performance of new 
catalysts. For the majority of the new complexes with sterically demanding aryl groups high 
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enantioselectivity and full conversion to propane-1,2-diyldibenzene (P1) were observed (table 
2.4). Only for catalyst (S)-2.62, (S)-2.71 and (S)-2.67 incomplete conversion and for catalyst 
(S)-2.67 moderate enantioselectivity were observed. All catalysts that showed incomplete 
conversion contain a six-membered aliphatic ring in the backbone. Also the parent complex 
with the phenyl substituent and the six-membered aliphatic ring showed reduced conversion 
for substrate S1 and a maximum of 47% conversion was obtained.
[52a]
 The catalysts with a 
sterically demanding aryl substituent and a six-membered ring in the backbone showed higher 
conversion when compared to the parent complex with a phenyl group at the 2-position of the 
pyridine moiety. 
 
Table 2.4: Hydrogenation of (E)-α-methylstilbene (S1). 
 
Entry
[a]
 
No. 
Cat. 
Time 
[h] 
n R
1
 R
2
 R
3
 
Conv. 
[%]
[b]
 
ee [%]
[c]
 
1 (S)-2.60 3 1 Ph CH3 
3,5-di-tert-butyl-
4-methoxyphenyl 
>99 99 (S) 
2 (S)-2.61 3 1 o-Tol CH3 
3,5-di-tert-butyl-
4-methoxyphenyl 
>99 99 (S) 
3 (R)-2.63 3 1 t-Bu CH3 
3,5-di-tert-butyl-
4-methoxyphenyl 
>99 94 (R) 
4 (S)-2.62 3 2 o-Tol H 
3,5-di-tert-butyl-
4-methoxyphenyl 
73 99 (S) 
5 (S)-2.65 15 1 o-Tol CH3 
[1,1':3',1''-
terphenyl]-5'-yl 
>99 99 (S) 
6 (S)-2.66 15 2 o-Tol H 
[1,1':3',1''-
terphenyl]-5'-yl 
>99 98 (S) 
7 (S)-2.68 15 1 o-Tol CH3 phenanthren-9-yl >99 >99 (S) 
8 (S)-2.69 15 1 t-Bu CH3 phenanthren-9-yl >99 96 (S) 
9 (S)-2.70 15 1 t-Bu CH3 2,6-difluorophenyl >99 99 (S) 
10 (S)-2.71 16 2 o-Tol H 2,6-difluorophenyl 99 99 (S) 
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11 (S)-2.72 16 2 t-Bu H 2,6-difluorophenyl >99 99 (S) 
12 (S)-2.67 15 2 o-Tol H 
[1,1'-biphenyl]-2-
yl 
21 76 (S) 
13
[52a]
 (S)-2.1 2 1 t-Bu H Ph >99 >99 (S) 
[a] Reaction run on 0.1 mmol scale; [b] Determined by GC analysis on an achiral stationary phase; [c] 
Determined by HPLC analysis on a chiral stationary phase. 
 
Again, almost all catalysts showed high activity and selectivity in the hydrogenation of (E)-1-
(but-2-en-2-yl)-4-methoxybenzene ((E)-S2) (table 2.5). With the exception of catalyst (S)-
2.67, the enantiomeric excess was in the range between 92% and 97% (entries 1-8). Catalyst 
(R)-2.63 reached with 97% the highest enantiomeric excess (entry 1). However, this value 
was lower compared to complex (S)-2.1 bearing a phenyl group which reached up to >99% ee 
(entry 10). 
 
Table 2.5: Hydrogenation of (E)-1-(but-2-en-2-yl)-4-methoxybenzene ((E)-S2). 
 
Entry
[a]
 
No. 
Cat. 
n R
1
 R
2
 R
3
 
Conv. 
[%]
[b]
 
ee [%]
[c]
 
1 (R)-2.63 1 t-Bu CH3 
3,5-di-tert-butyl-
4-methoxyphenyl 
>99 97 (R) 
2 (S)-2.62 2 o-Tol H 
3,5-di-tert-butyl-
4-methoxyphenyl 
>99 95 (S) 
3 (S)-2.65 1 o-Tol CH3 
[1,1':3',1''-
terphenyl]-5'-yl 
>99 96 (S) 
4 (S)-2.66 2 o-Tol H 
[1,1':3',1''-
terphenyl]-5'-yl 
>99 95 (S) 
5 (S)-2.68 1 o-Tol CH3 phenanthren-9-yl >99 96 (S) 
6 (S)-2.69 1 t-Bu CH3 phenanthren-9-yl >99 95 (S) 
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7 (S)-2.71 2 o-Tol H 2,6-difluorophenyl >99 92 (S) 
8 (S)-2.72 2 t-Bu H 2,6-difluorophenyl >99 95 (S) 
9 (S)-2.67 2 o-Tol H 
[1,1'-biphenyl]-2-
yl 
>99 72 (S) 
10 (S)-2.1 1 t-Bu H Ph >99 >99 (S) 
[a] Reaction run on 0.1 mmol scale; [b] Determined by GC analysis on an achiral stationary phase; [c] 
Determined by GC analysis on a chiral stationary phase. 
 
The hydrogenation of (Z)-1-(but-2-en-2-yl)-4-methoxybenzene ((Z)-S3), the first substrate 
with the double bond in (Z)-geometry, resulted almost exclusively in full conversion and high 
enantiomeric excess (table 2.6). Overall better results were obtained in comparison to 
substrate (E)-S2. The best result was obtained by the use of the phenathren-9-yl-substituted 
catalyst (S)-2.68 achieving 99% enantiomeric excess and full conversion (entry 6). This is 
even higher compared to the best result obtained employing the phenyl-substituted catalyst 
(S)-2.73. In this case 98% ee and full conversion were observed. 
 
Table 2.6: Hydrogenation of (Z)-1-(but-2-en-2-yl)-4-methoxybenzene ((Z)-S3). 
 
Entry
[a]
 
No. 
Cat. 
n R
1
 R
2
 R
3
 
Conv. 
[%]
[b]
 
ee [%]
[c]
 
1 (S)-2.61 1 o-Tol CH3 
3,5-di-tert-butyl-4-
methoxyphenyl 
>99 97 (R) 
2 (R)-2.63 1 t-Bu H 
3,5-di-tert-butyl-4-
methoxyphenyl 
>99 96 (S) 
3 (S)-2.62 2 o-Tol H 
3,5-di-tert-butyl-4-
methoxyphenyl 
>99 97 (R) 
4 (S)-2.65 1 o-Tol CH3 
[1,1':3',1''-
terphenyl]-5'-yl 
>99 96 (R) 
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5 (S)-2.66 2 o-Tol H 
[1,1':3',1''-
terphenyl]-5'-yl 
>99 96 (R) 
6 (S)-2.68 1 o-Tol CH3 phenanthren-9-yl >99 99 (R) 
7 (S)-2.69 1 t-Bu CH3 phenanthren-9-yl >99 98 (R) 
8 (S)-2.71 2 o-Tol H 2,6-difluorophenyl >99 97 (R) 
9 (S)-2.72 2 t-Bu H 2,6-difluorophenyl >99 96 (R) 
10 (S)-2.67 2 o-Tol H [1,1'-biphenyl]-2-yl 76 80 (R) 
11
[52a]
 (S)-2.73 1 o-Tol H Ph >99 98 (S) 
[a] Reaction run on 0.1 mmol scale; [b] Determined by GC analysis on an achiral stationary phase; [c] 
Determined by GC analysis on a chiral stationary phase. 
 
The hydrogenation of 1-(but-1-en-2-yl)-4-methoxybenzene (S4) resulted in the formation of 
the identical product P2 as the hydrogenation of (E)- and (Z)-1-(but-2-en-2-yl)-4-
methoxybenzene ((E)-S2) and (Z)-S3)). Although for the two previously screened substrates 
excellent results were obtained, shifting the double bond to the terminal position resulted in a 
molecule exposing a completely different environment around the C=C bond to the catalysts. 
Also, normally 1 bar hydrogen pressure in combination with a shorter reaction time are 
sufficient to reach full conversion for terminal C=C bonds. In addition higher 
enantioselectivities were achieved by the use of 1 bar H2 pressure.
[29a]
  
With regard to catalyst (S)-2.67, all catalysts from this series achieved full conversion in the 
hydrogenation of substrate S4 (table 2.7). Moderate to good enantiomeric excesses were 
observed for this olefin. The best ee with 82% is similar to the 80% ee obtained with the 
parent complex (entry 7 vs. entry 12) 
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Table 2.7: Hydrogenation of 1-(but-1-en-2-yl)-4-methoxybenzene (S4). 
 
Entry
[a]
 
No. 
Cat. 
n R
1
 R
2
 R
3
 
Conv. 
[%]
[b]
 
ee [%]
[c]
 
1 (S)-2.60 1 Ph CH3 
3,5-di-tert-butyl-4-
methoxyphenyl 
>99 66 (R) 
2 (S)-2.61 1 o-Tol CH3 
3,5-di-tert-butyl-4-
methoxyphenyl 
>99 76 (R) 
3 (R)-2.63 1 t-Bu CH3 
3,5-di-tert-butyl-4-
methoxyphenyl 
>99 72 (R) 
4 (S)-2.62 2 o-Tol H 
3,5-di-tert-butyl-4-
methoxyphenyl 
>99 70 (R) 
5 (S)-2.65 1 o-Tol CH3 
[1,1':3',1''-
terphenyl]-5'-yl 
>99 34 (R) 
6 (S)-2.66 2 o-Tol H 
[1,1':3',1''-
terphenyl]-5'-yl 
>99 80 (R) 
7 (S)-2.68 1 o-Tol CH3 phenanthren-9-yl >99 82 (R) 
8 (S)-2.69 1 t-Bu CH3 phenanthren-9-yl >99 17 (R) 
9 (S)-2.70 1 t-Bu CH3 2,6-difluorophenyl >99 26 (R) 
10 (S)-2.71 2 o-Tol H 2,6-difluorophenyl >99 32 (R) 
11 (S)-2.67 2 o-Tol H 
[1,1'-biphenyl]-2-
yl 
85 63 (R) 
12
[52a]
,
[d]
 (S)-2.73 1 o-Tol H Ph >99 80 (R) 
[a] Reaction run on 0.1 mmol scale; [b] Determined by GC analysis on an achiral stationary phase; [c] 
Determined by GC analysis on a chiral stationary phase; [d] 30 min reaction time. 
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Hydrogenation of 7-methoxy-4-methyl-1,2-dihydronaphthalene (S5) resulted in general in 
high enantioselectivities in combination with full conversion (table 2.8). Catalyst (S)-2.66 
containing a [1,1':3',1''-terphenyl]-5'-yl group on the aryl moiety reached even 99% 
enantiomeric excess and complete conversion (entry 6). These values were significantly 
higher when compared to the best result of the parent complex for which 92% ee was 
observed (entry 13). 
 
Table 2.8: Hydrogenation of 7-methoxy-4-methyl-1,2-dihydronaphthalene (S5). 
 
Entry
[a]
 
No. 
Cat. 
Time 
[h] 
n R
1
 R
2
 R
3
 
Conv. 
[%]
[b]
 
ee [%]
[c]
 
1 (S)-2.60 3 1 Ph CH3 
3,5-di-tert-butyl-4-
methoxyphenyl 
>99 97 (R) 
2 (S)-2.61 3 1 o-Tol CH3 
3,5-di-tert-butyl-4-
methoxyphenyl 
>99 97 (R) 
3 (R)-2.63 3 1 t-Bu CH3 
3,5-di-tert-butyl-4-
methoxyphenyl 
99 94 (S) 
4 (S)-2.62 3 2 o-Tol H 
3,5-di-tert-butyl-4-
methoxyphenyl 
>99 98 (R) 
5 (S)-2.65 15 1 o-Tol CH3 
[1,1':3',1''-
terphenyl]-5'-yl 
96 99 (R) 
6 (S)-2.66 15 2 o-Tol H 
[1,1':3',1''-
terphenyl]-5'-yl 
>99 99 (R) 
7 (S)-2.68 15 1 o-Tol CH3 phenanthren-9-yl >99 98 (R) 
8 (S)-2.69 15 1 t-Bu CH3 phenanthren-9-yl >99 97 (R) 
9 (S)-2.70 15 1 t-Bu CH3 2,6-difluorophenyl >99 88 (R) 
10 (S)-2.71 16 2 o-Tol H 2,6-difluorophenyl 98 98 (R) 
11 (S)-2.72 16 2 t-Bu H 2,6-difluorophenyl >99 97 (R) 
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12 (S)-2.67 15 2 o-Tol H [1,1'-biphenyl]-2-yl 87 73 (R) 
13
[52a]
 (S)-2.1 2 1 t-Bu H Ph >99 92 (R) 
[a] Reaction run on 0.1 mmol scale; [b] Determined by GC analysis on an achiral stationary phase; [c] 
Determined by HPLC analysis on a chiral stationary phase. 
 
With these promising results in hand, different cyclic olefins were tested as substrates in the 
hydrogenation with this newly synthesized catalyst. Replacement of the methyl substituent 
with an iso-propyl group resulted in a more challenging compound to reduce (table 2.9). In 
general incomplete conversion and the formation of up to 21% of the corresponding 
naphthalene P6b was observed. However, catalyst (S)-2.72, containing the 2,6-difluorophenyl 
substituent and the di-tert-butylphosphinite, showed with 98% ee, full conversion and no 
formation of the naphthalene P6b, excellent results (entry 5).  
Anthracen-9-yl-substituted catalyst (S)-2.74 afforded product P6a with 96% ee and 84% 
conversion (entry 6). However, these values could be increased to 98% ee and 99% 
conversion after optimization of the reaction conditions (entry 7).
[54a]
 
 
Table 2.9: Hydrogenation of 4-isopropyl-7-methoxy-1,2-dihydronaphthalene (S6). 
 
Entry
[a]
 
No. 
Cat. 
n R
1
 R
2
 R
3
 
Conv. 
[%]
[b]
 
ee 
[%]
[c]
 
P6b 
[%]
[b]
 
1 (S)-2.61 1 o-Tol CH3 
3,5-di-tert-butyl-
4-methoxyphenyl 
53 64 (R) 7 
2 (R)-2.63 1 t-Bu CH3 
3,5-di-tert-butyl-
4-methoxyphenyl 
>99 95 (S) 1 
3 (S)-2.62 2 o-Tol H 
3,5-di-tert-butyl-
4-methoxyphenyl 
14 28 (R) 4 
4 (S)-2.66 2 o-Tol H 
[1,1':3',1''-
terphenyl]-5'-yl 
71 63 (R) 21 
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5 (S)-2.72 2 t-Bu H 2,6-difluorophenyl >99 98 (R) 0 
6
[54a]
 (S)-2.74 2 o-Tol H anthracen-9-yl 84 96 (R) 2 
7
[54a],[d]
 (S)-2.74 2 o-Tol H anthracen-9-yl 99 98 (R) 1 
[a] Reaction run on 0.1 mmol scale; [b] Determined by GC analysis on an achiral stationary phase (P6a+6b); [c] 
Determined by HPLC analysis on a chiral stationary phase; [d] Reaction run at 2.0 mol% catalyst loading, 75 bar 
H2 pressure for 3 h. 
 
Next, the iso-propyl group was replaced by a tert-butyl group (table 2.10). Also in the 
hydrogenation of substrate S7 by far the best result was obtained with catalyst (S)-2.72 
reaching an excellent 99% conversion, 97% ee and only 1% of the corresponding naphthalene 
P7b (entry 5).  
 
Table 2.10: Hydrogenation of 4-(tert-butyl)-7-methoxy-1,2-dihydronaphthalene (S7). 
 
Entry
[a]
 
No. 
Cat. 
n R
1
 R
2
 R
3
 
Conv. 
[%]
[b]
 
ee 
[%]
[c]
 
P7b 
[%]
[b]
 
1 (S)-2.61 1 o-Tol CH3 
3,5-di-tert-butyl-
4-methoxyphenyl 
53 64 () 1 
2 (R)-2.63 1 t-Bu CH3 
3,5-di-tert-butyl-
4-methoxyphenyl 
96 47 (+) 1 
3 (S)-2.62 2 o-Tol H 
3,5-di-tert-butyl-
4-methoxyphenyl 
52 33 () 1 
4 (S)-2.66 2 o-Tol H 
[1,1':3',1''-
terphenyl]-5'-yl 
71 59 () 5 
5 (S)-2.72 2 t-Bu H 2,6-difluorophenyl 99 97 ()[d] 1 
6
[54a],[e]
 (S)-2.74 2 o-Tol H anthracen-9-yl 63 86 4 
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7
[54a],[f]
 (S)-2.74 2 o-Tol H anthracen-9-yl >99 97 13 
[a] Reaction run on 0.1 mmol scale; [b] Determined by GC analysis on an achiral stationary phase (P7a+7b); [c] 
Determined by HPLC analysis on a chiral stationary phase; [d] [α]
20
D  = 25.4 (c = 0.81, CHCl3); [e] Reaction run 
at 100 bar H2 pressure for 24 h; [f] Reaction run at 2.0 mol% catalyst loading, 100 bar H2 pressure, 1.0 M 
substrate concentration for 24 h. 
 
The allylic alcohol S8 is one of the more challenging substrates for Ir-catalyzed asymmetric 
hydrogenation and in the course of this process unpredictable side reactions such as oxidation, 
isomerization or polymerization can be observed.
[20]
 Only three out of twelve catalysts 
achieved full conversion in the hydrogenation of this substrate (table 2.11, entry 3, 6, 8). For 
catalysts (S)-2.71 and (S)-2.72 with the 2,6-difluorophenyl aryl moiety even completed 
decomposition of the substrate was observed. The best results were observed for catalyst (S)-
2.65, which reached full conversion and 95% ee. The enantiomeric excess is slightly lower 
compared to the best results obtained with catalyst (S)-2.1 bearing the phenyl substituent and 
achieving 97% ee and full conversion (entry 13). 
 
Table 2.11: Hydrogenation of (E)-2-methyl-3-phenylprop-2-en-1-ol (S8). 
 
Entry
[a]
 
No. 
Cat. 
Time 
[h] 
n R
1
 R
2
 R
3
 
Conv. 
[%]
[b]
 
ee [%]
[c]
 
1 (S)-2.60 3 1 Ph CH3 
3,5-di-tert-butyl-4-
methoxyphenyl 
70 92 (R) 
2 (S)-2.61 3 1 o-Tol CH3 
3,5-di-tert-butyl-4-
methoxyphenyl 
40 93 (R) 
3 (S)-2.61 5 1 o-Tol CH3 
3,5-di-tert-butyl-4-
methoxyphenyl 
>99 93 (R) 
4
[d] 
(R)-2.63 14 1 t-Bu CH3 
3,5-di-tert-butyl-4-
methoxyphenyl 
62 12 (S) 
5 (S)-2.62 16 2 o-Tol H 
3,5-di-tert-butyl-4-
methoxyphenyl 
34 86 (R) 
6 (S)-2.65 16 1 o-Tol CH3 
[1,1':3',1''-
terphenyl]-5'-yl 
>99 95 (R) 
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7 (S)-2.66 16 2 o-Tol H 
[1,1':3',1''-
terphenyl]-5'-yl 
78 97 (R) 
8 (S)-2.68 16 1 o-Tol CH3 phenanthren-9-yl >99 93 (R) 
9 (S)-2.69 16 1 t-Bu CH3 phenanthren-9-yl 24 67 (R) 
10
[e]
 (S)-2.71 16 2 o-Tol H 2,6-difluorophenyl -- -- 
11
[e]
 (S)-2.72 16 2 t-Bu H 2,6-difluorophenyl -- -- 
12 (S)-2.67 16 2 o-Tol H 
[1,1'-biphenyl]-2-
yl 
15 n.d. 
13
[52a]
 (S)-2.1 2 1 t-Bu H Ph >99 97 (R) 
[a] Reaction run on 0.1 mmol scale; [b] Determined by GC analysis on an achiral stationary phase; [c] 
Determined by GC analysis on a chiral stationary phase; [d] 15% unidentified byproduct observed; [e] Complete 
decomposition of the substrate was observed. 
 
Investigating (E)-β-methylcinnamic acid ethyl ester (S9) as substrate with these catalysts 
showed overall excellent enantioselectivities (table 2.12). All catalysts bearing the 2,6-
difluorophenyl substituent reached 99% enantiomeric excess with full conversion (entries 8, 9 
and 10). But also the phenyl-substituted complex (S)-2.1 achieved with >99% ee and full 
conversion excellent results in the hydrogenation of this substrate (entry 13). 
 
Table 2.12: Hydrogenation of (E)-β-methylcinnamic acid ethyl ester (S9). 
 
Entry
[a]
 
No. 
Cat. 
Time 
[h] 
n R
1
 R
2
 R
3
 
Conv. 
[%]
[b]
 
ee [%]
[c]
 
1 (S)-2.60 5 1 Ph CH3 
3,5-di-tert-butyl-4-
methoxyphenyl 
88 56 (S) 
2 (S)-2.61 5 1 o-Tol CH3 
3,5-di-tert-butyl-4-
methoxyphenyl 
96 92 (S) 
3 (R)-2.63 14 1 t-Bu CH3 
3,5-di-tert-butyl-4-
methoxyphenyl 
>99 93 (R) 
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4 (S)-2.62 5 2 o-Tol H 
3,5-di-tert-butyl-4-
methoxyphenyl 
8 71 (S) 
5 (S)-2.65 16 1 o-Tol CH3 
[1,1':3',1''-
terphenyl]-5'-yl 
76 93 (S) 
6 (S)-2.66 16 2 o-Tol H 
[1,1':3',1''-
terphenyl]-5'-yl 
77 97 (S) 
7 (S)-2.68 16 1 o-Tol CH3 phenanthren-9-yl >99 98 (S) 
8 (S)-2.69 16 1 t-Bu CH3 phenanthren-9-yl >99 >99 (S) 
9 (S)-2.72 16 1 t-Bu CH3 2,6-difluorophenyl >99 >99 (S) 
10 (S)-2.71 16 2 o-Tol H 2,6-difluorophenyl >99 99 (S) 
11 (S)-2.72 16 2 t-Bu H 2,6-difluorophenyl >99 99 (S) 
12 (S)-2.67 16 2 o-Tol H 
[1,1'-biphenyl]-2-
yl 
40 44 (S) 
13
[52a]
 (S)-2.1 2 1 t-Bu H Ph >99 >99 (S) 
[a] Reaction run on 0.1 mmol scale; [b] Determined by GC analysis on an achiral stationary phase; [c] 
Determined by GC analysis on a chiral stationary phase. 
 
The C=C bond of the α,β-unsaturated ester S10 was reduced with variable results. Catalyst 
(R)-2.63 with the 3,5-di-tert-butyl-4-methoxyphenyl-substituted pyridine ring achieved 95% 
ee and full conversion (table 2.13, entry 3). This is significantly higher compared to the best 
result obtained with the parent complex reaching a maximum of 69% ee (entry 6). However, 
the overall best result obtained from this new catalyst class was obtained with the mesitylene-
substituted catalyst (S)-2.75 with 97% ee and full conversion (entry 7).
[54a]
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Table 2.13: Hydrogenation of (E)-β-methylcinnamic acid ethyl ester (S10). 
 
Entry
[a]
 
No. 
Cat. 
n R
1
 R
2
 R
3
 
Conv. 
[%]
[b]
 
ee [%]
[c]
 
1 (S)-2.60 1 Ph CH3 
3,5-di-tert-butyl-4-
methoxyphenyl 
71 29 (R) 
2 (S)-2.61 1 o-Tol CH3 
3,5-di-tert-butyl-4-
methoxyphenyl 
98 8(R) 
3 (R)-2.63 1 t-Bu CH3 
3,5-di-tert-butyl-4-
methoxyphenyl 
>99 95 (S) 
4 (S)-2.62 2 o-Tol H 
3,5-di-tert-butyl-4-
methoxyphenyl 
39 6 (R) 
5 (S)-2.67 2 o-Tol H 
[1,1'-biphenyl]-2-
yl 
5 n.d. 
6
[52a]
 (S)-2.1 1 t-Bu H Ph >99 69 (R) 
7
[54a]
 (S)-2.75 1 t-Bu H mesityl >99 97 (R) 
[a] Reaction run on 0.1 mmol scale; [b] Determined by GC analysis on an achiral stationary phase; [c] 
Determined by GC analysis on a chiral stationary phase. 
 
In the hydrogenation of (E)-ethyl β-methyl-5-phenylpent-2-enoate (S11), these catalysts 
showed lower enantioselectivities compared to the other α,β-unsaturated esters S9 and S10 
(table 2.14). Catalyst (S)-2.71 containing a 2,6-difluoro substituent achieved with 88% ee and 
full conversion the best results. This is slightly better compared to the parent complex (entry 
9). However, the highest selectivity was observed with this catalyst class using the mesityl-
substituted catalyst (S)-2.75 with 94% ee while reaching full conversion (entry 10).
[54a]
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Table 2.14: Hydrogenation of (E)-ethyl β-methyl-5-phenylpent-2-enoate (S11). 
 
Entry
[a]
 
No. 
Cat. 
n R
1
 R
2
 R
3
 
Conv. 
[%]
[b]
 
ee [%]
[c]
 
1 (S)-2.60 1 Ph CH3 
3,5-di-tert-butyl-4-
methoxyphenyl 
>99 18 (R) 
2 (S)-2.61 1 o-Tol CH3 
3,5-di-tert-butyl-4-
methoxyphenyl 
>99 20 (R) 
3 (R)-2.63 1 t-Bu CH3 
3,5-di-tert-butyl-4-
methoxyphenyl 
>99 40 (S) 
4 (S)-2.62 2 o-Tol H 
3,5-di-tert-butyl-4-
methoxyphenyl 
>99 rac 
5 (S)-2.65 1 o-Tol CH3 
[1,1':3',1''-
terphenyl]-5'-yl 
75 84 (R) 
6 (S)-2.71 2 o-Tol H 2,6-difluorophenyl >99 88 (R) 
7 (S)-2.72 2 t-Bu H 2,6-difluorophenyl >99 65 (R) 
8 (S)-2.67 2 o-Tol H [1,1'-biphenyl]-2-yl 25 37 (R) 
9
[53a]
 (S)-2.1 1 t-Bu H Ph >99 86 (R) 
10
[53a]
 (S)-2.75 1 t-Bu H mesityl >99 94 (R) 
[a] Reaction run on 0.1 mmol scale; [b] Determined by GC analysis on an achiral stationary phase; [c] 
Determined by GC analysis on a chiral stationary phase. 
 
(E)-4-Phenylpent-3-en-2-one (S12) was not investigated as substrate with this catalyst class so 
far. Only the catalyst (S)-2.71 bearing the 2,6-difluorophenyl group reached full conversion 
but only moderate enantiomeric excess was observed (table 2.15). Switching from the di-o-
tolyl phosphinite to the di-tert-butyl phosphinite resulted in 89% enantiomeric excess but 
conversion remained at 50%. 
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Table 2.15: Hydrogenation of (E)-4-phenylpent-3-en-2-one (S12). 
 
Entry
[a]
 
No. 
Cat. 
n R
1
 R
2
 R
3
 
Conv. 
[%]
[b]
 
ee [%]
[c]
 
1 (S)-2.61 1 o-Tol CH3 
3,5-di-tert-butyl-4-
methoxyphenyl 
35 91 (S) 
2 (S)-2.62 2 o-Tol H 
3,5-di-tert-butyl-4-
methoxyphenyl 
3 n.d. 
3 (S)-2.65 1 o-Tol CH3 
[1,1':3',1''-
terphenyl]-5'-yl 
6 73 (S) 
4 (S)-2.66 2 o-Tol H 
[1,1':3',1''-
terphenyl]-5'-yl 
32 87 (S) 
5 (S)-2.71 2 o-Tol H 2,6-difluorophenyl >99 73 (S) 
6 (S)-2.72 2 t-Bu H 2,6-difluorophenyl 50 89 (S) 
7 (S)-2.67 2 o-Tol H [1,1'-biphenyl]-2-yl 3 n.d. 
[a] Reaction run on 0.1 mmol scale; [b] Determined by GC analysis on an achiral stationary phase; [c] 
Determined by GC analysis on a chiral stationary phase. 
 
Also (E)-3-methyl-4-phenylbut-3-en-2-one (S13) was not investigated as substrate with this 
catalyst class so far. In general high enantiomeric excesses between 96% and >99% in 
combination with full conversions were observed (table 2.16). Three catalysts of this series 
even achieved >99% ee (entries 2, 3 and 4). Therefore, the obtained data demonstrate the high 
efficiency of this catalyst class to hydrogenate the α,β-unsaturated ketone S13. In contrast to 
the β,β-disubstituted α,β-unsaturated ketone S12, both conversion and enantiomeric excess 
were significantly higher. 
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Table 2.16: Hydrogenation of (E)-3-methyl-4-phenylbut-3-en-2-one (S13). 
 
Entry
[a]
 
No. 
Cat. 
n R
1
 R
2
 R
3
 
Conv. 
[%]
[b]
 
ee [%]
[c]
 
1 (S)-2.1 1 t-Bu H Ph >99 99 () 
2 (S)-2.61 1 o-Tol CH3 
3,5-di-tert-butyl-
4-methoxyphenyl 
>99 >99 () 
3 (S)-2.62 2 o-Tol H 
3,5-di-tert-butyl-
4-methoxyphenyl 
>99 >99 () 
4 (S)-2.65 1 o-Tol CH3 
[1,1':3',1''-
terphenyl]-5'-yl 
>99 99 () 
5 (S)-2.66 2 o-Tol H 
[1,1':3',1''-
terphenyl]-5'-yl 
>99 >99 () 
6 (S)-2.71 2 o-Tol H 
2,6-
difluorophenyl 
>99 96 () 
7 (S)-2.72 2 t-Bu H 
2,6-
difluorophenyl 
>99 98 () 
8 (S)-2.67 2 o-Tol H 
[1,1'-biphenyl]-2-
yl 
13 98 () 
[a] Reaction run on 0.1 mmol scale; [b] Determined by GC analysis on an achiral stationary phase; [c] 
Determined by GC analysis on a chiral stationary phase. 
 
Imines represent another substrate class that can be reduced with high enantioselectivity with 
iridium N,P ligand complexes. (E)-N,1-Diphenylethan-1-imine (S14) showed low selectivities 
and incomplete conversions were reduced with all catalyst of this series (table 2.17). Recently 
our research group demonstrated that a C–H activation of the substrate plays a crucial role in 
the activity obtained for this substrate class.
[63]
 This might explain the lower reactivity for the 
sterically more encumbered complexes, because these catalysts should have a much lower 
affinity to form such Ir(III)-species. 
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Table 2.17: Hydrogenation of (E)-N,1-diphenylethan-1-imine (S14). 
 
Entry
[a]
 
No. 
Cat. 
n R
1
 R
2
 R
3
 
Conv. 
[%]
[b]
 
ee [%]
[c]
 
1 (S)-2.60 1 Ph CH3 
3,5-di-tert-butyl-4-
methoxyphenyl 
24 14 (S) 
2 (S)-2.61 1 o-Tol CH3 
3,5-di-tert-butyl-4-
methoxyphenyl 
14 31 (S) 
3 (R)-2.63 1 t-Bu CH3 
3,5-di-tert-butyl-4-
methoxyphenyl 
8 31 (R) 
4 (S)-2.62 2 o-Tol H 
3,5-di-tert-butyl-4-
methoxyphenyl 
13 29 (S) 
5 (S)-2.71 2 o-Tol H 2,6-difluorophenyl 14 28 (S) 
6 (S)-2.72 2 t-Bu H 2,6-difluorophenyl 40 rac 
7 (S)-2.67 2 o-Tol H [1,1'-biphenyl]-2-yl 39 rac 
8
[52a]
 (S)-2.2 1 o-Tol H Ph >99 82 (S) 
[a] Reaction run on 0.1 mmol scale; [b] Determined by GC analysis on an achiral stationary phase; [c] 
Determined by GC analysis on a chiral stationary phase. 
 
As last substrate (3E,7E)-farnesol (S15) was investigated in combination with this catalyst 
class (table 2.18). (3E,7E)-Farnesol (S15) is a mimic of the vitamin E side chain and was 
previous successfully hydrogenated employing the catalyst with a phenyl group at the 2-
position of the pyridine ring. In this case 92.2% of the main stereoisomer was obtained (entry 
4).
[53b]
 This result was further improved with the mesityl-substituted catalyst (S)-2.76, which 
afforded 95.1% of the major diastereoisomer. 
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Table 2.18: Hydrogenation of (3E,7E)-farnesol (S15). 
 
Entry
[a] 
Cat. 
(3S,7R) 
[%]
[b]
 
(3R,7R) 
[%]
[b]
 
(3R,7S) 
[%]
[b]
 
(3S,7S) 
[%]
[b]
 
ee [%] 
(3R,7R) 
de [%] 
1 (S)-2.61 26.2 62.5 7.3 3.3 90  32 
2 (S)-2.62 22.1 69.8 7.3 1.4 96  42 
3 (S)-2.76 4.1 95.1 0.8 0.1 >99  90 
4
[53b]
 (S)-2.2 6.4 92.2 1.3 0.3  >99 85 
[a] Full conversion was obtained for all entries; [b] Determined by GC on a chiral stationary phase.
[53b]
 Due to 
difficult separation the sum of all stereoisomers does not result in 100%. 
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2.4 Influence of the methyl group at the 4-position of the pyridine 
moiety  
 
As already discussed, the newly developed catalyst with more sterically demanding aryl 
groups emerged as superior in the hydrogenation of certain model substrates. However, the 
catalysts with an aliphatic five-membered ring in the backbone of the ligand differ from 
earlier established pyridyl-phosphinite catalysts not only on the aryl position, but also with 
respect to the methyl group at the 4-position of the pyridine ring. The introduction of this 
methyl group was part of the modification of the original synthetic route, which reduced the 
sequence by one step and allowed for the synthesis of these ligands starting from extremely 
cheap starting materials (see scheme 2.2).  
Based on the quadrant model used to predict the stereochemical outcome of iridium-catalyzed 
asymmetric hydrogenations developed by Andersson and co-workers, this additional methyl 
group points away from the chiral pocket formed by the ligand around the metal center (figure 
2.4). Therefore, no significant influence on both reactivity and selectivity is expected. On the 
other hand, the methyl group could have a slight influence on the electron density of the 
pyridine ring and could potentially interact with the aliphatic backbone of the ligand, thus 
influencing its geometry and ultimately the enantioselectivity of the overall process. 
 
 
Figure 2.4: Andersson's model explaining the enantioselectivity-determining step with the additional methyl 
group pointing away from the chiral pocket formed by the ligand. 
 
Therefore, catalysts of this ligand class, either bearing or lacking a methyl group at the 4-
position of the pyridine moiety, were prepared according to the previously described methods 
to investigate the influence of this structural element. 
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2.4.1 Crystal structures of iridium N,P ligand complexes with and without a 
methyl group at the 4-position of the pyridine moiety 
 
In the course of this project it was possible to grow crystals of complexes (R)-2.73, (R)-2.77 
and (R)-2.63 that were suitable for X-ray analysis. Such analyses allowed for the comparison 
of the crystal structures of the complexes with and without a methyl group at the 4-position of 
the pyridine ring (figure 2.5). The crystal structure of complex (S)-2.73 was kindly provided 
by Dr. Adnan Ganić. 
 
Figure 2.5: Crystal structures of complexes (S)-2.73, (S)-2.77 and (S)-2.73, (R)-2.63 bearing an additional 
methyl group (right); counterions were omitted for clarity. The crystal structure of (R)-2.63 is depicted as mirror 
image. 
 
By comparing the bond lengths, the angles and the orientation of the complex with and 
without the methyl group on the pyridine ring, almost identical values were obtained. Only 
the torsion angle between the pyridine plane and the plane of the aryl moiety for catalyst (S)-
2.73 and (R)-2.63 showed a notable discrepancy of 9°. However, the crystal structures 
depicted in figure 2.5 represent only the precatalyst and on their basis definite conclusions on 
the orientation of each group in the enantioselectivity-determining step of the hydrogenation 
would be just speculative. 
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Table 2.19: Selected bond lengths and angles of Ir-complexes (S)-2.73, (S)-2.77, (S)-2.78 and (R)-2.63. 
 
  
  
Ir-P [Å] 2.307 2.292 2.337 2.345 
Ir-N [Å] 2.094 2.098 2.132 2.103 
 P-Ir-N [°] 84.6 84.8 88.7 89.7 
torsion angle 
plane pyridine 
plane aryl-
substituent [°] 
44.7 45.2 68.1 59.2 
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2.4.2 Hydrogenation results 
 
Comparing the hydrogenation results revealed predominantly similar behavior for the catalyst 
with and without the methyl group (scheme 2.5). However, some small differences were 
observed. Especially for the catalysts (R)-2.63 and (S)-2.78, 94% vs. 98% ee and 94% vs. 
97% ee were observed for the tested substrates. Therefore, it is not possible to exclude an 
influence of the methyl group. 
 
Scheme 2.5: Comparison of catalysts differing only by a methyl group at the 4-position of the pyridine moiety.  
PYRIDYL PHOSPHINITE-BASED CATALYST  CHAPTER 2 
 
58 
2.5 Pyridine-based ligands with an axial chiral 8-(naphthalen-1-
yl)quinoline backbone 
 
As discussed in chapter 1, the synthesis and development of new catalysts and ligands can be 
seen as the fundament of any methodology dealing with catalytic transformations. A great 
variety of different iridium N,P ligand complexes enabling the hydrogenation of different 
substrate classes has been discussed so far. Nevertheless, there is still a demand for easily 
accessible catalysts, which can be applied to the iridium-catalyzed asymmetric hydrogenation. 
The number of iridium complexes forming larger chelates then six-membered rings is 
constantly increasing and these complexes were able to achieve excellent results in the 
hydrogenation of different substrate classes.
[36-37, 51, 64]
 Also several iridium complexes 
containing axial chirality were successfully applied as catalysts. Having demonstrated that 
pyridine-based catalysts can achieve excellent enantioselectivities and reactivities in the 
hydrogenation of unfunctionalized double bonds, it was envisioned to synthesized iridium-
based complexes of type A, containing an eight-membered chelate ring, axial chirality and a 
pyridine unit (scheme 2.6). Most importantly, these complexes should be accessible via a 
straightforward synthesis from commercially available starting materials, in only 3 steps. 
 Scheme 2.6: Retrosynthetic analysis for the preparation of iridium-based complexes of type A. 
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2.4.1 Synthesis 
 
The Suzuki–Miyaura cross-coupling between 2.81 and 2.82 afforded 1-(quinolin-8-
yl)naphthalen-2-ol (2.80) in poor to moderate yields (table 2.20). A maximum of 40% yield 
was obtained by the use of 8 mol% of (NHC)Pd(allyl)Cl (table 2.20). Although there is 
certainly room for improvement of this transformation, 40% yield was sufficient to investigate 
the next step of the reaction sequence. 
 
Table 2.20: Suzuki–Miyaura cross-coupling to afford 1-(quinolin-8-yl)naphthalen-2-ol (2.80). 
 
Entry Pd-cat. [mol%] Solvent Base Temp. Time 
Yield 
[%] 
1 
 
3  
iso-
propanol  
4 M 
NaOH  
60 °C  16 h  27  
2 8  
iso-
propanol  
4 M 
NaOH  
60 °C  16 h  40  
3 
 
3  THF  K3PO4 25 °C  4 h  21  
4 
Pd(OAc)2  
P(o-Tol)3  
3  
toluene/  
ethanol  
K
2
CO
3
 100 °C  6 h  9  
 
Next, the separation of the enantiomers of compound 2.80 by semi-preparative HPLC on a 
chiral stationary phase was tested. Although in an analytical scale sufficient separation of the 
two enantiomers was achieved, 1-(quinolin-8-yl)naphthalen-2-ol (2.80) showed only pure 
solubility in solvents which can be used for the separation. Therefore, the preparation of the 
corresponding iridium complexes was investigated first. By the use of previously described 
procedure starting from 1-(quinolin-8-yl)naphthalen-2-ol (2.80) (scheme 2.7), the formation 
of the di-ortho-tolylphosphinite complex 2.83 was achieved with 80% yield. However, the 
synthesis of the diphenylphosphinite and di-tert-butylphosphinite complexes failed. 
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Scheme 2.7: Synthetic sequences for the preparation of different iridium complexes starting from 1-(quinolin-8-
yl)naphthalen-2-ol (2.80). 
 
2.4.2 Hydrogenation results 
 
Having achieved the synthesis of complex 2.83, its performance in the hydrogenation of 
different test substrates was investigated (table 2.21). This iridium complex showed in general 
low reactivity in the hydrogenation of C=C bonds. Only in the reduction of imine S14 
moderate reactivity was obtained. 
 
Table 2.21: Hydrogenation of different substrates using catalyst 2.83. 
Conversion determined by GC on an achiral stationary phase. 
 
With these results in hand no further studies on the performance of this catalyst were carried 
out in view of the crystal structure which was obtained in the course of this project. 
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2.4.3 Crystal structure of 8-(naphthalen-1-yl)quinoline-based complex 2.83 
 
The crystal structure of complex 2.83 showed similar Ir–N and Ir–P bond lengths as for other 
complexes investigated in this chapter (figure 2.6, left). However, comparing the torsion 
angles between two bonds which should have a value of 180° for an unstrained geometry, it 
becomes obvious that the backbone of the catalyst cannot adopt this optimal geometry. In the 
case of the 8-(naphthalen-1-yl)quinoline (2.86), representing the major part of the free ligand, 
the torsion angles between the bond, which bridges the naphthalene and the quinoline unit, 
and the other bonds which should be parallel, are in the range between 179.1° and 179.5° 
(figure 2.6, right). For complex 2.83 these angles deviate significantly from optimal 180° 
alignment. This deviation might be the reason why the complexation was only successful in 
one case and that the obtained catalyst showed in general low reactivity in the hydrogenation 
of C=C bonds. 
 
 
Figure 2.6: Crystal structure of 8-(naphthalen-1-yl)quinoline-based iridium complex 2.83 and 8-(naphthalen-1-
yl)quinoline as reference. 
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2.6 Summary  
 
In summary, it was demonstrated that hindered pyridine-based N,P iridium complexes can be 
synthesized via a flexible route based on late stage derivatization to introduce the desired aryl 
moiety by a Suzuki–Miyaura cross-coupling. The obtained catalyst showed for several 
substrates higher reactivity and selectivity compared to their “parent” complexes with a 
phenyl group in the 2-position of the pyridine ring. Therefore, this new catalysts broaden the 
scope of this catalyst scaffold. In the next chapters, the applicability of these catalysts will be 
demonstrated in the hydrogenation of different substrate classes. 
The efforts to use pyridine base catalyst with a 8-(naphthalen-1-yl)quinoline backbone were 
unsuccessful. 
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Enantioselective Conjugated Reduction of α,β-Unsaturated 
Carboxylic Esters with Chiral Iridium N,P Ligand Complexes 
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3.1 Introduction 
 
The synthesis of enantiomerically enriched carboxylic esters is an important transformation 
leading to synthetically useful products which can be further elaborated by reactions at the 
ester group. Molecules accessible from such functionality are found in many natural products 
and many carboxylic ester derivatives that possess a tertiary stereogenic center in the α- or β-
position are known.
[65]
 Therefore, an efficient synthesis of such enantioenriched carboxylic 
esters would display a highly valuable strategy towards a class of versatile building blocks 
and enabling the access to a variety of different compounds.  
 
 
Figure 3.1: Selected compounds containing a tertiary stereogenic center at the α- or β-position of an ester or 
ester derived functional group. 
 
Due to the high synthetic value of this compound class, several research groups have been 
working on strategies to form enantiomerically enriched carboxylic esters. The conjugated 
reduction of α,β-unsaturated carboxylic esters is one of them and different approaches were 
conducted to apply this strategy. The use of sodium borohydride and cobalt-semicorrin 
complexes in the conjugated reduction of α,β-unsaturated carboxylic esters led to 
enantioenriched saturated esters in up to 93% ee (scheme 3.1, A).
[66]
 Lipshutz and co-workers 
developed a chiral version of the Stryker’s reagent[67] to afford saturated esters in up to 
99% ee. However, the method required an excess of polymethylhydrosiloxane and is 
restricted to the generation of β-chiral carboxylic esters (scheme 3.1, B).[68] Also, several 
examples of rhodium-based catalysts in the reduction of α,β-unsaturated esters are reported.[69] 
In general high enantiomeric excess is reached, but these catalysts are limited to substrates 
bearing an additional coordinating group such as, for example, a phosphonate (scheme 3.1, 
C).
[70]
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Scheme 3.1: Different approaches to access enantiomerically enriched carboxylic esters by conjugated reduction. 
 
Iridium-based N,P ligand complexes, such as catalyst 3.1, have been tested for the 
hydrogenation of trisubstituted α,β-unsaturated carboxylic esters since the first reports in this 
field. Especially ethyl trans-β-methylcinnamate (S9) was used as test substrate to investigate 
the performance of newly developed catalyst by many different research groups.
[71]
 Although 
high enantioselectivity was reached for this substrate using different catalysts, other α,β-
unsaturated carboxylic esters were comparably underexplored, with poor results usually 
obtained for substrates with other substitution patterns than substrate S9. For example shifting 
the methyl group from the β- to the α-position resulted in a drop of ee from >99% to 69% 
using catalyst 3.1 (scheme 3.2).
[52a]
 
 
 
Scheme 3.2: Hydrogenation of ethyl trans-β-methylcinnamate (S9) and ethyl trans-α-methylcinnamate (S10) 
with catalyst 3.1.
[52a]
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In general hydrogenations of α-substituted unsaturated carboxylic esters with iridium-based 
catalysts result in lower enantioselectivities than their β-substituted analogs. This behavior 
was explained by Andersson and co-workers on the basis of computational studies conducted 
on ethyl trans-β-methylcinnamate (S9) and ethyl trans-α-methylcinnamate (S10). They noted, 
that the hydrogen transfer to the α-carbon for substrate S10 occurs via a sterically favored but 
electronically disfavored alignment. For the β-substituted analog the calculation showed that a 
sterically and electronically favored orientation in the transition state is preferred and 
therefore this substitution pattern usually results in higher enantioselectivities (scheme 3.3).
[49]
 
In addition, these findings were used to explain that β,β-disubstituted unsaturated carboxylic 
esters normally react much faster compared to their α,β-disubstituted analogs. 
 
 
Scheme 3.3: Quadrant model applied by Andersson and co-workers to explain the lower enantioselectivity 
obtained in the hydrogenation of α-substituted unsaturated esters compared to their β-substituted analogs.[49] 
 
As demonstrated in chapter 2, the newly developed pyridine-based iridium N,P catalysts with 
a sterically demanding aryl-substituent at the 2-position of the pyridine moiety emerged as 
efficient catalysts in the hydrogenation of ethyl trans-α-methylcinnamate (S10) and ees up to 
97% with full conversion were reached. Therefore, we conducted a detailed study on the 
performance of the most successful of these modular pyridine-based catalyst described in 
chapter 2 in the hydrogenation of different α,β-unsaturated carboxylic esters. Additional 
results were obtained by Dr. D. Woodmansee or Dr. L. Tröndlin, who both worked on this 
project, and are included to allow for a more detailed discussion on the topic. These results 
are marked by a footnote (table 3.1).  
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3.2 Hydrogenation of α,β-unsaturated carboxylic esters 
 
3.2.1 Substrate synthesis 
 
All the α,β-unsaturated esters synthesized and tested in the course of this project were 
produced via the corresponding α,β-unsaturated carboxylic acid to allow the introduction of 
the different ester residues at the latest stage of the substrate synthesis (scheme 3.4). These 
carboxylic acids were synthesized via Horner–Emmons–Wittig reaction (for substrate 3.32),[72] 
Reformatsky reaction
[73]
 (for substrate 3.14) or were commercially available (3.2-3.5, S10, 
3.26-3.28 and 3.16-3.19). Coumarin 3.36 was synthesized by condensation of 2-
hydroxybenzaldehyde with phenyl acetic acid and 7-methoxy-4-methyl-2H-chromen-2-one 
(3.37) by methylation of the free alcohol. The α,β-unsaturated esters 3.12 and 3.34 were 
provided by Dr. Lars Tröndlin and the α,β-unsaturated ester (E)-3.24 by Dr. Christian Ebner 
in our research group. 
 
Scheme 3.4: Strategies employed for the synthesis of α,β-unsaturated carboxylic esters. 
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3.2.2 Hydrogenation results 
 
As already mentioned, the hydrogenation of α,β-unsaturated carboxylic ester S10 showed 
high selectivities of up to 97% ee by the use of the newly synthesized catalysts containing 
sterically demanding aryl groups at the 2-position of the pyridine moiety. Therefore, at the 
beginning of this project the influence of the different ester residues was tested by the use of 
the most promising catalyst bearing these modular pyridine-based ligands. For catalyst 3.10 a 
positive effect on the obtained enantioselectivity was achieved for ester groups with 
increasing steric demand. For the isopropyl ester 3.3 even 99% ee was obtained. Also for 
catalyst 3.1 the highest enantiomeric excess of 84% was obtained by the hydrogenation of the 
isopropyl ester analog 3.3. Catalyst 3.11 provided ees in the range between 74% and 95% but 
no clear trends could be deduced from the data. Furthermore, for all entries full conversion 
was observed demonstrating the high reactivity of these catalyst towards this substrate series 
(table 3.1). 
 
Table 3.1: Hydrogenation of different (E)-β-methyl cinnamic esters.
 
Cat. 
R = Me
[a] 
ee [%] 
R = Et
[a] 
ee [%] 
R = Hept
[a] 
ee [%] 
R = i-Pr
[a] 
ee [%] 
R = i-Bu
[a] 
ee [%] 
 
97
[b]
 97
[b]
 96 99
[b]
 97  
 
46 69
[c]
 78  84 75  
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76  95 74 93  89  
[a] Reaction run on 0.1 mmol scale, full conversion was observed for all entries; [b] Measured by Dr. David 
Woodmansee; [c] Measured by Dr. Lars Tröndlin. 
 
Next the α,β-unsaturated ester 3.12, which is a potential precursor in the synthesis of Lilial® 
(see figure 3.1), was tested. This substrate proved to be unexpectedly difficult to reduce and 
full conversion could not be reached with 1 mol% catalyst loading with different iridium 
complexes using standard reaction conditions (table 3.2). Why the remote tert-butyl group has 
such a pronounced effect is unclear. Nevertheless, by the use of catalyst 3.10 91% conversion 
with 94% enantiomeric excess was reached for this substrate (entry 1).  
 
Table 3.2: Enantioselective hydrogenation of ethyl (E)-3-(4-(tert-butyl)phenyl)-2-methylacrylate (3.12). 
 
Entry
[a]
 n R
1 
R
2
 R
3
 
Cat. 
(config.) 
Conv. 
[%]
[b]
 
ee [%]
[b]
 
1 1 t-Bu Me mesityl (S) 91  94 (R)  
2 1 t-Bu H Ph (S) 90  71 (R)  
3 2 o-Tol H Ph (R) 49  92 (S)  
4 1 t-Bu Me 
3,5-di-tert-butyl-4-
methoxyphenyl 
(R) 63  64 (S)  
5 1 o-Tol Me anthracen-9-yl (S) 48  82 (R)  
[a] Reaction on 0.1 mmol scale; [b] Determined by GC analysis on a chiral stationary phase. 
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In the next section, the substituent at the α-position to the ester group was varied. The α-ethyl-
substituted ester 3.14 proved to be a more problematic substrate than the α-methyl substituted 
analog 3.3 (table 3.3). Catalyst 3.10, which gave so far the best results, performed only with 
78% ee and incomplete conversion was observed (entry 1). Only catalyst 3.11 reached full 
conversion and with 88% ee still respectable enantioselectivity was obtained (entry 3).  
 
Table 3.3: Hydrogenation of (E)-isopropyl 2-benzylidenebutanoate (3.14). 
 
Entry
[a]
 R
1 
R
2
 R
3
 
Cat. 
(config.) 
Conv. 
[%]
[b]
 
ee [%]
[c]
 
1 t-Bu Me mesityl (S) 89  78 ()  
2 t-Bu H Ph (S) 36  n.d. 
3 t-Bu H 
3,5-di-tert-butyl-4-
methoxyphenyl 
(R) >99  88 (+)  
[a] Reaction run on 0.1 mmol scale; [b] Determined by GC analysis on a chiral stationary phase; [c] Determined 
by HPLC analysis on a chiral stationary phase. 
 
Afterwards, we tested the incorporation of a phenyl group at the α-position of the substrate in 
the asymmetric hydrogenation (table 3.4). These bulky esters proved very difficult to be 
reduced at 1 mol% catalyst loading and full conversion was not achieved in any of the 
attempted hydrogenations. However, useful levels of conversion and excellent 
enantioselectivity were obtained with catalyst 3.1, which gave the saturated isopropylester 
with 97% ee and 80% conversion. The more sterically hindered complexes 3.10 showed 
almost no reactivity towards these substrates, which is not surprising considering the severe 
steric shielding of the C=C bond by the two phenyl groups. Sterically more demanding ester 
residues such as tert-butyl or 2,4-dimethyl-3-pentyl resulted in lower conversion compared to 
their isopropyl analog 3.17. 
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Table 3.4: Enantioselective hydrogenation of different (E)-2,3-diphenylacrylic esters. 
 
 
Entry
[a]
 R n R
1 
R
2
 R
3
 
Cat. 
(config.) 
Conv. 
[%]
[b]
 
ee 
[%]
[c]
 
1 Et 1 t-Bu Me mesityl (S) 8 67 (R) 
2 Et 1 t-Bu Me 
3,5-di-tert-butyl-4-
methoxyphenyl 
(R) 90 57 (R) 
3 Et 1 t-Bu H Ph (S) 41 89 (S) 
4 Et 2 o-Tol H anthracen-9-yl (R) 3 39 (S) 
5 i-Pr  1 t-Bu Me 
3,5-di-tert-butyl-4-
methoxyphenyl 
(R) 86 82 () 
6 i-Pr  1 t-Bu H Ph (S) 80 97 (+) 
7 t-Bu  1 t-Bu H Ph (S) 35 n.d. 
8 
2,4-dimethyl-
3-pentyl 
1 t-Bu Me 
3,5-di-tert-butyl-4-
methoxyphenyl 
(R) 35
[d]
 n.d. 
9 
2,4-dimethyl-
3-pentyl 
1 t-Bu H Ph (S) 1 n.d. 
[a] Reaction run on 0.1 mmol scale; [b] Determined by GC analysis on a chiral stationary phase; [c] Determined 
by HPLC analysis on a chiral stationary phase; [d] 8% of the corresponding acid observed. 
 
Next, we switched to the β,β-diaryl substituted α,β-unsaturated ester (E)-3.24. β,β-Diaryl 
substitution is a motif which is frequently found in biologically active compounds.
[74]
 This 
substrate showed moderate reactivity and a significant degree of cis/trans isomerization was 
observed in these reactions. Interestingly, although 21% isomerized product was obtained by 
the use of catalyst 3.1, still 88% enantiomeric excess was observed for the hydrogenation of 
this substrate (table 3.5, entry 3). 
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Table 3.5: Enantioselective hydrogenation of ethyl (E)-3-phenyl-3-(p-tolyl)acrylate ((E)-3.24).  
 
Entry
[a]
 R R
1 
R
2
 R
3
 
Cat. 
(config.) 
3.25 
[%]
[b]
 
(Z)-3.26 
[%] 
ee [%]
[c]
 
1 Et t-Bu Me mesityl (S) 10 4  10  
2 Et t-Bu Me 
3,5-di-tert-butyl-4-
methoxyphenyl 
(R) 42  17  75  
3 Et t-Bu H Ph (S) 66  21  88  
[a] Reaction run on 0.1 mmol scale; [b] Determined by GC analysis on a chiral stationary phase; [c] Determined 
by HPLC analysis on a chiral stationary phase. 
 
The hydrogenation of the purely aliphatic esters 3.26-3.28 revealed in general lower 
enantioselectivity compared to ethyl trans-α-methylcinnamate (S10) (table 3.6). The 
enantioselectivity obtained by the use of catalyst 3.10 dropped from 97% to 71% (table 3.1 vs. 
table 3.6, entry 1). Notably, the remote phenyl group has a surprisingly strong effect, possibly 
by interaction of the π-system with the catalyst. The isopropyl analog 3.27 showed a similar 
trend as previously observed, and was reduced with a higher enantiomeric excess of 91%. The 
tert-butyl analog 3.28 was much less reactive und incomplete conversion was observed for all 
entries. 
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Table 3.6: Enantioselective hydrogenation of different (E)-2-methylpent-2-enoates. 
 
Entry
[a]
 R R
1 
R
2
 R
3
 
Cat. 
(config.) 
Conv. 
[%]
[b]
 
ee [%]
[b]
 
1 Et t-Bu Me mesityl (S) >99  71 ()  
2 Et t-Bu H Ph (S) >99 3 ()  
3 Et t-Bu Me 
3,5-di-tert-butyl-4-
methoxyphenyl 
(R) >99 42 ()  
4 i-Pr  t-Bu Me mesityl (S) >99 91 ()  
5 i-Pr  t-Bu Me 
3,5-di-tert-butyl-4-
methoxyphenyl 
(R) >99 82 (+)  
6 i-Pr  o-Tol Me Ph (S) >99 81 ()  
7 t-Bu  t-Bu Me mesityl (S) 36 86 ()  
8 t-Bu  t-Bu Me 
3,5-di-tert-butyl-4-
methoxyphenyl 
(R) 1 n.d.  
[a] Reaction run on 0.1 mmol scale; [b] Determined by GC analysis on a chiral stationary phase. 
 
Isopropyl (E)-2,4,4-trimethylpent-2-enoate (3.32) turned out to be a poorly suited substrate for 
the pyridine-based catalyst depicted in table 3.7. A maximum of 35% enantiomeric excess and 
96% conversion was reached employing catalyst 3.10 (entry 1). 
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Table 3.7: Enantioselective hydrogenation of isopropyl (E)-2,4,4-trimethylpent-2-enoate (3.32). 
 
Entry
[a]
 n R
1 
R
2
 R
3
 
Cat. 
(config.) 
Conv. 
[%]
[b]
 
ee [%]
[b]
 
1 1 t-Bu Me mesityl (S) 96  35 (+) 
2 1 t-Bu H Ph (S) 35  n.d.  
3 2 o-Tol H Ph (R) >99 27 () 
[a] Reaction run on 0.1 mmol scale; [b] Determined by GC analysis on a chiral stationary phase. 
 
In the hydrogenation of ethyl (E)-3-cyclohexyl-2-methylacrylate (3.35) very low 
enantioselectivity was observed. Both catalysts reached full conversion but only up to 45% ee 
with catalyst 3.10 was reached in the hydrogenation reaction (table 3.8, entry 1). 
 
Table 3.8: Enantioselective hydrogenation of ethyl (E)-3-cyclohexyl-2-methylacrylate (3.34). 
 
Entry
[a]
 R
1 
R
2
 R
3
 
Cat. 
(config.) 
Conv. [%]
[b]
 ee [%]
[b]
 
1 t-Bu Me mesityl (S) >99 45 (+) 
2 t-Bu H Ph (S) >99 13 () 
[a] Reaction run on 0.1 mmol scale; [b] Determined by GC analysis on a chiral stationary phase. 
 
Next, we tested the applicability of coumarins 3.36 and 3.37 under the reaction conditions 
outlined in scheme 3.5. Based on their biological activity, dihydrocoumarins are valuable 
structural elements that are found in a number of different natural products.
[75]
 In contrast to 
the previously tested substrates, no conversion was obtained with any of the tested catalyst 
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applying standard hydrogenation conditions (scheme 3.5). However, modification of the 
reaction parameters allowed for the reduction of these substrates (as described in chapter 6).  
 
 
Scheme 3.5: Different catalysts that showed no reactivity in the hydrogenation of coumarins 3.36 and 3.37. 
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3.3 Hydrogenation of dienoates with sterically demanding ester 
groups 
 
The hydrogenation of 1,3-conjugated dienes results in the formation of deoxypolyketide 
chirons, a structural motif frequently found in natural products.
[76]
 The applicability of 
iridium-based N,P ligand complexes in the hydrogenation of such dienes was extensively 
studied by Dr. Andreas Schumacher in our research group.
[77]
 In the course of this study 
considerable efforts were made to find a system which allows for the highly selective 
hydrogenation of methyl (2E,4E)-2,4-dimethylhexa-2,4-dienoate (3.44). The different 
investigated catalysts bearing N,P ligands which showed high selectivity in the hydrogenation 
of α,β-unsaturated esters showed no reactivity towards this specific substrate. Such a behavior 
was explained by the identification and isolation of the iridium-hydride-allyl complex 3.45 
formed by the reaction of iridium PHOX catalyst 3.43 in the presence of 5 eq. of substrate 
3.44 under hydrogen atmosphere (scheme 3.6).  
 
Scheme 3.6: Isolated iridium-hydride-allyl complex 3.45 formed in the presence of 5 eq. of substrate 3.44.
[77]
 
 
Full hydrogenation of this substrate was accomplished by the use of iridium N,P or C,N 
ligand complexes forming a seven-membered chelate ring. Although these catalysts enabled 
the reduction of this substrate, they reached only moderate enantio- and diastereoselectivties. 
Also other attempts conducted by Dr. Andreas Schumacher to apply six-membered iridium-
based N,P ligand complexes in the hydrogenation of substrate 3.44, such as modification of 
the reaction parameters (solvent, pressure or temperature), were unsuccessful. To enable the 
applicability of N,P ligand complexes forming a six-membered chelate ring to this substrate 
class, it was envisaged that a more sterically demanding ester residue would lead to a 
destabilization of iridium-hydride-allyl complexes such as 3.45 and thus avoid their formation 
or allow for a back reaction to regenerate the catalytically active species. To test this 
hypothesis different sterically more demanding dienoates 3.49-3.51, bearing an isopropyl-, a 
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tert-butyl- or a 2,4-dimethylpentan-3-yl-group were synthesized. The preparation of the 
different substrates was accomplished in 3 steps. Methyl (2E,4E)-2,4-dimethylhexa-2,4-
dienoate (3.44) obtained by Wittig reaction was saponified to afford the carboxylic acid 3.48, 
which was converted into the corresponding acyl chloride by treatment with oxalyl chloride 
and finally quenched with the relevant alcohol to afford the desired dienoates (scheme 3.7).  
 
 
Scheme 3.7: Synthesis of different dienoates 3.49-3.51 with sterically demanding ester groups. 
 
The dienoates bearing sterically demanding ester residues showed mainly low conversion 
similarly to their methyl analog 3.44 (table 3.9). Only for entries 13, 14 and 15 conversion to 
the fully saturated esters were observed. The diastereoisomeric ratio registered with a 
maximum of 62:38 remained poor. Interestingly, carbene catalysts 3.57 and 3.58 showed no 
or only moderate reactivity (23% conversion) in the hydrogenation of the methyl ester 3.44, 
even using forcing reaction conditions (2 mol% catalyst loading after 14 hours in CH2Cl2 by 
the use of 100 bar H2 pressure).
[77]
 Although this concept did not allow for the application of 
N,P ligand complexes forming a six-membered chelate ring, it showed that the conversion can 
be significantly increased for catalysts which in general show reactivity for the analogous 
methyl ester 3.44.  
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Table 3.9: Hydrogenation of different dienoates. 
 
Entry
[a]
 Cat. R 
Conv. to fully 
saturated ester [%]
[b]
 
dr
[b]
 
1 
 
isopropyl 0 -- 
2 tert-butyl 0 -- 
3 2,3,4-trimethylpentyl 0 -- 
4 
 
isopropyl 0 -- 
5 tert-butyl 0 -- 
6 2,3,4-trimethylpentyl 0 -- 
7 
 
isopropyl 0 -- 
8 tert-butyl 0 -- 
9 2,3,4-trimethylpentyl 0 -- 
10 
 
isopropyl decomposition -- 
11 tert-butyl decomposition -- 
12 2,3,4-trimethylpentyl decomposition -- 
13 
 
isopropyl >99 57:43 
14 tert-butyl decomposition -- 
15 2,3,4-trimethylpentyl >99 62:38 
16 
 
isopropyl 53 n.d. 
17 tert-butyl decomposition -- 
18 2,3,4-trimethylpentyl decomposition -- 
[a] Reaction run on 0.1 mmol scale; [b] Determined by GC analysis on a chiral stationary phase. 
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3.4 Conclusion 
The high enantioselectivities obtained in the hydrogenation of various α,β-unsaturated 
carboxylic esters with aryl or alkyl substituents at the C=C bond show that iridium complexes 
derived from chiral N,P ligands are efficient catalysts for this transformation. By changing the 
substitution pattern around the C=C bond and the ester moiety, different activities and 
selectivities were observed. As expected, none of the complexes that were evaluated emerged 
as a universal catalyst. Depending on the substitution pattern of the substrate, different ligands 
performed best. For instance, iridium complex 3.1 was superior for more sterically demanding 
substrates, whereas complex 3.11 showed the best results towards substrates with less 
sterically demanding substituents around the C=C bond. This highlights the advantage of a 
modular approach to the synthesis of catalysts and the need for such catalysts with tunable 
steric and electronic properties. The results outlined above also show that α,β-unsaturated 
carboxylic esters substituted at the α-position are less problematic substrates than originally 
anticipated based on previous studies. Furthermore, it was possible to transfer the results 
obtained in the hydrogenation of α,β-unsaturated carboxylic esters to dienoates. Unfortunately, 
high selectivity could not be achieved. However, significantly higher conversion in the 
hydrogenation of the isopropylester analog 3.49 was achieved for catalysts which previously 
demonstrated only low reactivity for this substrate class. 
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4.1 Towards a stereoselective large scale synthesis of (R,R,R)-α-
tocopherol 
 
The term vitamin E refers to a group of eight lipophilic isomeric tocopherol- and tocotrienol-
derivatives. Their nomenclature depends on the degree of methylation of the chromanol unit 
and the nature of the side chain, as summarized figure 4.1.
[78]
 Among these molecules, α-
tocopherol (4.1) is the most common and based on its increased biological activity also the 
most studied molecule of the vitamin E family.  
 
 
Figure 4.1: All eight members of the vitamin E family. 
 
It was found that the different compounds of vitamin E show anti-inflammatory activity and 
are also considered as the most important lipid-soluble antioxidants in biological systems.
[79]
 
These and other properties led to different studies, conducted mainly on α-tocopherol, 
proposing the benefit to mitigate cardiovascular disease, promoting plasma membrane repair 
and slowing Alzheimer’s disease progression.[80] From an industrial point of view, the most 
relevant product of this class is (all-rac)-α-tocopherol ((all-rac)-4.1), which represents an 
equimolar mixture of all eight stereoisomers of α-tocopherol, and exceeds a production of 
30000 tons per year worldwide and is constantly increasing.
[81]
 In the USA the recommended 
dietary allowance for adults is set to 15 mg/day for (R,R,R)-α-tocopherol ((R,R,R)-4.1).[82] 
The naturally occurring (R,R,R)-stereoisomer of α-tocopherol is approximately twice as 
biologically active in adults than its synthetic form, (all-rac)-α-tocopherol.[83] Hence, already 
in 1963 the research group of Isler published the first synthesis of the (R,R,R)-stereoisomer.
[84]
 
Nowadays roughly 10% of the industrially produced vitamin E consists of α-tocopherol in its 
isomerically pure (R,R,R) configuration which is produced in a semisynthetic way starting 
from soya deodorizer distillates, a waste stream from the production of the corresponding 
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vegetable oil.
[79]
 However, higher quantities of (R,R,R)-α-tocopherol ((R,R,R)-4.1) are not 
accessible due to insufficient amounts of natural source starting material.
[85]
 
Over the last years, extensive efforts to accomplish an efficient and stereoselective synthesis 
of (R,R,R)-α-tocopherol and its building blocks were made. These approaches were based on 
auxiliary-controlled reactions, the use of starting material from the chiral pool, optical 
resolution of the product, desymmetrization and asymmetric bio- and transition metal-
catalysis.
[84, 86]
 However, so far all these procedures do not fulfill the demands required for a 
large scale industrial production, as they suffer from complexity, limited space-time yield or 
high E-factors.
[79]
 
An alternative approach could be represented by a modification of the highly optimized 
industrial route to (all-rac)-α-tocopherol ((all-rac)-4.1) in order to allow for the 
enantioselective generation of the stereogenic centers. This route can be mainly divided in 3 
parts: 1) the final condensation reaction, 2) the formation of the aromatic building block 4.9 
and 3) the preparation of the isopytol side chain 4.10 (scheme 4.1). 
 
 
Scheme 4.1: Strategic disconnection in the industrial synthesis of (all-rac)-α-tocopherol ((all-rac)-4.1). 
 
With the application of asymmetric hydrogenation significant progress has been made in the 
stereoselective generation of the stereogenic centers in the phytyl tail 4.10. Based on the 
seminal work by Noyori and co-workers, Roche published on the hydrogenation of the side 
chain mimic (R,E)-3,7,11-trimethyldodec-2-en-1-ol ((R)-4.11) by the use of ((S)-p-Tol-
BINAP)Ru(O2CCF3)2. The reaction was performed with a substrate to catalyst ratio of 50000, 
reaching 99% conversion and an enantiomeric excess of 98% (C3) within only one hour of 
reaction time (scheme 4.2, A).
[87]
 Catalysts of this type usually require a coordinating group in 
close proximity to the target double bond, as in the case of the alcohol (R)-4.11. Therefore, an 
approach based on the use of ruthenium catalysts would imply a stepwise construction of the 
side chain with two asymmetric hydrogenation steps to be carried out. In addition, the 
required prochiral allylic alcohols are not direct intermediates in the industrially applied 
syntheses. 
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Scheme 4.2: Strategies to apply asymmetric hydrogenation to the generation of an enantiopure side chain. 
 
In contrast to ruthenium-based catalysts, N,P ligand-based iridium complexes emerged as 
efficient catalysts for the asymmetric hydrogenation of unfunctionalized double bonds. 
Taking advantage from this property of such iridium-catalysts, DSM Nutritional Products and 
the Pfaltz research group were able to obtain almost exclusively (all-R)--tocopheryl acetate 
((R,R,R)-4.14) by the application of a chiral pyridyl phosphinite-based iridium catalyst. The 
hydrogenation of the precursor (R)-4.13 resulted in the introduction of two stereogenic centers 
and the reduction of three double bonds in a single reaction step (scheme 4.2, B).
[53c]
 In a later 
publication the high efficiency of this catalyst for the generation of the desired stereoisomer in 
high enantiomeric purity from different geometric isomers of farnesol was also successfully 
demonstrated.
[53b]
  
As previously mentioned, the synthesis of the tocopherol side-chain is an important part in the 
production of vitamin E and is conducted by using various approaches in industry. In 
principle, these strategies are mainly based on a combination of C3 and C2 elongations 
starting from acetone or citral. Specific reaction types involved therein are ethynylation of 
ketones, Lindlar type hydrogenations, aldol condensations, Prins reaction and Saucy–Marbet 
or Carroll reactions. The latter two result in the formation of prochiral γ,δ-unsaturated ketones. 
These intermediates are potential targets for the selective introduction of the stereogenic 
centers embedded in the tocopherol side chain (scheme 4.3). 
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Scheme 4.3: Saucy–Marbet and Carroll reaction applied for the C3-elongation steps in the synthesis of 
tocopherol. 
 
Therefore, the applicability of chiral Ir-N,P ligand complexes to the hydrogenation of these 
intermediates was investigated in cooperation with DSM Nutritional Products and results are 
described in this chapter. 
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4.2 General information about the hydrogenation project 
4.2.1 Supply of substrates 
The substrates investigated within this chapter were all provided by DSM and consist of γ,δ-
unsaturated ketones with different chains lengths, different double bond geometries and 
different degrees of saturation (figure 4.4). 
 
4.2.2 Analysis of the hydrogenation products  
The conversion of the reactions was determined by GC using an achiral stationary phase. In 
the majority of the experiments the conversion to the fully reduced hydrogenation product or 
the amount of the remaining starting material is given.  
At the outset of this project, the amount of the different stereoisomers formed was determined 
by GC using a chiral stationary phase. For this purpose, the fully reduced farnesylacetone was 
derivatized with L- or D-diisopropyl tartrate (L-4.17 and D-4.17) and analyzed following the 
literature procedure reported by A. Knierzinger et al.
[88]
 This allowed for the determination of 
the major stereoisomer by using the corresponding tartrate for derivatization. Full assignment 
of all four stereoisomers can be done by an additional derivatization and analysis using the 
tartrate in its opposite configuration (scheme 4.4), but due to the time-consuming analysis of 
the selectivity the focus was laid on the determination of the amount of the major 
stereoisomer which gave sufficient data for the identification of the most selective catalysts. 
The selectivity was not determined for reactions showing incomplete conversion, as in this 
case, up to 20 different species could be formed and as a consequence overlapping signals 
were observed in the gas chromatogram. In these cases an accurate determination of the 
selectivity was therefore impossible. 
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Scheme 4.4: Analytic method for the determination of the selectivity of the reaction (GC traces incorporated 
from Knierzinger et al.
[88]
). 
 
During the course of this cooperation improved analytical methods for the direct 
determination of the different stereoisomers were developed by DSM.
[89]
 When the specific 
amount of all four stereoisomers was assigned, the selectivity was determined at DSM. Again, 
the selectivity could not be determined for reactions showing incomplete conversion. 
 
4.3 Optimization of the reaction conditions 
4.3.1 Catalyst screening 
The hydrogenation of (5E,9E) farnesylacetone (4.15), which from an industrial perspective is 
the most relevant and therefore most important intermediate for the synthesis of vitamin E, 
served as a starting point for this study. First the most selective catalysts for the 
hydrogenation of this substrate had to be identified and then used for the optimization of the 
reaction conditions. Therefore, different catalyst scaffolds were investigated and a detailed 
study of the most promising ones was conducted. The catalysts were divided in non-pyridine 
and pyridine-based complexes, to allow for a systematic classification. Hydrogenations were 
conducted under reaction conditions which previously emerged as efficient for many different 
substrate classes: 1.0 mol% catalyst loading, 50 bar H2 pressure, CH2Cl2 (0.2 M), room 
temperature, 14 hours (see scheme 4.5). 
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Scheme 4.5: General reaction conditions applied to the catalyst screening of (5E,9E)-farnesylacetone (4.15). 
 
4.3.1.1 Screening of non-pyridine-based catalysts 
 
Table 4.1: Non-pyridine-based catalyst in the hydrogenation of (5E,9E)-farnesylacetone (4.15) (reaction 
conditions: 0.2 mmol substrate, 1.0 mol% catalyst loading, 50 bar H2, CH2Cl2 (0.2 M), RT, 14 h). 
 
For the majority of the catalysts tested complete conversion to the fully reduced substrate 4.16 
was not observed. Only four catalysts (4.20, 4.28, 4.29, 4.31) provided full conversion, but in 
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each case only low selectivity was observed (table 4.1). Catalysts 4.28 and 4.29 bearing a 
phosphinite moiety showed even inverted selectivity for the preferred stereoisomer. 
 
4.3.1.2 Screening of pyridine-based catalysts 
 
Table 4.2: Pyridine-based catalysts in the hydrogenation of (5E,9E)-farnesylacetone (reaction conditions: 
0.2 mmol substrate, 1.0 mol% catalyst loading, 50 bar H2, CH2Cl2 (0.2 M), RT, 14 h). 
 
With all the catalysts of this series bearing a phosphine moiety incomplete conversion to the 
fully reduced product was observed. Only catalyst 4.35, featuring a phosphinite group, 
afforded full conversion to ketone 4.16 but low selectivity (table 4.2). 
 
 
  
Table 4.3: Bicylcic pyridine-based catalyst in the hydrogenation of (5E,9E)-farnesylacetone (reaction conditions: 
0.2 mmol substrate, 1.0 mol% catalyst loading, 50 bar H2, CH2Cl2 (0.2 M), RT, 14 h). 
 
Pyridine-based catalysts bearing an additional aliphatic ring showed full conversion in all 
cases. Methyl substitution at the 2-position revealed a selectivity of 88.3% for the major 
stereoisomer and showed the significant impact of this position on the selectivity (table 4.3). 
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Table 4.4: Bicylcic, phenyl substituted pyridine-based catalysts in the hydrogenation of (5E,9E)-farnesylacetone; 
reaction conditions: 0.2 mmol substrate, 1.0 mol% catalyst loading, 50 bar H2, CH2Cl2 (0.2 M), RT, 14 h). 
Complete conversion was obtained for all entries. 
 
All catalysts of this series, bearing a phenyl substituent at the 2-position of the pyridine 
moiety, reached complete conversion to the fully reduced substrate and revealed good to 
excellent selectivities. There was no general trend observed for the ring size in the backbone 
of the ligand scaffold and the phosphinite moiety. The more rigid catalyst scaffolds, bearing 
an aliphatic five-membered ring, seemed to be less sensitive to structural changes in the 
phosphinite unit. The replacement of the phosphinite by a carbene resulted in incomplete 
conversion at 1.0 mol% catalyst loading and significantly reduced selectivity at 2.0 mol% 
catalyst loading. Complex 4.45 emerged as the most selective catalyst within this series, 
enabling the formation of 96.6% of the desired stereoisomer (table 4.4).  
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Table 4.5: Bicylcic pyridine-based catalyst with large aryl substituents in the hydrogenation of (5E,9E)-
farnesylacetone (reaction conditions: 0.2 mmol substrate, 1.0 mol% catalyst loading, 50 bar H2, CH2Cl2 (0.2 M), 
RT, 14 h). Complete conversion was obtained for all entries. 
 
Next, the influence of larger aryl substituents at the 2-position of the pyridine moiety was 
studied. Complexes of this type had already emerged as efficient catalysts in the 
hydrogenation of (2E,6E)-farnesol (see chapter 2).
[90]
 Also in the hydrogenation of (5E,9E)-
farnesylacetone 4.15 these catalysts were capable of achieving higher selectivities compared 
to their analogs bearing the phenyl substituent. Especially the anthracenyl derivatives 
provided extraordinarily high selectivities. In this case, 97.4% and 98.5% of the major 
stereoisomer were obtained with catalyst 4.52 and 4.53 respectively (table 4.5). 
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4.3.1.3 Catalyst loading 
 
Although catalysts 4.52 and 4.53 showed superior selectivity than catalyst 4.45, the 
optimization of the reaction conditions was conducted with catalyst 4.45. Given that the 
synthesis of this complex is better investigated and thus can be achieved more efficiently. 
Moreover, since the price of the catalyst plays an important role towards a possible 
application, the use of catalyst 4.45 is preferred over catalysts 4.52 and 4.53. In addition, due 
to their sterically more congested environment around the metal center, in general lower 
reactivity was observed for these iridium complexes when compared to catalyst 4.45 (see 
chapter 2 and 3). 
 
Table 4.6: Hydrogenation of (5E,9E)-farnesylacetone (4.15): influence of catalyst loading. 
 
Entry Cat 
Cat loading  
[mol%]  
4.16 
[%]
[a]
 
Stereoisomers [%]
[b]
  
1 
 
1.0 >99 
96.6 (S,S) 
1.2 [(R,R)+(S,R)] 
2.2 (R,S) 
2 0.5 >99 
96.7 (S,S) 
0.8 [(R,R)+(S,R)] 
2.5 (R,S) 
3 0.2 >99 
95.2 (S,S) 
1.0 [(R,R)+(S,R)] 
3.8 (R,S) 
4 0.1 28 n.d. 
[a] Determined by GC analysis on an achiral stationary phase; [b] Determined by GC analysis after 
derivatization. 
 
The systematic reduction of the catalyst loading revealed that at 0.2 mol% still complete 
reduction was obtained. However, a small erosion of stereoselectivity was observed at 
reduced catalyst loading (table 4.6). 
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4.3.2 Solvent screening  
4.3.2.1 Screening of different solvents 
Table 4.7: Hydrogenation of (5E,9E)-farnesylacetone (4.15): solvent screening. 
 
Entry Cat  Cat loading 
[mol%]  Solvent  
4.16 
[%]
[a]
  
Stereoisomers 
[%]
[b]
  
1 
 
0.2 
propylene 
carbonate 
1 n.d. 
2 0.2 chlorobenzene 1 n.d. 
3 0.2 toluene 1 n.d. 
4 0.5 CF3CH2OH >99 
97.8 (S,S) 
0.9 [(R,R)+(S,R)] 
1.3 (R,S) 
5 0.2 CF3CH2OH 47 n.d. 
6 1 (CF3)2CHOH >99 
98.1 (S,S) 
0.7 [(R,R)+(S,R)] 
1.2 (R,S) 
7 0.1 (CF3)2CHOH 76 n.d. 
8 1 C6F6 >99 
97.1 (S,S) 
0.9 [(R,R)+(S,R)] 
2.0 (R,S) 
9 0.2 C6F6 18 n.d. 
10 1 fluorobenzene >99 
95.9 (S,S) 
1.1 [(R,R)+(S,R)] 
3.0 (R,S) 
11 0.2 fluorobenzene 3 n.d. 
12 1.0 trifluorotoluene >99 
95.7 (S,S) 
1.2 [(R,R)+(S,R)] 
3.1 (R,S) 
13 0.2 trifluorotoluene 1 n.d. 
[a] Determined by GC analysis on an achiral stationary phase; [b] Determined by GC analysis after 
derivatization. 
 
In the next step the applicability of different solvents was tested. Solvents such as propylene 
carbonate, chlorobenzene and toluene, which have been successfully applied in the 
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hydrogenation of other substrates, showed significantly reduced conversion compared to 
CH2Cl2 at 0.2 mol% catalyst loading. Fluorinated solvents such as CF3CH2OH (TFE) or 
(CF3)2CHOH (HFIP) showed full conversion with up to 98.1% selectivity for the major 
stereoisomer (table 4.7, entry 6). HFIP showed even higher TONs than CH2Cl2 (table 4.7, 
entry 7 vs. table 4.1, entry 4). Although these fluorinated solvents showed superior selectivity, 
their application to an industrial process poses a significant challenge due to their high price. 
For this reason only TFE can be considered as potential solvent and therefore different 
mixtures of CH2Cl2 and TFE were tested for their applicability in the hydrogenation of 
(5E,9E)-farnesylacetone (4.15) with the goal to achieve the selectivity provided by TFE and 
the TONs obtained in CH2Cl2. 
 
Table 4.8: Hydrogenation of (5E,9E)-farnesylacetone (4.15): screening of solvent mixtures. 
 
Entry Cat  Solvent  Ratio  4.16 [%][a] 
1 
 
CH2Cl2:CF3CH2OH 99:1 91 
2 CH2Cl2:CF3CH2OH 19:1 99 
3 CH2Cl2:CF3CH2OH 7:1 98 
4 CH2Cl2:CF3CH2OH 3:1 >99 
[a] Determined by GC analysis on an achiral stationary phase. 
 
The combination of CH2Cl2 and TFE proved inefficient in the hydrogenation of (5E,9E)-
farnesylacetone (4.15). Full conversion was only observed at a ratio of 3:1 with the use 
0.5 mol% catalyst loading (table 4.8, entry 4). However, at this catalyst loading both pure 
CH2Cl2 and TFE previously showed complete conversion to 6,10,14-trimethylpentadecan-2-
one (4.16). Due to the significantly reduced reactivity, the selectivity of the reactions 
conducted in the solvent mixtures was not determined. 
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4.3.3 Kinetic studies 
Table 4.9: Hydrogenation of (5E,9E)-farnesylacetone (4.15): kinetic study. 
 
Entry  Solvent  
Time 
[min]  
4.16 
[%]
[a]
 
Entry  Solvent  
Time 
[min]  
4.16 
[%]
[a]
 
1  CH2Cl2  40  27  5 CF3CH2OH  40  96  
2  CH2Cl2 120  51  6 CF3CH2OH  120  >99 
3  CH2Cl2 240  70  7 CF3CH2OH  240  >99  
4  CH2Cl2  360  81  8 CF3CH2OH  360  >99 
5  CH2Cl2 960  >99  10  CF3CH2OH  960  >99 
[a] Determined by GC analysis on an achiral stationary phase. 
Figure 4.2: Plot of the formation of 4.16 vs. time. 
 
To explore the differences between TFE and CH2Cl2, the reactivity of catalyst 4.45 in these 
two solvents was studied. After evaluating of the data obtained, it became clear that TFE 
provides a much faster reaction rate compared to CH2Cl2 (table 4.9 and figure 4.2).  
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4.4 Tris(perfluorophenyl)borane as additive in the hydrogenation 
 
Conversion is an important parameter for the application of Ir-catalysts to the hydrogenation 
of (5E,9E)-farnesylacetone (4.15). To further improve this parameter the influence of 
tris(perfluorophenyl)borane (4.55) and its properties as additive to quench nucleophilic 
impurities, like water, in the reaction mixture was investigated. The reaction of this borane 
with a nucleophile should result in the formation of negatively charged boron species with 
similar properties to the BArF counterion. 
 
Table 4.10: Hydrogenation of (5E,9E)-farnesylacetone (4.15) in the presence of tris(perfluorophenyl)borane 
(4.55). 
 
Entry [Ir-cat.] Additive  Additive 
[mol%]  
4.16 
[%]
[a]
  
1 
 
none 0 <1[b] 
2 (C6F5)3B  1  2 
3 (C6F5)3B 2.5  29 
4 (C6F5)3B 5  51 
[a] Determined by GC analysis on an achiral stationary phase; [b] Partially hydrogenated compounds were 
observed. 
 
Tris(perfluorophenyl)borane (4.55) showed excellent behavior to increase the TONs of the 
catalyst. In fact, in the presence of 5 mol% of tris(perfluorophenyl)borane the formation of 
51% of the fully reduced farnesylacetone was observed. In contrast, the control experiment 
without additive showed only traces of the fully reduced product 4.16 (table 4.10). One could 
assume that further increasing the amount of tris(perfluorophenyl)borane could result in full 
conversion, but its high price limits the amount of additive that can be employed for this 
reaction.  
To further study the applicability of tris(perfluorophenyl)borane as additive, the selectivity of 
the hydrogenation in the presence of this species was determined (scheme 4.11). 
 
ASYMMETRIC HYDROGENATION OF TOCOPHEROL SIDE CHAIN PRECURSORS  CHAPTER 4 
98 
Table 4.11: Hydrogenation of (5E,9E)-farnesylacetone (4.15) in the presence of (C6F5)3B.  
[a] Determined by GC analysis on an achiral stationary phase; [b] Determined by DSM. 
 
The addition of tris(perfluorophenyl)borane (4.55) led to lower selectivities. However, still 
93% of the main stereoisomer was formed compared to 95.7% for the reaction without the 
additive (table 4.11). Interestingly, the erosion of selectivity took place exclusively at C6. This 
stereogenic center is generated by the hydrogenation of the double bond, which is in the 
closest proximity to the ketone and at this position the strongest interaction between the 
substrate and the Lewis base is assumed. 
To analyze the role of tris(perfluorophenyl)borane, 
11
B NMR-experiments were carried out to 
better understand how the borane 4.55 interacts with the other species in the reaction mixture. 
The following samples were prepared under inert conditions inside a glove box and 
subsequently analyzed by NMR spectroscopy (figure 4.3): 1. tris(perfluorophenyl)borane in 
CD2Cl2 (red); 2. tris(perfluorophenyl)borane, (5E,9E)-farnesylacetone (20 eq.) in CD2Cl2 
(green); 3. tris(perfluorophenyl)borane, (5E,9E)-farnesylacetone (20 eq.), iridium catalyst 
4.45 (0.016 eq.) in CD2Cl2 (blue); 4. tris(perfluorophenyl)borane, iridium catalyst 4.45 
(0.016 eq.), 50 bar H2 then 1 bar N2 in CD2Cl2 (purple).  
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Figure 4.3: 
11
B NMR spectra of different reaction mixtures using (C6F5)3B as additive.  
 
The 
11
B NMR spectrum, of tris(perfluorophenyl)borane showed a broad singlet at 41.3 ppm 
(red). The addition of (5E,9E)-farnesylacetone (4.15) resulted in the formation of probably 
two new species showing two broad signals at 2.3 and 2.8 ppm (green). These values of 
chemical shifts are typical of tetravalent ate complexes between the borane and the ketone or 
other nucleophilic impurities, such as water. After addition of the catalyst, the reaction 
mixture was stirred for 14 h under 50 bar hydrogen pressure. A new signal at 27.0 ppm 
showed the formation of a new borane species (blue). This signal also appeared in the absence 
of the substrate 4.15 (purple) and therefore might belong to a species which is generated from 
a catalytic reaction of the iridium complex with tris(perfluorophenyl)borane. The formation of 
this species deriving from a stoichiometric reaction of tris(perfluorophenyl)borane with the 
iridium complex can be excluded based on the ratio of borane to catalyst (62.5:1) and the 
comparable high quantity of this newly formed peak. The nature of this species could not be 
identified. The 
11
B-signal for the counterion of the catalyst appeared as small spike at 
6.6 ppm. 
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The main conclusions drawn from this and additional experiments on the effect of 
tris(perfluorophenyl)borane are:  
1. 1H NMR, 13C NMR and GC-MS showed neither polymerization product nor formation 
of the corresponding alcohol which might occur as a result of the activation of the 
ketone by the borane species. 
2. The fact that in each 11B NMR spectra free tris(perfluorophenyl)borane was observed, 
indicates that tris(perfluorophenyl)borane is probably not irreversible bond to the 
ketone and therefore not entirely quenched in the course of the reaction. 
3. No borohydride was observed which could be generated by hydride exchange with the 
activated catalyst. An additional hydride is necessary for the formation of the inactive 
trinuclear iridium hydride complex observed for PHOX complexes and is assumed as 
the main deactivation pathway for these catalysts.
[25]
 
In addition, the hydrogenation conducted for the NMR experiment showed complete 
conversion applying identical reaction conditions as described before (5.0 mol% boron 
species, 0.08 mol% catalyst loading, figure 4.3 (blue)). In the previous experiment 51% 
conversion to the fully reduced product 4.16 was observed. The main difference between 
these experiments is that in the case of full conversion the reaction mixture was stirred longer 
before applying hydrogen pressure. 
Therefore several experiments were conducted to disclose the optimal order of addition and 
the influence on the different reaction components. The different reaction mixtures were 
stirred for 24 h at room temperature under N2 atmosphere in the glove box. Then 50 bar 
hydrogen pressure were applied. The following reactions were carried out at 0.03 mol% 
catalyst loading to further reduce the amount of catalyst. 
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Table 4.12: Hydrogenation of (5E,9E)-farnesylacetone (4.15) in the presence of tris(perfluorophenyl)borane 
(4.55). 
[a] Determined by GC analysis on an achiral stationary phase; [b] TONs were calculated based on the number of 
C=C bonds reduced per catalyst molecule; [c] Partially hydrogenated compounds were observed. 
 
The way how tris(perfluorophenyl)borane was applied as additive in the hydrogenation of 
(5E,9E)-farnesylacetone had a significant influence on the TONs (table 4.12). If the substrate 
was stirred for 24 h in the presence of tris(perfluorophenyl)borane followed by hydrogenation, 
the highest TON value was achieved. In contrast, if the borane was added directly prior to the 
hydrogenation significantly lower TONs were obtained.  
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4.5 Hydrogenation of γ,δ-unsaturated ketones 
 
To further demonstrate the applicability of iridium-based catalysts in the hydrogenation of 
intermediates in the synthesis of the tocopherol side chain, several γδ-unsaturated ketones 
were tested using the best catalysts identified from the previous screening (figure 4.4). 
Additionally, the determination of the selectivity was in this case performed by DSM. This 
method allowed for the assignment of all four stereoisomers. The entries in the following 
tables are arranged by selectivity in decreasing order. 
 
Figure 4.4: -Unsaturated ketones screened using selected iridium catalysts. 
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4.5.1 Hydrogenations of (5E,9E)-farnesylacetone  
 
Table 4.13: Hydrogenation of (5E,9E)-farnesylacetone (4.15). 
 
Entry  
Cat/ 
(config)  
Solvent  
Cat 
loading  
[mol%]  
4.16 
[%]
[a]
  
(6R, 
10S) 
[%]
[b]
 
(6S, 
10R)  
[%]
[b]
  
(6R, 
10R)  
[%]
[b]
 
(6S, 
10S) 
[%]
[b]
  
ee 
[%]
[c]
 
dr  
1 4.52/(R) TFE 1.0 >99 0.8 0.00 0.1 99.1 >99 124:1 
2  4.52/(R)  HFIP  1.0  >99  0.7  0.4  0.0  98.9  >99  94:1  
3  4.53/(S)  TFE  1.0  >99  0.5  1.6  97.9  0.0  >99  48:1  
4  4.45/(R)  HFIP  1.0  >99  1.7  1.1  0.00  97.2  >99  34:1  
5  4.45/(R)  TFE  1.0  >99  1.7  1.4  0.0  96.9  >99  31:1  
6  4.45/(R)  TFE  0.5  >99  1.8  1.6  0.0  96.6  >99  29:1  
7  4.53/(S)  HFIP  1.0  >99  2.0  1.6  96.4  0.0  >99  27:1  
8  4.45/(R)  CH2Cl2  1.0  >99  3.0  1.4  0.0  95.7  >99  22:1  
9  4.45/(R)  CH2Cl2  0.5  >99  2.8  1.5  0.00  95.7  >99  22:1  
[a] Determined by GC analysis on an achiral stationary phase; [b] Determined by DSM; [c] Enantiomeric excess 
of the major stereoisomer. 
 
Catalyst 4.52 and TFE emerged as the most selective combination for the hydrogenation of 
(5E,9E)-farnesylacetone (4.15). In this case almost exclusively the desired stereoisomer was 
formed (99.1%) with a dr of 124:1 (table 4.13, entry 1). For catalyst 4.45 slightly higher 
selectivity was obtained in HFIP compared to TFE (entries 4 and 5). In addition, a slight 
erosion of selectivity was observed when reducing the catalyst loading for catalyst 4.45 (entry 
6). 
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4.5.2 Hydrogenation of (5Z,9Z)-farnesylacetone  
 
Table 4.14: Hydrogenation of (5Z,9Z)-farnesylacetone (4.59). 
 
Entry  
Cat/ 
(config)  
Solvent  
Cat 
loading  
[mol%]  
4.16 
[%]
[a]
  
(6R, 
10S) 
[%]
[b]
 
(6S, 
10R) 
[%]
[b]
 
(6R, 
10R) 
[%]
[b]
 
(6S, 
10S) 
[%]
[b]
 
ee 
[%]
[c]
 
dr 
1  4.52/(R)  TFE  1.0  >99  1.8 3.1 95.1 0.0 >99 19:1 
2  4.45/(R)  TFE  1.0  >99  2.2 3.4 94.4 0.0 >99 17:1 
3  4.45/(R)  TFE  0.5  >99  2.4 3.3 94.3 0.0 >99 17:1 
4  4.45/(R)  CH2Cl2  1.0  >99  2.4 3.4 94.2 0.0 >99 16:1 
5  4.52  CH2Cl2  1.0  70  n.d. n.d. n.d. n.d. -- -- 
6  4.45  CH2Cl2  0.5  41  n.d. n.d. n.d. n.d. -- -- 
7  4.53  CH2Cl2  1.0  7  n.d. n.d. n.d. n.d. -- -- 
[a] Determined by GC analysis on an achiral stationary phase; [b] Determined by DMS; [c] Enantiomeric excess 
of the major stereoisomer. 
 
The hydrogenation of (5Z,9Z)-farnesylacetone showed a different reactivity compared to 
(5E,9E)-farnesylacetone. In the case of the opposite geometry of the C=C double bonds TFE 
proved to be superior to CH2Cl2 in terms of selectivity and also reactivity. The best selectivity 
was obtained with catalyst 4.52 in TFE, affording the desired stereoisomer in 95.1% (table 
4.14, entry 1). In general, the selectivities and reactivities were lower than those obtained with 
(5E,9E)-farnesylacetone (4.15). 
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4.5.3 Hydrogenation of (5E,10R)-tetrahydrofarnesylacetone 
 
Table 4.15: Hydrogenation of (5E,10R)-tetrahydrofarnesylacetone (4.56). 
 
Entry  Cat/ 
(config)  Solvent  
Cat 
loading  
[mol%]  
Conv. 
[%]
[a]
 
(6R, 
10S) 
[%]
[b]
 
(6S, 
10R) 
[%]
[b]
 
(6R, 
10R) 
[%]
[b]
 
(6S, 
10S) 
[%]
[b]
 
ratio (C6)  
1  4.45/(R)  TFE  0.5  >99  0.0  97.1  1.5  1.4  98.5:1.5  
2  4.45/(S)  TFE  1.0  >99  1.3  1.7  97.0  0.0  98.3:1.7  
3  4.52/(R)  TFE  1.0  >99  0.0  97.0  0.9  2.1  99.1:0.9  
4 4.52/(S)  CH2Cl2  1.0  >99  1.3  1.8  96.9  0.0  98.2:1.8  
5  4.45/(R)  TFE  1.0  >99  0.0  96.1  1.9  2.0  98.1:1.9  
6  4.45/(S)  CH2Cl2  1.0  >99  1.6  2.5  96.0  0.0  97.5:2.5  
7  4.45/(R)  CH2Cl2  0.5  >99  0.0  95.8  2.7  1.5  97.3:2.7  
8  4.45/(R)  CH2Cl2  1.0  >99  0.0  95.6  2.9  1.5  97.1:2.9  
[a] Determined by GC analysis on an achiral stationary phase; [b] Determined by DSM. 
 
A similar order of selectivity at C6 was observed in the hydrogenation (5E,10R)-
tetrahydrofarnesylacetone compared with (5E,9E)-farnesylacetone. TFE in combination with 
catalyst 4.52 provided a ratio of 99.1:0.9 on C6 (table 4.15, entry 3). Furthermore, no 
significant influence of the stereogenic center at C10 on the selectivity of the hydrogenation 
was observed (entry 1 vs. 2 and entry 6 vs. 8). 
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4.5.4 Hydrogenation (5E)-dihydrogeranylacetone 
 
Table 4.16: Hydrogenation of (5E)-dihydrogeranylacetone (4.61). 
 
Entry  
Cat/ 
(config)  
Solvent  
Cat loading  
[mol%]  
Conv. 
[%]
[a]
 
(6R) [%]
[b]
 (6S) [%]
[b]
 ee [%]  
1 4.52/(R) TFE 1.0 >99 0.7 99.3 99 (S) 
2 4.53/(S) CH2Cl2 1.0 >99 98.9 1.1 98 (R) 
3 4.45/(R) TFE 1.0 >99 98.6 1.4 97 (S) 
4 4.52/(R) CH2Cl2 1.0 >99 1.4 98.6 97 (S) 
5 4.45/(R) CH2Cl2 1.0 >99 2.3 97.7 95 (S) 
6 4.45/(R) TFE 0.5 >99 3.6 96.4 93 (S) 
7 4.45/(R) CH2Cl2 0.5 >99 6.7 93.2 87 (S) 
[a] Determined by GC analysis on an achiral stationary phase; [b] Determined by DSM. 
 
(5E)-Dihydrogeranylacetone (4.61)is one of the side chain precursors which would allow for a 
stepwise introduction of the stereogenic centers. In this series excellent selectivities were 
obtained, especially if the presence of the (Z)-isomer (0.25%) in the starting material is taken 
into account. As for the previous substrates, the combination of catalyst 4.52 and TFE 
afforded the highest enantiomeric excess with 99% (table 4.16, entry 1). Catalyst 4.53 
emerged as slightly superior to catalyst 4.52 when the reaction was performed in CH2Cl2 
(entry 2). 
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4.5.5 Hydrogenation of (5E,9E)-dihydrofarnesylacetone 
 
Table 4.17: Hydrogenation of (5E,9E)-dihydrofarnesylacetone (4.57). 
 
Entry  
Cat/ 
(config)  
Solvent  
4.16 
[%]
[a]
  
(6R, 
10S) 
[%]
[b]
 
(6S, 
10R)  
[%]
[b]
 
(6R, 
10R)  
[%]
[b]
 
(6S, 
10S) 
[%]
[b]
 
ee [%]
[c]
 dr  
1 4.52/(R) TFE >99 0.0 4.4 0.0 95.6 >99 22:1 
2 4.52/(R) CH2Cl2 >99 1.0 4.4 0.0 94.6 >99 18:1 
3 4.53/(S) CH2Cl2 >99 4.6 0.9 94.5 0.0 >99 17:1 
4 4.45/(R) TFE >99 1.1 5.5 0.0 93.4 >99 14:1 
5 4.45/(R) CH2Cl2 >99 2.3 5.5 0.0 92.2 >99 12:1 
[a] Determined by GC analysis on an achiral stationary phase; [b] Determined by DSM; [c] Enantiomeric excess 
of the major stereoisomer. 
 
In the hydrogenation of (5E,9E)-dihydrofarnesylacetone (4.57) in general lower selectivities 
were observed compared to (5E,9E)-farnesylacetone (4.15). Catalyst 4.52 showed the best 
result in TFE with 95.6% selectivity for the major stereoisomer. Catalysts 4.52 and 4.53 
performed almost similarly in CH2Cl2 (table 4.17, entry 2 and 3). 
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4.5.6 Hydrogenation of (5Z,9Z)-dihydrofarnesylacetone 
 
Table 4.18: Hydrogenation of (5Z,9Z)-dihydrofarnesylacetone (4.58). 
 
Entry  
Cat/ 
(config)  
Solvent  
Cat 
loading  
[mol%]  
4.16 
[%]
[a]
 
(6R, 
10S) 
[%]
[b]
  
(6S, 
10R)  
[%]
[b]
  
(6R, 
10R)  
[%]
[b]
  
(6S, 
10S) 
[%]
[b]
  
ee 
[%]
[c]
 
dr  
1  4.52/(R)  TFE 1.0 >99  1.3  1.6  97.2  0.00  >99  35:1  
2  4.53/(S)  TFE 1.0 >99  1.6  1.3  0.00  97.1  >99  33:1  
3  4.52/(R)  CH2Cl2 1.0 >99  1.2  2.2  96.6  0.00  >99  28:1  
4  4.53/(S)  CH2Cl2 1.0 >99  2.2  1.3  0.0  96.5  >99  28:1  
5  4.45/(R)  TFE 0.5 >99  1.7  2.0  96.3  0.0  >99  26:1  
6  4.45/(R)  TFE 1.0 >99  1.7  2.0  96.3 0.0  >99  26:1  
7  4.45/(R)  CH2Cl2 1.0 >99  1.8  2.2  96.0  0.0  >99  24:1  
8  4.45/(R)  CH2Cl2 0.5 >99  1.8  2.4  95.8  0.0  >99  23:1  
9  4.45/(R)  TFE  0.2  81  n.d. n.d. n.d. n.d. -- -- 
10  4.45/(R)  CH2Cl2 0.2 39 n.d. n.d. n.d. n.d. -- -- 
[a] Determined by GC analysis on an achiral stationary phase; [b] Determined DSM; [c] Enantiomeric excess of 
the major stereoisomer. 
 
Comparing the hydrogenation of (5Z,9Z)-dihydrofarnesylacetone 4.58 and (5Z,9Z)-
farnesylacetone 4.59, almost identical values were obtained. Catalyst 4.52 in TFE emerged as 
the most selective combination with 97.2% for the desired stereoisomer (table 4.18, entry 1). 
In addition, higher conversions to the fully reduced substrate could be obtained by the use of 
the partially saturated substrate dihydrofarnesylacetone 4.58 (table 4.18, entry 8 vs. table 4.14 
entry, 6). 
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4.5.7 Hydrogenation of (5E)-geranylacetone 
 
Table 4.19: Hydrogenation of (5E)-geranylacetone (4.60). 
 
 
Entry Cat/ 
(config.) 4.62 [%]
[a]
 (S) [%]
[b]
 (R) [%]
[b]
 
1 
 
>99  >98%  <2%  
2 
 
>99 <2%  >98%  
[a] Determined by GC analysis on an achiral stationary phase; [b] Determined by DSM. 
 
In the hydrogenation of (5E)-geranylacetone (4.60), both catalysts tested provided excellent 
selectivity and full conversion using 1.0 mol% catalyst loading in CH2Cl2 (table 4.19). 
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4.6 Hydrogenation of γ,δ-unsaturated ketones using a di-o-
tolylphosphinite-tert-butyl-simplePHOX-based catalyst 
 
In the course of the screening, the simplePHOX-based catalyst 4.20 achieved excellent 
selectivity at the C6 position in the hydrogenation of (5E,9E)-dihydrofarnesylacetone (4.57) 
(table 4.20, entry 1). This catalyst is significantly easier to synthesize than the catalyst 
scaffold applied before. Therefore, additional experiments were conducted to test the 
applicability of a stepwise hydrogenation/chain elongation/hydrogenation sequence by the use 
of this catalyst. 
 
Table 4.20: Hydrogenations of (5E,9E)-dihydrofarnesylacetone (4.57) using di-o-tolylphosphinit-tert-butyl-
simplePHOX (4.20). 
 
 
Entry  Solvent  
Cat 
loading 
[mol%]  
4.16 
[%]
[a]
  
(6R, 
10S) 
[%]
[b]
  
(6S, 
10R)  
[%]
[b]
  
(6R, 
10R)  
[%]
[b]
  
(6S, 
10S) 
[%]
[b]
  
selectivity 
(C6)  
dr  
1  CH2Cl2  1.0  >99  1.2  26.2  0.4  72.2  59:1  2.6:1  
2  TFE  1.0  >99  1.3  36.8  0.7  61.2  49:1  1.6:1  
3  TFE  0.5  83  n.d. n.d. n.d. n.d. -- -- 
4  CH2Cl2  0.5  8  n.d. n.d. n.d. n.d. -- -- 
5  TFE  0.2  4  n.d. n.d. n.d. n.d. -- -- 
6  CH2Cl2  0.2  <1
[c] 
 n.d. n.d. n.d. n.d. -- -- 
[a] Determined by GC analysis on an achiral stationary phase; [b] Determined by DSM, [c] Partially 
hydrogenated compounds were observed. 
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The hydrogenations with the simplePHOX-based catalyst 4.20 showed inverse behavior 
compared to the pyridine-based catalyst investigated before. In CH2Cl2 a higher selectivity 
and in TFE higher conversion were observed. In general, the reactivity was lower, leading to 
incomplete conversion already at 0.5 mol% catalyst loading (table 4.20, entry 4). Taking into 
account that in this hydrogenation only one double bond is reduced, the catalyst is more than 
three times less reactive. Therefore derivatives of this catalyst were tested in order to find a 
more active analog. 
 
Table 4.21: Hydrogenations of (5E,9E)-dihydrofarnesylacetone (4.56) using simplePHOX derivatives. 
 
Entry Cat 
4.16 
[%]
[a]
 
(6R, 
10S) 
[%]
[b]
 
(6S, 
10R) 
[%]
[b]
 
(6R, 
10R) 
[%]
[b]
 
(6S, 
10S) 
[%]
[b]
 
selectivity 
(C6) dr 
1 
 
>99 14.5 35.9 12.1 37.5 2.8:1 1:1 
2 
 
83 n.d. n.d. n.d. n.d. -- -- 
3 
 
>99 15.1 34.6 17.3 33.0 2.1:1 1:1 
4 
 
45  n.d. n.d. n.d. n.d. -- -- 
[a] Determined by GC analysis on an achiral stationary phase; [b] Determined by DSM. 
 
All catalysts of this series showed either incomplete conversion at 1.0 mol% catalyst loading 
or poor selectivity at C6 (table 4.21). As a result, catalyst 4.20 remains the most promising 
candidate for a stepwise approach to introduce the stereogenic centers in the tocopherol side 
chain. 
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Table 4.22: Substrates involved in a stepwise approach for the introduction of the stereogenic centers.  
 
[a] Determined by GC analysis on an achiral stationary phase; [b] Determined by DSM. 
 
Complex 4.20 emerged as an efficient catalyst to introduce the second stereogenic center in 
the hydrogenation of (5E,10R)-tetrahydrofarnesylacetone (4.56). A ratio of 98.2:1.8 at C6 was 
observed (table 4.22). Surprisingly, the hydrogenation of (5E)-dihydrogeranylacetone (4.61) 
showed significantly lower selectivity when compared to (5E,10R)-tetrahydrofarnesylacetone. 
With respect to the results obtained applying the pyridine based catalyst in which similar 
selectivity at C6 was observed for the hydrogenation of all farnesyl and geranyl derivates, this 
significant drop of selectivity for (5E)-dihydrogeranylacetone was rather unexpected. 
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4.7 Conclusion 
 
In summary, iridium-based N,P ligand complexes emerged as efficient catalysts for the 
hydrogenation of tocopherol side chain precursors. Especially, the hydrogenation of (5E,9E)-
farnesylacetone, from an industrial perspective the most relevant precursor, resulted in the 
formation of 99.1% of the desired stereoisomer. In addition, good reactivity was observed in 
the hydrogenation of this substrate. The reaction reached complete conversion to the saturated 
ketone using only 0.2 mol% catalyst loading. This is especially remarkable considering that 
three double bonds are reduced in one single step. If and to what extent this methodology can 
be applied to the stereoselective synthesis of (R,R,R)-α-tocopherol depends on many factors. 
In that context, many parameters such as the efficiency of the introduction of the last 
stereogenic center, the extent to which the reactivity can be increased on a larger scale and the 
price development for all-rac-α-tocopherol and in particular (R,R,R)-α-tocopherol have to be 
taken into account. However, with the encouraging results obtained from this study in hands, 
further investigations towards the industrial stereoselective synthesis of (R,R,R)-α-tocopherol 
seem to be promising.  
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5.1 Introduction  
 
The synthesis of bromide containing molecules by hydrobromination of alkenes is one of the 
reactions which is felt to be in the toolbox of every organic chemist ever since. The bromide 
itself is a group which allows for many synthetic transformations
[91]
 and when attached to a 
stereogenic center, stereospecific SN2 displacement may be used to retain chirality, in order to 
generate a diversity of optically enriched products. In this context it is rather surprising, that 
methods to generate enantioenriched molecules with a bromide directly attached to the 
stereogenic center have not been extensively investigated or are limited in substrate scope. 
Catalytic methods which allow the introduction of a “bromonium-ion” to an α-acidic position 
of compounds such as ketones or acid chlorides have been better explored and high 
enantioselectivities can be reached (scheme 5.1, A).
[92]
 An alternative approach is the 
asymmetric brominantion of olefins. This strategy can lead to high enantioselectivity but only 
for substrates containing an additional nucleophile which is capable to attack the bromonium-
ion formed within the reaction to generate five or six-membered rings (scheme 5.1, B). In a 
few cases this strategy was successfully applied to substrates which are capable to trap the 
bromonium-ion by a rearrangement. Furthermore, for both methods predominantly only 
moderate yields were obtained (scheme 5.1, C).
[93]
 
 
 
Scheme 5.1: Different approaches to synthesize enantiomerically enriched compounds containing a bromide at 
the stereogenic center. α-Bromination,[94] A; Enantioselective haloetherification,[95] B; Organocatalytic 
asymmetric bromination/semipinacol rearrangement,
[96]
 C. 
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There is no report demonstrating the application of iridium N,P ligand complexes in the 
hydrogenation of vinyl bromides up to date. However, vinyl fluorides and vinyl chlorides 
have been tested as substrates with varying degrees of success. Although these substrates 
differ from vinyl bromides, to a certain extent important conclusions can be drawn based on 
the results obtained in these reports. Andersson and co-workers published on the 
hydrogenation of vinyl fluorides (scheme 5.2, A). Excellent results were only obtained for 
substrate 5.1 containing an additional hydroxyl group. The fluoride substituted allylic alcohol 
5.1 reacted with 97% conversion and 99% enantiomeric excess was obtained. Other substrates 
bearing an additional coordinating group showed inferior results.
[97]
 In addition, the 
tetrasubstituted substrate 5.3 showed higher reactivity but significant amounts of 
defluorinated product was formed compared to the trisubstituted analog 5.2, which showed no 
reactivity at all. These results show that this substrate class is highly structure dependent and 
even higher reactivity of tetra substituted substrates over trisubstituted ones can be observed. 
The hydrogenation of vinyl fluorides containing no additional functional group was 
investigated by Dr. David Woodmansee.
[54a]
 In this study no reactivity was obtained by 
applying harsh reaction conditions with 4 mol% catalyst, 100 bar hydrogen pressure and 
48 hours reaction time. Even for the terminal vinyl fluoride 5.5 no conversion to the desired 
product was observed (scheme 5.2, B). 
 
 
Scheme 5.2: Hydrogenation of vinyl fluorides containing an additional functional group, A; and attempts to 
hydrogenate vinyl fluorides without an additional coordinating group, B. 
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Parker and co-workers reported the hydrogenation of an alkyne by the use of Crabtree’s 
catalyst. The vinyl iodide moiety in this molecule remained completely intact (scheme 5.3, 
A).
[98]
 The most promising results in this field were obtained in the enantioselective 
hydrogenation of (1-chloro-1-alkenyl) boronic esters (scheme 5.3, B).
[99]
 Although relatively 
high amounts of dechlorination was observed, the high enantioselectivity obtained with this 
method, makes it the most straightforward approach to synthesize these versatile chiral 
building blocks. 
 
 
Scheme 5.3: Application of Crabtree’s catalyst in the presents of a vinyl iodine, A; and the hydrogenation of (1-
chloro-1-alkenyl) boronic esters by iridium N,P ligand complexes. 
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5.2 Hydrogenation of vinyl bromides 
 
To start the evaluation of vinyl bromides as substrates for the asymmetric hydrogenation with 
iridium N,P ligand complexes, the terminal vinyl bromide 5.8 was synthesized via the 
addition of boron tribromide to 4-phenyl-1-butyne (5.7), which led to the corresponding 2-
bromo-alkenylborane. This intermediate was subsequently hydrolyzed by acetic acid to afford 
(3-bromobut-3-en-1-yl)benzene (5.8) followed by purification on semi-preparative HPLC 
(scheme 5.4).  
 
 
 
Scheme 5.4: Synthesis of (3-bromobut-3-en-1-yl)benzene (5.8). 
 
In the hydrogenation of terminal substrates in general a significantly improved enantiomeric 
excess is reached when the reaction is conducted at 1 bar instead of 50 bar hydrogen 
pressure.
[29a, 53d]
 However, at 1 bar hydrogen pressure only traces of the desired product 5.9 
were observed (table 5.1). A maximum of 2% (3-bromobutyl)benzene (5.9) and 1% of the 
debrominated product butylbenzene (5.10), were observed for catalyst 5.11. All other 
catalysts showed ≤0.2% formation of (3-bromobutyl)benzene (5.9). 
 
Table 5.1: Catalyst screening for the hydrogenation of (3-bromobut-3-en-1-yl)benzene (5.8) at 1 bar H2.  
 
Conversion to 5.9 and 5.10 determined by GC on an achiral stationary phase. 
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Due to the low conversion obtained at 1 bar hydrogen pressure more forcing conditions with 
50 bar hydrogen pressure and 16 hours reaction time were chosen. These conditions resulted 
in full conversion of the terminal vinyl bromide 5.8 and 72% ee was obtained, applying 
catalyst 5.11 (table 5.2). Although by the use of catalysts 5.11 and 5.18 full conversion was 
observed, all other catalysts of this series showed poor conversion, which therefore remained 
the major problem to be solved for this reaction. 
 
Table 5.2: Catalyst screening for the hydrogenation of (3-bromobut-3-en-1-yl)benzene (5.8) at 50 bar H2.  
Conversion to 5.9 and 5.10 determined by GC on an achiral stationary phase. Enantiomeric excess was 
determined by HPLC on a chiral stationary phase. 
 
Next, different solvents were screened (table 5.3). Both THF and CF3CH2OH showed lower 
conversion compared to CH2Cl2. 
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Table 5.3: Screened solvents in the hydrogenation of (3-bromobut-3-en-1-yl)benzene (5.8). 
 
Entry Cat. Solvent 5.9 [%]
[a]
 
ee (5.9) 
[%]
[b]
 
5.10 [%]
[a]
 
1 
 
CH2Cl2 99 72 1  
2 THF 48 n.d. 2 
3 CF3CH2OH 97 60 2 
[a] Conversion to 5.9 and 5.10 determined by GC on an achiral stationary phase; [b] Enantiomeric excess 
determined by HPLC on a chiral stationary phase. 
 
The origin of the low reactivity of vinyl bromides in the asymmetric hydrogenation with 
iridium-based catalysts can be manifold. The double bond character with an additional 
halogen is significantly reduced compared to unfunctionalized olefins.
[100]
 On the other hand, 
the sigma C–Br bond is significantly shortened to 1.86 Å in vinyl bromide compared to 
1.91 Å in CH3Br.
[101]
 Furthermore, the metal could insert into the C–Br which might result in 
debromination or catalyst decomposition. To get a vague idea on these effects we performed 
the hydrogenation of the trisubstituted olefin S1 in the presence of vinyl bromide 5.8 (table 
5.4). In the absence of the vinyl bromide 5.8, depending on the catalyst used, trans-
methylstilbene (S1) was converted in 51% or 14% conversion to compound P1 (entries 1 and 
3). By the addition of 0.3 eq. of vinyl bromide 5.8 the conversion of the trisubstituted olefin 
S1 remained below 1%. However the vinyl bromide 5.8 was converted with 42% when 
catalyst 5.11 was used (entry 2). Based on these experiments it can be assumed that the 
problem is not that the substrates are inert towards reaction with the catalysts, but that an 
undesired deactivation of the catalyst occurs upon reaction between the iridium complex and 
vinyl bromide 5.8. Thus it can be speculated that a bromide might be liberated in the course of 
the reaction, which could result in a counterion exchange resulting in deactivation of the 
catalyst. 
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Table 5.4: Hydrogenation of trans-methyl stilbene (S1) in the presence of vinyl bromide 5.8. 
 
Entry Cat. 5.8 [eq.] 
Conv. of  
S1 [%]
[a]
 
Conv. of 
5.8 [%]
[a]
 
5.10 [%] 
1 
 
-- 51 -- -- 
2 0.3 0.5 42 0 
3 
 
-- 14 -- -- 
4 0.3 0 0 0 
[a] Conversions determined by GC on an achiral stationary phase. 
 
Therefore, different additives were tested, which potentially could act as scavenger and trap a 
bromide or perform an additional counterion exchange. In the absence of an additive 31% 
conversion was reached with 0.5 mol% catalyst loading (table 5.5). Indeed, by the addition of 
0.1 eq. NaBArF to the reaction mixture the conversion increased to 59% (entry 2). Other 
additives such as B(OCH(CH3)2)3 resulted with 39% in only slightly higher conversions (entry 
8). Although the addition of 0.1 eq. NaBArF almost doubled the conversion, this increase was 
not enough to apply catalysts with other ligand classes tested in the previous screening (table 
5.1 and 5.2). Also a further increase of the amount of NaBArF used as additive, would lead to 
an expensive protocol due to the high price of NaBArF. 
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Table 5.5: Screening of different additives in the hydrogenation of (3-bromobut-3-en-1-yl)benzene (5.8). 
 
Entry Additive Eq. 5.9 [%]
[a]
 5.10 [%]
[b]
 
1 -- -- 31  1  
2 NaBArF 0.1  59  2  
3 AgBArF 0.1  42  7  
4 AgSbF6 0.1  20  2  
5 AgBF4 0.1  2  6  
6 AgNO3 0.1  0  1  
7 B(C6F5)3 0.1  35  1  
8 B(OCH(CH3)2)3 0.5  39  0.5  
9 B(OCH3)3 0.5  38  1  
10 bis(pinacolato)diborone 0.1  33  1  
11 tris(pentafluorophenyl)borane  0.1  22  0.5  
[a] Conversions determined by GC on an achiral stationary phase. 
 
Next, different substrates were tested to gain a deeper insight on whether this low reactivity is 
substrate specific or a general characteristic of this substrate class. In this context, the 
substrates 5.25, 5.26 and 5.27 were tested. (1-Bromovinyl)benzene (5.25) was commercially 
available and was purified by distillation, 1-((2-bromoallyl)oxy)-4-methoxybenzene (5.26) 
and 1-((2-chloroallyl)oxy)-4-methoxybenzene (5.27) were synthesized by substitution of 2,3-
dichloroprop-1-ene or 2,3-dibromoprop-1-ene with 4-metoxyphenol. In the hydrogenation of 
these substrates significant amounts of dehalogenation, isomerization and decomposition were 
observed and no better results compared to the hydrogenation of (3-bromobut-3-en-1-
yl)benzene (5.8) were obtained (scheme 5.5) 
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Scheme 5.5: Additional vinyl bromides tested in the asymmetric hydrogenation with iridium-based catalysts. 
 
Next, trisubstituted vinyl bromides were investigated as substrates. Therefore, 1-(4-
methoxyphenyl)propan-2-one (5.28) was treated with bromine and triphenyl phosphite to 
afford a mixture of three different vinyl bromides (scheme 5.6). Purification by semi-
preparative HPLC resulted in the separation of (E)-isomer (E)-5.29 and a 2:1 mixture of the 
(Z)-isomer (Z)-5.30 and the vinyl bromide 5.31 containing a terminal C=C bond. 
 
 
Scheme 5.6: Different isomers obtained from the reaction of 1-(4-methoxyphenyl)propan-2-one (5.28) with 
bromide and triphenyl phosphite. 
 
In the hydrogenation of both trisubstituted vinyl bromides no consumption of the substrate 
was observed. Similar to the previously investigated vinyl bromide 5.8 with a terminal C=C 
bond, vinyl bromide 5.31 showed full conversion under the applied reaction conditions 
(scheme 5.7). No suitable conditions for the analysis of the enantiomeric excess of the product 
resulting from this reaction were found. However, based on the similar environment around 
the double bond compared to substrate 5.8 and the HPLC data which revealed partial 
separation of the two enantiomers similar results as for the terminal substrate 5.8 can be 
assumed.  
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Scheme 5.7: Hydrogenation of trisubstituted vinyl bromide (E)-5.29 and of the mixture of trisubstituted vinyl 
bromide (E)-5.30 and vinyl bromide 5.31 containing a terminal C=C bond. [a] Separation of the enantiomers was 
not possible. 
 
5.3 Conclusion 
 
The reduction of vinyl bromides proved to be difficult using state-of-the-art iridium catalysts. 
At 1 bar hydrogen pressure which was previously demonstrated to be essential to achieve high 
enantioselectivities for terminal double bonds, only traces of the desired product were formed 
in the hydrogenation of the vinyl bromide 5.8. Also at 50 bar hydrogen pressure only a few 
catalysts showed full conversion of the substrate and enantioselectivity of up to 72% were 
reached. The trisubstituted vinyl bromides were completely unreactive applying the most 
reactive catalyst identified in the previous screening.  
As demonstrated for vinyl fluorides, an additional coordinating group might result in 
significant higher reactivity and would be a good starting point for further studies. On the 
other hand, this approach would considerably reduce the substrate scope. 
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6.1 Introduction 
 
6.1.1 Synthesis of enantiomerically enriched nitriles 
 
Most of the synthetic transformations carried out by organic chemists rely on functional 
groups. Among these functionalities, the cyano group plays an important role and is 
frequently used in many research areas. Nitriles are highly versatile building blocks in organic 
synthesis. They are commonly applied in cycloaddition reactions
[102]
 and can be converted by 
simple manipulations into many different functional groups, such as carboxylic acids, ketones, 
aldehydes, β-keto esters, amines, imines or amides.[103] In addition, moieties bearing a 
stereogenic center at the α- or β-position to a cyano group are frequently found in natural 
products.
[104]
 Furthermore, the cyano group promotes adhesion of polymers to many 
substrates,
[105]
 is known as pharmacophore in biologically active compounds
[104b]
 and based 
on its weak σ-donor and π-acceptor ability, it is extensively used for the preparation of 
transition metal complexes.
[106]
 The importance of nitriles, especially chiral ones, in organic 
chemistry prompts to the development of reliable, broadly applicable protocols for the 
enantioselective synthesis of molecules containing this specific group. However, synthetic 
protocols enabling the asymmetric synthesis of this compound class are limited. Asymmetric 
hydrocyanation of carbon-carbon double bonds provides the most obvious access to such 
molecules. Indeed, this transformation was studied by different research groups but only 
moderate selectivity is generally obtained.
[107]
 Recently, Fu and co-workers published on a 
catalytic asymmetric synthesis of secondary nitriles via stereoconvergent Negishi arylation 
and alkenylation of racemic α-bromonitriles (scheme 6.1, A).[108] Although ees up to 94% 
could be reached, high catalyst loadings, long reaction times and the limitation to aryl groups 
in α-position are clear drawbacks of this method. An alternative approach was reported by 
List and co-workers on the catalytic asymmetric protonation of silyl ketene imines to generate 
α-chiral nitriles (scheme 6.1, B).[109] With this protocol ees of around 90% were obtained, but 
only for silyl ketene imines bearing an aryl moiety directly attached to the double bond. 
Furthermore, the silyl ketene imines are synthesized from the racemic nitriles, by 
deprotonation and protection with a TBS-group. Therefore, this approach cannot be 
considered as a direct and atom economic way to generate enatiomerically enriched nitriles. 
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 Scheme 6.1: State-of-the-art enantioselective synthesis of chiral nitiriles.  
 
6.1.2 Synthesis of enantiomerically enriched nitriles via asymmetric reductions 
 
Besides the previously described methods, only a few protocols to generate enantiomerically 
enriched nitriles by asymmetric reductions of -unsaturated nitriles have been reported so 
far. Examples are the conjugate reduction with sodium borohydride catalyzed by semicorrin-
cobalt complexes, copper-catalyzed reduction with hydrosiloxanes and rhodium-catalyzed 
asymmetric hydrogenation. In contrast to reductions of unsaturated esters and amides, which 
afforded ee values of >90%, the reduction of corresponding unsaturated nitriles with sodium 
borohydride catalyzed by semicorrin cobalt complexes led to moderate enantioselectivity (up 
to 69% ee) (scheme 6.2, A).
[66]
 Albeit the chiral version of the Stryker’s reagent,[67] based on 
Cu-Josiphos and polymethylhydrosiloxane (PMHS) as reducing agent, gave excellent 
enantioselectivities (of up to 99% ee), the relatively high catalyst loadings (3 mol%), a 
fourfold excess of PMHS, and strongly basic work-up conditions (aq. NaOH) are drawbacks 
of this method (scheme 6.2, B).
[110]
 Although rhodium-catalyzed hydrogenation with 
hydrogen gas can provide high enantioselectivities, only unsaturated nitriles with an 
additional coordinating acetamido substituent or a carboxylate group at the C=C bond have 
been successfully applied, limiting considerably the chemical diversity accessible by this 
protocol (scheme 6.2, C).
[111]
 In summary, despite the considerable synthetic value of 
enantioenriched nitriles and the efforts made within the last years, the number of methods 
enabling an efficient and broad access to this compound class is overall still limited. The goal 
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of the project discussed in this chapter was to study the application of iridium N,P ligand 
complexes in the hydrogenation of α,β-unsaturated nitriles.  
  
 
Scheme 6.2: Different approaches to access enantiomerically enriched nitriles by conjugated reduction.  
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6.2 Hydrogenation of α,β-unsaturated nitriles with iridium 
complexes 
 
At the beginning of this project several α,β-unsaturated nitriles with different substitution 
patterns, electronic properties and double bond geometry were synthesized, to screen the 
performance of iridium-based catalysts in the hydrogenation of those substrates. All initial 
attempts to apply iridium-based complexes to the asymmetric hydrogenation of -
unsaturated nitriles under standard reaction conditions, which had proved optimal for a wide 
variety of functionalized and unfunctionalized alkenes, were unsuccessful (2.0 mol% Ir-cat., 
CH2Cl2 (0.2 M), 50 bar H2 pressure, room temperature and 18 h). None of the many Ir-
catalysts tested showed any reactivity towards this substrate class (scheme 6.3).  
 
 
Scheme 6.3: Combinations of different substrates and catalysts screened.  
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As previously mentioned, cyano groups have a high affinity to bind to transition metals and 
consequently the substrate might act as a catalyst inhibitor. Therefore, the hydrogenation of 
the cyclic olefin S5, which is reduced with full conversion using catalysts 6.5 under 
previously described reaction conditions (scheme 6.4, A), was investigated in the presence of 
(E)-3-phenylbut-2-enenitrile (6.3). Performing the reaction in the presence of 0.3 eq. of nitrile 
6.3 relative to the cyclic olefin S5, neither conversion of the cyclic olefin to the 
tetrahydronaphtalene P5, nor any reduction of the unsaturated nitrile 6.3 was observed. This 
experiment confirmed the first assumption, that the α,β-unsaturated nitrile 6.3 inhibits the 
catalytically active species produced from iridium complex 6.5 under hydrogen atmosphere. 
To further investigate if this catalyst deactivation is caused by interaction with the electron 
deficient double bond, the coordinating ability of the cyano group or due to combination of 
both effects further experiments were performed. For this purpose, an analog of the α,β-
unsaturated ester 6.11 bearing an additional cyano group at the para-position of the aryl 
moiety was synthesized. The α,β-unsaturated ester S9 was hydrogenated under previously 
mentioned standard conditions with full conversion using catalyst 6.5.
[52b]
 However, 
subjecting analog 6.11 bearing the cyano group even a higher catalyst loading and longer 
reaction times did not led to any conversion of the substrate (scheme 6.4, B). Furthermore, the 
hydrogenation of ethyl (E)-3-phenylbut-2-enoate (S9) under the conditions depicted in 
scheme 6.4, B with additives, such as acetonitrile (0.1 eq.) or benzonitrile (0.1 eq.) was tested, 
but did not show any conversion. Similar reactivity was also observed by Crabtree and co-
workers applying [Ir(COD)(PMePh)2]BF4 in the hydrogenation of cyclohexene in the 
presence of 1 eq. acetonitrile with respect to metal.
[22c]
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Scheme 6.4: Hydrogenation of model substrate S5 in the presence of the α,β-unsaturated nitrile 6.3, A; and the 
influence of an additional attached nitrile group to the model substrate 6.11, B. 
 
In order to explore the nature of the deactivated catalytic species, 70 bar hydrogen pressure 
was applied to a mixture of catalyst 6.12 and the α,β-unsaturated nitrile 6.3 in a 1:4 ratio in 
CH2Cl2. After work-up (for details see the experimental part) a colorless product was obtained 
which was identified by 2D NMR analysis and ESI-MS spectrometry as the iridium(III)–
dihydride-species 6.13 coordinated by two substrate molecules. This complex contains 18 
valence electrons and is lacking a free coordination site that is necessary for catalytic activity. 
The COD ligand is reduced to cyclooctane and dissociates from the metal center. The 
resulting free coordination sites are occupied by two substrate molecules and two hydrides 
both in trans-orientation to the nitrogen atom. Based on the typical constant for a hydride in 
trans-position to a phosphorus atom (100-200 Hz)
[112]
 and the width of the overlapping 
hydride signals (55 Hz), such an orientation of a hydride can be excluded. The configuration 
of the iridium center was assigned based on the NOESY contact of one hydride with the tert-
butyl group on the dihydrooxazole unit (scheme 6.5, A). Additional data was gained by ESI-
MS spectrometry. These data collected from the reaction mixture revealed two signals 
assigned to the iridium(III)–dihydride-species 6.13 minus the counterion and to the 
iridium(III)–dihydride-species 6.13 minus the counterion and one substrate molecule 6.3 
(scheme 6.5, B). Furthermore, the orientation of the hydrides is in accordance with the major 
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species observed in the reaction of similar complexes with H2 investigated by Mazet et al. by 
NMR spectroscopy at 40 °C. In this case iso-propyl PHOX is used as a ligand and THF 
adopts the position which is occupied by the cyano groups in complex 6.13.
[113]
  
0
100
re
l. 
In
t.
m/z
Scheme 6.5: Isolated iridium(III)–dihydride-species 6.13 obtained by reaction of nitrile 6.3 with iridium 
complex 6.12 after applying 70 bar H2 pressure for 1 h and a section of the obtained NOESY spectrum, A; ESI-
MS spectrum collected from the reaction mixture, B.  
 
Based on these results, we concluded that it would be difficult to find an iridium complex 
enabling the hydrogenation of α,β-unsaturated nitriles under “standard” reaction conditions. 
An approach to overcome this problem could be the protection of the cyano group prior to 
hydrogenation, in order to prevent substrate coordination to the metal center and subsequent 
catalyst inhibition. In general, cyano groups have a high affinity to bind to many different 
transition metals and therefore this could be one approach to find a suitable “protection 
group”. However, such an approach would be unpractical as it would require large amounts of 
a second transition metal to be used as sacrificial binding species. In fact, considering a 
catalyst loading of 1 mol% of iridium complex, and the necessity of at least one free binding 
site, at least 99 mol% of a "protecting" metal would be needed to render the nitrile innocuous 
and allow the desired catalytic process. Recently, it was demonstrated by Stephan and co-
workers, that tris(perfluorophenyl)borane can be used as protecting group for nitriles in the 
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hydrogenation of nitriles to amines by frustrated Lewis pairs.
[114]
 Based on this publication the 
applicability of tris(perfluorophenyl)borane for iridium-catalyzed C–H activation reactions on 
substrates containing a cyano group was demonstrated by Dr. M. Parmentier.
[115]
 Thus, the 
use of tris(perfluorophenyl)borane as additive in the hydrogenation of substrates bearing a 
cyano group was tested. In addition to tris(perfluorophenyl)borane, it was decided to test 
boron trifluoride, which is a slightly weaker Lewis acid but inexpensive and more convenient 
to handle.
[116]
 Ethyl (E)-3-(4-cyanophenyl)but-2-enoate (6.11) was chosen as test substrate for 
two reasons:  
1.   This substrate should offer enough space between the cyano group and the double 
bond to avoid a strong shielding of the C=C bond by the potential protecting 
group. 
2.  The ester group should give some indication if this approach would be applicable 
in the presence of weakly nucleophilic oxygen atoms and therefore allow the 
application of the methodology to a sufficiently broad substrate range.  
If this strategy showed encouraging results, extension to the hydrogenation of α,β-unsaturated 
nitriles would be the next logical step. Unfortunately, the hydrogenation of ethyl (E)-3-(4-
cyanophenyl)but-2-enoate (6.11) in the presence of either tris(perfluorophenyl)borane or 
boron trifluoride as additives failed to afford the saturated ester 6.14 (table 6.1). 
 
Table 6.1: Hydrogenation of substrate 6.11 in the presence of additives. 
 
Entry Additive Conv. [%]
[a]
 
1 none 0 
2 B(C6F5)3 (1.2 eq.) 0 
3 BF3•Et2O (2.0 eq.) 0 
[a] Determined by GC analysis on an achiral stationary phase. 
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Another approach to enable the hydrogenation of α,β-unsaturated nitriles was based on the 
work of Semeniuchenko et al., who reported on the hydrogenation of electron deficient 
double bond by the use of the iridium PHOX catalyst 6.18 with N,N-diisopropylethylamine 
(DIPEA) as additive. The examples reported mainly dealt with different coumarin derivatives, 
but also α,β-unsaturated dinitriles were tested (scheme 6.6, A).[117] Interestingly, the use of 
this additive was previously reported to deactivate iridium catalysts employed in the 
hydrogenation of unfunctionalized olefins.
[118]
 Similar conditions to those used by 
Semeniuchenko et al. were tested in the hydrogenation of the model substrate 6.3. In this case 
0.3% conversion to the desired saturated nitrile 6.17 was observed. Although such a value 
accounts for less than one turnover of the catalyst, further investigations, were carried out 
(scheme 6.6, B). 
 
 
Scheme 6.6: Hydrogenation conducted by Semeniuchenko et al.,
[117a]
 A; hydrogenation conducted under similar 
reaction conditions, B. 
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6.2.1 Hydrogenation of β,β-disubstituted α,β-unsaturated nitriles 
 
Several different N,P ligand complexes were screened in this reaction (table 6.2). Indeed 
several catalysts did show higher conversion compared to the Ir-PHOX complex 6.18. 
Furthermore, the commercially available ThrePHOX-based catalyst 6.20 induced by far the 
highest selectivity while reaching almost full conversion. It should be mentioned, that this 
reaction emerged to be extraordinarily sensitive to small changes within the ligand structure. 
Only small variations showed immense differences in terms of enantioselectivity and 
conversion (table 6.2, 6.18 vs. 6.12 or 6.20 vs. 6.21). Both steric and electronic factors seemed 
to play a role, but no clear trends could be deduced from the data. 
 
Table 6.2: Catalyst screening for the hydrogenation of α,β-unsaturated nitrile 6.3. 
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Conversion determined by GC analysis on an achiral stationary phase. Enantiomeric excess determined by 
HPLC on a chiral stationary phase. 
 
With these promising results in hand a detailed study was conducted using various derivates 
of catalyst 6.20 that had been previously synthesized in the Pfaltz group (table 6.3). First, the 
removal of the methyl group on the dihydrooxazole unit revealed a drop from 94% to 88% ee. 
By using the diastereomeric ligand complex 6.33, significantly lower conversion and 
considerable erosion of the ee compared to catalyst 6.20 was observed. Next, the influence of 
substituents on the aryl moiety directly attached to the dihydrooxazole unit was tested. 
Electron withdrawing groups led to significant lower selectivity and conversion whereas 
electron donating groups resulted in only slightly lower enantiomeric excesses (cat. 6.34-6.37). 
All changes in the dibenzyl units of the ligand bridging the phosphonite with the 
dihydrooxazole part caused a significant drop in both conversion and enantioselectivity (cat. 
6.38-6.42). Therefore, iridium complex 6.20 still remained the most promising catalyst for 
this reaction. 
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Table 6.3: Different derivatives of catalyst 6.20 screened in the hydrogenation of α,β-unsaturated nitrile 6.3. 
 
Conversion determined by GC analysis on an achiral stationary phase. Enantiomeric excess determined by 
HPLC on a chiral stationary phase. 
 
Next, the reaction conditions were further investigated, using the most promising catalysts 
identified in the previous screening. An increase of hydrogen pressure from 50 to 100 bar 
resulted in higher conversion for all catalysts (table 6.4). Only a minimal effect of the 
hydrogen pressure on the enantioselectivity was observed but no general trend could be drawn. 
At 1 bar hydrogen pressure only catalyst 6.23 achieved still full conversion to the saturated 
nitrile 6.17. 
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Table 6.4: Hydrogenation of α,β-unsaturated nitrile 6.3 at different hydrogen pressures. 
 
 
Entry Catalyst 
H2 Pressure 
[bar] 
Conv. [%]
[a]
 ee [%]
[b]
 
1 
 
1 >99 64 () 
2 50 >99 55 () 
3 100 >99 58 () 
4 
 
50 71 65 () 
5 100 64 69 () 
6 
 
1 34 97 (+) 
7 50 98 94 (+) 
8 100 >99 94 (+) 
9 
 
50 4 50 (+) 
10 100 18 52 (+) 
11 
 
50 4 50 (+) 
12 100 18 52 (+) 
[a] Determined by GC analysis on an achiral stationary phase; [b] Determined by HPLC on a chiral stationary 
phase. 
 
As next parameter, the amount of DIPEA used in the reaction was varied (table 6.5), which 
turned out to have a crucial influence on the outcome of the hydrogenation. Both increasing 
and decreasing the equivalents of DIPEA resulted in significantly reduced conversion 
combined with a drop in enantioselectivity (entries 2-3 and 5-7). Even employing DIPEA as 
the reaction medium (entry 1) allowed for the reaction to occur but conversion remained 
below 50% and the enantioselectivity dropped to 83% ee. In the case of 0.5 eq. and 0.1 eq. 
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DIPEA only 95% and 70% conversion was observed, but this showed that the base can be 
applied in substochiometric amounts (entries 6 and 7). 
 
Table 6.5: Hydrogenation of α,β-unsaturated nitrile 6.3 using different stoichiometry of DIPEA. 
 
Entry DIPEA [eq.] Conv. [%]
[a]
 ee [%]
[b]
 
1 Solvent 41  83 (+)  
2 18 74  88 (+)  
3 9.0 85  88 (+)  
4 4.5 >99 95 (+)  
5 1.5 99  82 (+)  
6 0.5 95  75 (+)  
7 0.1 70  69 (+)  
[a] Determined by GC analysis on an achiral stationary phase; [b] Determined by HPLC on a chiral stationary 
phase. 
 
Thereafter, the influence of different nitrogen containing bases (table 6.6) was tested. 
Triethylamine performed almost as well as DIPEA in combination with all catalysts. The use 
of N-isopropyl-N-methyl-tert-butylamine, which can form different diastereoisomers upon 
coordination to the metal center, resulted in a drop of the enantiomeric excess with all tested 
catalysts. 1,8-Diazabicycloundec-7-ene (DBU) as additive showed almost no conversion. 
Interesting results were obtained applying 2,6-lutidine. The two ThrePHOX-based catalysts 
showed no activity, whereas a significantly increased selectivity was found for the two 
pyridine-based catalysts with up to 93% ee for catalyst 6.5 but only 27% conversion. Based 
on these results, different structures related to lutidine, like pyridine or 2,6-di-tert-
butylpyridine, were tested. The use of pyridine as additive resulted in almost complete loss of 
reactivity whereas 2,6-di-tert-butylpyridine gave full conversion in combination with catalyst 
6.23 and 82% ee.  
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Table 6.6: Different bases applied to the hydrogenation of (E)-3-phenylbut-2-enenitrile (6.3). 
 
Base 
    
Conv. 
[%]
[a]
 
ee 
[%]
[b]
 
Conv. 
[%]
[a]
 
ee 
[%]
[b]
 
Conv. 
[%]
[a]
 
ee 
[%]
[b]
 
Conv. 
[%]
[a]
 
ee 
[%]
[b]
 
DIPEA >99 58 () 64 69 () >99 94 (+) 8
[c]
 47
 
(+)
[c]
 
Et3N >99 59 () >99 71 () >99 95 (+) 13 43 (+) 
t-Bui-PrMeN >99 53 () 58 29 () >99 88 () 24 2 () 
DBU 4 n.d. 4 n.d. 4 n.d. 6 n.d. 
1,2,2,6,6-
Pentamethylp
iperidine 
>99 57 () 38 65 () >99 94 () 24 13 () 
2,6-Lutidine >99 67 () 27 93 () 1 n.d. 0 -- 
Pyridine 2 n.d. 0 -- -- -- -- -- 
2,6-Di-tert-
butylpyridine 
>99 82 () 5 91 () -- -- -- -- 
[a] Determined by GC analysis on an achiral stationary phase; [b] Determined by HPLC on a chiral stationary 
phase; [c] Reaction performed at 50 bar H2 pressure. 
 
Based on the results obtained from the additive screening with 2,6-lutidine, we tried to 
increase the reactivity and selectivity using a mixture of DIPEA and 2,6-lutidine. Indeed, 
three out of the four tested catalysts showed higher enantioselectivity with this approach 
(table 6.7). Only for catalyst 6.20, which showed so far the highest enantioselectivity, a drop 
of both ee and activity was observed. 
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Table 6.7: Hydrogenation of α,β-unsaturated nitrile 6.3 applying a mixture of DIPEA and 2,6-lutidine. 
 
 
Base 
    
Conv. 
[%]
[a]
 
ee 
[%]
[b]
 
Conv. 
[%]
[a]
 
ee 
[%]
[b]
 
Conv. 
[%]
[a]
 
ee 
[%]
[b]
 
Conv. 
[%]
[a]
 
ee 
[%]
[b]
 
4.5 eq. DIPEA 
and 4.5 eq. 
2,6-lutidine  
>99  66 ()  63  82 ()  46  92 (+)  5  72 (+)  
4.5 eq. DIPEA >99  59 ()  60  71 ()  >99  94 (+)  18  43
 
(+)  
[a] Determined by GC analysis on an achiral stationary phase; [b] Determined by HPLC on a chiral stationary 
phase. 
 
Based on the results obtained by the addition of 2,6-lutidine, the significantly increased 
selectivity might be explained by a coordination of lutidine to the metal center. In order to test 
the influence of other coordinating ligands, experiments with 1.0 mol% of different 
phosphines were performed (table 6.8). The combination of tricyclohexylphosphine with 
catalyst 6.5 showed higher conversion (>99%) compared to the reaction without the 
phosphine (64%) but lower enantioselectivity (table 6.8, entry 2 vs. table 6.4, entry 5). For the 
threonine-based catalyst 6.20 both triphenylphosphine and tricyclohexylphosphine resulted in 
significantly lower conversion. 
 
Table 6.8: Hydrogenation of α,β-unsaturated nitrile 6.3 using phosphines as additives. 
 
Entry Catalyst Phosphine Conv. [%]
[a]
 ee [%]
[b]
 
1 
 
PPh3 24 15 ( 
2 PCy3 >99 62 ( 
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3 
 
PPh3 1 n.d. 
4 PCy3 19 93 (+) 
[a] Determined by GC analysis on an achiral stationary phase; [b] Determined by HPLC on a chiral stationary 
phase. 
 
As solvents can have a significant impact on the coordinating ability of ligands, the solvent 
effect in the hydrogeantion of (E)-3-phenylbut-2-enenitrile (6.3) with different ligand 
complexes was investigated (table 6.9). The range of solvents tolerated proved to be 
remarkably broad. Surprisingly, even in strongly coordinating solvents such as methanol or 
acetonitrile, which are known to inhibit iridium-based catalysts, catalytic activity was retained. 
Among all polar protic and aprotic solvents that were tested, only DMSO was found to be 
unsuitable. The highest ee was observed in DMF with catalyst 6.20 (97%), but the reaction 
did not go to completion. Full conversion and excellent enantioselectivities of 94-95% ee 
were achieved in alcoholic solvents and in even water. Although, the substrate is not soluble 
in water, the remarkable water tolerance of this catalyst system is an attractive feature 
enhancing its scope and practicality. Only trifluorethanol resulted in a siginficant drop of 
enantioselectivity for the threonine-based catalyst 6.20. In this solvent catalyst 6.5, which was 
less selective in all other solvents, showed the highest enantiomeric excess (79%).  
 
Table 6.9: Hydrogenation of α,β-unsaturated nitrile 6.3 in different solvents. 
 
Solvent 
    
Conv. 
[%]
[a]
 
ee 
[%]
[b]
 
Conv. 
[%]
[a]
 
ee 
[%]
[b]
 
Conv. 
[%]
[a]
 
ee 
[%]
[b]
 
Conv. 
[%]
[a]
 
ee 
[%]
[b]
 
Toluene >99 58 () 64 69 () >99 94 (+) 8
[c]
 47
 
(+)
[c]
 
CH2Cl2 >99 60 () 75 32 () >99 93 (+) 17 62 (+) 
THF 94 59 () 18 51 () >99 96 () 18 16 (+) 
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CF3CH2OH >99 70 () 81 79 () 99 68 (+) 10 4 (+) 
MeOH >99 66 () 84 62 () >99 95 (+) 28 n.d.  
i-PrOH >99 66 ( 16 71 ( >99 94 (+) 47 63 (+) 
Ethanol >99 69 () 97 62 () >99 95 (+) 29 60 (+) 
H2O -- -- -- -- >99 95 (+) -- -- 
DMF 60 71 () 2 n.d. 85 97 () 3 n.d. 
DMSO 0 -- 0 -- 0 -- 0 -- 
CH3CN >99 49 () 84 10 () >99 87 (+) 25 62 (+) 
[a] Determined by GC analysis on an achiral stationary phase; [b] Determined by HPLC on a chiral stationary 
phase; [c] Reaction performed at 50 bar H2 pressure. 
 
Lowering the temperature is known to often have a positive impact on the enantioselectivity. 
Indeed, the ee could be further increased by carrying out the reaction at lower temperature 
(table 6.10). Hydrogenations at 8 °C revealed for all tested catalysts a higher enantiomeric 
excess. For catalyst 6.20 even 99% ee was observed but conversion remained below 50%. 
Therefore, the combination of the most suitable parameters obtained from the previous 
screening with catalyst 6.20 in methanol at 0 °C was explored. Indeed, under these reaction 
conditions full conversion with 98% enantiomeric excess was reached (table 6.10). 
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Table 6.10: Hydrogenation of α,β-unsaturated nitrile 6.3 at reduced temperature.  
 
 
Temp. 
    
Conv. 
[%]
[a]
 
ee 
[%]
[b]
 
Conv. 
[%]
[a]
 
ee 
[%]
[b]
 
Conv. 
[%]
[a]
 
ee 
[%]
[b]
 
Conv. 
[%]
[a]
 
ee 
[%]
[b]
 
RT >99 58 () 64 69 () >99 94 (+) 8
[c]
 47
 
(+)
[c]
 
0 °C -- -- -- -- >99
[d]
 98 (+)
[d]
 -- -- 
–8 °C 91 75 () 21 94 () 48 99 (+) 2 82
 
(+) 
[a] Determined by GC analysis on an achiral stationary phase; [b] Determined by HPLC on a chiral stationary 
phase; [c] Reaction run at 50 bat H2 pressure; [d] Reaction performed in MeOH. 
 
Combining the optimal reaction parameters indentified from the previous screenings of 
substrate 6.3, the scope of catalyst 6.20 in the hydrogenation of different α,β-unsaturated 
nitriles was tested. These substrates were almost exclusively synthesized by Horner–
Wadsworth–Emmons reaction from the corresponding arylketone precursors. First, the 
different substitution patterns on the aryl ring and the influence of electron withdrawing and 
electron donating groups were investigated (table 6.11). Changing the double bond geometry 
from trans to cis caused a large drop in enantioselectivity and conversion (6.43). Introduction 
of an ortho substituent into the phenyl group, which destabilizes a coplanar arrangement of 
the C=C bond and the aromatic -system and causes higher steric hindrance around the target 
C=C bond, also reduced the reactivity and ee, but to a lower extent (6.44 and 6.45). Electron 
donating or withdrawing substituents in meta- or ortho-position of the aryl moiety had no or 
only a minor influence on the conversion and the enantioselectivity (6.46-6.51). These 
substrates were reduced with ees between 95% and 98% with full conversion.  
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Table 6.11: Substrate scope of the hydrogenation of α,β-unsaturated nitriles. 
All conversions determined by GC on an achiral stationary phase. Enantiomeric excess determined by HPLC on 
a chiral stationary phase.  
 
Next, the influence of the alkyl substituent on the C=C bond was investigated (table 6.12). 
Replacing the methyl group by iso-propyl, similar results as for ortho-substitution on the aryl 
moiety was observed. Since it is known that an iso-propyl group in this position results in a 
similar change in geometry to that caused by an ortho-substitution on the aryl moiety,
[119]
 a 
drop of enantioselectivity was expected for these substrates. Other alkyl substituents, smaller 
then iso-propyl but larger than methyl, such as ethyl, n-propyl or sec-butyl on the C=C bond 
revealed full conversion with similar or even higher enantiomeric excess between 96% and 
99% (6.54, 6.55 and 6.56).  
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Table 6.12: Substrate scope of the hydrogenation of α,β-unsaturated nitriles with different alkyl substituents at 
the β-position. 
 
All conversions determined by GC on an achiral stationary phase. Enantiomeric excess determined by HPLC on 
a chiral stationary phase. 
 
Next, the functional group tolerance of this reaction was tested (table 6.13). Substrates 
containing a pyridine, primary amine or diene unit, which have been recognized as 
challenging substrates under base-free conditions,
[24, 77, 118]
 also showed significantly reduced 
catalyst reactivity was observed under base-promoted conditions (6.65, 6.66 and 6.67). 
Despite these results, this catalyst system showed high functional group tolerance overall, as 
exemplified by the fluoro-, chloro-, bromo-, acetamido-, carbomethoxy-, cyano-, and nitro-
substituted compounds that were successfully hydrogenated (6.57–6.63). In contrast to the 
substrate 6.63 containing a nitro-group in the meta-position, the para-substituted analog 6.64 
showed almost no conversion. 
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Table 6.13: Substrate scope of the hydrogenation of α,β-unsaturated nitriles containing different functional 
groups. 
All conversions determined by GC on an achiral stationary phase. Enantiomeric excess determined by HPLC or 
GC on a chiral stationary phase. 
 
In a next step, the amount of DIPEA and the catalyst loading were investigated (table 6.14). In 
methanol with 1.0 mol% catalyst the amount of DIPEA could be reduced to 0.1 eq. without 
affecting the ee and conversion (entries 1-5). This is an significant advantage compared to the 
reactions in toluene, in which the outcome of the reaction is significantly dependent on the 
stoichiometry of DIPEA. In methanol even in the absence of DIPEA the reaction went to 
completion, but the ee dropped from 95% to 86% (entry 6). Furthermore, the catalyst loading 
could be considerably reduced. By using only 0.23 eq. of DIPEA, as little as 0.05 mol% 
catalyst was enough to achieve full conversion with an enantiomeric excess of 95% within 
16 h (entry 15). Further experiments in this direction showed that by increasing the reaction 
time even with 0.005 mol% catalyst loading 96.5% conversion and 95% ee was observed 
(entry 17). This corresponds to 19300 turnovers of the catalyst. 
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Table 6.14: Variation of catalyst loading and the DIPEA amount in methanol for the hydrogenation of α,β-
unsaturated nitrile 6.3. 
 
Entry Catalyst Time [h] 
Cat. 
loading 
[mol%] 
DIPEA 
[eq.] 
Conv. 
[%]
[a]
 
ee [%]
[b]
 
1 
 
16 1.0 18 >99 96 (+) 
2 16 1.0 4.5 >99 95 (+) 
3 16 1.0 1.5 >99 95 (+) 
4 16 1.0 0.5 >99 95 (+) 
5 16 1.0 0.1 >99 95 (+) 
6 16 1.0 none >99 86 (+) 
7 
 
4  0.5  0.5  >99  96 ()  
8 4  0.2  0.5  >99  96 ()  
9 4  0.1  0.5  >99  95 ()  
10 4  0.05  0.5  97  96 ()  
11 4  0.1  1  >99  97 ()  
12 4  0.1  0.5  >99  97 ()  
13 4  0.1  0.1  >99  96 ()  
14 4  0.1  0.01  >99  96 ()  
15 16 0.05 0.23 >99 96 () 
16 72  0.05  0.005  99.5  96 ()  
17
[c]
 112 0.005 0.023 96.5 95 (–) 
[a] Determined by GC analysis on an achiral stationary phase; [b] Determined by HPLC on a chiral stationary 
phase; [c] Reaction run on 1.5 mmol scale. 
 
The observation that the reaction in methanol could be carried out in the absence of DIPEA, 
prompted a more detailed investigation of the possibility to avoid the use of a base. Therefore, 
the catalyst loading in the absence of DIPEA was systematically reduced while keeping the 
reaction time constant (table 6.15). While the conversion gradually decreased lowering the 
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catalyst loading, the enantiomeric excess followed the opposite trend, reaching 95% at 49% 
conversion with 0.05 mol% catalyst loading. 
 
Table 6.15: Hydrogenations of α,β-unsaturated nitrile 6.3 at reduced catalyst loadings in the absence of an 
additional base. 
 
Entry Cat. loading [mol%] Conv. [%]
[a]
 ee [%]
[b]
 
1 1.0 >99 86 (+)  
2 0.5 92 86 (+)  
3 0.1 76 93 (+)  
4 0.05 49 95 (+)  
[a] Determined by GC analysis on an achiral stationary phase; [b] Determined by HPLC on a chiral stationary 
phase. 
 
The use of methanol as solvent allowed for the employment of different bases which are not 
soluble in toluene. In this context, different inorganic bases were screened (table 6.16). In 
general, similar results to those observed in pure methanol were obtained. Only in the 
presence of NaHCO3 a higher selectivity of 92% ee was achieved. 
 
Table 6.16: Hydrogenation of α,β-unsaturated nitrile 6.3 using different inorganic bases. 
 
Entry Base 
Cat. loading 
[mol%] 
Time [h] Conv. [%]
[a]
 ee [%]
[b]
 
1 Na2CO3  1.0  16  >99  89 (+)  
2 Na2CO3  0.2  3  >99  86 (+)  
3 Na2CO3  0.1  3  >99  87 (+)  
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4 Na2CO3  0.05  3  88  88 (+)  
5 NaOH  1.0  16  >99  85 (+)  
6 NaOMe  1.0  16  >99  66 (+)  
7 NaHCO3  1.0  16  >99  92 (+)  
8 NaHCO3  0.1  3  98  90 (+)  
[a] Determined by GC analysis on an achiral stationary phase; [b] Determined by HPLC on a chiral stationary 
phase. 
 
In a next study, the low catalyst loading of 0.05 mol% was applied to different substrates in 
the presence of 0.23 mol% of DIPEA (table 6.17). Remarkably, for all substrates 99% to full 
conversion was achieved with similar enantioselectivity. Only for substrate 6.46 containing a 
methyl substituent in the para-position of the aryl moiety a drop in enantioselectivity from 
95% to 91% was observed compared to the reaction at 1.0 mol% catalyst loading and 4.5 eq. 
DIPEA (table 6.12, entry 3 vs. table 6.12, 6.46). 
 
Table 6.17: Hydrogenation of various of α,β-unsaturated nitriles at 0.05 mol% catalyst loading. 
 
Entry R
1
 R
2
 Time [h] Conv. [%]
[a]
 ee [%]
[b]
 
1 Me H 4 97  96 () 
2 Me H 16 >99 96 () 
3 Me 4-Me 18 >99 91 (S) 
4 Me 4-Br 16 >99 96 (+) 
5 Me 4-NHCOCH3 16 >99 97 () 
6 Me 3-OMe 18 >99 95 (+) 
7 Me 3-Cl 18 >99 96 (+) 
8 Et H 18 99 97 (+) 
[a] Determined by GC analysis on an achiral stationary phase; [b] Determined by HPLC on a chiral stationary 
phase. 
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Subsequently, the kinetics of the reaction was investigated varying the electron density on the 
aryl substituent (graph 6.1). In general no clear trend was observed but it became obvious that 
18 h were not mandatory to achieve complete conversion for all substrates. For example the 
more electron deficient double bond of substrate 6.51 containing a chlorine atom at the meta-
position of the aryl ring showed 98% conversion after only 2 hours at 0.05 mol% catalyst 
loading. In addition, a general erosion of the enantiomeric excess over time was observed, in 
line with the observation that the lowest enantiomeric excess was registered for the substrate 
with the slowest reaction rate. To found out whether the drop in enantioselectivity was a result 
of racemization, a control experiment was performed: the enantioenriched nitrile 6.17 was 
stirred for 16 h under hydrogenation conditions. As no erosion of the enantiomeric excess 
after that time was observed, a postreaction racemization could be excluded. 
 
  
 
Graph 6.1: Kinetic data obtained for the hydrogenation of different substrates. Due to overlap with the substrate 
for meta-metoxy substitution the ee was not determined for samples revealing incomplete conversion. 
 
Further investigations focused on the hydrogenation of ,-dialkyl-substituted acrylonitriles 
(table 6.18). In contrast to substrates containing an aryl substituent on the C=C bond they 
exhibited lower reactivity and required 2.0 mol% of catalyst and longer reaction time to reach 
full conversion at 0 °C. The enantioselectivities were also lower compared to those obtained 
in the hydrogenation of the phenyl methyl analog 6.3. Interestingly, the (Z)-isomer (Z)-6.69 
afforded higher ee than the (E)-isomer (E)-6.68, contrary to the results obtained with (E)-6.3 
and (Z)-6.43. The best results were achieved at 0 °C, which led to the saturated nitrile 6.70 
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with 82% ee and full conversion. At –15 °C the ee raised to 88%, but conversion amounted to 
only 51%. The hydrogenation product obtained in this case is known as Citralis nitrile
®
, a 
compound that frequently finds application in fragrances.
[120]
 
 
Table 6.18: Hydrogenation of Citralis nitrile
® 
precursors applying different reaction conditions. 
 
Entry T [°C] 
Double bond 
geometry 
Cat. loading 
[mol%] 
Solvent 
DIPEA 
[eq.] 
Conv. 
[%]
[a]
 
ee 
[%]
[a]
 
1 25 (E) 1.0 MeOH 4.5 99 48 (+) 
2 0 (E) 2.0 MeOH 4.5 >99 64 (+) 
3 0 (E) 2.0 MeOH 0.5 92 65 (+) 
4 0 (E) 1.0 MeOH 0.1 31 70 (+) 
5 15 (E) 2.0 MeOH 9.0 32 79 (+) 
6 0 (E) 2.0 i-PrOH 9.0 >99 68 (+) 
7 25 (Z) 1.0 MeOH 4.5 >99 64 () 
8 0 (Z) 2.0 MeOH 4.5 >99 82 () 
9 0 (Z) 2.0 MeOH 0.5 98 78 () 
10 0 (Z) 1.0 MeOH 0.1 33 79 () 
11 15 (Z) 2.0 MeOH 9.0 51 88 () 
12 0 (Z) 2.0 i-PrOH 9.0 >99% 75 () 
[a] Determined by GC analysis on a chiral stationary phase. 
 
Furthermore, different catalysts were screened in the hydrogenation of the Citralis nitrile
® 
precursors (E)-6.68 and (Z)-6.69 (table 6.19). The catalysts showed the same order of 
selectivity as observed for the phenyl methyl analog 6.3 and no higher enantiomeric excess 
was reached. Therefore, no further screening of other catalysts was conducted. 
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Table 6.19: Hydrogenation of Citralis nitrile
® 
precursors (E)-6.68 and (Z)-6.69 with different catalysts. 
 
 
Entry Catalyst 
Double bond 
geometry 
Conv. [%]
[a]
 ee [%]
[a]
 
1 
 
(E)  >99  30 (+)  
2 (Z)  >99  2 (+)  
3 
 
(E)  33  19 (+)  
4 (Z)  65  14 ()  
5 
 
(E)  99  48 (+)  
6 (Z)  >99  65 ()  
7 
 
(E)  11  26 ()  
8 (Z)  21  34 (+)  
[a] Determined by GC analysis on a chiral stationary phase. 
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6.2.2 Hydrogenation of α,β-disubstituted α,β-unsaturated nitriles 
 
Having investigated so far β,β-disubstituted substrates, the focus was set on substrates 
containing a substituent at the α-position of the C=C bond. First, different catalysts in the 
hydrogenation of (Z)-2,3-diphenylacrylonitrile (6.2) were tested. Out of eight tested catalysts, 
enantioselectivities below 20% were obtained (table 6.20). Furthermore, the reactivity of each 
catalyst observed for substrate 6.2 was completely different compared to the phenyl methyl 
analog 6.3. For this substrate, only the pyridine-based catalysts achieved full conversion, 
whereas the ThrePHOX-based catalysts 6.21 and 6.20 gave only 25% product. 
 
Table 6.20: Catalyst screening in the hydrogenation of (Z)-2,3-diphenylacrylonitrile (6.2). 
Conversion determined by GC analysis on an achiral stationary phase. Enantiomeric excess determined by 
HPLC on a chiral stationary phase. 
 
The results outlined above were obtained before carrying out the optimization of the reaction 
conditions for the α,β-unsaturated nitriles described in section 6.2.1. Thus, it was decided to 
deploy the reaction conditions developed for α,β-disubstituted acrylonitriles also to their α,β-
disubstituted analogs. To this end, (E)-2-methyl-3-phenylacrylonitrile ((E)-6.72) and (Z)-2-
methyl-3-phenylacrylonitrile ((Z)-6.73) were subjected to the previously established 
conditions (table 6.21). Reduced reactivity and poor selectivity (ee up to 40%) were observed 
BASE-PROMOTED ASYMMETRIC HYDROGENATION OF α,β-UNSATURATED NITRILES  CHAPTER 6 
  
156 
in the hydrogenation of (Z)-6.73. The low enantioselectivity observed might be related to the 
isomerization of the C=C bond of the starting material under the reaction conditions. In fact, 
in the case of hydrogenations showing incomplete conversion, the unreacted acrylonitrile was 
detected as a mixture of (E)- and (Z)-isomer. Such an in situ isomerization could favor the 
coordination of the isomerized substrate to the metal center by the opposite enantioface and 
therefore might result in drastically reduced ee values. 
 
Table 6.21: Hydrogenation of (E)-2-methyl-3-phenylacrylonitrile ((E)-6.72) or (Z)-2-methyl-3-
phenylacrylonitrile ((Z)-6.73). 
 
 
Catalyst 
Substrate = (E)-6.72 Substrate = (Z)-6.73 
Conv. 
[%]
[a]
 
Isomerization 
[%]
[a]
 
ee 
[%]
[b]
 
Conv. 
[%]
[a]
 
Isomerization 
[%]
[a]
 
ee 
[%]
[b
 
 
>99  -- 5  >99  -- 40  
 
96  21 n.d.  96  20  n.d.  
 
11  1  n.d.  35  -- 20  
 
10  2  n.d.  9  -- rac  
[a] Determined by GC analysis on an achiral stationary phase; [b] Determined by HPLC on a chiral stationary 
phase. 
 
In order to fully test the applicability of this methodology, also the tetrasubstituted α,β-
unsaturated nitrile 6.75 was investigated as substrate in the asymmetric hydrogenation with 
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DIPEA as additive (table 6.22). Using the four complexes, which had been identified in the 
previous optimization of the reaction conditions as the most active and selective catalysts, 
only low conversion up to 6% was observed.  
 
Table 6.22: Hydrogenation of the tetrasubstituted (E)-2-methyl-3-phenylbut-2-enenitrile (6.75).  
 
Conversion determined by GC on an achiral stationary phase. 
 
Finally, (Z)-3-bromo-3-phenylacrylonitrile (6.77), which was readily synthesized by the 
conversion of benzoylacetonitrile with phosphorus tribromide, was tested with catalyst 6.20. 
Indeed, reduction of the C=C bond, but also cleavage of the C–Br bond was observed within 
1.5 hours, leading to the unfunctionalized achiral nitrile 6.78 (scheme 6.7)  
 
Scheme 6.7: (Z)-3-Bromo-3-phenylacrylonitrile (6.77) as substrate in the base-promoted hydrogenation. 
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6.2.3 DIPEA as additive in the hydrogenation of other substrate classes 
 
To investigate the scope of the base-activated catalysts system, substrates other than 
unsaturated nitriles were subjected to hydrogenation with DIPEA as additive and catalyst 6.5. 
This iridium complex was chosen as it displayed some reactivity for both β,β-disubstituted 
and α,β-disubstituted α,β-unsaturated nitriles. As substrates, unfunctionalized olefins S1, S5, 
6.79, α,β-unsaturated ester S9, α,β-unsaturated ketone S13, prochiral imine S14 and different 
α,β-unsaturated carboxylic acids 6.81, 6.82, 6.83, which have been successfully hydrogenated 
with Ir-complexes by Zhou and co-workers in the presence of a base,
[36-37, 64a]
 were selected 
(table 6.23). In this series, reactivity was observed for the α,β-unsaturated ester S9 and the 
α,β-unsaturated ketone S13 but conversion remained below 25%. For all other substrates no 
conversion at all was registered. 
 
Table 6.23: Hydrogenation of different substrates under base-promoted conditions. 
Conversion determined by GC on an achiral stationary phase. 
 
These results indicate, that the cyano group is essential for catalytic activity under basic 
conditions. Therefore, control experiments were performed, where two unfunctionalized 
olefins were mixed in a one to one ratio with the α,β-unsaturated nitrile 6.3 and subjected to 
hydrogenation conditions (scheme 6.8). Indeed, both tested substrates without a cyano group 
on the C=C bond showed no significant conversion, whereas the double bond of the α,β-
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unsaturated nitrile 6.3 was reduced with full conversion and similar enantioselectivity as 
observed in the absence of another substrate. 
 
 
Scheme 6.8: Hydrogenation of unfunctionalized olefins in the presence of (E)-3-phenylbut-2-enenitrile (6.3). 
 
In order to further explore the applicability of the methodology, the β,β-disubstituted 
nitroalkene 6.83 was synthesized. This should represent a substrate class with a more electron 
deficient C=C bond (table 6.24). However, for this substrate only moderate reactivity with up 
to 31% conversion was observed. Furthermore, the order of reactivity of the tested catalysts 
changed notably compared to the hydrogenation of α,β-unsaturated nitrile 6.3. 
 
Table 6.24: Hydrogenation of (E)-(1-nitroprop-1-en-2-yl)benzene (6.83) under base-promoted conditions. 
Conversion determined by GC on an achiral stationary phase. 
 
Finally the two coumarin derivatives 6.85 and 6.87 were investigated. It should be noted, that 
for these substrates no reactivity under base free conditions was observed (see chapter 3). 
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Indeed, addition of base resulted in increased reactivity and 74% and >99% conversion 
respectively were obtained (scheme 6.9). However, the products were racemic. 
 
Scheme 6.9: Hydrogenation of the coumarin derivates 6.85 and 6.87. 
 
In order to further explore why α,β-unsaturated nitriles were hydrogenated with high 
enantioselectivity, whereas unfunctionalized olefins were not reduced under the same reaction 
conditions, a deeper investigation of the reaction parameters was performed. For example, 
applying catalyst 6.20 in the hydrogenation of the three selected unfunctionalized olefins 
under standard base-free reaction conditions, full conversion was observed for all of them 
(scheme 6.10, A).
[28b]
 However, in MeOH, which gave excellent results in the hydrogenation 
of α,β-unsaturated nitriles, the raction resulted in reduced conversions and considerably 
reduced enantioselectivity (scheme 6.10, B). Furthermore, by the addition of DIPEA catalyst 
6.20 showed almost no reactivity (scheme 6.10, C). Hydrogenation of a 1:1 mixture of (E)-3-
phenylbut-2-enenitrile (6.3) and the unfunctionalized olefin S1, S2 or S5, less than 1% 
conversion was detected for all three unfunctionalized olefins. On the other hand the α,β-
unsaturated nitrile 6.3 was reduced with full conversion and with identical enantiomeric 
excess as in the absence of an unfunctionalized olefin (scheme 6.10, D). The observed 
chemoselectivity demonstrates the capability of this protocol to selectively reduce the C=C 
bond of an α,β-unsaturated nitrile in the presence of other less electrophilic double bonds. 
BASE-PROMOTED ASYMMETRIC HYDROGENATION OF α,β-UNSATURATED NITRILES  CHAPTER 6 
  
161 
 
 
Scheme 6.10: Reactivity and selectivity studies of -unsaturated nitriles and unfunctionalized alkenes. 
 
Since so far this chemoselectivity was demonstrated on intermolecular systems, it was of 
interest to test whether this protocol could also be successfully applied to α,β-unsaturated 
nitriles containing an additional unfunctionalized C=C bond like 6.94. The synthesis of 
compound 6.94 was accomplished by protection of 4'-bromoacetophenone (6.89), followed by 
Grignard addition to acetone and subsequent saponification of the acetal to afford the 
acetophenone derivative 6.91. Elimination of the tertiary alcohol 6.91 followed by a Horner–
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Wadsworth–Emmons reaction with ketone 6.92 resulted in the formation of the desired α,β-
unsaturated nitrile 6.94 in 4 steps and 61% overall yield (scheme 6.11). 
 
 
Scheme 6.11: Synthesis of α,β-unsaturated nitrile 6.94. 
 
Applying the substrate 6.94 in the Ir-catalyzed hydrogenation in the presence of DIPEA again 
a remarkably high chemoselectivity in favor of the double bond conjugated to the cyano 
group over the terminal C=C bond was observed. Under optimized conditions a ratio of 93.2 
to 6.2 for the monohydrogenated product 6.95 was observed, with 96% ee for the major 
species (table 6.25, entry 11). This high chemoselectivity is remarkable considering the high 
reactivity of terminal C=C bonds under standard base-free conditions (1-(but-1-en-2-yl)-4-
methoxybenzene, 1.0 mol% catalyst 6.20, 0 °C, 1 bar H2, 30 min reaction time, full 
conversion).
[28b]
 
 
Table 6.25: Hydrogenation of the α,β-unsaturated nitrile 6.94 containing an additional terminal double bond. 
 
Entry Cat. 
Cat.  
[mol%] 
solvent 
T 
[°C] 
p(H2) 
[bar] 
6.95 
[%] 
6.96 
[%] 
6.97 
[%] 
6.95 
ee 
[%] 
1
[a]
 
 
3.0 MeOH 25 100 44 18 18 n.d. 
BASE-PROMOTED ASYMMETRIC HYDROGENATION OF α,β-UNSATURATED NITRILES  CHAPTER 6 
  
163 
2
[a]
 
 
0.5 MeOH 25 50 84 0 4 n.d. 
3
[a]
 
 
1.0 MeOH 25 100 71 0 29 n.d. 
4
[a]
 0.5 MeOH 25 50 77 0 23 n.d. 
5
[a]
 1.0 toluene 25 100 84 0 4 n.d. 
6
[a]
 1.0 CH3CN 25 100 91 0 4 96 
7
[a]
 0.5 MeOH 25 50 78 0 22 95 
8
[b]
 0.3 MeOH 25 100 71 0 29 87 
9
[b]
 0.2 MeOH 25 100 80 0 20 89 
10
[b]
 0.1 MeOH 25 100 87 0 13 88 
11
[a]
 1.0 MeOH 0 100 93.2 0 6.2 96 
Conversion determined by GC on an achiral stationary phase. Enantiomeric excess determined by HPLC on a 
chiral stationary phase. [a] 4.5 eq. DIPEA were used; [b] DIPEA: 10 fold in terms of cat.-loading. 
 
In order to further demonstrate the scope of this chemoselective hydrogenation method, an 
additional molecule containing two double bonds, geranyl nitrile was explored. In the 
hydrogenation of the commercially available (E/Z)-mixture (ratio ~1:1) 30% conversion in 
toluene with no preference for either the (E)- or the (Z)-isomer was observed (scheme 6.12). 
After separation of the (E/Z)-isomers by semi-preparative HPLC and hydrogenation in 
methanol full conversion to the mono-reduced nitrile 6.100 was observed starting from pure 
(E)-substrate 6.98. In this case the unfunctionalized double bond remained completely 
untouched (scheme 6.12). Although no conditions for the determination of the enantiomeric 
excess were found, this example further demonstrates the high selectivity to reduce double 
bonds in conjugation to a cyano group by the use of this base-promoted protocol. 
 
Scheme 6.12: Hydrogenation of geranyl nitrile under base-promoted conditions.
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6.3 Influence of the counterion in base-promoted hydrogenations 
 
Next, the influence of the counterion was investigated. BArF emerged as the counterion of 
choice for iridium-based catalysts used in the hydrogenation of C=C bonds.
[71a]
 As discussed 
in detail in chapter one, BArF as counterion was found to suppress the formation of 
catalytically inactive trinuclear Ir clusters, in contrast to more strongly coordinating 
counterions such as PF6.
[25]
 Therefore, BArF complexes display significantly higher catalytic 
activity and turnover numbers.
[19]
 Furthermore iridium complexes are less sensitive to 
moisture and air. In fact, reactions usually can be set up under normal atmosphere without the 
need of specially dried solvents. Therefore, BArF salts of iridium complexes are considerably 
more robust and easier to handle, compared to their PF6-analogs.
[24]
 On the other hand, 
compared to PF6, the BArF counterion is more expensive and has a higher molecular weight, 
that accounts for about one half of the overall weight of the catalyst. Therefore, the 
replacement of BArF as counterion with a less expensive, lighter anion would result in an less 
expensive catalysts with lower molecular weight. As the base-promoted Ir-catalyzed 
hydrogenation behaves differently compared to previously reported systems, the influence of 
the counterion was investigated by applying iridium complexes, with different counterions 
(table 6.26). Indeed, by comparing the same cationic complexes with PF6 and BArF as 
counterions, no difference in terms of catalytic activity and selectivity could be observed 
neither for catalyst 6.5 (entry 1 vs. 2) nor 6.12 (entry 3 vs. 4). 
 
Table 6.26: Hydrogenation of α,β-unsaturated nitrile 6.3 with catalysts containing different counterions. 
 
Entry Catalyst Counterion Conv. [%]
[a]
 ee [%]
[b]
 
1 
 
BArF 32 -- 
2
[c]
 PF6 32 -- 
3 
 
BArF 13 21 () 
4 PF6 12 21 () 
[a] Determined by GC analysis on an achiral stationary phase; [b] Determined by HPLC on a chiral stationary 
phase; [c] Average value of two runs. 
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This observation suggested the possibility to design complexes with a completely different 
counterion, in order to tune the catalyst. A chloride would probably be the cheapest 
alternative but these complexes showed significantly reduced conversions. As just shown, the 
PF6 counterion gave no particular advantage in terms of reactivity when compared to BArF. 
Moreover, despite the lower cost of PF6, the ThrePHOX catalyst 6.20 is commercially 
available as BArF complex and its conversion to the PF6 equivalent would have to bring 
appreciable advantage to justify its preparation and use. Therefore, the idea came up to use a 
basic counterion, which might overtake the role of DIPEA in the reaction. Hence, for 
exploratory studies conducted in this direction the applicability of 2,6-di-tert-butylphenolate 
6.103, which contains a sterically shielded oxygen atom, was investigated as counterion. 
However, all attempts to obtain the corresponding iridium complex 6.105 failed. The reaction 
mixture turned increasingly black and a black precipitate was collected, which could not be 
structurally characterized. Based on the observed color and the insolubility of the precipitate 
in organic solvents, most likely metallic iridium species was formed. Formation of metallic 
precipitates could be explained by the reduction of the Ir complex by the electron rich 
phenolate 6.103. Therefore, the more electron deficient 2,6-di-tert-butyl-4-nitrophenolate 
6.104 was tested, and indeed the desired complex 6.106 could be isolated in 83% yield 
(scheme 6.13). 
Scheme 6.13: Synthesis of phenolate analogs of PHOX-iridium complexes. 
 
With this new catalyst in hand, its applicability to the hydrogenation of unsaturated nitrile 6.3 
in the absence of DIPEA in CH2Cl2 as solvent was tested. Indeed, this iridium phenolate 
complex 6.106 showed similar conversion and enantiomeric excess as observed with the 
BArF-analog of this catalyst with DIPEA as additive (table 6.27). 
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Table 6.27: Hydrogenation of α,β-unsaturated nitrile 6.3; comparison of BArF and 2,6-di-tert-butyl-4-
nitrophenolate as counterion. 
 
Entry 
Catalyst loading 
[mol%] 
DIPEA [eq.] Counterion Conv. [%]
[a]
 ee [%]
[b]
 
1 1.0 4.5. BArF 10 33 () 
2 2.0 9.0 BArF 20 33 () 
3 3.0 -- 
2,6-di-tert-butyl-
4-nitrophenolate 
28 32 () 
[a] Determined by GC analysis on an achiral stationary phase; [b] Determined by HPLC on a chiral stationary 
phase. 
 
Next, this concept was tested on a ligand complex which emerged to be more selective and 
reactive in the hydrogenation of αβ-unsaturated nitriles. Therefore, the SerPHOX complex 
bearing 2,6-di-tert-butyl-4-nitrophenolate as counterion was synthesized, for which the ligand 
was readily available in our group (scheme 6.14, A). The phenolate complex 6.108 was 
obtained in moderate yields and, in contrast to the previously described complex 6.106, this 
catalyst turned out to be not stable for 24 h in CD2Cl2 solution. The 
31
P NMR showed several 
new species and a considerable amount of precipitate was observed in the NMR tube (scheme 
6.14, B). 
 
Scheme 6.14: Synthesis of catalyst 6.108, A; 
31
P NMR spectra of complex 6.108 after isolation and after 24 h in 
CD2Cl2, B. 
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Nevertheless, the applicability of this complex in the hydrogenation of various α,β-
unsaturated nitriles was tested. Comparing the results to those obtained with the BArF analog 
6.20 and DIPEA similar selectivity was achieved (table 6.28). With 92% conversion at 
0.2 mol% catalyst loading still high reactivity was observed although the maximum 
achievable turnover numbers are lower than with the DIPEA-modified catalyst system. 
 
Table 6.28: Hydrogenations of α,β-unsaturated nitrile 6.3 using iridium phenolate complex 6.106 at reduced 
catalyst loading. 
 
Entry 
Catalyst 
loading [mol%] 
Time [h] Conv. [%]
[a]
 ee [%]
[b]
 
1 1.0 4 >99 94 (+)  
2 0.5 4 >99 94 (+)  
3 0.2 4 92 92 (+)  
4 0.1 4 31 95 (+)  
5 0.05 16 4 95 (+)  
6 0.05 72 7 94 (+)  
[a] Determined by GC analysis on an achiral stationary phase; [b] Determined by HPLC on a chiral stationary 
phase. 
 
In view of to the high catalytic activity of the phenolate complex, its applicability in the 
hydrogenation of unfunctionalized olefins was tested (scheme 6.15, A). By using 1 mol% 
catalyst loading, for trans-methylstilbene S1 less than 1% conversion was obtained, whereas 
for the terminal olefin S4 only 4.8% conversion was observed. Furthermore, the phenolate salt 
6.108 showed high chemoselectivity in the hydrogenation of substrate 6.94. Although only 
47% conversion at 0.5 mol% catalyst loading was reached, the catalyst showed a high 
preference of 47:1 for the double bond conjugated to the cyano group (scheme 6.15, B). The 
newly synthesized phenolate complex 6.108 is soluble in the test substrate 6.3 and therefore 
the hydrogenation was performed without a solvent. At 0.05 mol% catalyst loading slightly 
higher conversion than in CH2Cl2 was obtained, but the enantiomeric excess dropped to 84% 
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(scheme 6.15, C), close to the value which was observed performing the reaction in 
acetonitrile as solvent. 
 
 
Scheme 6.15: Hydrogenations conducted with iridium complex 6.108. 
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6.4 Mechanistic studies 
 
The experimental observations obtained in the previous chapters indicate, that the base-
modified catalyst system must operate through a different mechanism than under standard 
base-free conditions, for which the mechanism was discussed in chapter 1. Thus the question 
came up on the role of DIPEA, how it affects the reaction mechanism and whether 
mechanistic insight could be used to develop a more efficient catalyst system. The starting 
point for mechanistic studies was the iridium(III)-dihydride species 6.13 (scheme 6.5), which 
was isolated and characterized by standard analytical methods. 
In order to check if the formation of iridium(III)-dihydride-dinitrile-species, such as 6.13, is a 
dead-end of the catalytic cycle and if DIPEA as additive might avoid the formation of such a 
species, (E)-3-phenylbut-2-enenitrile (6.3) and catalyst 6.20 were subjected to hydrogenation 
conditions without DIPEA, to from the corresponding iridium(III) species of catalyst 6.20. An 
aliquot was taken from the colorless reaction mixture, which revealed no conversion of the 
α,β-unsaturated nitrile 6.3 after four hours. DIPEA was added and the reaction mixture was 
again subjected to the same hydrogenation conditions as before. Analysis of the reaction 
mixture 16 hours after addition of DIPEA revealed full conversion to the saturated nitrile 6.17 
with the same enantiomeric excess, as when DIPEA was added before applying hydrogen 
pressure (scheme 6.16). Similar behavior was observed when the isolated PHOX-based 
iridium(III)-dihydride-dinitrile-species 6.13 was applied in the hydrogenation of the α,β-
unsaturated nitrile 6.3 in the presence of DIPEA. These results demonstrate that the active 
catalytic species can be generated from inactive iridium complexes, such as 6.13. 
 
 
Scheme 6.16: Addition of DIPEA after the inhibition of the catalyst. 
 
Based on the strong affinity of the cyano group to coordinate to the metal center, it was 
speculated that one substrate molecule might be bound during the enantioselectivity 
determining step to the metal center. In one scenario, one of the two substrate molecules 
which are coordinated to the metal center in pure CH2Cl2 (C, scheme 6.17), might remain 
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coordinated after the addition of base over the course of the reaction. In this case an influence 
on the enantiomeric excess and conversion could be expected. Therefore, the following 
experiments were performed (scheme 6.16).  
First, a mixture of iridium complex (cat) and different nitriles (A) in a ratio of 1:10 was 
activated under weak pressure of H2 in CH2Cl2. During the activation period iridium(III)–
dihydride-species of type C should be formed. Afterwards the desired substrate (B) and 
DIPEA were added and the reaction mixture was subjected to hydrogenation conditions 
(100 bar H2). 
 
 
Scheme 6.17: Schematic diagram to illustrate the protocol applied to test for a coordination of a substrate during 
the enantioselectivity determining step. 
 
In the different combinations of nitriles, substrates and catalysts tested no significant 
influence on the enantioselectivity was observed compared to the usual hydrogenation 
procedure (table 6.29, entry 1). The application of an achiral catalyst in combination with 
enantioenriched nitriles resulted in racemic samples (entry 5 and 6). When enantiopure 
catalysts were used only small differences in the enantioselectivity were observed. Such a 
small difference might also result from the different protocol applied. Furthermore, it was 
tested, if the conversion of substrate 6.64 might by increased with this “preactivation” of the 
catalyst (entry 11). But also in this case similar activity was observed. In light of these results, 
a coordination of a cyano group to the metal center during the enantioselectivity determining 
step cannot be excluded, but this assumption led not to the development a more efficient 
protocol for the base-promoted hydrogenation of α,β-unsaturated nitriles.  
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Table 6.29: Hydrogenations starting from different iridium(III)–dihydride-species of type C (scheme 6.16). 
 
Entry Cat. 
Cat. 
loading 
[mol%] 
A B 
Conv. (B) 
[%] 
ee (B) [%] 
1
[a]
 6.20 0.5 -- 6.62 >99 98 (+) 
2
[a]
 6.20 0.5 6.17 6.62 >99 95 (+) 
3
[a]
 6.20 0.5 6.17-() 6.62 >99 97 (+) 
4
[a]
 6.20 0.5 6.17-() 6.62 >99 97 (+) 
5
[a]
 6.111 3.0 6.17-() 6.62 >99 rac 
6
[a]
 6.101 3.0 6.17-() 6.62 >99 rac 
7
[b]
 6.20 1.0 6.17 (E)-6.98 >99 53 (+) 
8
[b]
 6.20 1.0 -- (E)-6.98 99 48 (+) 
9
[b]
 6.20 1.0 6.17 (Z)-6.99 >99 65 () 
10
[b]
 6.20 1.0 -- (Z)-6.99 >99 70 () 
11
[a]
 6.20 1.0 6.109 6.64 9 -- 
12
[a]
 6.20 1.0 -- 6.64 6 -- 
[a] Coversion determined by GC analysis on an achiral stationary phase; ee determined by HPLC on a chiral 
stationary phase; [b] Conversion and the ee determined by GC analysis on a chiral stationary phase. 
 
Based on a previously conducted experiments obtaining 70% conversion of the α,β-
unsaturated nitrile 6.3 with 0.1 eq. DIPEA in toluene (table 6.5, entry 7), a stoichiometric 
reaction of the base with the substrate can be excluded. Therefore, it is reasonable to assume a 
catalytic effect of the base. One possibility is a deprotonation step being involved in the 
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generation of the active catalytic species. As previously demonstrated, under hydrogen 
atmosphere the COD-ligand is reduced to cyclooctane and iridium(III)-dihydride-species, 
such as 6.13, are formed.
[113]
 Ir-hydrides of this type are known to be strong Brønsted acids.
[41]
 
Thus, the hydrides of such a iridium(III)-dihydride-species might be acidic enough to be 
deprotonated by DIPEA. Furthermore, starting from these intermediates it might be possible 
that iridium(V)-hydride species can be formed under hydrogen pressure, similar to those 
iridium(V)-hydride species postulated by Burgess and co-workers (figure 6.1). A pka of 9.8 in 
acetonitrile was calculated for such a putative intermediate for phosphinite-based ligand 
6.112.
[41]
  
 
 
 
Figure 6.1: Acidity calculated by Burgess and co-workers for selected ligands on putative iridium(IV)-
intermediates in hydrogenations. 
 
Hence, the activation of such iridium(III)-dihydride-species, such as 6.13, was tested. In this 
case, instead of DIPEA sodium hydride was added to the reaction mixture. Also for this 
experiment 74% conversion to the saturated nitrile and 94% enantiomeric excess was 
observed (scheme 6.18, A). Therefore, the reaction can be triggered by a base without a 
potentially additional heteroatom. As next experiment a possible incorporation of protons 
from protic solvents such as methanol was investigated by a labeling study with deuterium 
gas. Such a incorporations might be a hint for a deprotonation step involved in the catalytic 
cycle which is not irreversible. As full incorporation of the deuterium in the final product was 
observed (scheme 6.17, C), proton transfer from solvent to catalyst can be ruled out. 
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Scheme 6.18: Several experiments conducted to gain an insight on the mechanism of this reaction. 
 
Further investigations on iridium(III)-dihydride intermediates were performed in close 
collaboration with Dr. C. Kohrt during her two month PhD exchange within the research 
group of Prof. A. Pfaltz and are reported in this section (page 170 to 172) to reveal a complete 
picture of the mechanistic studies conducted in this project. The major goal of this study was 
to obtain the corresponding iridium(III)-dihydride-species of the most active catalysts and 
detect a deprotonation step starting from these intermediates. Therefore, the most selective 
catalyst 6.20 and the most reactive catalyst 6.23 were tested. 
During careful investigation of different reaction conditions, which should lead to the 
isolation of the ThrePHOX-iridium(III)-dihydride species 6.114 it was found that the desired 
species could be obtained in solution. After removal of the solvent the 
1
H NMR spectrum 
showed the signal of a monohydride, which could not be structurally characterized. However, 
after addition of nitrile 6.3 to a solution containing the mixture of the monohydride species 
and complexe 6.114 under hydrogen atmosphere the monohydride species was converted to 
the dihydride-species 6.114 (scheme 6.19). 
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Scheme 6.19: Formation of the ThrePHOX-iridium(III)-dihydride species 6.114 and decomposition by the 
applied work-up. 
 
Next, the behavior of catalyst 6.23, which was the only catalyst that showed complete 
conversion at 1 bar hydrogen pressure, was investigated. Also this catalyst showed not such 
clean spectra as observed for the PHOX-based iridium complex 6.12. In the case of catalyst 
6.23 the 
31
P NMR spectra showed the formation of 2 different species in the presence of 
nitrile 6.3 under hydrogen atmosphere. By applying different reaction conditions it was 
possible to selectively isolate both species. The assignment of the identity of the first species 
was not possible with certainty. The second species was assigned to the expected iridium(III)-
dihydride-species analogous to 6.115 of catalyst 6.23. In this case, several hydride signals 
were observed. Furthermore, the 
31
P NMR spectra showed only one species. NMR 
experiments at 40 °C resulted in a splitting of the phosporus signal into 3 different peaks. By 
further NMR experiments, it was shown that the different hydride species are in exchange 
with each other and contain two different conformers of the expected dihydride-species 6.115 
of catalyst 6.23.  
As next step, a possible deprotonation of the different dihydride species was investigated by 
adding different equivalents of DIPEA to the different dihydride species. For the PHOX 
derived iridium(III)-dihydride-species 6.13 no change in the NMR spectrum was observed. 
The addition of DIPEA to the iridium(III)-dihydride-species 6.114 of the ThrePHOX catalyst 
6.20 resulted in the formation of many different species. Only the pyridine-based iridium(III)-
dihydride-species 6.115 was converted in the presence of 1.0 eq. DIPEA into a single species 
(scheme 6.20). This compound was identified as the dinuclear complex 6.116 containing three 
hydrides and revealing a C–H insertion in each phenyl unit. This dinuclear complex was first 
observed by Dr. Andreas Schumacher in the context of diene reductions, and its structure was 
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verified by single crystal X-ray analysis.
[77]
 In hydrogenation experiments no reactivity of this 
dinuclear cluster for α,β-unsaturated nitrile 6.3 was observed. Therefore, it can be considered 
as a dead-end of the catalytic cycle.  
 
Scheme 6.20: Identification of the C–H inserted dinuclear cluster 6.116, A; which showed no reactivity in the 
hydrogenation of the α,β-unsaturated nitrile 6.3, B. 
 
All the experiments conducted so far did not lead to the identification of a 
deprotonation step involved in the catalytic cycle. In an attempt to demonstrate that such a 
deprotonation actually occurs, further studies using the SerPHOX-phenolate iridium complex 
6.108 in the hydrogenation of α,β-unsaturated nitriles were conducted. In the case of this 
catalyst a perfect ratio of metal to base is predefined by its structure. Indeed, subjecting this 
catalyst to hydrogen atmosphere, the 
31
P NMR spectrum showed selective formation of only 
one new compound with a P signal at 88.2 ppm compared to 99.9 ppm for catalyst 6.108 
(scheme 6.21). The 
1
H NMR spectrum revealed the formation of four new signals in the 
hydride region with a ratio of 1:1:2:2. One hydride as triplet at 7.02 ppm with a coupling of 
81 Hz, a singlet at 8.23 ppm, a multiplet at 17.00 ppm and a singlet at 19.99 ppm. Based 
on NMR spectroscopy, the structure of this species was assigned to the C2 symmetric 
dinuclear iridium species 6.117 bearing two bridging hydrides. One of these hydrides is 
located trans to two phosphorus atoms resulting in the triplet with 81 Hz coupling (green). 
The other bridged hydride with an integral of one occurs as singulet at 8.31 ppm (blue). The 
signals with an integral of two belong to two pairs of terminal hydrides. The first pair of 
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terminal hydrides (red) is located in axial position trans to a nitrogen atom and on the 
opposite side of the plane defined by the two iridium atoms and the two bridging hydrides. 
The other pair (brown) is found in the plane defined by the two iridium atoms and the two 
bridging hydrides. Overall this complex is neutral and the shift of the obtained hydrides is 
similar to a neutral dinuclear complex of this geometry observed for hemilabile pincer ligands 
described by Gusev and co-workers.
[121]
 
 
 
Scheme 6.21: Observed dimeric species 6.117 after applying hydrogen atmosphere to complex 6.108, A; 
hydride region of the 
1
H NMR spectrum, B; 
31
P NMR spectrum, C. 
 
With this dinuclear iridium complex in hand, several hydrogenations were performed. First, 
the dinuclear iridium complex 6.117 was applied as catalyst in the hydrogenation of the α,β-
unsaturated nitrile 6.3. It was found that significantly different results were obtained 
depending on the handling of the dinuclear iridium complex 6.117. Significantly reduced 
conversion and selectivity compared to hydrogenations by the phenolate complex 6.108 were 
observed when the dinuclear iridium complex 6.117 was stored for 4 h under inert conditions 
in solution (scheme 6.22, A). If dimer 6.117 was used directly after formation, the reaction 
gave 88% conversion and 90% ee, similar to the results obtained with phenolate complex 
6.108. Furthermore, complex 6.117 showed only 1.5% conversion in the hydrogenation of the 
stilbene S1 with 2.0 mol% catalyst based on iridium. Taking into account that complex 6.117 
already contains six hydrides, the question came up if it can be used as a stoichiometric 
hydrogenation reagent. Unfortunately, no conversion was obtained by stirring the 
hexahydride-dimer 6.117 in the presence of the α,β-unsaturated nitrile 6.3. 
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Scheme 6.22: Several experiments conducted with the dinuclear iridium complex 6.117. 
 
Although it was not possible to demonstrate the occurance of a deprotonation step in the base-
promoted hydrogenation of the α,β-unsaturated nitriles, several experiments support this 
hypothesis. A neutral iridium hydride complex formed by a deprotonation would be expected 
to be less electrophilic and, consequently, release a bound nitrile more easily, opening up a 
free coordination site, which is required for the reaction. Moreover, the hydride would be 
more nucleophilic than hydrides in a cationic dihydride complex, facilitating hydride transfer 
to the electrophilic C=C bond of an -unsaturated nitrile. 
 
6.5 Conclusion 
 
In summary, it was found that addition of an external sterically hindered amine base or the 
presence of a basic counterion in the catalyst dramatically enhance the catalytic activity of 
iridium N,P ligand complexes in the hydrogenation of -unsaturated nitriles. While these 
catalysts show no reactivity towards -unsaturated nitriles under base-free conditions, the 
base-activated catalyst systems allow smooth hydrogenation at low catalyst loadings, 
affording the corresponding saturated nitriles with high conversion and excellent 
enantioselectivity. In contrast, other alkenes lacking a conjugated cyano group do not react 
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under these conditions. So it becomes possible to selectively reduce the cyano-substituted 
C=C bond of an -unsaturated nitrile, leaving other types of C=C bonds in the molecule 
intact. Thus the catalyst systems described herein enable enantio- and chemoselective 
hydrogenations, for which no suitable catalysts were available before. 
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7.1 Introduction 
As demonstrated in the previous chapters, the asymmetric hydrogenation with iridium N,P 
ligand complexes has emerged as an efficient tool for the introduction of stereogenic centers 
starting from prochiral olefins. Although, when compared to other catalysts based on Ru and 
Rh, they have found more limited application,
[11b]
 this is mainly due to the fact that Rh- and 
Ru-based catalyst have been investigated since long before the first successful application of 
chiral iridium-based N,P ligand complexes was reported in 1998.
[19]
 In addition, iridium-
based catalysts normally do not achieve high turnover numbers, as those that can be reached 
by Rh- or Ru-based systems in the hydrogenation of prochiral alkenes. Furthermore, for those 
catalysts the mechanism is well understood.
[122]
 For iridium-based systems, many experiments 
and calculations have been conducted, based on Ir
I/III 
or Ir
III/V 
catalytic cycles proposing 
different pathways, but on the obtained data it is difficult to draw a definite conclusion at this 
point.
[46, 123]
 
A fundamental impact on the design of more reactive and stable catalysts is based on the 
understanding of the catalytic cycle, but also the elucidation of decomposition pathways, 
generating catalytically inactive or less stereoselective species, plays a crucial role. In this 
context, it was demonstrated in previous studies that iridium-based catalysts bearing 
monodentate N and P ligands, such as [Ir(COD)(PCy3)(py)]PF6, form trimeric and tetrameric 
iridium hydride clusters under hydrogenation conditions.
[26, 124]
 This behavior was also 
observed for iridium-based catalyst 7.1 bearing a chiral bidentate N,P ligand. Upon treatment 
of [Ir(COD)(PHOX)]PF6 7.1 with hydrogen, the formation of the trinuclear cluster 7.2 was 
observed (scheme 7.1).
[25]
 
 
Scheme 7.1: Formation of the catalytically inactive trinuclear cluster 7.2. 
 
All of these iridium polyhydride clusters are inactive as hydrogenation catalysts and all efforts 
to convert the trinuclear cluster 7.2 into an active catalytic species were not unsuccessful, so 
far.
[25]
 Therefore, the formation of these clusters reveals a pathway whose understanding and 
suppression should result in the development of more efficient hydrogenation processes.  
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Recent studies facing this issue were conducted in our research group by Dr. Stefan 
Gruber.
[125]
 In the course of his investigations it was found that Ir-SimplePHOX catalyst 7.3 is 
converted almost quantitatively (>95%) to dimeric Ir-hydride complex 7.4 in the presence of 
[H(OEt2)2]BArF (scheme 7.2). 
 
 
 
Scheme 7.2: Dimeric Ir-hydride complex 7.4 obtained in the presence of [H(OEt2)2]BArF. 
 
[H(OEt2)2](BArF) was employed as acidic additive to suppress the formation of the 
corresponding trinuclear complex which needs the liberation of a proton (see scheme 7.1). 
When the reaction was repeated in the absence of [H(OEt2)2](BArF), the formation of ~20% 
of corresponding trinuclear complex of this type as 7.2 was observed by 
1
H NMR under 
otherwise identical reaction conditions.  
Further, it was shown during this study that by the addition of acetonitrile it is possible to 
break up dinuclear clusters like 7.4. This behavior was not observed while stirring the 
trinuclear clusters 7.2 in the presence of acetonitrile. In addition, the dinuclear clusters 
described by Dr. Stefan Gruber showed notable catalytic reactivity in the hydrogenation of 
unfunctionalized olefins. Such observations led to the assumption that dinuclear clusters can 
be split by olefins and to go one step further, also by the addition of 1,5-cyclooctadiene (COD) 
to regenerate the precatalyst used in the asymmetric hydrogenation. Indeed, by the addition of 
COD to the dimer 7.4, complete and clean regeneration of catalyst 7.3 was achieved (scheme 
7.3). Further to these results, efforts were made in collaboration with Dr. Stefan Gruber to 
establish a method for the recovery of Ir catalysts from reaction mixtures. Results of such 
investigations are discussed in this chapter. 
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Scheme 7.3: Quantitative recovery of catalyst 7.3 by the addition of COD. 
 
 
7.2 Formation of dimeric iridium complexes in solution 
 
The above observation led to the idea that it should be possible to suppress the formation of 
trimers during the hydrogenation reaction by the addition of an acid, such as [H(OEt2)2]BArF. 
However, even the addition of a catalytic amount of [H(OEt2)2]BArF had a detrimental effect 
on the reactivity and selectivity of the hydrogenation reaction.
[125]
 To explore the applicability 
of this concept, the behavior of different catalysts under hydrogen pressure in the absence of 
substrate was investigated. The goal was to get an insight on how fast and to what extent 
dimeric and trinuclear iridium complexes were formed. At first, the pyridine-based catalyst 
7.5 was considered, as it shows high efficiency in the hydrogenation of tocopherol side-chain 
precursors and -tocotrienyl acetate (see chapter 4),[53b, 53c, 126] and therefore is at the moment 
the most promising candidate for a possible industrial application. Moreover, the synthesis of 
this catalyst is rather laborious and hence represents one of the most interesting candidates for 
recovery of the catalyst. Therefore, NMR studies were conducted to gain a first impression on 
how this catalyst reacts in the absence of a substrate under hydrogen pressure. Hence, catalyst 
7.5 was dissolved in CD2Cl2 and stirred under 50 bar hydrogen pressure for 2 h (scheme 7.4). 
Interestingly, the NMR spectra revealed the formation of almost exclusively one species. Also 
after longer reaction times under a hydrogen atmosphere no significant decomposition of this 
species or conversion to a polynuclear cluster could be detected. After evaluation of the NMR 
spectra, the species could be assigned as the dinuclear iridium hydride complex 7.6, bearing in 
total four hydrides, two bridging hydrides and one on each metal center in axial position on 
the opposite side of the Ir2(-H)2 plane. The anti orientation of the two phosphinite units 
confers a C2 symmetry to the dimer, with the rotation axis through the two bridging hydrides. 
Only small amounts (<5%) of different hydride species were formed. However, it was found 
by NOE experiments that these species are in exchange with the dimer in its major 
conformation. 
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Scheme 7.4: Formation of the new dinuclear hydride complex 7.6 from catalyst 7.5 (□ refers to a vacant 
coordination site). 
 
With this result in hand, the behavior of the dimer 7.6 was further investigated. In particular, 
it was interesting to ascertain whether such dimer could be reconverted to the precatalyst 7.5 
by addition of COD, whether it would be catalytically active and how would it react upon 
addition of a substrate. First, the isolation of the dimer 7.6 by simple evaporation of the 
solvent was tested. Indeed, the dimer could be isolated when carefully handled under an argon 
atmosphere and only slow decomposition was observed by storing it at 25 °C under an inert 
atmosphere. This allowed us to compare the catalytic behavior of dimer 7.6 and its precursor 
complex 7.5 (table 7.1). The comparison of both metal complexes showed a somewhat higher 
reactivity for the metal complex bearing the COD ligand 7.5. Only trans-α-methylstilbene S1, 
showed similar low conversion. The enantiomeric excesses induced by the dimer 7.6 and its 
precursor catalyst 7.5, were identical. 
 
Table 7.1: Comparison of catalyst 7.5 and dimer 7.6 in the hydrogenation of selected substrates. 
 
 
Conversion determined by GC on an achiral stationary phase; Enantiomeric excess determined by HPLC on a 
chiral stationary phase.  
7.3 Influence of the counterion for catalyst 7.5 
 
As already discussed in the case of iridium PHOX catalysts, the counterion has a significant 
influence on the conversion reached in the hydrogenation of olefins (chapter 1).
[27]
 
Tetrakis(3,5-bis-trifluoromethyl-phenyl)borate (BArF) emerged as the counterion of choice 
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showing significantly longer life time of the active catalytic species. Although the application 
of BArF as counterion results in the formation of a more robust catalyst, this anion is not ideal 
owing to its high price and molecular weight. It was observed that the PF6 salt reacts with 
lower rates compared to BArF, although they are still respectable.
[27]
 However, these 
complexes undergo the previously mentioned deactivation to the trinuclear cluster of the type 
of 7.2. The formation of such a trinuclear cluster was not observed for the iridium complex 
7.5 under hydrogen atmosphere in the absence of substrate. As a consequence we wondered if 
a counterion exchange might result in the formation of a less expensive catalyst with similar 
properties. Therefore the PF6-analog of catalyst 7.7 was synthesized and its behavior in the 
presence and absence of a substrate was investigated. First, the two analogs were compared in 
the hydrogenation of different model substrates (table 7.2). The data obtained with PF6 7.7 
and BArF-analog 7.5 revealed that higher conversions are obtained with the latter. For the 
allyl alcohol S8 even more than 11 times higher conversion was observed. Only (5E,9E)-
farnesylacetone 7.8 was converted almost completely to the fully saturated substrate 
regardless of the catalyst used. Also the enantioselectivity remained lower for the iridium 
complex with the PF6 counterion compared to its analog BArF salt. 
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Table 7.2: Hydrogenation of selected model substrates by the use of the PF6 and BArF analogs 7.5 and 7.7. 
 
Conversion determined by GC on an achiral stationary phase; Enantiomeric excess determined by HPLC on a 
chiral stationary phase. 
 
To get a better insight on the different behavior of these two catalysts, the conversion after 2 h 
and 15.5 h in the hydrogenation of (5E,9E)-farnesylacetone (7.8) was determined at reduced 
catalyst loading (table 7.3). The hydrogenation conducted with the BArF salt 7.5 showed after 
2 h still reactivity and conversion to the fully reduced product 7.9 raised from 35% after 2 h to 
82% after 15.5 h. For the PF6 salt 7.7 the conversion raised only from 19% to 23% comparing 
the results after 2 h and 15.5 h.  
 
Table 7.3: Hydrogenation of (5E,9E)-farnesylacetone (7.8) at reduced catalyst loading. 
 
[Ir-cat.] 
7.9 [%]
[a]
 
2 h 15.5 h 
7.5 35 82 
7.7 19 23 
[a] Determined by GC analysis on an achiral stationary phase. 
 
With these results in hand, it became clear that the pyridine-based catalyst 7.5 bearing BArF 
as counterion is longer active when compared to its PF6 analog 7.7. This is in agreement with 
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the results obtained in the detailed study conducted by Smidt et al. on the counterion 
influence for PHOX-based iridium catalysts.
[27]
 Furthermore, NMR studies of the PF6-analog 
7.7 in the presence of hydrogen revealed, that the selective formation of the previously 
described dimeric Ir-hydride complex 7.6 was no longer observed after counterion exchange. 
The spectra showed a complex mixture of different hydride species (figure 7.1). 
 
 
Figure 7.1: 
1
H NMR spectrum of the hydride region collected for catalyst 7.7 after the application of 50 bar H2. 
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7.4 Recovery of different catalyst classes from the reaction 
mixture 
 
With promising results in hand obtained in the study of the BArF-analog of catalyst 7.5, a 
potential recovery after the hydrogenation of model substrates in combination with different 
catalysts was tested. Therefore, the following protocol, which represents a slight modification 
of a typical hydrogenation procedure was applied. First, the substrate was stirred in the 
presence of 1.0 mol% iridium complex under 50 bar hydrogen atmosphere for 2 h without 
measuring the conversion. After release of H2, 0.1 eq. of COD was added and the reaction 
mixture was stirred for 1 h followed by evaporation of the solvent. The residue was separated 
by a simple filtration over a short plug of silica. First eluting the substrate and the excess of 
COD with a mixture of pentane:Et2O (4:1), followed by pure CH2Cl2 afforded recovered 
iridium complex. The excess of COD was removed in high vacuum. 
 
Scheme 7.5: Schematic diagram of the protocol applied for the recovery of the catalyst from the reaction 
mixture. 
 
In this context four different catalysts were investigated: the two most broadly applied 
pyridine-based catalysts 7.5 and 7.10, the complex 7.11 of the PHOX family (one of the first 
applied iridium catalyst in the asymmetric hydrogenation of unfunctionalized double bonds) 
and commercially available ThrePHOX catalyst 7.12. 
Indeed, the obtained data revealed, that the protocol depicted in scheme 7.5 allows for the 
recovery of different catalysts after the complete hydrogenation of the substrate. As expected, 
this method is not viable for all catalysts (table 7.4). However, only for the ThrePHOX 
catalyst 7.12 this method was not successful. The three other catalysts were recovered in 
yields between 60 and 70% with this slight modification of a typical hydrogenation procedure. 
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Table 7.4: Recovery of different hydrogenation catalysts from the reaction mixture (conditions see scheme 7.5). 
Entry Cat. Substrate
[a]
 
Amount of 
cat. [mg] 
Recovered 
cat. [%] 
1 
 
 
40 70 
2 
 
 
30 60 
3 
 
 
30 67 
4 
 
 
25 0 
[a] Full conversion was obtained for all entries. 
 
In light of these results, we wondered whether catalysts 7.10 and 7.11 form a similar dimeric 
species as previously described for catalyst 7.5 under hydrogen atmosphere. The 
31
P NMR 
spectra of complex 7.10 after treatment with 50 bar H2 for 2 h showed the appearance of one 
new broad signal at 136.6 ppm (compared to 141.8 ppm for the COD iridium complex) with a 
width of over 53 Hz (figure 7.2, A). The 
1
H NMR spectrum showed also broad peaks. 
Predominantly two broad peaks, with completely different shifts compared to the dimer 7.6, 
were observed (figure 7.2, B). The broad signals made it difficult at this point to identify the 
nature of the major species. Low temperature NMR experiments could have helped with the 
identification of this species but were not conducted up to this point. 
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Figure 7.2: 
31
P NMR spectrum of catalyst 7.10 after applying 50 bar H2, A; hydride region of catalyst 7.10 after 
applying 50 bar H2, B. 
 
The NMR studies of the PHOX catalyst 7.11 after applying 50 bar hydrogen pressure showed 
a completely different picture. In this case, several new signals in the 
31
P NMR and in the 
hydride region of the 
1
H NMR appeared (figure 7.3). Such new signals could not be assigned 
to a major species. This process is interesting especially for catalyst 7.11 since 67% of it 
could be recovered after the hydrogenation reaction. That it was still possible to recover 67% 
of the catalyst might be explained by the assumption that the different species are in 
equilibrium under hydrogen atmosphere. Therefore, one or more of these species could be 
reconverted to precatalyst 7.11 by the addition of COD. Another explanation could be that the 
amount of the formed polyclusters species is significantly smaller under normal 
hydrogenation conditions, which are roughly 10 times more diluted compared to the NMR 
experiments. 
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Figure 7.3: A: 
31
P NMR spectrum of the of catalyst 7.11 after applying 50 bar H2; B: hydride region of under 
identical conditions as A. 
 
 
7.5 Hydrogenations with recovered catalyst 
 
To confirm, that the recovered catalyst 7.11re performs with similar reactivity and selectivity 
compared to the original catalyst, these two complexes were compared in the hydrogenation 
of trans--methylstilbene (S1). The obtained data reveal no difference between the original 
and the recovered catalyst. At 1.0 and 0.2 mol% catalyst loading identical enantiomeric 
excesses were observed (table 7.5). The reaction with the recovered catalyst 7.11re showed an 
even slightly higher conversion. Although this difference in reactivity is within the range of 
tolerated experimental error, a possible explanation for the observed increased reactivity 
could be that the quality of the recovered catalyst is somehow higher than that of the older 
batch of the same complex, that might have undergone oxidation and degradation processes. 
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Table 7.5: Hydrogenation of trans-α-methylstilbene (S1) with two different batches of catalyst 7.11 and 7.11re. 
 
Entry
[a]
 [Ir-cat.] Cat. loading [mol%] Conv. [%]
[b]
 ee [%]
[c]
 
1 7.11 1 >99 86 (R) 
2 7.11re 1 >99 86 (R) 
3 7.11 0.2 37 87 (R) 
4 7.11re 0.2 40 87 (R) 
[a] Reaction run on 0.1 mmol scale; [b] Determined by GC analysis on an achiral stationary phase; [c] 
Determined by HPLC analysis on a chiral stationary phase. 
 
7.6 Conclusion 
In summary, in collaboration with Dr. Stefan Gruber, it was successfully demonstrated that it 
is possible to recover Ir-N,P ligand complexes effectively and easily from the reaction 
mixture by the addition of COD. By simple filtration over a short plug of silica the recovered 
catalyst can be separated from the hydrogenation product and recovered in up to 70% yield. 
The application of such a protocol is particularly interesting for reactions conducted on a 
larger scale and for catalysts which are difficult to synthesize and therefore more expensive. 
In addition, this concept might become interesting for reactions that normally require longer 
reaction times. In this case, a higher catalyst loading could significantly shorten the reaction 
times and the catalyst could be recovered afterwards from the reaction mixture. It was also 
shown that the recovery of the iridium complexes is not possible for every catalyst and 
substrate combination. However, assuming that the decomposition rate of the catalyst 
increases when the substrate is used up, there might be significant potential for optimizations 
of this procedure with increasing yields for the catalyst just by monitoring the reaction 
progress.  
This approach has significant advantages over the only previous example reported on the 
recovery of Ir-N,P ligand complexes by Börner and co-workers.
[127]
 In their work, propylene 
carbonate was utilized as solvent and the substrate was extracted after the reaction by the 
addition of hexane whereas the catalyst remained in the propylene carbonate layer. The fact 
that hydrogenation conducted in propylene carbonate show lower conversion and longer 
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reaction times, and that this method can only be applied to substrates being insoluble in 
propylene carbonate makes the new procedure for catalyst recovery clearly superior. 
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8.1 General Informations 
 
8.1.1 Working Techniques 
Commercially available reagents were purchased from Acros, Aldrich, Alfa-Aesar, Fluka, 
Fluorochem, Frontier Scientific, Maybridge, Strem or TCI and used as received without 
further purification unless otherwise noted. The solvents were collected from a purification 
column system (PureSolv, Innovative Technology Inc.)
[128]
 or purchased from Aldrich or 
Fluka in sure/sealedTM bottles over molecular sieves. Column chromatographic purifications 
were performed on Fluka silica gel 60 (particle size 40-63 nm) according to the procedure 
published by Still and Mitra.
[129]
 The eluents were of technical grade and distilled prior to use. 
As far as not mentioned external temperature data was assigned. If nothing different is noted a 
high vacuum of 0.05 mbar was applied. 
 
8.1.2 Analytical Methods 
Thin Layer Chromatography (TLC): TLC plates were obtained from Macherey-Nagel 
(Polygram SIL G/UV254, 0.2 mm silica with fluorescence indicator, 40 × 80 mm). For 
visualization UV light (254 nm, 366 nm) or basic permanganate solution [KMnO4 (3.0 g), 
K2CO3 (20 g), 5% aq. NaOH (5 mL), H2O (300 mL)] were used. 
Melting Points (MP): Melting points were determined on a Büchi B-545 apparatus and were 
not corrected. 
Nuclear Magnetic Resonance-Spectroscopy (NMR): NMR spectra were measured either on 
a Bruker DPX-NMR (400MHz), on a Bruker BZH NMR (250 MHz) or a Bruker Avance 
DRX-NMR (500 MHz) spectrometer equipped with BBO broadband probe heads. Chemical 
shifts (δ) are reported in parts per million (ppm) relative to residual solvent peaks and 
coupling constants (J) are reported in (Hz). Deuterated NMR solvents were obtained from 
Cambridge Isotope Laboratories, Inc. (Andover, MA, USA). The measurements were 
performed at 25 °C, if nothing else is reported. The chemical shift δ values were corrected to 
7.26 ppm (
1
H NMR)
[130]
 and 77.16 ppm (
13
C NMR)
[130]
 for CHCl3, 5.32 ppm (
1
H NMR)
[130]
 
and 54.0 ppm (
13
C NMR)
[130]
 for CH2Cl2, CH3OH 3.31 (
1
H NMR)
[130]
 and 49.0 ppm (
13
C 
NMR).
[130]
 
31
P NMR spectra were calibrated relative to 85% phosphoric acid (δ = 0 ppm), 19F 
NMR spectra relative to CFCl3 (δ = 0 ppm) and 
11
B NMR spectra relative to BF3·OEt2 (δ = 0 
ppm) as external standards. The assignment of 
1
H and 
13
C signals was partly made by DEPT 
and 2D-NMR, namely COSY, HMQC, HMBC and NOSY. Multiplicities are reported as 
follows: s = singlet, d = doublet, t = triplet, q = quartet, quin = quintet, sept = septet, m = 
multiplet. Thr note br indicates a broad signal shape. 
Mass Spectrometry (MS): Mass spectra were measured by Dr. H. Nadig (Department of 
Chemistry, University of Basel) on a VG70-250 (electron ionization (EI)) mass spectrometer 
or a Finnigan MAR 312 (fast atom bombardment (FAB)) mass spectrometer. FAB was 
performed with 3-nitrobenzyl alcohol (NBA) as matrix. ESI-MS spectra were measured by Dr. 
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C. Ebner, Mr. F. Bächle or Mr P. Isenegger (Department of Chemistry, University of Basel) 
on a Finnigan MAT LCQ Varian Quadropol 1200 MS/MS spectrometer. The signals are 
given in mass to charge ratio (m/z) with the relative intensities in brackets.  
Mass Spectrometry (HRMS-EI): Mass spectra were measured by O. Greter (Mass 
Spectrometry Service Facility at LOC, ETH Zurich) on a Waters' Micromass AutoSpec 
Ultima (EI-triSector-MS). 
Mass Spectrometry (HRMS-ESI): Mass spectra were measured by Dr. H. Nadig 
(Department of Chemistry, University of Basel) on a bruker maXis 4G. 
Infrared Spectroscopy (IR): The IR spectra were recorded on a Shimadzu FTIR-8400S 
Fourier Transform spectrometer with ATR/Golden Gate technology. Infrared spectra of 
liquids collected between two sodium chloride plates or those of solid samples in a potassium 
bromide matrix were measured on a Perkin Elmer 1600 series FTIR spectrometer. The 
absorption bands are given in wave numbers ṽ (cm−1). The peak intensity is assigned with s 
(strong), m (medium) and w (weak). The note br stands for a broad peak shape. 
Elemental Analysis (EA): Elemental analyses were measured by Mr. W. Kirsch or Sylvie 
Mittelheiser (Department of Chemistry, University of Basel) on a Leco CHN-900 analyzer or 
on a Vario Micro Cube by Elementar (C-, H-, N detection). The data are indicated in mass 
percent. 
Optical Rotation ([α]
20
D ): Optical rotations were measured on a Perkin Elmer Polarimeter 341 
in a 1 dm cuvette at 20 ˚C. The concentration (c) is given in g/100 mL. 
Gas Chromatography (GC): Gas chromatograms were collected on Shimadzu GC 2010-
Plus or Carlo Erba HRGC Mega2 Series 800 (HRGS Mega2) instruments. Achiral separations 
were performed on a Restek Rtx®-1701 column (30 m × 0.25 mm × 0.25μm) or on a Optima 
5-Amine (30 m × 0.25 mm × 0.25 μm) using He as carrier gas. For the separations of 
enantiomers Chiraldex G-TA, γ–cyclodextrin TFA column (30 m × 0.25 mm × 0.25 μm), 
Macherey-Nagel Hydrodex-ß-3P (25 m × 0.25 mm × 0.25 μm), Brechbühler SE54 ß-
cyclodextrin DEtTButSil (25 m × 0.25 mm × 0.25 μm), Varian CP Chiralsil-dex CB (25 m × 
0.25 mm × 0.25 μm), Varian CP-Sil 88 (50 m × 0.25 mm × 0.25 μm) were used with H2 as 
carrier gas. 
Gas Chromatography-Mass Spectrometry (GC-MS): The GC-MS spectra were recorded 
on A Shimadzu GCMS-QP2010 SE equipped with a Restek Rtx®-5MS column (30 m × 
0.2 mm × 0.2 μm). For this instrument the carrier gas was He. In addition a HP5890 gas 
chromatograph with a HP5970A detector equipped with a Macherey and Nagel Optima5 (5% 
polyphenylmethylsiloxane column, 25 m × 0.2 mm × 35 μm) and a HP5890 gas 
chromatograph with a HP5971 detector equipped with a Agilent HP1 (1% dimethylsiloxane 
column, 15 m × 0.2 mm × 33 μm) were used. For both instruments the flow was set to 
1 mL/min with 20:1 split ratio. 
High Performance Liquid Chromatography (HPLC): HPLC analysis was measured on 
Shimadzu Class-VP Version 5.0 systems with SCL-10A system controller, LC-10AD pump 
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system, SIL-10AD auto injector, CTO-10AC column oven, DGU-14A degasser and 
SPDM10Adiode array- or UV/VIS detector or on Shimadzu LC-20A prominence with LC-
20AD pump system, SIL-20AHT auto injector, CTO-10AS column oven, SPD-M20A diode 
array, DGU-20A3 degasser. Chiral columns Chiralcel OD-H, OJ and OJ-H or Chiralpak AD-
H, IC and AS-H (4.6 mm × 250 mm) from Daicel Chemical Industries were used. 
 
Semipreparative High Performance Liquid Chromatography (Semipreparative HPLC): 
Separations by semipreparative HPLC were performed on Shimadzu systems with SIL 10 
Advp autosampler, CTO 10 ASVP column oven, LC 10 Atvp pump system, FCV 10 Alvp 
degasser and SPD M10 Acp diode array detector. As column with chiral stationary phase 
Chiralcel OD (2 × 25 cm) from Daicel Chemical Industries was used. 
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8.2 Development and study of pyridyl phosphite based catalyst with 
sterically demanding aryl substituents 
 
8.2.1 Synthesis of chiral pyridyl alcohols 
 
4-Methyl-1,5,6,7-tetrahydro-2H-cyclopenta[b]pyridin-2-one (2.24) 
 
A mixture of ethyl acetoacetate (116 g, 113 mL, 0.89 mol, 1.00 eq.), cyclopentanone (84.0 g, 
88.5 mL, 1.00 mol, 1.12 eq.) and ammonium acetate (77.8 g, 1.00 mol, 1.12 eq.) was stirred 
for 18 h at reflux. The reaction mixture was concentrated to a volume of 90 mL. The residue 
was filtered off and washed with Et2O (50 mL) and H2O (50 mL). Recrystallization from H2O 
(3.0 L) followed by recrystallization from ethyl acetate (1.0 L) afforded the product (19.5 g, 
0.13 mol, 15%) as a pale gray solid. 
C9H11NO (149.19 g/mol):  
MP: 248 °C. 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 13.04 (s, 1H, NH), 6.20 (s, 1H, ar-H), 2.90 (t, 
3
JHH = 
7.5 Hz, 2H, CH2), 2.67 (t, 
3
JHH = 7.5 Hz, 2H, CH2), 2.13 (s, 3H, CH3), 2.17-2.05 (m, 2H, CH2). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 166.3 (s, C=O), 151.2 (s, ar-qC), 148.5 (s, ar-qC), 
120.8 (s, ar-qC), 115.4 (s, ar-C), 31.3 (s, CH2), 28.6 (s, CH2), 22.5 (s, CH2), 20.0 (s, CH3). 
IR (KBr): ṽ/cm-1 = 3449 (w), 2858 (m), 1654 (s), 1620 (m), 1578 (m), 1470 (m), 1426 (m), 
1371 (w), 1327 (m), 1220 (w), 1176 (w), 1026 (w), 933 (m), 901 (w), 860 (w), 806 (w). 
Obtained data are in accordance with literature data.
[57c]
 
 
3-(2-Oxocyclohexyl)propanenitrile (2.22) 
 
A solution of cyclohexane (64.0 mL, 60.6 g, 618 mmol, 1.00 eq.), acrylonitrile (43.4 mL, 
34.8 mL, 648 mmol, 1.05 eq.), cyclohexylamine (2.54 mL 2.21 g, 22.2 mmol, 0.04 eq.) and 
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acetic acid (248 L, 260 mg, 4.32 mmol, 0.01 eq.) was stirred for 3 h at 120 °C. All volatiles 
were removed under reduced pressure and the residue was diluted with Et2O (300 mL) and 
washed with 1 M HCl solution (3 × 100 mL). The organic layer was dried over MgSO4 and 
the solvent evaporated under reduced pressure. Distillation of the residue (0.6 mbar, 110 °C) 
afforded the product (67.0 g, 444 mmol, 72%) as a colorless oil. 
C9H13NO (151.21 g/mol): 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 2.47-2.22 (m, 5H, alkyl-H), 2.13-1.90 (m, 3H, alkyl-
H), 1.90-1.74 (m, 1H, alkyl-H), 1.71-1.24 (m, 4H, alkyl-H). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 211.7 (s, C=O), 119.7 (s, C≡N), 48.8 (s, CH), 
42.1 (s, CH2), 34.1 (s, CH2), 27.9 (s, CH2), 25.6 (s, CH2), 25.1 (s, CH2), 15.1 (s, CH2). 
Obtained data are in accordance with literature data.
[131]
 
 
5,6,7,8-Tetrahydroquinolin-2(1H)-one (2.25) 
 
3-(2-Oxocyclohexyl)propanenitrile (30.0 g, 198 mmol, 1.00 eq.) was added to 98% sulfuric 
acid (200 mL) over a peridode of 45 min at 0 °C. The reaction mixture was allowed to warm 
to room temperature and stirred for additional 45 min. The reaction mixture was poured on a 
mixture of crushed ice (1 kg) and 32% ammonium hydroxide solution (430 mL). The aqueous 
solution was extracted with chloroform (3 × 150 mL). The combined organic layers were 
dried over MgSO4 and the solvent evaporated under reduced pressure. The residue was 
recrystallized from H2O (800 mL) to afford the product (13.9 g, 93.2 mmol, 47%) as a 
colorless solid. 
C9H11NO (149.19 g/mol): 
MP: 208-210 °C. 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 13.29 (s, 1H, NH), 7.15 (d, J = 9.1 Hz, 1H, ar-H), 6.33 
(d, J = 9.1 Hz, 1H, ar-H), 2.66 (t, J = 6.1 Hz, 2H, CH2), 2.44 (t, J = 5.8 Hz, 2H, CH2), 1.92-
1.30 (m, 4H, CH2). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 165.1 (s, C=O), 143.8 (s, ar-C), 143.3 (s, ar-C), 
116.8 (s, ar-C), 114.5 (s, ar-C), 26.8 (s, CH2), 26.1 (s, CH2), 22.6 (s, CH2), 21.7 (s, CH2). 
Obtained data are in accordance with literature data.
[132]
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2-Chloro-4-methyl-6,7-dihydro-5H-cyclopenta[b]pyridine (2.26) 
 
A solution of 4-methyl-1,5,6,7-tetrahydro-2H-cyclopenta[b]pyridin-2-one (19.5 g, 130 mmol, 
1.00 eq.) in phenylphosphoryl dichloride (49.7 mL, 353 mmol, 2.71 eq.) was stirred for 18 h 
at reflux under an inert atmosphere. The reaction mixture was poured into an Erlenmeyer 
flask containing a mixture of H2O (250 mL), chloroform (250 mL), sodium carbonate (58 g) 
and ice (~750 g). The pH-value was adjusted to 8 by addition sodium carbonate. The organic 
phase was separated and the aqueous phase was separate and extracted with chloroform (3 × 
150 mL). The combined organic layers were dried over MgSO4 and all volatiles evaporated 
under reduced pressure. The residue was purified by bulb-to-bulb distillation (190 °C, 3 mbar) 
to afford the product (17.5 g, 104 mmol, 80%) as a colorless solid. 
C9H10ClN (167.64 g/mol):  
MP: 49-54 °C. 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 6.91 (s, 1H, ar-H), 2.99 (t, 
3
JHH = 5.0 Hz, 2H, CH2), 
2.83 (t, 
3
JHH = 5.0 Hz, 2H, CH2), 2.23 (s, 3H, CH3), 2.13 (tt, 
3
JHH = 5.0 Hz, 
3
JHH = 5.0 Hz, 2H, 
CH2). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 166.7 (s, ar-qC), 149.4 (s, ar-qC), 146.1 (s, ar-qC), 
135.3 (s, ar-qC), 122.0 (s, ar-C), 34.3 (s, CH2), 28.8 (s, CH2), 22.6 (s, CH2), 19.0 (s, CH3).  
IR (KBr): ṽ/cm-1 = 3448 (w), 2955 (m), 2920 (m), 2840 (w), 1588 (s), 1563 (s), 1429 (s), 
1377 (s), 1307 (m), 1264 (m), 1188 (m), 1099 (s), 883 (s). 
Obtained data are in accordance with literature data.
[56]
 
 
2-Chloro-5,6,7,8-tetrahydroquinoline (2.27) 
 
5,6,7,8-Tetrahydro-2(1H)-quinolinone (4.66 g, 31.2 mmol, 1.00 eq.) was added in a 50 mL 
two-necked flask. The flask was flushed with argon for 5 min and phenylphosphonic 
dichloride (11.9 mL, 86.4 mmol, 2.80 eq.) was added. The yellow reaction mixture was stirred 
for 17 h at 150 °C. The resulting brown oil was poured onto a mixture of K2CO3 and crushed 
ice (20 g/180 g) and CHCl3 (40 mL) was added. The suspension was stirred for 1 h at room 
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temperature. The phases were separated and the aqueous layer was extracted with CH2Cl2 (3 × 
40 mL). The combined organic layers were dried over MgSO4 and filtered. The solvent was 
evaporated under reduced pressure and the resulting brown oil was purified by bulb-to-bulb 
distillation (130 °C, 0.17 mbar) to afford the product (4.98 mg, 29.8 mmol, 96%) as a 
colorless liquid. 
C9H10ClN (167.64 g/mol):  
TLC: Rf = 0.52 (SiO2, hexane:ethyl acetate (5:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.30 (d, 
3
JHH = 7.8 Hz, 1H, ar-H), 7.04 (d, 
3
JHH = 
7.8 Hz, 1H, ar-H), 2.88 (t, 
3
JHH = 6.4 Hz, 2H, CH2), 2.72 (t, 
3
JHH = 7.8 Hz, 2H, CH2), 1.89-
1.83 (m, 2H, CH2), 1.81-175 (m, 2H, CH2). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 158.2 (s, ar-C), 147.7 (s, ar-C), 139.7 (s, ar-C), 
131.1 (s, ar-C), 121.3 (s, ar-C), 32.3 (s, CH2), 28.1 (s, CH2), 22.7 (s, CH2), 22.5 (s, CH2). 
Obtained data are in accordance with literature data.
[57b]
 
 
2-Chloro-4-methyl-6,7-dihydro-5H-cyclopenta[b]pyridine 1-oxide (2.28) 
 
mCPBA (9.15 g, 53.0 mmol, 1.60 eq.) was added to a solution of 2-chloro-4-methyl-6,7-
dihydro-5H-cyclopenta[b]pyridine (5.40 g, 32.3 mmol, 1.00 eq.) in CH2Cl2 (70 mL) and the 
reaction mixture was stirred for 2 h at reflux. The obtained yellow solution was washed with 
sat. NaHCO3-solution (3 × 30 mL), H2O (3 × 20 mL) and brine (2 × 20 mL). The aqueous 
layers were back extracted each time with CH2Cl2 (2 × 20 mL). The combined organic layers 
were dried over MgSO4 and filtered. Evaporation of the solvent afforded the product as a 
colorless solid (4.81 g, 26.3 mmol, 81%).  
C9H10ClNO (183.63 g/mol):  
MP: 79-81 °C. 
TLC: Rf = 0.42 (SiO2, CH2Cl2:MeOH (9:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.14 (s, 1H, ar-H), 3.23 (t, 
3
JHH = 7.6 Hz, 2H, CH2), 
2.92 (t, 
3
JHH = 7.6 Hz, 2H, CH2), 2.22 (s, 3H, CH3), 2.22-2.18 (m, 2H, CH2). 
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13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 153.4 (s, ar-C), 133.8 (s, ar-C), 133.7 (s, ar-C), 
125.3 (s, ar-C), 30.7 (s, CH2), 30.4 (s, CH2), 22.0 (s, CH2), 18.0 (s, CH3). 
IR (NaCl): ṽ/cm-1 = 3041 (m), 2970 (m), 2928 (m), 2840 (w), 1804 (w), 1606 (w), 1548 (w), 
1463 (s), 1440 (s), 1384 (s), 1307 (m), 1272 (s), 1239 (m), 1181 (s), 1076 (m), 1022 (w), 907 
(w), 840 (s), 732 (w), 679 (w). 
MS (EI, 70 eV, 200 °C) m/z (%): 185.1 (22), 183.1 (68), 169.1 (14), 168.1 (35), 167.1 (48), 
166.1 (100), 165.1 (11), 152.1 (17), 151.1 (20), 132.2 (54), 131.1 (96), 130.1 (61), 128.1 (11), 
117.1 (17), 103.1 (31), 91.1 (11), 77.1 (29), 65.1 (18), 63.1 (13), 51.1 (20). 
 
2-Chloro-5,6,7,8-tetrahydroquinoline 1-oxide (2.29) 
 
mCPBA (6.08 g, 35.2 mmol, 1.70 eq.) was added to a solution of 2-chloro-5,6,7,8-
tetrahydroquinoline (3.46 g, 20.7 mmol, 1.00 eq.) in CH2Cl2 (45 mL). The reaction mixture 
was stirred for 2 h at reflux. The obtained yellow solution was washed with sat. NaHCO3-
solution (3 × 30 mL), H2O (3 × 20 mL) and brine (2 × 20 mL). The aqueous layers were back 
extracted each time with CH2Cl2 (2 × 20 mL). The combined organic layers were dried over 
MgSO4. Filtration and evaporation of the solvent afforded the product (3.08 g, 16.7 mmol, 
81%) as a brownish solid. 
C9H10ClNO (183.63 g/mol):  
MP: 90-94 °C. 
TLC: Rf = 0.42 (SiO2, CH2Cl2:MeOH (9:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.26 (d, 
3
JHH = 8.0 Hz, 1H, ar-H), 6.96 (d, 
3
JHH = 
8.0 Hz, 1H, ar-H), 2.95 (t, JHH = 5.7 Hz, 2H, CH2), 2.72 (t, JHH = 5.7 Hz, 2H, CH2), 1.88-1.83 
(m, 2H, CH2), 1.76-1.69 (m, 2H, CH2). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 150.5 (s, ar-C), 139.1 (s, ar-C), 134.2 (s, ar-C), 
125.8 (s, ar-C), 122.9 (s, ar-C), 28.3 (s, CH2), 25.5 (s, CH2), 21.7 (s, CH2), 21.4 (s, CH2). 
Obtained data are in accordance with literature data.
[57b]
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2-Chloro-4-methyl-6,7-dihydro-5H-cyclopenta[b]pyridin-7-yl acetate (2.30) 
 
A mixture of 2-chloro-4-methyl-6,7-dihydro-5H-cyclopenta[b]pyridine 1-oxide (4.12 g, 
22.5 mmol, 1.00 eq.) in acetic anhydride (36.0 mL, 39.1 mmol, 9.20 eq.) was stirred at room 
temperature until all starting material was dissolved (~1 h). Afterwards, the reaction mixture 
was stirred for 5 h at 80 °C. All volatiles were evaporated under reduced pressure. Column 
chromatography (SiO2, d × h: 3 × 30 cm, hexane  hexane:ethyl acetate (1:2)) afforded the 
product (2.78 g, 12.3 mmol, 55%) as a colorless oil. 
C11H12ClNO2 (225.67 g/mol):  
TLC: Rf = 0.24 (SiO2, hexane:ethyl acetate (5:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.07 (s, 1H, ar-H), 6.01 (dd, JHH = 4.4 Hz, JHH = 
4.4 Hz, 1H, HCOAc), 3.00-2.91 (m, 1H, CH2), 2.80-2.73 (m, 1H, CH2), 2.68-2.62 (m, 1H, 
CH2), 2.28 (s, 3H, CH3), 2.09 (s, 3H, CH3), 2.10-2.02 (m, 1H, CH2).  
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 170.8 (s, O2CCH3), 160.1 (s, ar-C), 150.8 (s, ar-
C), 147.3 (s, ar-C), 136.3 (s, ar-C), 124.6 (s, ar-C), 77.2 (s, COAc), 30.6 (s, CH2), 26.2 (s, 
CH2), 21.4 (s, O2CCH3), 18.7 (s, CH3). 
Obtained data are in accordance with literature data.
[56]
 
 
2-Chloro-5,6,7,8-tetrahydroquinolin-8-yl acetate (2.31) 
 
A mixture of 2-chloro-5,6,7,8-tetrahydroquinoline 1-oxide (3.70 g, 20.2 mmol, 1.00 eq.) in 
acetic anhydride (32.0 mL, 34.3 mmol, 9.20 eq.) was stirred at room temperature until all 
starting material was dissolved (~1 h). Afterwards, the reaction mixture was stirred for 5 h at 
80 °C. All volatiles of the resulting brown solution were evaporated under reduced pressure. 
Column chromatography (SiO2, d × h: 3 × 30 cm, hexane  hexane:ethyl acetate (1:2)) 
afforded the product (2.07 g, 9.17 mmol, 45%) as a colorless oil. 
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C11H12ClNO2 (225.67 g/mol):  
TLC: Rf = 0.16 (SiO2, hexane:ethyl acetate (10:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.40 (d, 
3
JHH = 8.0 Hz, 1H, ar-H), 7.18 (d, 
3
JHH = 
8.0 Hz, 1H, ar-H), 5.85 (t, JHH = 4.4 Hz, 1H, CHOAc), 2.83 (dt, JHH = 16.7, 4.9 Hz, 1H, CH2), 
2.75-2.67 (m, 1H, CH2), 2.19-2.12 (m, 1H, CH2), 2.09 (s, 3H, CH3), 2.03-1.78 (m, 3H, CH2). 
13
C{
1
H} NMR (126 MHz, CDCl3): ppm = 170.3 (s, O2CCH3), 153.9 (s, ar-C), 149.0 (s, ar-
C), 140.1 (s, ar-C), 132.6 (s, ar-C), 124.0 (s, ar-C), 70.6 (s, COAc), 28.7 (s, CH2), 27.9 (s, 
CH2), 21.5 (s, CH3), 18.2 (s, CH2). 
Obtained data are in accordance with literature data.
[57b]
 
 
2-(3,5-Di-tert-butyl-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-7-yl acetate  
 
A mixture of 2-(3,5-di-tert-butyl-4-methoxyphenyl)-6,7-dihydro-5H-yclopenta[b]pyridine 1-
oxide
[133]
 (1.73 g, 4.91 mmol, 1.00 eq.) in acetic anhydride (4.61 g, 4.27 mL, 45.2 mmol, 
9.20 eq.) was stirred at room temperature until all starting material was dissolved (~1 h). 
Afterwards, the reaction mixture was stirred for 5 h at 80 °C. All volatiles of the resulting 
brown solution were evaporated under reduced pressure. Column chromatography (SiO2, d × 
h: 6 × 25 cm, hexane:ethyl acetate (1:4)) afforded the product (1.33 g, 3.34 mmol, 68%) as a 
colorless solid. 
C25H33NO3 (395.54 g/mol):  
MP: 92-93 °C. 
TLC: Rf = 0.28 (SiO2, hexane:ethyl acetate (5:1), UV).  
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.82 (s, 2H, ar-H), 7.62 (d, JHH = 8.0 Hz, 1H, ar-H), 
7.55 (d, JHH = 8.0 Hz, 1H, ar-H), 6.19 (dd, J = 7.3 Hz, J = 4.6 Hz, 1H, HCOAc), 3.72 (s, 3H, 
OCH3), 3.09 (ddd, JHH = 16.2, 8.7, 5.7 Hz, 1H, CH2), 2.90 (ddd, JHH = 16.3, 8.4, 5.7 Hz, 1H, 
CH2), 2.64 (dddd, JHH = 12.8, 8.5, 7.4, 5.4 Hz, 1H, CH2), 2.35 (s, 3H, CH3), 2.16-2.08 (m, 1H 
CH2), 2.14 (s, 3H, OCOCH3), 1.48 (s, 18H, 2 × C(CH3)3).  
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 171.2 (s, CO2CH3), 160.8 (s, ar-C), 160.7 (s, ar-
C), 158.3 (s, ar-C), 144.1 (s, ar-C), 135.3 (s, ar-C), 134.1 (s, ar-C), 133.6 (s, ar-C), 125.9 (s, 
EXPERIMENTAL PART   CHAPTER 8  
207 
ar-C), 120.8 (s, ar-C), 77.6 (s, COAc), 64.6 (s, OCH3), 36.1 (s, C(CH3)3), 32.3 (s, C(CH3)3), 
31.3 (s, CH2), 27.8 (s, CH2), 21.6 (s, CH3). 
IR (ATR): ṽ/cm-1 = 3011 (w), 2951 (m), 2907 (w), 2864 (w), 1738 (s), 1591 (m), 1562 (w), 
1445 (m), 1410 (m), 1367 (m), 1227 (s), 1161 (s), 970 (m), 891 (m), 827 (s), 781 (m). 
MS (EI, 70 eV, 200 °C) m/z (%): 396.3 (13), 395.3 (50), 352.3 (17), 336.3 (14), 335.5 (40), 
321.3 (24), 320.2 (100), 290.2 (24), 278.2 (11), 264.2 (10). 
EA (C25H33NO3): calc.: C 75.91, H 8.41, N 3.54; found: C 76.09, H 8.52, N 3.59. 
 
2-Chloro-4-methyl-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol (2.32) 
 
K2CO3 (1.52 g, 11.1 mmol, 1.00 eq.) was added to solution of 2-chloro-4-methyl-6,7-dihydro-
5H-cyclopenta[b]pyridin-7-yl acetate (2.50 g, 11.1 mmol, 1.00 eq.) in MeOH (40 mL). The 
yellowish suspension was stirred for 2 h at room temperature. K2CO3 was filtered off and all 
volatiles were evaporated under reduced pressure. The yellow residue was dissolved in 
CH2Cl2 (50 mL) and washed with H2O (3 × 30 mL). The organic layer was dried over MgSO4 
and filtered. Evaporation of the solvent afforded the product (1.95 g, 10.7 mmol, 96%) as a 
colorless oil. 
C9H10ClNO (183.63 g/mol):  
TLC: Rf = 0.06 (SiO2, hexane:ethyl acetate (5:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.02 (s, 1H, ar-H), 5.18 (t, JHH = 6.0 Hz, 1H, CHOH), 
3.36 (s, 1H, OH), 2.90 (ddd, JHH = 16.2 Hz, JHH = 9.0 Hz, JHH = 4.2 Hz, 1H, CH2), 2.68-2.60 
(m, 1H, CH2), 2.53-2.45 (m, 1H, CH2), 2.26 (s, 3H, CH3), 2.08-1.99 (m, 1H, CH2). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 164.7 (s, ar-C), 150.0 (s, ar-C), 147.4 (s, ar-C), 
134.8 (s, ar-C), 123.6 (s, ar-C), 74.2 (s, COH), 32.3 (s, CH2), 25.6 (s, CH2), 18.6 (s, CH3). 
Obtained data are in accordance with literature data.
[56]
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2-Chloro-5,6,7,8-tetrahydroquinolin-8-ol (2.33) 
 
K2CO3 (1.16 g, 8.46 mmol, 1.00 eq.) was added to a solution of 2-chloro-5,6,7,8-
tetrahydroquinolin-8-yl acetate (1.91 g, 8.46 mmol, 1.00 eq.) in MeOH (38 mL). The 
yellowish suspension was stirred for 2 h at room temperature. K2CO3 was filtered off and all 
volatiles were evaporated under reduced pressure. The yellow residue was dissolved in 
CH2Cl2 (50 mL) and washed with H2O (3 × 30 mL). The organic layer was dried over MgSO4 
and filtered. Evaporation of the solvent afforded the product (1.40 g, 7.62 mmol, 90%) as a 
colorless oil. 
C9H10ClNO (183.63 g/mol):  
TLC: Rf = 0.07 (SiO2, hexane:ethyl acetate (5:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.37 (d, JHH = 8.0 Hz, ar-H), 7.13 (d, JHH = 8.0 Hz, ar-
H), 4.68 (dd, JHH = 6.0 Hz, JHH = 5.2 Hz, 1H, CHOH), 3.54 (s br, 1H, OH), 2.83-2.70 (m, 2H, 
CH2), 2.26-2.21 (m, 1H, CH2), 2.02-1.95 (m, 1H, CH2), 1.86-1.77 (m, 2H, CH2). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 158.8 (s, ar-C), 148.5 (s, ar-C), 134.0 (s, ar-C), 
130.7 (s, ar-C), 123.1 (s, ar-C), 68.7 (s, COH), 30.4 (s, CH2), 27.9 (s, CH2), 19.3 (s, CH2).  
Obtained data are in accordance with literature data.
[57b]
 
 
2-(3,5-Di-tert-butyl-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol  
 
A solution of 2-(3,5-di-tert-butyl-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-7-
yl acetate (1.20 g, 3.03 mmol, 1.00 eq.) in a mixture of MeOH (5 mL), 2 N NaOH solution 
(2 mL) and THF (5 mL) was stirred for 10 h at room temperature. MeOH and THF were 
evaporated under reduced pressure. The aqueous phase was extracted with CH2Cl2 (3 × 
20 mL) and the combined organic layers were dried over MgSO4. Column chromatography 
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(SiO2, d × h: 4.5 × 20 cm, cyclohexane:ethyl acetate (1:5)) afforded the the product (1.00 g, 
2.83 mmol, 93%) as a colorless solid. 
C23H31NO2 (353.51 g/mol):  
MP: 95-97 °C. 
TLC: Rf = 0.16 (SiO2, hexane:ethyl acetate (5:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.80 (s, 2H, ar-H), 7.59 (d, JHH = 8.0 Hz, 1H, ar-H), 
7.59 (d, JHH = 8.0 Hz, 1H, ar-H), 5.25-5.22 (m, 1H, CHOH), 3.72 (s, 3H, OCH3), 3.58 (br s, 
1H, OH), 3.01 (ddd, JHH = 16.1 Hz, JHH = 8.9 Hz, JHH = 3.9 Hz, 1H, CH2), 2.86-2.78 (m, 1H, 
CH2), 2.59-2.50 (m, 1H, CH2), 2.09-2.00 (m, 1H, CH2), 1.48 (s, 18H, C(CH3)3). 
13
C{
1
H} NMR (100.6 MHz, CDCl3): ppm = 164.9 (s, ar-C), 160.9 (s, ar-C), 157.9 (s, ar-C), 
144.3 (s, ar-C), 134.3 (s, ar-C), 134.3 (s, ar-C), 133.9 (s, ar-C), 126.0 (s, ar-C), 120.5 (s, ar-C), 
75.2 (s, COH), 64.7 (s, OCH3), 36.3 (s, C(CH3)3), 33.41 (s, CH2), 32.5 (s, CH3), 27.6 (s, CH2). 
IR (ATR): ṽ/cm-1 = 3412 (w, br), 2959 (m), 2916 (m), 2869 (w), 1466 (m), 1446 (m), 1408 (s), 
1360 (m), 1259 (m), 1219 (s), 1113 (m), 1009 (s), 887 (m), 827 (s), 669 (m). 
MS (EI, 70 eV, 200 °C) m/z (%): 354.3 (26), 353.3 (100), 339.3 (19), 338.2 (76), 320.2 (14), 
290.2 (34), 264.2 (11). 
HRMS (ESI, 4500 V, 180 °C): (m/z) calc. for C23H32NO
+
: 354.2428 [M+H]
+
; found: 
354.2432. 
HPLC: Daicel, Chiralpak AD-H (0.46 cm × 25 cm, heptane/iso-propanol = 98:02, 
0.5 mL/min, 25 °C, 220 nm): tR = 10.6 min and 12.2 min. 
 
7-((tert-Butyldimethylsilyl)oxy)-2-chloro-4-methyl-6,7-dihydro-5H-
cyclopenta[b]pyridine (2.32) 
 
A round bottom flask was charged with 2-chloro-4-methyl-6,7-dihydro-5H-
cyclopenta[b]pyridin-7-ol (1.39 g, 7.57 mmol, 1.00 eq.), imidazole (1.56 g, 22.7 mmol, 
3.00 eq.) and TBSCl (1.71 mg, 11.4 mmol, 1.50 eq.), and purged for 5 min with argon. DMF 
(12 mL) was added and the resulting colorless solution was stirred for 18 h at room 
temperature. DMF was evaporated in HV and CH2Cl2 (90 mL) was added. The solution was 
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washed with H2O (3 × 90 mL) and the organic layer was dried over MgSO4. Filtration and 
evaporation of the solvent afforded the product (2.20 g, 7.38 mmol, 98%) as a colorless solid. 
C15H24ClNOSi (297.90 g/mol):  
MP: 116-117 °C. 
TLC: Rf = 0.72 (SiO2, hexane:ethyl acetate (5:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 6.97 (s, 1H, ar-H), 5.11 (dd, JHH = 7.0 Hz, JHH = 
4.6 Hz, 1H, CHOSi), 2.92 (ddd, JHH = 16.1 Hz, JHH = 8.7 Hz, JHH = 5.3 Hz, 1H, CH2), 2.64 
(ddd, JHH = 14.5 Hz, JHH = 8.5 Hz, JHH = 5.5 Hz, 1H, CH2), 2.40 (dddd, JHH = 12.5 Hz, JHH = 
8.5 Hz, JHH = 7.2 Hz, JHH = 5.3 Hz, 1H, CH2), 2.23 (s, 3H, CH3), 2.05-1.97 (m, 1H, CH2), 
0.91 (s, 9H, C(CH3)3), 0.20 and 0.15 (s, 6H, Si(CH3)2). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 164.6 (s, ar-C), 150.3 (s, ar-C), 146.6 (s, ar-C), 
134.6 (s, ar-C), 123.5 (s, ar-C), 75.9 (s, COSi), 33.9 (s, CH2), 26.0 (s, C(CH3)3), 25.7 (s, CH2), 
18.6 (s, CH3), 4.0 and 4.6 (s, Si(CH3)2). 
IR (NaCl): ṽ/cm-1 = 2953 (s), 2928 (s), 2855 (s), 1590 (m), 1472 (m), 1441 (s), 1387 (w), 
1254 (s), 1189 (m), 1123 (m), 1104 (s), 938 (w), 837 (s), 778 (s). 
MS (FAB NBA): m/z (%): 300.1 (14), 299.2 (12), 298.1 (52), 296.1 (12), 282.1 (17), 242.1 
(28), 241.1 (20), 240.1 (100), 168.1 (20), 166.0 (61), 130.0 (10), 75 (21), 73.0 (32). 
EA (C15H24ClNOSi): calc.: C 60.48, H 8.12, N 4.70; found: C 60.62, H 8.39, N 4.59. 
 
8-((tert-Butyldimethylsilyl)oxy)-2-chloro-5,6,7,8-tetrahydroquinoline (2.33) 
 
A round bottom flask was charged with 2-chloro-5,6,7,8-tetrahydroquinolin-8-ol (1.48 g, 
8.05 mmol, 1.00 eq.), imidazole (1.66 g, 24.1 mmol, 3.00 eq.) and TBSCl (1.70 g, 11.3 mmol, 
1.40 eq.), sealed with a rubber septum and purged for 5 min with argon. DMF (8 mL) was 
added and the resulting colorless solution was stirred for 18 h at room temperature. DMF was 
evaporated in HV and CH2Cl2 (30 mL) was added. The solution was washed with H2O (3 × 
30 mL) and the organic layer dried over MgSO4. Evaporation of the solvent afforded the 
product (2.06 mg, 6.92 mmol, 86%) as a pale brownish oil. 
C15H24ClNOSi (297.90 g/mol):  
TLC: Rf = 0.68 (SiO2, hexane:ethyl acetate (5:1), UV). 
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1
H NMR
 
(500 MHz, CDCl3): /ppm = 7.32 (d, JHH = 8.1 Hz, 1H, ar-H), 7.09 (d, JHH = 8.1 Hz, 
1H, ar-H), 4.74 (t, JHH = 4.4 Hz, 1H, SiOCH), 2.78 (dt, JHH = 17.0 Hz, JHH = 5.1 Hz, 1H, CH2), 
2.68-2.61 (m, 1H, CH2), 2.09-1.96 (m, 2H, CH2), 1.91-1.85 (m, 1H, CH2), 1.76-1.70 (m, 1H, 
CH2), 0.89 (s, 9H, C(CH3)3), 0.21 and 0.10 (s, 6H, Si(CH3)2). 
13
C{
1
H} NMR (126 MHz, CDCl3): ppm = 158.2 (s, ar-C), 148.3 (s, ar-C), 139.8 (s, ar-C), 
131.1 (s, ar-C), 122.9 (s, ar-C), 69.6 (s, COSi), 32.3 (s, CH2), 28.0 (s, CH2), 26.0 (s, C(CH3)3), 
18.5 (s, C(CH3)3), 17.9 (s, CH2), 4.0 and 4.8 (s, Si(CH3)2). 
IR (NaCl): ṽ/cm-1 = 2950 (s), 2929 (s), 2855 (s), 1580 (m), 1472 (m), 1443 (s), 1360 (w), 
1253 (m), 1135 (m), 1089 (s), 991 (s), 881 (m), 835 (s), 778 (s). 
MS (EI, 70 eV, 25 °C) m/z (%): 240.1 (100) [M-C(CH3)3)]
+
, 75.0 (11). 
MS (FAB NBA): m/z (%): 300.1 (13), 298.1 (35), 282.1 (14), 242.1 (37), 241.1 (19), 240.1 
(100), 168.0 (11), 166.0 (34), 73.0 (26). 
EA (C15H24ClNOSi): calc.: C 60.48, H 8.12, N 4.70; found: C 60.46, H 8.34, N 4.60. 
 
(S)-7-((tert-Butyldimethylsilyl)oxy)-2-chloro-4-methyl-6,7-dihydro-5H-
cyclopenta[b]pyridine ((S)-2.36) and (R)-2-chloro-4-methyl-6,7-dihydro-5H-
cyclopenta[b]pyridin-7-yl acetate ((R)-2.34) 
 
Vinyl acetate (40.0 mL, 433 mmol, 39.7 eq.) and CAL-B [200 mg, immobilized on acrylic 
resin from Sigma (L47777)] was added to a solution of 2-chloro-4-methyl-6,7-dihydro-5H-
cyclopenta[b]pyridin-7-ol (2.00 g, 10.9 mmol, 1.00 eq.) in dry i-Pr2O (400 mL). The resulting 
solution was stirred at 60 °C until HPLC on chiral stationary phase showed full consumption 
of the (R)-enantiomer (20 h). The enzyme was filtered off and washed with EtOAc (3 × 
20 mL). Evaporation of the solvent afforded a pale yellow residue which was dissolved in 
DMF (9 mL). Imidazole (2.22 g, 32.7 mmol, 3.00 eq.) and TBSCl (4.10 g, 27.2 mmol, 
2.50 eq.) were added under an argon atmosphere. The resulting colorless solution was stirred 
for 18 h at room temperature. The solvent was evaporated in HV and the resulting pale yellow 
residue was dissolved in CH2Cl2 (10 mL) and H2O (10 mL) was added. The organic layer was 
separated and the aqueous layer was extracted with CH2Cl2 (2 × 10 mL). The combined 
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organic layers were dried over MgSO4, filtered and the solvent evaporated under reduced 
pressure to afford a colorless residue. Column chromatography (SiO2, d × h: 2 × 12 cm, 
hexane:ethyl acetate ((1:20)  (1:1)) afforded the TBS ether (1.46 g, 4.91 mmol, 40%, 
>99.9% ee) as a colorless solid and the acetate (1.13 g, 5.00 mmol, 41%, 94% ee) as a 
colorless oil. 
HPLC: Daicel, Chiralpak AD-H (0.46 cm × 25 cm, heptane/iso-propanol = 95:05, 
0.5 mL/min, 40 °C, 220 nm): tR = 12.7 min ((R)-acetate (2.34), 13.7 min ((S)-acetate (2.34) 
and 17.2 min ((S)-alcohol 2.32), 19.5 min ((R)-alcohol 2.32). and  
C15H24ClNOSi (297.90 g/mol):  
[α]
20
D  =+3.9 (c = 0.45, CHCl3). 
Additional analytical data matches the data of the racemic silyl ether 2.36. 
C10H10ClNO2 (211.65 g/mol): 
[α]
20
D  =42.9 (c = 0.88, CHCl3). 
Additional analytical data matches the data of the racemic acetate 2.34. 
 
(S)-8-((tert-Butyldimethylsilyl)oxy)-2-chloro-5,6,7,8-tetrahydroquinoline ((S)-2.37) and 
(R)-2-chloro-5,6,7,8-tetrahydroquinolin-8-yl acetate ((R)-2.35) 
 
Vinyl acetate (120 mL, 1.30 mol, 38.4 eq.) and CAL-B [971 mg, immobilized on acrylic resin 
from Sigma (L47777)] was added to a solution of 2-chloro-5,6,7,8-tetrahydroquinolin-8-ol 
(6.20 g, 33.8 mmol, 1.00 eq.) in dry i-Pr2O (650 mL). The resulting solution was stirred at 
60 °C until HPLC on a chiral stationary phase showed full consumption of the (R)-enantiomer 
(20 h). The enzyme was filtered off and washed with EtOAc (3 × 20 mL). Evaporation of the 
solvent afforded a pale yellow residue which was dissolved in DMF (35 mL). Imidazole 
(6.95 g, 102 mmol, 3.00 eq.) and TBSCl (13.1 g, 86.9 mmol, 2.57 eq.) were added under an 
argon atmosphere. The resulting colorless solution was stirred for 18 h at room temperature. 
The solvent was evaporated in HV and the resulting pale yellow residue was dissolved in 
CH2Cl2 (10 mL) and H2O (10 mL) was added. The organic layer was separated and the 
aqueous layer was extracted with CH2Cl2 (2 × 10 mL). The combined organic layers were 
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dried over MgSO4, filtered and the solvent evaporated under reduced pressure to afford a 
colorless residue. Column chromatography (SiO2, d × h: 5 × 15 cm, hexane:ethyl acetate 
(1:20  1:1)) afforded the TBS ether (4.60 g, 15.4 mmol, 46%, >99.9% ee) as a colorless 
liquid and the acetate (3.65 g, 16.2 mmol, 48%, 82% ee) as a colorless oil. 
HPLC: Daicel, Chiralpak AD-H (0.46 cm × 25 cm, heptane/iso-propanol = 95:05, 
0.5 mL/min, 40 °C, 220 nm): tR = 12.1 min ((R)-acetate (2.35), 13.8 min ((S)-acetate (2.35) 
and 15.8 min ((S)-alcohol 2.33), 17.2 min ((R)-alcohol 2.33). 
C15H24ClNOSi (297.90 g/mol):  
[α]
20
D  =+6.2 (c = 0.68, CHCl3). 
Additional analytical data matches the data of the racemic silyl ether 2.37. 
 
5-Bromo-1,3-di-tert-butyl-2-methoxybenzene 
 
4-Bromo-2,6-di-tert-butylphenol (5.90 g, 20.7 mmol, 1.00 eq.) was dissolved in DMF (20 mL) 
and cooled to 0 °C. NaH (60% in mineral oil, 1.83 g, 45.8 mmol, 2.20 eq.) was added in small 
portions over a period of 20 min. The yellow suspension was stirred for 30 min at room 
temperature. The reaction mixture was cooled to 0 °C and MeI (5.07 mL, 82.0 mmol, 4.00 eq.) 
was added dropwise over a period of 15 min. The resulting red solution was allowed to warm 
slowly to room temperature and stirred for 16 h. The reaction mixture was cooled to 0 °C and 
H2O (50 mL) was added slowly. Hexane (50 mL) was added to the solution and the layers 
were separated. The aqueous layer was extracted with hexane (3 × 30 mL). The combined 
organic layers were dried over MgSO4, filtered and the solvent was evaporated under reduced 
pressure to obtain a red oil. Column chromatography (SiO2, d × h: 6 × 24 cm, hexane  
hexane:ethyl acetate (10:1)) afforded a colorless oil. Drying in HV afforded the product 
(5.01 g, 16.7 mmol, 81%) as a colorless crystals. 
C15H23BrO (299.25 g/mol): 
TLC: Rf = 0.45 (SiO2, hexane, UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.34 (s, 2H, ar-H), 3.69 (s, 3H, OCH3), 1.41 (s, 18H, 
C(CH3)3). 
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13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 158.9 (s, ar-C-OCH3), 146.2 (s, ar-C-C(CH3)3), 
129.7 (s, ar-C), 116.5 (s, ar-C-Br), 64.5 (s, OCH3), 36.1 (s, C(CH3)3), 32.0 (s, C(CH3)3). 
Obtained data are in accordance with literature data.
[134]
 
 
2-(3,5-Di-tert-butyl-4-methoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
 
A solution of 5-bromo-1,3-di-tert-butyl-2-methoxybenzene (1.00 g, 3.35 mmol, 1.00 eq.) in 
THF (8 mL) was cooled to 78 °C. n-BuLi (5.4 mL, 1.6 M in hexane, 8.64 mmol, 2.60 eq.) 
was added dropwise. The resulting colorless suspension was stirred for 1 h at 78 °C. 2-
Isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.58 mL, 3.35 mmol, 1.00 eq.) was 
added dropwise. The suspension was allowed to warm slowly to room temperature and stirred 
for 14 h. The colorless solution was quenched with EtOH (3 mL) and all volatiles were 
evaporated under reduced pressure. The residue was taken up in CH2Cl2 (30 mL) and H2O 
(30 mL) was added. The layers were separated and the aqueous layer was extracted with 
CH2Cl2 (2 × 30 mL). The combined organic layers were dried over MgSO4, filtered and the 
solvent was evaporated under reduced pressure. Column chromatography (SiO2, d × h: 3 × 
20 cm, hexane  hexane:ethyl acetate (10:1)) afforded the product (0.80 g, 2.31 mmol, 69%) 
as a colorless solid.  
C21H35BO3 (346.32 g/mol): 
TLC: Rf = 0.63 (SiO2, hexane:ethyl acetate (20:1), UV).  
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.71 (s, 2H, ar-H), 3.69 (s, 3H, OCH3), 1.46 (s, 18H, 2 
× C(CH3)3), 1.34 (s, 12H, 4 × CH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 162.7 (s, ar-C), 143.1 (s, ar-C), 133.5 (s, ar-C), 
83.6 (s, COB), 64.4 (s, OCH3), 35.8 (s, C(CH3)3), 32.3 (s, C(CH3)3), 25.0 (s, CH3). 
Obtained data are in accordance with literature data.
[135]
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General procedure: Suzuki–Miyaura cross couplings GP1 
 
8-((tert-Butyldimethylsilyl)oxy)-2-(3,5-di-tert-butyl-4-methoxyphenyl)-5,6,7,8-
tetrahydroquinoline (2.41) 
 
A microwave vial was charged with 8-((tert-butyldimethylsilyl)oxy)-2-chloro-5,6,7,8-
tetrahydroquinoline (0.70 g, 2.35 mmol, 1.00 eq.), 2-(3,5-di-tert-butyl-4-methoxyphenyl)-
4,4,5,5-tetramethyl-1,3,2-dioxaborolane (1.22 g, 3.52 mmol, 1.50 eq.), allyl[1,3-bis(2,6-
diisopropylphenyl)imidazol-2-ylidene]chloropalladium(II) (50 mg, 3.0 mol%) and sealed. The 
vial was purged with argon for 15 min. Afterwards, degassed i-PrOH (12 mL) and degassed 
4 M NaOH-solution (1.76 mL) were added. The solution was stirred for 18 h at 50 °C. The 
reaction mixture was allowed to cool to room temperature, the resulting dark gel was 
dissolved in CH2Cl2 (30 mL) and H2O (10 mL) was added. The organic layer was separated 
and the aqueous layer was extracted with CH2Cl2 (2 × 30 mL). The combined organic layers 
were dried over MgSO4, filtered and the solvent was evaporated under reduced pressure to 
afford a dark solid. Purification by column chromatography (SiO2, d × h: 3 × 12 cm, 
hexane:CH2Cl2 (4:1)) afforded the product (1.10 g, 2.28 mmol, 97%) as a colorless solid. 
C30H47NO2Si (481.80 g/mol):  
MP: 107-108 °C. 
TLC: Rf = 0.60 (SiO2, CH2Cl2, UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.91 (s, 2H, ar-H), 7.51 (d, JHH = 8.0 Hz, 1H, ar-H), 
7.42 (d, JHH = 8 Hz, 1H, ar-H), 4.92 (t, JHH = 3.5 Hz, 1H, CHOSi), 3.74 (s, 3H, OCH3), 2.89-
2.83 (m, 1H, CH2), 2.72-2.68 (m, 1H, CH2), 2.23-2.16 (m, 1H, CH2), 2.14-2.09 (m, 1H, CH2), 
1.92-1.82 (m, 1H, CH2), 1.79-1.75 (m, 1H, CH2), 1.52 (s, 18H, 2 × C(CH3)3), 0.94 (s, 9H, 
C(CH3)3), 0.36 and 0.12 (s, 6H, Si(CH3)2). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 160.4 (s, ar-C), 156.9 (s, ar-C), 155.3 (s, ar-C), 
143.8 (s, ar-C), 137.8 (s, ar-C), 134.0 (s, ar-C), 130.1 (s, ar-C), 125.5 (s, ar-C), 119.2 (s, ar-C), 
70.1 (s, CHOSi), 64.4 (s, OCH3), 36.1 (s, C(CH3)3), 32.5 (s, CH2), 32.3 (s, C(CH3)3), 28.4 (s, 
CH2), 26.1 (s, C(CH3)3), 18.4 (s, C(CH3)), 17.5 (s, CH2), 3.6 and 4.6 (s, Si(CH3)2). 
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IR (KBr): ṽ/cm-1 = 2954 (s), 2867 (m), 1593 (w), 1473 (m), 1412 (m), 1359 (m), 1247 (m), 
1221 (m), 1081 (m), 993 (m), 833 (m), 776 (m). 
MS (FAB NBA): m/z (%): 484.4 (11), 483.3 (37), 482.3 (94), 481.3 (11), 480.3 (10), 466.3 
(10), 426.2 (11), 425.2 (34), 424.2 (100), 350.3 (26), 348.2 (14), 73.1 (28), 57.1 (14). 
EA (C30H47NO2Si): calc.: C 74.79, H 9.83, N 2.91; found: C 74.60, H 9.89, N 2.93.  
 
7-((tert-Butyldimethylsilyl)oxy)-2-(3,5-di-tert-butyl-4-methoxyphenyl)-4-methyl-6,7- 
dihydro-5H-cyclopenta[b]pyridine (2.38) 
 
The reaction was set up as described in the general procedure GP1 except using 7-((tert-
butyldimethylsilyl)oxy)-2-chloro-4-methyl-6,7-dihydro-5H-cyclopenta[b]pyridine (600 mg, 
2.01 mmol, 1.00 eq.), 2-(3,5-di-tert-butyl-4-methoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-
dioxaborolane (1.00 g, 2.88 mmol, 1.40 eq.), allyl[1,3-bis(2,6-diisopropylphenyl)imidazol-2-
ylidene]chloropalladium(II) (40.0 mg, 3.0 mol%), i-PrOH (12 mL) and 4 M NaOH-solution 
(1.5 mL). Extraction and column chromatography (SiO2, d × h: 6 × 21 cm, hexane:CH2Cl2 
(20:1)) afforded the product (840 mg, 1.77 mmol, 88%) as a colorless solid. 
C30H47NO2Si (481.80 g/mol):  
MP: 84-87 °C. 
TLC: Rf = 0.78 (SiO2, hexane:ethyl acetate (5:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.94 (s, 2H, ar-H), 7.33 (s, 1H, ar-H), 5.24 (dd, JHH = 
6.4 Hz, JHH = 5.1 Hz, 1H, CHOSi), 3.72 (s, 3H, OCH3), 3.03-2.96 (m, 1H, CH2), 2.74-2.67 (m, 
1H, CH2), 2.49-2.42 (m, 1H, CH2), 2.31 (s, 3H, CH3), 2.09-2.00 (m, 1H, CH2), 1.49 (s, 18H,  
2 × C(CH3)3), 0.99 (s, 9H, C(CH3)3), 0.30 and 0.22 (s, 6H, Si(CH3)2). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 164.0 (s, ar-C), 160.3 (s, ar-C), 157.1 (s, ar-C), 
143.8 (s, ar-C), 143.7 (s, ar-C), 134.3 (s, ar-C), 133.5 (s, ar-C), 125.6 (s, ar-C), 120.1 (s, ar-C), 
76.6 (s, HCOSi), 64.4 (s, OCH3), 36.1 (s, 2 × C(CH3)3), 33.9 (s, CH2), 32.3 (s, 2 × C(CH3)3), 
26.2 (s, C(CH3)3), 26.0 (s, CH2), 18.9 (s, CH3), 18.8 (s, C(CH3)3), 3.9 and 4.4 (s, Si(CH3)2). 
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IR (KBr): ṽ/cm-1 = 2955 (s), 2856 (m), 1597 (w), 1472 (m), 1406 (m), 1360 (m), 1252 (m), 
1218 (m), 1113 (m), 1062 (m), 1001 (m), 912 (w), 867 (m), 836 (m), 778 (m). 
MS (FAB NBA): m/z (%): 483.2 (27), 482.2 (64), 481.2 (13), 480.2 (17), 466.2 (11), 425.2 
(34), 424.1 (100), 351.1 (12), 350.2 (34), 75.0 (10), 73 (25), 57 (11). 
EA (C30H47NO2Si): calc: C 74.79, H 9.83, N 2.91; found: C 74.79, H 9.97, N 2.93. 
 
7-((tert-Butyldimethylsilyl)oxy)-4-methyl-2-(3,4,5-trimethoxyphenyl)-6,7-dihydro-5H-
cyclopenta[b]pyridine (2.39) 
 
The reaction was set up as described in the general procedure GP1 except using 7-((tert-
butyldimethylsilyl)oxy)-2-chloro-4-methyl-6,7-dihydro-5H-cyclopenta[b]pyridine (700 mg, 
2.35 mmol, 1.00 eq.), (3,4,5-trimethoxyphenyl)boronic acid (850 mg, 4.00 mmol, 1.70 eq.), 
allyl[1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene]chloropalladium(II) (50.0 mg, 
3.0 mol%), i-PrOH (6 mL) and 4 M NaOH-solution (1.76 mL). Extraction and column 
chromatography (SiO2, d × h: 6 × 32 cm, hexane:ethyl acetate (4:1)) afforded the product 
(960 mg, 2.23 mmol, 95%) as a colorless solid. 
C24H35NO4Si (429.63 g/mol): 
MP: 88-90 °C.  
TLC: Rf = 0.35 (SiO2, hexane:ethyl acetate (4:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.36 (s, 1H, ar-H), 7.35 (s, 2H, ar-H), 5.25 (dd, JHH = 
7.2 Hz, JHH = 5.7 Hz, 1H, HCOSi), 3.95 (s, 6H, 2 × OCH3), 3.90 (s, 3H, OCH3), 2.95 (ddd, 
JHH = 16.2 Hz, JHH = 8.9 Hz, JHH = 4.3 Hz, 1H, CH2), 2.76-2.68 (m, 1H, CH2), 2.50-2.42 (m, 
1H, CH2), 2.30 (s, 3H, CH3), 2.07-1.99 (m, 1H, CH2), 0.99 (s, 9H, C(CH3)3), 0.27 and 0.23 (s, 
6H, Si(CH3)2). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 164.0 (s, ar-C), 155.9 (s, ar-C), 153.4 (s, ar-C), 
144.0 (s, ar-C), 138.7 (s, ar-C), 135.6 (s, ar-C), 134.1 (s, ar-C), 119.9 (s, ar-C), 104.0 (s, ar-C), 
76.5 (s COSi), 61.1 (s, OCH3), 56.3 (s, OCH3), 33.9 (s, CH2), 26.2 (s, C(CH3)3), 25.9 (s, CH2), 
18.9 (s, CH3), 18.8 (s, C(CH3)3), 4.0 and 4.4 (s, Si(CH3)2). 
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IR (KBr): ṽ/cm-1 = 2996 (m), 2932 (m), 2855 (m), 1586 (m), 1507 (m), 1465 (m), 1444 (m), 
1414 (m), 1367 (m), 1357 (m), 1135 (s), 1062 (m), 1083 (w), 910 (w), 839 (w), 766 (w). 
MS (EI, 70 eV, 200 °C) m/z (%): 429.2 (2) [M]
+
, 372.2 (100) [M-C(CH3)3]
+
. 
EA (C24H35NO4Si): calc.: 67.10, H 8.21, N 3.26; found: 68.92, H 8.29, N 3.37. 
 
8-((tert-Butyldimethylsilyl)oxy)-2-(3,4,5-trimethoxyphenyl)-5,6,7,8-tetrahydroquinoline 
(2.42) 
 
The reaction was set up described as in the general procedure GP1 except using 8-((tert-
butyldimethylsilyl)oxy)-2-chloro-5,6,7,8-tetrahydroquinoline (350 mg, 1.18 mmol, 1.00 eq.), 
(3,4,5-trimethoxyphenyl)boronic acid (400 mg, 1.88 mmol, 1.60 eq.), allyl[1,3-bis(2,6-
diisopropylphenyl)imidazol-2-ylidene]chloropalladium(II) (25 mg, 3 mol%), i-PrOH (3 mL) 
and 4 M NaOH-solution (0.88 mL). Extraction, column chromatography (SiO2, d × h: 3 × 
21 cm, hexane:ethyl acetate (10:1  1:3)) and recrystallization from hexane afforded the 
product (455 mg, 1.07 mmol, 91%) as a colorless solid. 
C24H35NO4Si (429.63 g/mol):  
MP: 97-99 °C. 
TLC: Rf = 0.30 (SiO2, hexane:ethyl acetate (10:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.53 (d, JHH = 8.0 Hz, 1H, ar-H), 7.43 (d, JHH = 8.0 Hz, 
1H, ar-H), 7.32 (s, 2H, ar-H), 4.88 (s br, 1H, CHOSi), 3.95 (s, 6H, 2 × OCH3), 3.90 (s, 3H, 
OCH3), 2.88-2.81 (m, 1H, CH2), 2.75-2.67 (m, 1H, CH2), 2.18-2.05 (m, 2H, CH2), 1.93-1.85 
(m, 1H, CH2), 1.79-1.74 (m, 1H, CH2), 0.91 (s, 9H, C(CH3)3), 0.30 and 0.11 (s, 6H, Si(CH3)2). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 157.0 (s, ar-C), 154.0 (s, ar-C), 153.7 (s, ar-C), 
138.8 (s, ar-C), 137.9 (s, ar-C), 135.3 (s, ar-C), 130.9 (s, ar-C), 111.8 (s, ar-C), 104.0 (s, ar-C), 
70.1 (s, OCH3), 61.1 (s, OCH3), 56.3 (s, COSi), 32.6 (s, CH2), 28.4 (s, CH2), 26.1 (s, C(CH3)3), 
18.5 (s, C(CH3)3), 17.6 (s, CH2). 3.7 and 4.6 (s, Si(CH3)2). 
IR (KBr): ṽ/cm-1 = 2998 (m), 2935 (s), 1593 (m), 1564 (m), 1468 (s), 1339 (m), 1233 (m), 
1130 (s), 1082 (m), 1031 (m), 1005 (m), 833 (m), 775 (m), 686 (m). 
MS (EI, 70 eV, 200 °C) m/z (%): 429.2 (1) [M]
+
, 372.2 (100) [M-C(CH3)3]
+
. 
EA (C24H35NO4Si): calc.: C 67.10, H 8.21, N 3.26; found: C 67.28 H 8.34, N 3.42. 
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2-(3,5-Bis(trifluoromethyl)phenyl)-7-((tert-butyldimethylsilyl)oxy)-4-methyl-6,7-dihydro-
5H-cyclopenta[b]pyridine (2.40) 
 
The reaction was setup as described in the general procedure GP1 except using 7-((tert-
butyldimethylsilyl)oxy)-2-chloro-4-methyl-6,7-dihydro-5H-cyclopenta[b]pyridine (350 mg, 
1.18 mmol, 1.00 eq.), (3,5-bis(trifluoromethyl)phenyl)boronic acid (608 mg, 2.35 mmol, 
2.00 eq.), allyl[1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene]chloropalladium(II) 
(35.0 mg, 4.0 mol%), i-PrOH (3 mL) and 4 M NaOH-solution (0.88 mL). Extraction and 
column chromatography (SiO2, d × h: 3 × 13 cm, hexane:CH2Cl2 (4:1)) afforded the product 
(484 mg, 1.01 mmol, 86%) as a colorless solid. 
C23H27F6NO4Si (475.55 g/mol): 
MP: 115-116 °C. 
TLC: Rf = 0.45 (SiO2, hexane:CH2Cl2 (3:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 8.58 (s, 2H, ar-H), 7.87 (s, 1H, ar-H), 7.50 (s, 1H, ar-
H), 5.27 (dd, JHH = 7.1 Hz, JHH = 6.1 Hz, 1H, CHOSi), 3.01 (ddd, JHH = 16.4 Hz, JHH = 8.9 Hz, 
JHH = 4.0 Hz, 1H, CH2), 2.78-2.70 (m, 1H, CH2), 2.52 (dddd, JHH = 12.6 Hz, JHH = 8.3 Hz, JHH 
= 7.5 Hz, JHH = 4.1 Hz, 1H, CH2), 2.36 (s, 3H, CH3), 2.10-2.02 (m, 1H, CH2), 1.02 (s, 9H, 
C(CH3)3), 0.26 and 0.24 (s, 6H, Si(CH3)2). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 165.0 (s, ar-C), 152.9 (s, ar-C), 144.8 (s, ar-C), 
141.9 (s, ar-C), 135.9 (s, ar-C), 132.0 (q, JCF = 33 Hz, ar-C), 126.8 (s, ar-C), 123.7 (q, JCF = 
273 Hz, CF3), 121.9 (sept, JCF = 3 Hz, ar-C), 120.3 (s, ar-C), 76.2 (s, COSi), 34.0 (s, CH2), 
26.0 (s, C(CH3)3), 25.9 (s, CH2), 18.9 (s, CH3), 18.8 (s, C(CH3), 4.3 and 4.4 (s, Si(CH3)2). 
19
F{
1
H} NMR (376 MHz, CDCl3): ppm = 63.2 (s). 
IR (KBr): ṽ/cm-1 = 2956 (m), 2935 (m), 2857 (m), 1600 (w), 1391 (m), 1375 (w), 1349 (w), 
1319 (m), 1282 (s), 1254 (m), 1282 (s), 1254 (m), 1179 (s), 1125 (s), 942 (w), 915 (w), 894 
(m), 858 (m), 781 (m), 683 (m). 
MS (EI, 70 eV, 200 °C) m/z (%): 418.1 (100) [M-C(CH3)3]
+
, 344.1 (13) [M-OTBS]
+
, 75.1 (9).  
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MS (FAB NBA): m/z (%): 476.2 (30) [M+1]
+
, 418.1 (100) [M-C(CH3)3]
+
, 344.1 (49) [M-
OTBS]
+
, 73.1 (26). 
EA (C23H27F6NOSi): calc.: C 58.09, H 5.72, N 2.95; found: C 57.97, H 5.72, N 3.08. 
 
(S)-7-((tert-Butyldimethylsilyl)oxy)-4-methyl-2-(phenanthren-9-yl)-6,7-dihydro-5H-
cyclopenta[b]pyridine ((S)-2.43) 
 
The reaction was setup as described in the general procedure GP1 except using (S)-7-((tert-
butyldimethylsilyl)oxy)-2-chloro-4-methyl-6,7-dihydro-5H-cyclopenta[b]pyridine (200 mg, 
0.67 mmol, 1.00 eq.), 9-phenanthracenylboronic acid (224 mg, 1.01 mmol, 1.50 eq.), 
allyl[1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene]chloropalladium(II) (17.0 mg, 
4.0 mol%), i-PrOH (3.5 mL) and 4 M NaOH-solution (0.50 mL). Extraction and column 
chromatography (SiO2, d × h: 3 × 25 cm, pentane:Et2O (20:1)) afforded the product (295 mg, 
0.67 mmol, quant.) as a colorless solid. 
C29H33NOSi (439.67 g/mol):  
MP: 159-160 °C. 
TLC: Rf = 0.56 (SiO2, pentane:Et2O (10:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 8.77 (d, J = 8.3 Hz, 1H, ar-H), 8.73 (d, J = 8.2 Hz, 1H, 
ar-H), 8.36 (dd, J = 8.4, 1.4 Hz, 1H, ar-H), 7.91 (dd, J = 7.8, 1.1 Hz, 1H, ar-H), 7.86 (s, 1H, 
ar-H), 7.71-7.64 (m, 2H, ar-H), 7.64-7.58 (m, 1H, ar-H), 7.54 (ddd, J = 8.2, 7.0, 1.1 Hz, 1H, 
ar-H), 7.33 (s, 1H, ar-H), 5.28 (dd, J = 6.9, 4.2 Hz, 1H, CHOSi), 3.16-3.06 (m, 1H, CH2), 
2.87-2.76 (m, 1H, CH2), 2.55-2.43 (m, 1H, CH2), 2.37 (s, 3H, CH3), 2.18-2.07 (m, 1H, CH2), 
0.96 (s, 9H, C(CH3)3), 0.21 and 0.17 (s, 6H, Si(CH3)). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 164.0 (s, ar-C), 158.4 (s, ar-C), 144.0 (s, ar-C), 
137.8 (s, ar-C), 134.3 (s, ar-C), 131.7 (s, ar-C), 130.9 (s, ar-C), 130.5 (s, ar-C), 130.5 (s, ar-C), 
129.0 (s, ar-C), 128.6 (s, ar-C), 127.6 (s, ar-C), 126.9 (s, ar-C), 126.8 (s, ar-C), 126.5 (s, ar-C), 
126.5 (s, ar-C), 125.1 (s, ar-C), 122.8 (s, ar-C), 122.7 (s, ar-C), 76.6 (s, COSi), 34.0 (s, CH2), 
26.2 (s, CH2), 26.1 (s, C(CH3)3), 18.9 (s, CH3), 18.7 (s, C(CH3)3), 4-0 and 4.4 (s, Si(CH3)2). 
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IR (ATR): ṽ/cm-1 = 3062 (w), 2951 (m), 2852 (m), 2361 (w), 1596 (m), 1459 (m), 1381 (m), 
1297 (w), 1249 (m), 1082 (s), 992 (m), 924 (m), 837 (s), 769 (s), 745 (s), 684 (m). 
HRMS (ESI, 4500 V, 180 °C): (m/z) calc. for C29H34NOSi
+
: 440.2404 [M+H]
+
; found: 
440.2403. 
[α]
20
D  = 85.4 
(c = 0.60, CHCl3). 
 
(S)-2-([1,1':3',1''-Terphenyl]-5'-yl)-7-((tert-butyldimethylsilyl)oxy)-4-methyl-6,7-
dihydro-5H-cyclopenta[b]pyridine ((S)-2.42) 
 
The reaction was set up as described in the general procedure GP1 except using (S)-7-((tert-
butyldimethylsilyl)oxy)-2-chloro-4-methyl-6,7-dihydro-5H-cyclopenta[b]pyridine (200 mg, 
0.67 mmol, 1.00 eq.), (3,5-diphenylphenyl)boronic acid (276 mg, 1.01 mmol, 1.50 eq.), 
allyl[1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene]chloropalladium(II) (17.0 mg, 
4 mol%), i-PrOH (3.5 mL) and 4 M NaOH-solution (0.5 mL). Extraction and column 
chromatography (SiO2, d × h: 3 × 25 cm, pentane:Et2O (20:1)) afforded the product (197 mg, 
0.40 mmol, 60%) as a colorless solid. 
C33H45NOSi (491.75 g/mol):  
MP: 124-125 °C. 
TLC: Rf = 0.53 (SiO2, pentane:Et2O (10:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): δ/ppm = 8.31 (d, J = 1.8 Hz, 2H, ar-H), 7.83 (t, J = 1.8 Hz, 1H, 
ar-H), 7.78-7.71 (m, 4H, ar-H), 7.54 (s, 1H, ar-H), 7.53-7.45 (m, 4H, ar-H), 7.43-7.35 (m, 2H, 
ar-H), 5.28 (dd, J = 7.2, 5.3 Hz, 1H, CHOSi), 3.08-2.97 (m, 1H, CH2), 2.79-2.68 (m, 1H, 
CH2), 2.57-2.43 (m, 1H, CH2), 2.34 (s, 3H, CH3), 2.14-1.99 (m, 1H, CH2), 1.01 (s, 9H, 
C(CH3)3), 0.29 (s, 3H Si(CH3)), 0.25 (s, 3H Si(CH3)). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 164.2 (s, ar-C), 156.0 (s, ar-C), 144.0 (s, ar-C), 
142.0 (s, ar-C), 141.3 (s, ar-C), 140.8 (s, ar-C), 134.3 (s, ar-C), 128.8 (s, ar-C), 127.4 (s, ar-C), 
127.3 (s, ar-C), 126.0 (s, ar-C), 124.8 (s, ar-C), 120.3 (s, ar-C), 76.4 (s, COSi), 33.9 (s, CH2), 
26.1 (s, C(CH3)3), 25.8 (s, CH2), 18.8 (s, CH3), 18.7 (s, C(CH3)3), 4.2 and 4.5 (s, Si(CH3)2). 
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IR (ATR): ṽ/cm-1 = 3063 (w), 2953 (m), 2854 (m), 2056 (w), 1595 (m), 1469 (m), 1407 (m), 
1346 (w), 1245 (m), 1118 (m), 1008 (w), 836 (s), 758 (s), 697 (s). 
HRMS (ESI, 4500 V, 180 °C): (m/z) calc. for C33H38NOSi
+
: 492.2717 [M+H]
+
; found: 
492.2720. 
[α]
20
D  = +2.8 (c = 0.25, CHCl3). 
 
(S)-2-([1,1':3',1''-Terphenyl]-5'-yl)-8-((tert-butyldimethylsilyl)oxy)-5,6,7,8-
tetrahydroquinoline ((S)-2.45) 
 
The reaction was set up as described in the general procedure GP1 except using (S)-8-((tert-
butyldimethylsilyl)oxy)-2-chloro-5,6,7,8-tetrahydroquinoline (200 mg, 0.67 mmol, 1.00 eq.), 
(3,5-diphenylphenyl)boronic acid (282 mg, 1.03 mmol, 1.50 eq. allyl[1,3-bis(2,6-
diisopropylphenyl)imidazol-2-ylidene]chloropalladium(II) (25.0 mg, 4 mol%), i-PrOH 
(3.5 mL) and 4 M NaOH-solution (0.5 mL). Extraction and column chromatography (SiO2, d 
× h: 3 × 25 cm, pentane:Et2O (20:1)) afforded the product (282 mg, 0.57 mmol, 83%) as a 
colorless solid. 
C33H37NOSi (491.75 g/mol):  
MP: 51-52 °C. 
TLC: Rf = 0.78 (SiO2, pentane:Et2O (10:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): δ/ppm = 8.32 (d, J = 1.7 Hz, 2H, ar-H), 7.87 (t, J = 1.7 Hz, 1H, 
ar-H), 7.80-7.74 (m, 4H, ar-H), 7.71 (d, J = 8.0 Hz, 1H, ar-H), 7.56-7.47 (m, 5H, ar-H), 7.46-
7.38 (m, 2H, ar-H), 4.96 (t, J = 4.1 Hz, 1H, CHOSi), 2.93-2.86 (m, 1H, CH2), 2.84-2.70 (m, 
1H, CH2), 2.26-2.06 (m, 2H, CH2), 2.00-1.93 (m, 1H, CH2), 1.85-1.77 (m, 1H, CH2), 0.97 (s, 
9H, C(CH3)3), 0.35 and 0.18 (s, 6H, Si(CH3)2). 
13
C{
1
H} NMR (101 MHz, CDCl3): δ/ppm = 157.2 (s, ar-C), 154.2 (s, ar-C), 142.1 (s, ar-C), 
141.3 (s, ar-C), 140.6 (s, ar-C), 137.8 (s, ar-C), 131.2 (s, ar-C), 128.8 (s, ar-C), 127.5 (s, ar-C), 
127.4 (s, ar-C), 126.3 (s, ar-C), 124.7 (s, ar-C), 119.1 (s, ar-C), 70.1 (CHOSi), 32.6 (s, CH2), 
28.4 (s, CH2), 26.0 (s, C(CH3)3), 18.5 (s, C(CH3)3), 17.7 (s, CH2), 3.8 and 4.6 (s, Si(CH3)2). 
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IR (ATR): ṽ/cm-1 = 3060 (w), 3033 (w), 2927 (m), 2853 (m), 1594 (m), 1564 (m), 1498 (m), 
1471 (m), 1454 (m), 1436 (m), 1410 (m), 1387 (m), 1358 (m), 1249 (w), 1190 (w), 1153 (m), 
1080 (m), 1048 (m), 1027 (w), 1005 (m), 990 (m), 938 (w), 880 (m), 871 (m), 831 (s), 806 
(m), 775 (s), 755 (s), 696 (s), 613 (m). 
MS (ESI, MeOH) m/z (%): 492 [M+H]
+
. 
EA (C33H37NOSi): calc.: C 80.60, H 7.58, N 2.85; found: C 80.54, H 7.58, N 3.00. 
[α]
20
D  = +26.7 (c = 0.52, CHCl3). 
 
(S)-((7-([1,1'-Biphenyl]-2-yl)-1,2,3,4-tetrahydronaphthalen-1-yl)oxy)(tert-butyl) dimethyl 
silane ((S)-2.46) 
 
The reaction was set up as described in the general procedure GP1 except using (S)-8-((tert-
butyldimethylsilyl)oxy)-2-chloro-5,6,7,8-tetrahydroquinoline (400 mg, 1.35 mmol, 1.00 eq.), 
[1,1'-biphenyl]-3-ylboronic acid (402 mg, 2.03 mmol, 1.50 eq.), allyl[1,3-bis(2,6-
diisopropylphenyl)imidazol-2-ylidene]chloropalladium(II) (25.0 mg, 4 mol%), i-PrOH 
(7.0 mL) and 4 M NaOH-solution (1.0 mL). Extraction and column chromatography (SiO2, d × 
h: 25 × 3 cm, cyclohexane:ethyl acetate (50:1)) afforded the product (200 mg, 0.49 mmol, 
36%) as a colorless resin. 
C27H33NOSi (415.65 g/mol): 
TLC: Rf = 0.35 (SiO2, cyclohexane:ethyl acetate (50:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): δ/ppm = 7.85-7.83 (m, 1H, ar-H), 7.48-7.39 (m, 3H, ar-H), 
7.28-7.24 (m, 3H, ar-H), 7.24-7.19 (m, 2H, ar-H), 7.01 (d, 
3
JHH = 8.0 Hz, 1H, ar-H), 6.59 (d, 
3
JHH = 8.0 Hz, 1H, ar-H), 4.88 (t, 
3
JHH = 4.8 Hz, 1H, HCOSi), 2.79-2.72 (m, 1H, CH2), 2.67-
2.59 (m, 1H, CH2), 2.16-2.04 (m, 2H, CH2), 1.97-1.89 (m, 1H, CH2), 1.78-1.70 (m, 1H, CH2), 
0.92 (s, 9H, C(CH3)3), 0.25 (s, 3H, SiCH3), 0.11 (s, 3H, SiCH3).  
13
C{
1
H} NMR (101 MHz, CDCl3): δ/ppm = 157.0 (s, ar-C), 155.8 (s, ar-C), 141.8 (s, ar-C), 
140.5 (s, ar-C), 139.6 (s, ar-C), 135.8 (s, ar-C), 131.0 (s, ar-C), 130.4 (s, ar-C), 129.8 (s, ar-C), 
128.1 (s, ar-C), 128.0 (s, ar-C), 127.4 (s, ar-C), 126.6 (s, ar-C), 124.2 (s, ar-C), 70.1 (s, COSi), 
32.5 (s, CH2), 28.2 (s, CH2), 26.9 (s, CH2), 26.0 (s, C(CH3)3), 17.7 (s, C(CH3)3), 3.9 and 4.8 
(s, Si(CH3)2).  
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IR (ATR): ṽ/cm-1 = 3062 (w), 2951 (m), 2852 (m), 2361 (w), 1596 (m), 1459 (m), 1381 (m), 
1297 (w), 1249 (m), 1082 (s), 992 (m), 924 (m), 837 (s), 769 (s), 745 (s), 684 (m). 
HRMS (ESI, 4500 V, 180 °C): (m/z) calc. for C27H34NOSi
+
: 416.2404 [M+H]
+
; found: 
416.2408. 
[α]
20
D  = +22.6 (c = 0.48, CHCl3). 
 
Palladium complex (2.49) 
 
A mixture of Pd(OAc)2 (100 mg, 0.45 mmol, 1.00 eq.) and 2-amino-biphenyl (78 mg, 
0.46 mmol, 1.00 eq.) in toluene (2.7 mL) was stired for 45 min at 60 °C under an argon 
atmophere, whereupon a grey precipitate had formed. After cooling to room temperature, 
toluene was decantated. The remaining solid was washed with touluene (3 × 1.0 mL) and 
suspended in acetone (2.7 mL). After addition of lithium chloride (57 mg, 1.34 mmol, 
3.00 eq.), the reaction mixture was stirred for 1 h at room temperature. XPhos (202 mg, 
0.42 mmol, 0.95 eq.) was added in small portions and the mixture was stirred for 2 h at room 
temperature. The solvent was removed under reduced pressure to afford a yellow slurry, 
which was treated with MTBE (0.6 mL) and pentane (1.5 mL). The mixture was placed in the 
refrigerator ( °C) overnight. The product was then collected by filtration, washed with H2O 
(3 × 1.0 mL), and dried under reduced pressure to afford the palladium complex as a grey 
solid (219 mg, 280 mol, 62%). 
C45H59ClNPPd (786.82 g/mol): 
1
H NMR
 
(400 MHz, CDCl3): δ/ppm = complex spectrum, identic to literature. 
31
P{
1
H} NMR (161 MHz, CDCl3): /ppm = 66.8 (s), 64.1 (s), (rotamers). 
Obtained data are in accordance with literature data.
[62]
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(S)-7-((tert-Butyldimethylsilyl)oxy)-2-(2,6-difluorophenyl)-4-methyl-6,7-dihydro-5H-
cyclopenta[b]pyridine ((S)-2.44)  
 
(S)-7-((tert-Butyldimethylsilyl)oxy)-2-chloro-4-methyl-6,7-dihydro-5H-cyclopenta[b]pyridine 
(250 mg, 0.84 mmol, 1.00 eq.), (2,6-difluorophenyl)boronic acid (199 mg, 1.26 mmol, 
1.50 eq.) and the palladium complex (2.49) (20 mg, 3 mol%) were added to a microwave vial 
and sealed. The vessel was evacuated and backfilled with argon for 3 times. Afterwards, 
degassed THF (1.7 mL) and degassed 0.5 M K3PO4-solution (3.4 mL) were added. The 
solution was stirred for 1 h at room temperature. Et2O (10 mL) and H2O (10 mL) were added 
and the aqueous phase was extracted with Et2O (3 × 10 mL). The organic phase was dried 
over MgSO4, all volatiles evaporated under reduced pressure and the residue was purified by 
column chromatography (SiO2, d × h: 3 × 23 cm, pentane:Et2O (20:1)) to afford the product 
(300 mg, 0.80 mmol, 95%) as a colorless solid. 
C21H27F2NOSi (375.53 g/mol):  
MP: 45-46 °C. 
TLC: Rf = 0.69 (SiO2, pentane:Et2O (4:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): δ/ppm = 7.34-7.26 (tt, J = 8.4, 6.0 Hz, 1H, ar-H), 7.13 (s, 1H, 
ar-H), 7.01-6.92 (m, 2H, ar-H), 5.22 (dd, J = 6.8, 4.2 Hz, 1H, CHOSi), 3.04 (ddd, J = 16.2, 
8.5, 5.8 Hz, 1H, CH2), 2.74 (ddd, J = 16.2, 8.5, 5.1 Hz, 1H, CH2), 2.49-2.36 (m, 1H, CH2), 
2.31 (s, 3H, CH3), 2.13-2.02 (m, 1H, CH2), 0.92 (s, 9H, C(CH3)3)), 0.21 and 0.11 (s, 6H, 
Si(CH3)). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 164.4 (s, ar-C), 160.8 (dd, JCF = 250, 7.0 Hz, ar-
C), 148.0 (s, ar-C), 143.6 (s, ar-C), 135.3 (s, ar-C), 129.5 (t, JCF = 10 Hz, ar-C), 125.8 (s, ar-C), 
118.9 (t, JCF = 18 Hz, ar-C), 112.7-109.9 (m, ar-C), 76.5 (s, COSi), 33.9 (s, CH2), 26.2 (s, 
CH2), 26.1 (s, C(CH3)3), 18.7 (s, CH3), 18.6 (s, C(CH3)3), 4.2 and 4.6 (s, Si(CH3)2). 
19
F{
1
H} NMR (376 MHz, CDCl3): /ppm = 114.0. 
IR (ATR): ṽ/cm-1 = 2929 (w), 2856 (w), 1628 (m), 1596 (w), 1465 (m), 1358 (w), 1251 (m), 
1158 (w), 1116 (m), 1066 (w), 1001 (m), 938 (w), 915 (w), 859 (m), 836 (m), 776 (s), 732 
(m), 645 (s). 
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HRMS (ESI, 4500 V, 180 °C): (m/z) calc. for C21H28F2NOSi
+
: 376.1903 [M+H]
+
; found: 
376.1907. 
[α]
20
D  = +3.4 
(c = 1.02, CHCl3). 
 
(S)-8-((tert-Butyldimethylsilyl)oxy)-2-(2,6-difluorophenyl)-5,6,7,8-tetrahydroquinoline 
((S)-2.48)  
 
(S)-8-((tert-Butyldimethylsilyl)oxy)-2-chloro-5,6,7,8-tetrahydroquinoline (503 mg, 
1.69 mmol, 1.00 eq.), (2,6-difluorophenyl)boronic acid (400 mg, 2.53 mmol, 1.50 eq.) and the 
palladium complex (2.49) (40 mg, 3 mol%) were added to a microwave vial and sealed. The 
vessel was evacuated and backfilled with argon for 3 times. Afterwards, degassed THF 
(3.4 mL) and degassed 0.5 M K3PO4-solution (6.8 mL) were added. The solution was stirred 
for 1 h at room temperature. Et2O (20 mL) and water (20 mL) were added and the aqueous 
phase was extracted with Et2O (3 × 20 mL). The organic phase was dried over MgSO4, all 
volatiles evaporated under reduced pressure and the residue was purified by column 
chromatography (SiO2, d × h: 3 × 25 cm, pentane:Et2O (50:1)) to afford the product (627 mg, 
1.59 mmol, 94%) as a colorless oil. 
C21H27F2NOSi (375.53 g/mol):  
TLC: Rf = 0.40 (SiO2, pentane:Et2O (50:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): δ/ppm = 7.49 (d, J = 7.9 Hz, 1H, ar-H), 7.41-7.31 (m, 2H, ar-H), 
7.05-6.93 (m, 2H, ar-H), 4.89 (t, J = 4.3 Hz, 1H, OCH), 2.98-2.85 (m, 1H, CH2), 2.85-2.67 (m, 
1H, CH2), 2.25-2.03 (m, 2H, CH2), 2.03-1.91 (m, 1H, CH2), 1.88-1.72 (m, 1H, CH2), 0.91 (s, 
9H, C(CH3)3), 0.22 (s, 3H, SiCH3), 0.04 (s, 3H, SiCH3).  
13
C{
1
H} NMR (101 MHz, CDCl3): δ/ppm = 160.8 (dd, 
1
JCF = 250 Hz, 
3
JCF = 7 Hz, ar-C), 
157.8 (s, ar-qC), 146.6 (s, ar-qC), 137.1 (s, ar-CH), 131.8 (s, ar-qC), 129.7 (t, 
3
JCF = 10 Hz, ar-
qC), 124.5 (d, 
3
JCF = 2.0 Hz, ar-CH), 118.6 (t, 
2
JCF = 18.0 Hz, ar-qC), 112.0 (dd, J = 18 Hz, J = 
8.0 Hz, ar-CH), 70.2 (s, CHOSi), 32.5 (s, CH2), 28.5 (s, CH2), 26.0 (s, C(CH3)3), 18.5 (s, 
C(CH3)3), 17.9 (s, CH2), 4.3 and 5.0 (s, Si(CH3)2). 
19
F{
1
H} NMR (376 MHz, CDCl3): δ/ppm = 119.2 (s). 
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IR (ATR): ṽ/cm-1 = 2930 (m), 2854 (m), 1626 (w), 1467 (s), 1232 (m), 999 (s), 924 (m), 830 
(s), 776 (s). 
HRMS (ESI, 4500 V, 180 °C): (m/z) calc. for C21H28F2NOSi
+
: 376.1903 [M+H]
+
; found: 
376.1902. 
[α]
20
D  = +11.3 
(c = 0.92, CHCl3).  
 
General procedure: TBS deprotections GP2 
 
2-(3,5-di-tert-Butyl-4-methoxyphenyl)-5,6,7,8-tetrahydroquinolin-8-ol ((S)-2.51) 
 
The analogous TBS ether (0.40 g, 0.93 mmol, 1.00 eq.) was dissolved in THF (15 mL) and 
TBAF × 3 H2O (1.17 g, 3.72 mmol, 4.00 eq.) was added. The resulting yellow solution was 
stirred for 4 h at 50 °C. The solvent was evaporated under reduced pressure to obtain a brown 
oil. This oil was taken up in CH2Cl2 (30 mL) and washed with H2O (30 mL). The organic 
layer was separated and the aqueous layer was extracted with CH2Cl2 (2 × 30 mL). The 
combined organic layers were dried over MgSO4, filtered and the solvent was evaporated 
under reduced pressure. The brown residue was purified by column chromatography (SiO2, d 
× h: 3 × 11 cm, hexane:ethyl acetate (20:1  1:1)) to afford the product (0.26 g, 0.82 mmol, 
88%) as a colorless solid. 
C24H33NO2 (367.53 g/mol): 
MP: 188-189 °C. 
TLC: Rf = 0.49 (SiO2, CH2Cl2, UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.84 (s, 2H, ar-H), 7.51 (d, JHH = 8.0 Hz, 1H, ar-H), 
7.46 (d, JHH = 8.0 Hz, 1H, ar-H), 4.74 (dd, JHH = 9.0 Hz, JHH = 4.4 Hz, 1H, HCOH), 4.34 (s, 
1H, OH), 3.72 (s, 3H, OCH3), 2.91-2.78 (m, 2H, CH2), 2.40-2.34 (m, 1H, CH2), 2.06-2.03 (m, 
1H, CH2), 1.91-1.75 (m, 2H, CH2), 1.49 (s, 18H, 2 × C(CH3)3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 160.8 (s, ar-C), 157.6 (s, ar-C), 155.2 (s, ar-C), 
144.1 (s, ar-C), 137.8 (s, ar-C), 133.3 (s, ar-C), 129.2 (s, ar-C), 125.4 (s, ar-C), 119.4 (s, ar-C), 
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69.2 (s, COH), 64.5 (s, OCH3), 36.1 (s, C(CH3)3), 32.2 (s, C(CH3)2, 30.8 (s, CH2), 28.1 (s, 
CH2), 19.8 (s, CH2).  
IR (KBr): ṽ/cm-1 = 3475 (m), 2944 (s), 2866 (m), 1589 (m), 1472 (m), 1450 (s), 1414 (s), 
1248 (m), 1225 (s), 1117 (m), 1066 (m), 1013 (m), 824 (m). 
MS (EI, 70 eV, 200 °C) m/z (%): 368.3 (27), 367.3 (100), 366.2 (12), 353.2 (15), 352.2 (59), 
339.3 (10), 338.2 (22), 334.2 (21), 311.2 (29), 304.2 (29), 292.2 (10), 278 (11).  
EA (C24H33NO2): calc.: C 78.43, H 9.05, N 3.81; found: C 78.16, H 9.17, N 3.84.  
HPLC: Daicel, Chiralcel OD-H (0.46 cm × 25 cm, heptane/iso-propanol = 98:02, 0.5 mL/min, 
25 °C, 220 nm): tR = 13.2 min and 15.6 min. 
 
2-(3,5-di-tert-Butyl-4-methoxyphenyl)-4-methyl-6,7-dihydro-5H-cyclopenta[b]pyridin-7-
ol ((S)-2.50) 
 
The reaction was set up as described in the general procedure GP2 except using the analogous 
TBS ether (800 mg, 1.66 mmol, 1.00 eq.) and TBAF × 3 H2O (2.09 g, 6.64 mmol, 4.00 eq.) 
dissolved in THF (8 mL). Extraction and purification by column chromatography (SiO2, d × h: 
3 × 15 cm, hexane:ethyl acetate (20:1  10:1)) afforded the product (488 mg, 1.48 mmol, 
79%) as a colorless solid. 
C24H33NO2 (367.53 g/mol): 
MP: 153-155 °C. 
TLC: Rf = 0.16 (SiO2, hexane:ethyl acetate (5:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.77 (s, 2H, ar-H), 7.30 (s, 1H, ar-H), 5.25 (t, JHH = 
6.4 Hz, 1H, CHOH), 4.21 (s br, 1H, OH), 3.72 (s, 3H, OCH3), 2.96 (ddd, JHH = 16.1, 8.9, 
4.2 Hz, 1H, CH2), 2.77-2.69 (m, 1H, CH2), 2.54-2.46 (m, 1H, CH2), 2.33 (s, 3H, CH3), 2.07-
1.99 (m, 1H, CH2), 1.47 (s, 18 H, 2 × C(CH3)3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 164.2 (s, ar-C), 160.4 (s, ar-C), 157.9 (s, ar-C), 
144.5 (s, ar-C), 143.8 (s, ar-C), 134.1 (s, ar-C), 133.6 (s, ar-C), 125.8 (s, ar-C), 121.3 (s, ar-C), 
74.9 (s, CHOH), 64.4 (s, OCH3), 36.0 (s, 2 × C(CH3)3), 32.5 (s, CH2), 32.2 (s, 2 × C(CH3)3), 
26.0 (s, CH2), 18.9 (s, CH3). 
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IR (KBr): ṽ/cm-1 = 3197 (m, br), 3004 (m), 2960 (s), 1597 (m), 1442 (m), 1405 (m), 1216 (s), 
1114 (m), 1002 (m), 867 (m). 
MS (EI, 70 eV, 200 °C) m/z (%): 368.3 (26), 367.3 (100), 353.2 (19), 352.2 (75), 334.2 (16), 
310.2 (11), 304.2 (27). 
EA (C24H33NO2): calc.: C 78.43, H 9.05, N 3.81; found: C 78.74, H 9.21, N 3.87. 
HPLC: Daicel, Chiralcel OD-H (0.46 cm × 25 cm, heptane/iso-propanol = 98:02, 0.5 mL/min, 
25 °C, 220 nm): tR = 11.4 min and 13.3 min. 
 
4-Methyl-2-(3,4,5-trimethoxyphenyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol (2.52) 
 
The reaction was set up as described in the general procedure GP2 except using the analogous 
TBS ether (800 mg, 1.86 mmol, 1.00 eq.) and TBAF × 3 H2O (2.35 g, 7.44 mmol, 4.00 eq.) 
dissolved in THF (8 mL). Extraction and purification by column chromatography (SiO2, d × h: 
15 × 3 cm, hexane:ethyl acetate (10:1  1:3)) afforded the product (482 mg, 1.60 mmol, 86%) 
as a colorless solid. 
C18H21NO4 (315.37 g/mol): 
MP: 149-151 °C. 
TLC: Rf = 0.15 (SiO2, hexane:ethyl acetate (1:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.31 (s, 1H, ar-H), 7.15 (s, 2H, ar-H), 5.25 (dd, JHH = 
7.2, 5.7 Hz, 1H, HCOH), 5.51 (s br, 1H, OH), 3.86 (s, 9H, 3 × OCH3), 2.95 (ddd, JHH = 16.2, 
8.9, 4.3 Hz, 1H, CH2), 2.76-2.68 (m, 1H, CH2), 2.54-2.45 (m, 1H, CH2), 2.32 (s, 3H, CH3), 
2.07-1.99 (m, 1H, CH2). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 164.3 (s, ar-C), 156.6 (s, ar-C), 153.4 (s, ar-C), 
144.9 (s, ar-C), 138.8 (s, ar-C), 135.2 (s, ar-C), 134.4 (s, ar-C), 121.0 (s, ar-C), 104.4 (s, ar-C), 
74.9 (s, COH), 61.0 (s, OCH3), 56.2 (s, OCH3), 32.5 (s, CH2), 26.0 (s, CH2), 18.9 (s, CH3). 
IR (KBr): ṽ/cm-1 = 3184 (w, br), 2938 (w), 1585 (m), 1466 (m), 1246 (w), 1230 (w), 1121 (s), 
1009 (m), 964 (w), 832 (w). 
MS (EI, 70 eV, 200 °C) m/z (%): 315.1 (100), 300.1 (43), 272.1 (12), 242.1 (10). 
EA (C18H21NO4): calc.: C 68.55, H 6.71, N 4.44; found: C 68.29, H 6.92, N 4.42. 
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HPLC: Daicel, Chiralpak AD-H (0.46 cm × 25 cm, heptane/iso-propanol = 85:15, 
0.5 mL/min, 25 °C, 220 nm): tR = 30.5 min and 33.4 min.  
 
2-(3,4,5-Trimethoxyphenyl)-5,6,7,8-tetrahydroquinolin-8-ol (2.53) 
 
The reaction was set up as described in the general procedure GP2 except using the analogous 
TBS ether (400 mg, 0.93 mmol, 1.00 eq.) and TBAF × 3 H2O (1.17 g, 3.72 mmol, 4.00 eq.) 
dissolved in THF (15 mL). Extraction and purification by column chromatography (SiO2, d × 
h: 3 × 11 cm, hexane:ethyl acetate (20:1  1:1)) afforded the product (260 mg, 0.82 mmol, 
88%) as a colorless solid. 
C18H21NO4 (315.37 g/mol): 
MP: 151-152 °C. 
TLC: Rf = 0.40 (SiO2, hexane:ethyl acetate (1:1), UV). 
1
H NMR
 
(500 MHz, CDCl3): /ppm = 7.52 (d, JHH = 6.4 Hz, 1H, ar-H), 7.48 (d, JHH = 6.4 Hz, 
1H, ar-H), 7.21 (s, 2H, ar-H), 4.74 (dd, JHH = 9.0, 5.0 Hz, 1H, HCOH), 4.28 (s, 1H, COH), 
3.95 (s, 6H, 2 × OCH3), 3.90 (s, 3H, OCH3), 2.90-2.80 (m, 2H, CH2), 2.38-2.34 (m, 1H, CH2), 
2.07-2.01 (m, 1H, CH2), 1.90-1.77 (m, 2H, CH2). 
13
C{
1
H} NMR (126 MHz, CDCl3): ppm = 157.6 (s, ar-C), 154.1 (s, ar-C), 153.5 (s, ar-C), 
139.1 (s, ar-C), 137.9 (s ar-C), 134.6 (s, ar-C), 129.9 (s, ar-C), 119.2 (s, ar-C), 104 (s, ar-C), 
69.1 (s, COH), 61.0 (s, OCH3), 56.3 (s, OCH3), 30.7 (s, CH2), 28.0 (s, CH2), 19.6 (s, CH2). 
IR (KBr): ṽ/cm-1 = 3165 (m, br), 2935 (m), 1590 (m), 1565 (m), 1511 (w), 1472 (m), 1465 
(m), 1349 (m), 1237 (m), 1135 (s), 1103 (m), 965 (m), 817 (m). 
MS (EI, 70 eV, 200 °C) m/z (%): 315.1 (100), 300.1 (23), 286.2 (23), 259.1 (42), 244.1 (11). 
EA (C18H21NO4): calc.: C 68.55, H 6.71, N 4.44; found: C 68.72, H 6.70, N 4.48. 
HPLC: Daicel, Chiralpak IC (0.46 cm × 25 cm, heptane/iso-propanol = 50:50, 0.5 mL/min, 
25 °C, 220 nm): tR = 23.1 min and 27.9 min 
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2-(3,5-Bis(trifluoromethyl)phenyl)-4-methyl-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol  
 
The reaction was setup as described in the general procedure GP2 except using the analogous 
TBS ether (430 mg, 0.90 mmol, 1.00 eq.) and TBAF × 3 H2O (1.14 g, 3.61 mmol, 4.00 eq.) 
dissolved in THF (5 mL). Extraction and purification by column chromatography (SiO2, d × h: 
3 × 15 cm, hexane:ethyl acetate (20:1  1:1)) afforded the product (280 mg, 0.78 mmol, 86%) 
as a colorless solid. 
C17H13F6NO (361.29 g/mol): 
MP: 165-166 °C. 
TLC: Rf = 0.20 (SiO2, CH2Cl2, UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 8.42 (s, 2H, ar-H), 7.87 (s, 1H, ar-H), 7.46 (s, 1H, ar-
H), 5.27 (t, JHH = 6.6 Hz, 1H, CHOH), 3.54 (d, JHH = 2.8 Hz, 1H, OH), 3.03 (ddd, JHH = 16.4, 
8.9, 3.9 Hz, 1H, CH2), 2.84-2.76 (m, 1H, CH2), 2.63-2.58 (m, 1H, CH2), 2.38 (s, 3H, CH3), 
2.13-2.04 (m, 1H, CH2). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 165.0 (s, ar-C), 153.6 (s, ar-C), 145.4 (s, ar-C), 
141.6 (s, ar-C), 136.1 (s, ar-C), 132.1 (q, JCF = 33 Hz, ar-C), 127.1 (s, ar-C), 123.6 (q, JCF = 
272 Hz, CF3), 122.1 (sept, JCF = 4 Hz, ar-C), 121.1 (s, ar-C), 75.0 (s, COH), 32.6 (s, CH2), 
26.1 (s, CH2), 18.9 (s, CH3). 
19
F{
1
H} NMR (376 MHz, CDCl3): ppm = 63.0 (s). 
IR (KBr): ṽ/cm-1 = 3420 (m, br), 3073 (w), 2984 (w), 2932 (w), 1390 (m), 1334 (m), 1289 (s), 
1236 (w), 1164 (m), 1127 (s), 899 (m), 684 (m). 
MS (EI, 70 eV, 200 °C) m/z (%): 361.1 (22) [M]
+
, 342.1 (14), 333.1 (100), 305.1 (30). 
EA (C17H13F6NO): calc.: C 56.52, H 3.63, N 3.88; found: C 56.18, H 3.71, N 4.04.  
HPLC: Daicel, Chiralpak AD-H (0.46 cm × 25 cm, heptane/iso-propanol = 95:05, 
0.5 mL/min, 25 °C, 220 nm): tR = 15.6 min and 18.8 min. 
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(S)-4-Methyl-2-(phenanthren-9-yl)-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol ((S)-2.57)  
 
The reaction was setup as described in the general procedure GP2 except using the analogous 
TBS ether (250 mg, 0.57 mmol, 1.00 eq.) and TBAF × 3 H2O (1.72 g, 2.27 mmol, 4.00 eq.) 
dissolved in THF (5 mL). Extraction and purification by column chromatography (SiO2, d × h: 
3 × 15 cm, pentane:Et2O (1:3)) afforded the product (160 mg, 0.49 mmol, 86%) as a colorless 
solid. 
C23H19NO (325.41 g/mol): 
MP: 232 °C (decomposition). 
TLC: Rf = 0.30 (SiO2, pentane:Et2O (1:3), UV). 
1
H NMR
 
(400 MHz, CDCl3): δ/ppm = 8.77 (d, J = 8.4 Hz, 1H, ar-H), 8.72 (d, J = 8.3 Hz, 1H, 
ar-H), 8.02 (dd, J = 8.3, 1.3 Hz, 1H, ar-H), 7.91 (dd, J = 7.8, 1.4 Hz, 1H, ar-H), 7.81 (s, 1H, 
ar-H), 7.72-7.65 (m, 2H, ar-H), 7.64-7.59 (m, 1H, ar-H), 7.58-7.52 (m, 1H, ar-H), 7.31 (s, 1H, 
ar-H), 5.36-5.22 (m, 1H, HCO), 3.12-3.00 (m, 2H, CH2 and OH), 2.95-2.77 (m, 1H, CH2), 
2.70-2.56 (m, 1H, CH2), 2.38 (s, 3H, CH3), 2.19-2.04 (m, 1H, CH2). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 164.0 (s, ar-C), 158.4 (s, ar-C), 144.6 (s, ar-C), 
137.4 (s, ar-C), 134.4 (s, ar-C), 131.5 (s, ar-C), 130.9 (s, ar-C), 130.7 (s, ar-C), 130.5 (s, ar-C), 
129.1 (s, ar-C), 128.4 (s, ar-C), 127.1 (s, ar-C), 126.9 (s, ar-C), 126.8 (s, ar-C), 126.8 (s, ar-C), 
126.7 (s, ar-C), 125.5 (s, ar-C), 123.0 (s, ar-C), 122.7 (s, ar-C), 75.4 (s, CHOH), 32.4 (s, CH2), 
26.2 (s, CH2), 18.9 (s, CH3). 
IR (ATR): ṽ/cm-1 = 3353 (w), 3063 (w), 2964 (w), 1966 (w), 1592 (m), 1449 (m), 1381 (w), 
1316 (w), 1261 (m), 1091 (m), 1026 (m), 954 (w), 889 (m), 801 (m), 749 (m), 710 (s). 
HRMS (ESI, 4500 V, 180 °C): (m/z) calc. for C23H20NO
+
: 326.1539 [M+H]
+
; found: 326.1538. 
[α]
20
D  = +0.5 (c = 1.00, CHCl3). 
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(S)-2-([1,1':3',1''-Terphenyl]-5'-yl)-4-methyl-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol 
((S)-2.54) 
 
The reaction was set up as described in the general procedure GP2 except using the analogous 
TBS ether (180 mg, 0.37 mmol, 1.00 eq.) and TBAF × 3 H2O (462 mg, 1.46 mmol, 4.00 eq.) 
dissolved in THF (7 mL). Extraction and purification by column chromatography (SiO2, d × h: 
3 × 15 cm, pentane:Et2O (1:3)) afforded the product (122 mg, 0.32 mmol, 88%) as a colorless 
solid. 
C27H23NO (467.77 g/mol):  
MP: 178-179 °C. 
TLC: Rf = 0.27 (SiO2, pentane:Et2O (1:3), UV). 
1
H NMR
 
(400 MHz, CDCl3): δ/ppm = 8.15 (d, J = 1.8 Hz, 2H, ar-H), 7.83 (t, J = 1.7 Hz, 1H, 
ar-H), 7.75-7.70 (m, 4H, ar-H), 7.52-7.45 (m, 5H, ar-H), 7.42-7.36 (m, 2H, ar-H), 5.26 (t, J = 
6.5 Hz, 1H, HCO), 3.23-3.14 (m, 1H, OH), 3.05-2.94 (m, 1H, CH2), 2.84-2.71 (m, 1H, CH2), 
2.62-2.54 (m, 1H, CH2), 2.35 (s, 3H, CH3), 2.14-2.01 (m, 1H, CH2). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 164.3 (s, ar-C), 156.9 (s, ar-C), 144.7 (s, ar-C), 
142.4 (s, ar-C), 141.3 (s, ar-C), 140.8 (s, ar-C), 134.5 (s, ar-C), 128.9 (s, ar-C), 127.6 (s, ar-C), 
127.5 (s, ar-C), 126.5 (s, ar-C), 125.1 (s, ar-C), 121.5 (s, ar-C), 75.3 (s, CHOH), 32.6 (s, CH2), 
26.0 (s, CH2), 19.0 (s, CH3). 
IR (ATR): ṽ/cm-1 = 3154 (w), 3057 (w), 2894 (w), 2844 (w), 1593 (s), 1500 (m), 1410 (m), 
1312 (w), 1158 (w), 1059 (m), 1015 (m), 960 (m), 886 (m), 804 (m), 759 (s), 696 (s). 
MS (ESI, MeOH) m/z (%): 378.5 [M+H]
+
. 
HRMS (ESI, 4500 V, 180 °C): (m/z) calc. for C27H24NO
+
: 378.1852 [M+H]
+
; found: 
378.1853. 
[α]
20
D  = +26.3 (c = 1.02, CHCl3). 
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(S)-2-([1,1':3',1''-Terphenyl]-5'-yl)-5,6,7,8-tetrahydroquinolin-8-ol ((S)-2.55)  
 
The reaction was set up as described in the general procedure GP2 except using the analogous 
TBS ether (230 mg, 0.47 mmol, 1.00 eq.) and TBAF × 3 H2O (660 mg, 1.87 mmol, 4.00 eq.) 
dissolved in THF (10 mL). Extraction and purification by column chromatography (SiO2, d × 
h: 3 × 15 cm, pentane:CH2Cl2 (1:3)  CH2Cl2) afforded the product (141 mg, 0.38 mmol, 
80%) as a colorless solid. 
C27H23NO (377.49 g/mol):  
MP: 141-142 °C. 
TLC: Rf = 0.49 (SiO2, pentane:CH2Cl2 (1:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): δ/ppm = 8.19 (d, J = 1.8 Hz, 2H, ar-H), 7.85 (t, J = 1.7 Hz, 1H, 
ar-H), 7.77-7.65 (m, 5H, ar-H), 7.56-7.46 (m, 5H, ar-H), 7.45-7.38 (m, 2H, ar-H), 4.80-4.77 
(m, 1H, CHOH), 4.38 (s, 1H, CHOH), 3.00-2.77 (m, 2H, CH2), 2.48-2.30 (m, 1H, CH2), 2.14-
1.98 (m, 1H, CH2), 1.99-1.76 (m, 2H, CH2). 
13
C{
1
H} NMR (101 MHz, CDCl3): δ/ppm = 158.0 (s, ar-C), 154.3 (s, ar-C), 142.4 (s, ar-C), 
141.2 (s, ar-C), 140.2 (s, ar-C), 137.9 (s, ar-C), 130.3 (s, ar-C), 129.0 (s, ar-C), 127.7 (s, ar-C), 
127.5 (s, ar-C), 126.8 (s, ar-C), 124.8 (s, ar-C), 119.6 (s, ar-C), 69.3 (s, CHOH), 30.8 (s, CH2), 
28.2 (s, CH2), 19.8 (s, CH2). 
IR (ATR): ṽ/cm-1 = 3036 (w), 2938 (m), 2851 (m), 1588 (m), 1567 (m), 1466 (m), 1406 (m), 
1254 (m), 1073 (m), 1042 (m), 1010 (m), 961 (m), 877 (m), 827 (m), 747 (s), 690 (s), 615 
(m), 589 (m), 540 (m), 499 (w), 426 (w). 
MS (ESI, MeOH) m/z (%): 378.5 [M+H]
+
. 
EA (C27H23NO): calc.: C 85.91, H 6.14, N 3.71; found: C 85.81, H 6.27, N 3.83. 
[α]
20
D  = +81.7 (c = 0.96, CHCl3). 
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(S)-2-(2,6-Difluorophenyl)-4-methyl-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol ((S)-2.58)  
 
The reaction was set up as described in the general procedure GP2 except using the analogous 
TBS ether (250 mg, 0.67 mmol, 1.00 eq.) and TBAF × 3 H2O (840 mg, 2.66 mmol, 4.00 eq.) 
dissolved in THF (12 mL). Extraction and purification by column chromatography (SiO2, d × 
h: 3 × 10 cm, pentane:Et2O (1:3)) afforded the product (172 mg, 0.66 mmol, 99%) as a 
colorless solid. 
C15H13F2NO (261.27 g/mol):  
MP: 126-127 °C. 
TLC: Rf = 0.20 (SiO2, pentane:Et2O (1:3), UV). 
1
H NMR
 
(400 MHz, CDCl3): δ/ppm = 7.31 (tt, J = 8.4, 6.3 Hz, 1H, ar-H), 7.13 (s, 1H, ar-H), 
7.01-6.92 (m, 2H, ar-H), 5.27-5.21 (m, 1H, HCO), 3.77-3.62 (m, 1H, OH), 3.05-2.91 (m, 1H, 
CH2), 2.82-2.68 (m, 1H, CH2), 2.59-2.44 (m, 1H, CH2), 2.32 (s, 3H, CH3), 2.10-1.97 (m, 1H, 
CH2). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 164.5 (s, ar-C), 160.6 (dd, JCF = 250, 7 Hz, ar-C), 
147.8 (s, ar-C), 144.4 (s, ar-C), 135.4 (s, ar-C), 129.9 (t, JCF = 10 Hz, ar-C), 126.0 (s, ar-C), 
118.2 (t, JCF = 19 Hz, ar-C), 113.2-109.9 (m, ar-C), 74.8 (d, JCF = 13 Hz, CHOH), 32.4 (d, JCF 
= 7 Hz, CH2), 26.1 (s, CH2), 18.7 (s, CH3). 
19
F{
1
H} NMR (376 MHz, CDCl3): d/ppm = 114.1. 
IR (ATR): ṽ/cm-1 = 3295 (w), 2962 (w), 2854 (w), 2451 (w), 1599 (m), 1467 (s), 1372 (w), 
1312 (w), 1272 (m), 1233 (m), 1167 (w), 1087 (s), 1001 (s), 954 (m), 926 (m), 877 (m), 860 
(w), 791 (s), 735 (s), 644 (m). 
HRMS (ESI, 4500 V, 180 °C): (m/z) calc. for C15H14F2NO
+
: 262.1038 [M+H]
+
; found: 
262.1040. 
[α]
20
D  = +4.1 (c = 0.98, CHCl3). 
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(S)-2-(2,6-Difluorophenyl)-5,6,7,8-tetrahydroquinolin-8-ol ((S)-2.59)  
 
The reaction was set up as described in the general procedure GP2 except using the analogous 
TBS ether (580 mg, 1.57 mmol, 1.00 eq.) and TBAF × 3 H2O (3.24 g, 10.3 mmol, 4.00 eq.) 
dissolved in THF (25 mL). Extraction and purification by column chromatography (SiO2, d × 
h: 3 × 15 cm, pentane:Et2O (1:3)) afforded the product (324 mg, 1.25 mmol, 85%) as a 
colorless solid. 
C15H13NO (261.27 g/mol):  
MP: 94-96 °C. 
TLC: Rf = 0.35 (SiO2, pentane:Et2O (1:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): δ/ppm = 7.43 (d, J = 7.9 Hz, 1H, ar-H), 7.33-7.22 (m, 2H, ar-
2H), 6.97-6.82 (m, 2H, ar-H), 4.67 (t, J = 5.9 Hz, 1H, CHOH), 3.97 (s, 1H, CHOH), 2.87-2.69 
(m, 2H, CH2), 2.31-2.19 (m, 1H, CH2), 2.02-1.90 (m, 1H, CH2), 1.84-1.69 (m, 2H, CH2). 
13
C{
1
H} NMR (101 MHz, CDCl3): δ/ppm = 160.7 (dd, 
1
J = 250 Hz, 
3
J = 7 Hz, ar-qC), 158.2 
(s, ar-qC), 146.5 (s, ar-qC), 137.2 (s, ar-CH), 131.1 (s, ar-qC), 130.0 (t, 
3
J = 10 Hz, ar-qC), 
124.6 (t, 
3
J = 2 Hz, ar-C), 117.9 (t, 
2
J = 18 Hz, ar-qC), 111.9 (dd, J = 18, 8 Hz, ar-C), 69.1 (s, 
CHOH), 30.7 (s, CH2), 28.3 (s, CH2), 19.6 (s, CH2). 
19
F{
1
H} NMR (376 MHz, CDCl3): /ppm = 114.4 (s). 
IR (ATR): ṽ/cm-1 = 3258 (br m), 2942 (m), 2860 (m), 1624 (w), 1467 (s), 1232 (m), 998 (s), 
924 (m), 830 (s), 776 (s). 
MS (ESI, MeOH (m/z): 284.1 (80) [M+Na]
+
, 545.3 (100) [2M+Na]
+
. 
EA (C15H13NOF2): calc.: C 68.96, H 5.02, N 5.36; found: C 68.60, H 5.10, N 5.55.  
[α]
20
D  = +74.1 (c = 0.58, CHCl3). 
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(S)-2-([1,1'-Biphenyl]-2-yl)-5,6,7,8-tetrahydroquinolin-8-ol ((S)-2.56) 
 
The reaction was set up as described in the general procedure GP2 except using the analogous 
TBS ether (217 mg, 0.523 mmol, 1.00 eq.) and TBAF × 3 H2O (0.634 mg, 2.18 mmol, 
4.00 eq.) dissolved in THF (8 mL). Extraction and purification by column chromatography 
(SiO2, d × h: 3 × 10 cm, pentane:Et2O (1:1)) afforded the product (122 mg, 0.405 mmol, 77%) 
as a colorless solid. 
C21H19NO (301.17 g/mol) 
MP: 46-49 °C. 
TLC: Rf = 0.38 (SiO2, pentane:Et2O (1:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): δ/ppm = 7.64-7.58 (m, 1H, ar-H), 7.42-7.33 (m, 3H, ar-H), 
7.24-7.17 (m, 3H, ar-H), 7.15 (d, J = 7.9 Hz, 1H, ar-H), 7.11-7.06 (m, 2H, ar-H), 6.87 (d, J = 
7.9 Hz, 1H, ar-H), 4.50 (t, J = 7.8 Hz, 1H, OCH), 3.40 (s, 1H, COH), 2.80-2.58 (m, 2H, CH2), 
2.26-2.10 (m, 1H, CH2), 1.95-1.81 (m, 1H, CH2), 1.79-1.59 (m, 2H, CH2). 
13
C{
1
H} NMR (101 MHz, CDCl3): δ (ppm) = 157.2 (s, ar-C), 156.1 (s, ar-C), 141.9 (s, ar-C), 
141.0 (s, ar-C), 138.9 (s, ar-C), 136.6 (s, ar-C), 130.8 (s, ar-C), 130.3 (s, ar-C), 129.5 (s, ar-C), 
129.1 (s, ar-C), 128.5 (s, ar-C), 128.1 (s, ar-C), 127.6 (s, ar-C), 126.6 (s, ar-C), 123.4 (s, ar-C), 
68.8 (s, CHOH), 30.6 (s, CH2), 28.0 (s, CH2), 19.5 (s, CH2). 
[α]
20
D  = +45.4 (c = 0.50, CHCl3). 
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General procedure: Kinetic enzymatic resolutions GP3 
 
(S)-8-((tert-Butyldimethylsilyl)oxy)-2-(3,5-di-tert-butyl-4-methoxyphenyl)-5,6,7,8-
tetrahydroquinoline ((S)-2.41) and (R)-2-(3,5-Di-tert-butyl-4-methoxyphenyl)-5,6,7,8-
tetrahydroquinolin-8-yl acetate 
 
Vinyl acetate (1.30 mL, 21.1 mmol, 15.0 eq.) and CAL-B [250 mg, immobilized on acrylic 
resin from Sigma (L47777)] was added to a solution of the racemic alcohol 2.51 (514 mg, 
1.40 mmol, 1.00 eq.) in dry i-Pr2O (60 mL). The resulting solution was stirred at 60 °C for 
5.5 h until chiral HPLC showed full consumption of one enantiomer. The enzyme was filtered 
off and washed with EtOAc (3 × 20 mL). Evaporation of the solvent afforded a pale yellow 
residue which was dissolved in DMF (5 mL). Imidazole (160 mg, 2.35 mmol, 1.70 eq.) and 
TBSCl (170 mg, 1.12 mmol, 0.80 eq.) were added under an argon atmosphere. The resulting 
colorless solution was stirred for 18 h at room temperature. The solvent was evaporated in HV 
and the resulting pale yellow residue was taken up in CH2Cl2 (10 mL) and H2O (10 mL) was 
added. The organic layer was separated and the aqueous layer was extracted with CH2Cl2 (2 × 
10 mL). The combined organic layers were dried over MgSO4, filtered and the solvent 
evaporated under reduced pressure to afford a colorless residue. Column chromatography 
(SiO2, d × h: 6 × 30 cm, hexane:ethyl acetate (1:20  1:1)) afforded the TBS ether (S)-2.41 
(310 mg, 0.64 mmol, 46%) as a colorless solid and the (R)-acetate (250 mg, 0.61 mmol, 44%) 
as a colorless oil. 
TBS ether (S)-2.41 
C24H35NO4Si (429.63 g/mol): 
[α]
20
D  = +30.8 (c = 0.73, CHCl3). 
Additional analytical data matches the data of the racemic silyl ether 2.41. 
 
(R)-Acetate 
C26H35NO3 (409.57 g/mol): 
TLC: Rf = 0.64 (SiO2, CH2Cl2, UV). 
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1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.86 (s, 2H, ar-H), 7.53 (d, JHH = 8.0 Hz, 1H, ar-H), 
7.45 (d, JHH = 8.0 Hz, 1H, ar-H), 6.08 (t, JHH = 5.7 Hz, 1H, HCOAc), 3.71 (s, 3H, OCH3), 
2.87 (dt, JHH = 16.7, 6.2 Hz, 1H, CH2), 2.77 (dt, JHH = 16.7, 6.2 Hz, 1H, CH2), 2.17-2.10 (m, 
2H, CH2), 2.15 (s, 3H, CH3), 2.03-1.95 (m, 1H, CH2), 1.91-1.83 (m, 1H, CH2), 1.47 (s, 18H, 2 
× C(CH3)3).  
13
C{
1
H} NMR (101 MHz, CDCl3): 170.8 (s, O2CCH3), 160.7 (s, ar-C), 155.9 (s, ar-C), 153.3 
(s, ar-C), 143.9 (s, ar-C), 137.6 (s, ar-C), 133.6 (s, ar-C), 130.9 (s, ar-C), 125.4 (s, ar-C), 119.5 
(s, ar-C), 71.2 (s, COAc) 64.4 (OCH3), 36.1 (s, C(CH3)3), 32.2 (s, C(CH3)3), 29.3 (s, CH2), 
28.2 (s, CH2), 21.6 (s, CH3), 19.4 (s, CH2). 
IR (NaCl): ṽ/cm-1 = 2956 (s), 1739 (s), 1593 (w), 1559 (w), 1412 (m), 1369 (w), 1236 (s), 
1115 (w), 1012 (m), 756 (w). 
MS (EI, 70 eV, 200 °C) m/z (%): 410.3 (17), 409.3 (59), 367.3 (14), 366.3 (49), 350.3 (12), 
349.3 (29), 335.3 (24), 334.3 (100), 304.2 (11). 
HPLC: Daicel, Chiralcel OD-H (0.46 cm × 25 cm, heptane/iso-propanol = 99.5:0.5, 
0.5 mL/min, 25 °C, 220 nm): tR = 26.4 min and 32.1 min. 
[α]
20
D  = +19.6 (c = 0.53, CHCl3). 
 
(S)-7-((tert-Butyldimethylsilyl)oxy)-2-(3,5-di-tert-butyl-4-methoxyphenyl)-4-methyl-6,7-
dihydro-5H-cyclopenta[b]pyridine ((S)-2.38) and (R)-2-(3,5-di-tert-Butyl-4-
methoxyphenyl)-4-methyl-6,7-dihydro-5H-cyclopenta[b]pyridin-7-yl acetate  
 
The reaction was set up as described in the general procedure GP3 except using vinyl acetate 
(2.00 mL, 32.5 mmol, 32.5 eq.), CAL-B (200 mg) and the analogous racemic alcohol (370 mg, 
1.00 mmol, 1.00 eq.) in dry i-Pr2O (80 mL) stirred at 60 °C for 4.5 h. After workup the 
mixture was dissolved in DMF (8 mL). Imidazole (115 mg, 1.69 mmol, 1.70 eq.) and TBSCl 
(125 mg, 0.82 mmol, 0.80 eq.) were added to the solution under an argon atmosphere and the 
reaction was stirred for 18 h. Evaporation of the solvent, extraction and column 
chromatography (SiO2, d × h: 6 × 30 cm, hexane:ethyl acetate (1:20  1:3)) afforded the TBS 
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ether (S)-2.38 (240 mg, 0.49 mmol, 49%) as a colorless solid and the (R)-acetate (200 mg, 
0.48 mmol, 48%) as a colorless oil.  
TBS ether (S)-2.38 
C24H35NO4Si (429.63 g/mol): 
[α]
20
D  = +12.1 (c = 0.94, CHCl3). 
Additional analytical data matches the data of the racemic silyl ether (S)-2.38 
 
(R)-Acetate 
C26H35NO3 (409.57 g/mol): 
TLC: Rf = 0.26 (SiO2, hexane:ethyl acetate (5:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.78 (s, 2H, ar-H), 7.35 (s, 1H, ar-H), 6.17 (dd, JHH = 
7.3, 4.4 Hz, 1H, HCOAc), 3.71 (s, 3H, OCH3), 3.02 (ddd, JHH = 16.1, 8.8, 5.4 Hz, 1H, CH2), 
3.83 (ddd, JHH = 16.0, 8.6, 5.3 Hz, 1H, CH2), 2.68-2.59 (m, 1H, CH2), 2.35 (s, 3H, CH3), 
2.16-2.08 (m, 1H CH2), 2.13 (s, 3H, O2CCH3), 1.48 (s, 18H, 2 × C(CH3)3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 171.1 (s, O2CCH3), 160.6 (s, ar-C), 160.0 (s, ar-
C), 158.5 (s, ar-C), 144.3 (s, ar-C), 143.8 (s, ar-C), 134.9 (s, ar-C), 134.3 (s, ar-C), 125.8 (s, 
ar-C), 121.7 (s, ar-C), 77.9 (s, COAc), 64.5 (s, OCH3), 36.0 (s, C(CH3)3), 32.2 (s, C(CH3)3), 
30.7 (s, CH2), 26.4 (s, CH2), 21.5 (s, CH3), 19.0 (s, CH3). 
IR (NaCl): ṽ/cm-1 = 2965 (m), 1734 (s), 1597 (w), 1444 (w), 1405 (m), 1363 (m), 1242 (s), 
1219 (s), 1115 (w), 1003 (m), 889 (w). 
MS (EI, 70 eV, 200 °C) m/z (%): 410.3 (15), 409.3 (51), 366.3 (19), 350.3 (17), 349.2 (45), 
348.3 (12), 335.3 (26), 334.2 (100), 304.2 (25), 292.2 (16), 278.2 (11). 
 [α]
20
D  = 29.2 (c = 0.84, CHCl3). 
HPLC: Daicel, Chiralpak IC (0.46 cm × 25 cm, heptane/iso-propanol = 50:50, 0.5 mL/min, 
25 °C, 220 nm): tR = 22.5 min and 23.5 min. 
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(S)-7-((tert-Butyldimethylsilyl)oxy)-2-(3,5-di-tert-butyl-4-methoxyphenyl)-6,7-dihydro-
5H-cyclopenta-[b]pyridine and (R)-2-(3,5-Di-tert-butyl-4-methoxyphenyl)-6,7-dihydro-
5H-cyclopenta[b]pyridin-7-yl acetate  
 
The reaction was set up as described in the general procedure GP3 except using vinyl acetate 
(7.80 mL, 84.3 mmol, 45.8 eq.), CAL-B (46.8 mg) and 2-(3,5-di-tert-butyl-4-
methoxyphenyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol (650 mg, 1.84 mmol, 1.00 eq.) in 
dry i-Pr2O (65 mL) stirred for 3 h at 60 °C. After workup the mixture was dissolved in DMF 
(5 mL). Imidazole (202 mg, 2.97 mmol, 1.70 eq.) and TBSCl (220 mg, 1.44 mmol, 0.80 eq.) 
were added to the solution under an argon atmosphere and the reaction was stirred for 18 h. 
Evaporation of the solvent, extraction and column chromatography (SiO2, d × h: 6 × 30 cm, 
pentane:Et2O (40:1  1:1)) afforded the (S)-TBS ether (386 mg, 830 mol, 45%, >99.9% ee) 
as a colorless solid and the (R)-acetate (371 mg, 938mol, 45%, 82% ee) as pale yellow solid. 
C29H45NO2Si (467.77 g/mol):  
TLC: Rf = 0.50 (SiO2, pentane:Et2O (40:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.97 (s, 2H, ar-H), 7.54 (s, 2H, ar-H), 5.26-5.32 (m, 
1H, HCOSi), 3.73 (s, 3H, OCH3), 3.09-3.02 (m, 1H, CH2), 2.82-2.75 (m, 1H, CH2), 2.51-2.42 
(m, 1H, CH2), 2.10-2.07 (m, 1H, CH2), 1.50 (s, 18H, 2 × C(CH3)3), 1.00 (s, 9H, SiC(CH3)3), 
0.31 and 0.24 (s, 6H, SiCH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): δ/ppm = 163.3 (s, ar-C), 159.3 (s, ar-C), 155.6 (s, ar-C), 
142.6 (s, ar-C), 132.9 (s, ar-C), 132.8 (s, ar-C), 132.1 (s, ar-C), 124.3 (s, ar-C), 117.9 (s, ar-C), 
75.2 (s, CHOSi), 63.2 (s, OCH3), 34.9 (s, 2 × C(CH3)3), 33.3 (s, CH2), 31.1 (s, 2 × C(CH3)3), 
26.1 (s, CH2), 25.0 (s, SiC(CH3)3), 17.6 (s, SiC(CH3)3), 5.1 and 5.6 (s, Si(CH3)2).  
IR (ATR): ṽ/cm-1 = 2955 (m), 2854 (m), 1591 (w), 1444 (m), 1411 (m), 1389 (m), 1360 (m), 
1318 (w), 1244 (m), 1220 (m), 1156 (w), 1104 (m), 1079 (m), 860 (m), 826 (s), 780 (s), 679 
(w), 616 (w). 
HRMS (ESI, 4500 V, 180 °C): (m/z) calc. for C29H46NO2Si
+
: 468.3292 [M+H]
+
; found: 
468.3297. 
[α]
20
D  = +24.6 (c = 0.98, CHCl3). 
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C25H33NO3 (395.54 g/mol):  
[α]
20
D  = 14.6 (c = 0.54, CHCl3). 
Additional analytical data matches the data of the racemic acetate. 
 
(S)-8-((tert-Butyldimethylsilyl)oxy)-2-(3,4,5-trimethoxyphenyl)-5,6,7,8-
tetrahydroquinoline ((S)-2.42) and (R)-2-(3,4,5-trimethoxyphenyl)-5,6,7,8-
tetrahydroquinolin-8-yl acetate  
 
The reaction was setup as described in the general procedure GP3 except using vinyl acetate 
(0.28 mL, 4.55 mmol, 7.50 eq.), CAL-B (500 mg) and the racemic alcohol 2.53 (183 mg, 
0.61 mmol, 1.00 eq.) in dry i-Pr2O (100 mL) stirred at 60 °C for 7 h. After workup the 
mixture was dissolved in DMF (5 mL). Imidazole (800 mg, 1.17 mmol, 1.90 eq.) and TBSCl 
(800 mg, 0.52 mmol, 0.80 eq.) were added. Evaporation of the solvent, extraction and column 
chromatography (SiO2, d × h: 6 × 30 cm, hexane:ethyl acetate (1:20  3:1)) afforded the TBS 
ether (S)-2.42 (120 mg, 2.77 mmol, 45%) as a colorless solid and the (R)-acetate (100 mg, 
0.28 mmol, 46%) as a colorless oil.  
(R)-Acetate  
C20H23NO5 (357.41 g/mol): 
TLC: Rf = 0.56 (SiO2, hexane:ethyl acetate (1:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.56 (d, JHH = 8.1 Hz, 1H, ar-H), 7.48 (d, JHH = 8.1 Hz, 
1H, ar-H), 7.25 (s, 2H, ar-H), 6.04 (t, JHH = 5.4 Hz, 1H, HCOAc), 3.94 (s, 6H,  
2 × OCH3), 3.88 (s, 3H, OCH3), 2.85 (dt, JHH = 16.9, 5.8 Hz, 1H, CH2), 2.78-2.71 (m, 1H, 
CH2), 2.16-2.07 (m, 2H, CH2), 2.14 (s, 3H, CH3), 2.05-1.95 (m, 1H, CH2), 1.91-1.84 (m, 1H, 
CH2). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 170.7 (s, O2CCH3), 154.6 (s, ar-C), 153.5 (s, ar-
C), 153.2 (s, ar-C), 139.1 (s, ar-C), 138.0 (s, ar-C), 134.7 (s, ar-C), 131.7 (s, ar-C), 119.5 (s, 
ar-C), 104.1 (s, ar-C), 71.1 (s, HCOAc), 61.1 (s, OCH3), 56.3 (s, OCH3), 29.1 (s, CH2), 28.2 (s, 
CH2), 21.6 (s, CH3), 19.0 (s, CH2). 
 
EXPERIMENTAL PART   CHAPTER 8  
243 
(S)-7-((tert-Butyldimethylsilyl)oxy)-4-methyl-2-(3,4,5-trimethoxyphenyl)-6,7-dihydro-
5H-cyclopenta[b]pyridine ((S)-2.39) and (R)-4-methyl-2-(3,4,5-trimethoxyphenyl)-6,7-
dihydro-5H-cyclopenta[b]pyridin-7-yl acetate 
 
The reaction was set up as described in the general procedure GP3 except using vinyl acetate 
(1.20 mL, 19.48 mmol, 15.0 eq.), CAL-B (100 mg) and the analogous racemic alcohol 2.52 
(390 mg, 1.30 mmol, 1.00 eq.) in i-Pr2O (180 mL) stirred at 60 °C for 5.5 h. After work up the 
mixture was dissolved in DMF (5 mL). Imidazole (120 mg, 1.75 mmol, 1.50 eq.) and TBSCl 
(150 mg, 0.98 mmol, 0.80 eq.) were added under an argon atmosphere and the reaction was 
stirred for 18 h. Evaporation of the solvent, extraction and column chromatography (SiO2, d × 
h: 6 × 30 cm, hexane:ethyl acetate (5:1  1:3)) afforded the TBS ether (S)-2.39 (118 mg, 
0.27 mmol, 21%) and the (R)-acetate (167 mg, 0.47 mmol, 36%) both as a colorless solids. 
TBS ether (S)-2.39 
C24H35NO4Si (429.63 g/mol): 
[α]
20
D  = +16.9 (c = 0.65, CHCl3). 
Additional analytical data matches the data of the racemic silyl ether 2.39. 
 
(R)-Acetate  
C20H23NO5 (357.41 g/mol): 
MP: 130-133 °C. 
TLC: Rf = 0.40 (SiO2, hexane:ethyl acetate (1:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.39 (s, 1H, ar-H), 7.18 (s, 2H, ar-H), 6.15 (dd, JHH = 
7.1, 4.0 Hz, 1H, HCOAc), 3.95 (s, 6H, 2 × OCH3), 3.88 (s, 3H, OCH3), 3.06-2.98 (m, 1H, 
CH2), 2.83 (ddd, JHH = 16.0, 8.6, 4.7 Hz, 1H, CH2), 2.67-2.58 (m, 1H, CH2), 2.36 (s, 3H, CH3), 
2.16-2.08 (m, 1H, CH2), 2.12 (s, 3H, CH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 171.0 (s, O2CCH3), 160.0 (s, ar-C), 157.2 (s, ar-
C), 153.3 (s, ar-C), 144.7 (s, ar-C), 139.0 (s, ar-C), 135.8 (s, ar-C), 135.4 (s, ar-C), 121.6 (s, 
ar-C), 104.5 (s, ar-C), 77.8 (s, COAc), 61.0 (s, OCH3), 56.4 (s, OCH3), 30.7 (s, CH2), 26.4 (s, 
CH2), 21.5 (s, O2CCH3), 19.0 (s, CH3). 
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MS (EI, 70 eV, 250 °C) m/z (%): 358.2 (21), 357.1 (100), 314.1 (35), 298.1 (16), 297.1 (35), 
296.1 (30), 283.1 (10), 282.1 (56), 266.1 (10), 254.1 (11), 251.1 (12), 224.1 (14). 
IR (NaCl): ṽ/cm-1 = 3012 (w), 2951 (m), 2827 (w), 1723 (s), 1586 (m), 1509 (m), 1264 (m), 
1413 (m), 1363 (m), 1232 (s), 1130 (s), 1024 (m), 1004 (m), 959 (m), 846 (m), 771 (w). 
[α]
20
D  = 42.1 (c = 0.43, CHCl3). 
HPLC: Daicel, Chiralpak AD-H (0.46 cm × 25 cm, heptane/iso-propanol = 80:20, 
0.5 mL/min, 25 °C, 220 nm): tR = 17.6 min and 19.3 min. 
 
(S)-3-(((2-(3,5-Bis(trifluoromethyl)phenyl)-4-methyl-6,7-dihydro-5H-
cyclopenta[b]pyridin-7-yl)oxy)carbonyl)benzoic acid and (R)-2-(3,5-
Bis(trifluoromethyl)phenyl)-4-methyl-6,7-dihydro-5H-cyclopenta[b]pyridin-7-yl acetate  
 
Vinyl acetate (0.5 mL, 8.12 mmol, 14.8 eq.) and CAL-B [107 mg, immobilized on acrylic 
resin from Sigma (L47777)] was added to a solution of the analogous racemic alcohol 
(200 mg, 0.55 mmol, 1.00 eq.) in i-Pr2O (27 mL). The resulting solution was stirred at 60 °C 
for 5.5 h until HPLC showed full consumption of one enantiomer. The enzyme was filtered 
off and washed with EtOAc (3 × 20 mL). Evaporation of the solvent afforded a pale yellow 
residue. The residue was dissolved in CH2Cl2 (15 mL). Phthalic anhydride (53 mg, 0.35 mmol, 
0.60 eq.), and Et3N (54 L) were added. The solution was heated to reflux for 6 h. The 
mixture was washed with sat. NH4Cl solution (2 × 20 mL) and the organic phase was dried 
over MgSO4, filtered and concentrated on a rotovap. Purification by column chromatography 
(SiO2, d × h: 3 × 30 cm, hexane:CH2Cl2:methanol (10:1:0  0:10:1)) afforded the (S)-benzoic 
acid (133 mg, 0.26 mmol, 46%) and the (R)-acetate (103 mg, 0.26 mmol, 46%) both as a 
colorless solids. 
(S)-Carboxylic acid 
C25H17F6NO5 (509.40 g/mol): 
TLC: Rf = 0.48 (SiO2, CH2Cl2:MeOH (20:1), UV).  
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1
H NMR
 
(400 MHz, CDCl3): 8.46 (s, 2H, ar-H), 7.88 (s, 1H, ar-H), 7.79 (s, 2H, ar-H), 7.58-
7.43 (m, 3H, ar-H), 6.47-6.40 (m, 1H, HCO), 3.12-2.97 (m, 2H, CH2), 2.92-2.69 (m, 2H, 
CH2), 2.36 (s, 3H, CH3), 2.29-2.22 (m, 1H, CH2). 
19
F{
1
H} NMR (376 MHz, CDCl3): ppm = 63.0 (s). 
IR (ATR): ṽ/cm-1 = 2920 (m), 2850 (m), 1727 (m), 1702 (m), 1596 (m), 1558 (m), 1449 (m), 
1391 (m), 1320 (m), 1275 (s), 1175 (m), 1122 (s), 1074 (m), 1029 (w), 933 (w), 896 (m), 745 
(m), 710 (m), 680 (m). 
MS (EI, 70 eV, 250 °C) m/z (%): 510.0 (21), 344.3 (100). 
 
(R)-Acetate  
C19H15F6NO2 (403.32 g/mol): 
TLC: Rf = 0.60 (SiO2, CH2Cl2, UV).  
1
H NMR
 
(400 MHz, CDCl3): /ppm = 8.44 (s, 2H, ar-H), 7.88 (s, 1H, ar-H), 7.52 (s, 1H, ar-
H), 6.17 (dd, JHH = 7.2 Hz, JHH = 4.4 Hz, 1H, HCOAc), 3.06 (ddd, JHH = 16.1 Hz, JHH = 
8.8 Hz, JHH = 5.4 Hz, 1H, CH2), 2.88 (ddd, JHH = 16.6 Hz, JHH = 8.6 Hz, JHH = 5.3 Hz, 1H, 
CH2), 2.73-2.64 (m, 1H, CH2), 2.40 (s, 3H, CH3), 2.19-2.11 (m, 1H, CH2), 2.16 (s, 3H, 
O2CCH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 170.9 (s, O2CCH3), 160.9 (s, ar-C), 154.04 (s, ar-
C), 145.5 (s, ar-C), 141.4 (s, ar-C), 137.5 (s, ar-C), 132.1 (q, JCF = 33 Hz, ar-C), 127.2 (s, ar-
C), 123.8 (q, JCF = 271 Hz, CF3), 122.4-122.2 (m, ar-C), 121.9 (s, ar-C), 77.4 (s, COAc), 30.7 
(s, CH2), 26.5 (s, CH2), 21.5 (s, CH3), 19.1 (s, CH3). 
19
F{
1
H} NMR (376 MHz, CDCl3): ppm = 63.0 (s). 
IR (ATR): ṽ/cm-1 = 2961 (w), 2920 (w), 2850 (w), 1717 (s), 1596 (m), 1446 (w), 1391 (m), 
1380 (m), 1284 (s), 1254 (m), 1241 (m), 1164 (m), 1121 (s), 1087 (m), 1024 (m), 951 (m), 
896 (m), 796 (m), 697 (m). 
MS (EI, 70 eV, 200 °C) m/z (%): 403.1 (3), 360.0 (99), 343.0 (100). 
HPLC: Daicel, Chiralpak AD-H (0.46 cm × 25 cm, heptane/iso-propanol = 95:05, 
0.5 mL/min, 25 °C, 220 nm): tR = 12.9 min and 17.3 min. 
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General procedure: Saponifications of carboxylic acid esters GP4 
 
(R)-2-(3,5-Di-tert-butyl-4-methoxyphenyl)-5,6,7,8-tetrahydroquinolin-8-ol  
 
The analogous acetate (250 mg, 0.61 mmol, 1.00 eq.) was dissolved in a mixture of 
MeOH:THF ((1:1), 4 mL) and 2 M NaOH (2 mL) was added. The pale yellow solution was 
stirred for 16 h at room temperature. The solvent was evaporated under reduced pressure and 
CH2Cl2 (30 mL) and H2O (30 mL) were added. The organic layers was separated and washed 
with H2O (2 × 30 mL). The organic layer was dried over MgSO4 and filtered. Evaporation of 
the solvent and drying in HV afforded the product (212 mg, 0.57 mmol, 95%, 99.1% ee) as a 
colorless solid. 
C24H33NO2 (357.41 g/mol): 
[α]
20
D  = 97.6 (c = 0.82, CHCl3). 
Additional analytical data match the racemic alcohol. 
 
(R)-2-(3,5-Di-tert-butyl-4-methoxyphenyl)-4-methyl-6,7-dihydro-5H-
cyclopenta[b]pyridin-7-ol  
 
The reaction was set up as described in the general procedure GP4 except using the analogous 
(R)-acetate (200 mg, 0.48 mmol, 1.00 eq.) in a mixture of MeOH:THF ((1:1), 4 mL) and 2 M 
NaOH (1.8 mL). Extraction and drying in HV afforded the alcohol (R)-2.50 (175 mg, 
0.48 mmol, 98%, 98.6% ee) as a colorless solid. Recrystallization from hexane (8.5 mL), 
filtration of the scalemic crystals and evaporation of the solvent afforded the product (167 mg, 
0.46 mmol, 95%) in enriched enantioselectivity (99.2% ee) as a colorless solid. 
C24H33NO2 (357.41 g/mol): 
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[α]
20
D  = 14.9 (c = 0.75, CHCl3). 
Additional analytical data match the racemic alcohol. 
 
(R)-2-(3,4,5-Trimethoxyphenyl)-5,6,7,8-tetrahydroquinolin-8-ol  
 
The reaction was set up as described in the general procedure GP4 except using the analogous 
(R)-acetate (90.0 mg, 0.25 mmol, 1.00 eq.) in a mixture of MeOH (2 mL) and 2 M NaOH 
(0.9 mL). Extraction and purification by column chromatography (SiO2, d × h: 3 × 30 cm, 
hexane:ethyl acetate (10:1  1:2)) afforded the product (56.0 mg, 0.18 mmol, 71%, 97.2% ee) 
as a colorless solid. 
C18H21NO4 (357.41 g/mol): 
[α]
20
D  = 104.7 (c = 0.56, CHCl3). 
Additional analytical data match the racemic alcohol 2.51. 
 
(R)-4-Methyl-2-(3,4,5-trimethoxyphenyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol ((R)-
2.52) 
 
The reaction was set up as described in the general procedure GP4 except using the analogous 
(R)-acetate (200 mg, 0.56 mmol, 1.00 eq.) in a mixture of MeOH:THF ((1:1), 4.0 mL) and 
2 M NaOH (1.8 mL). Extraction afforded the product (141 mg, 0.45 mmol, 80%, 98.5% ee) as 
a colorless solid. 
C18H21NO4 (357.41 g/mol): 
[α]
20
D  = 14.4 (c = 0.68, CHCl3). 
Additional analytical data match the racemic alcohol. 
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(R)-2-(3,5-Bis(trifluoromethyl)phenyl)-4-methyl-6,7-dihydro-5H-cyclopenta[b]pyridin-7-
ol  
 
The reaction was set up as described in the general procedure GP4 except using the analogous 
(R)-acetate (103 mg, 0.26 mmol, 1.00 eq.) in a mixture of MeOH (5 mL) and 2 M NaOH 
(2.0 mL). Extraction afforded the product (85.0 mg, 0.23 mmol, 89%, 99.1% ee) as a colorless 
solid.  
C17H13NF6NO (357.41 g/mol): 
[α]
20
D  = +18.9 (c = 0.43, CHCl3). 
Additional analytical data match the racemic alcohol. 
 
(S)-2-(3,5-Bis(trifluoromethyl)phenyl)-4-methyl-6,7-dihydro-5H-cyclopenta[b]pyridin-7-
ol  
 
The reaction was set up as described in the general procedure GP4 except using the analogous 
(S)-carboxylic acid (133 mg, 0.26 mmol, 1.00 eq.) in MeOH (5 mL) and 2 M NaOH (2.0 mL). 
The solution was stirred for 6 h at reflux. Extraction and workup afforded the product 
(86.0 mg, 0.24 mmol, 95%, 99.8% ee) as a colorless solid. 
C17H13NF6NO (357.41 g/mol): 
[α]
20
D  = 18.9 (c = 0.43, CHCl3). 
Additional analytical data match the racemic alcohol. 
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(S)-2-(3,5-Di-tert-butyl-4-methoxyphenyl)-5,6,7,8-tetrahydroquinolin-8-ol ((S)-2.51) 
 
The reaction was setup as described in the general procedure GP3 for the racemic silyl ethers. 
Deprotection of the analogous (S)-TBS ether (300 mg, 6.23 mmol) afforded the product 
(190 mg, 5.17 mmol, 83%, 99.8% ee) as a colorless solid. 
C24H33NO2 (357.41 g/mol): 
[α]
20
D  = +97.5 (c = 0.83, CHCl3). 
Additional analytical data match the racemic alcohol. 
 
(S)-2-(3,5-Di-tert-butyl-4-methoxyphenyl)-4-methyl-6,7-dihydro-5H-
cyclopenta[b]pyridin-7-ol  
 
The reaction was setup as described in the general procedure GP3 for the racemic silyl ethers. 
Deprotection of the analogous (S)-TBS ether (240 mg, 4.99 mmol) afforded the product 
(180 mg, 4.90 mmol, 98%, 99.8% ee) as a colorless solid. 
C24H33NO2 (357.41 g/mol): 
[α]
20
D  = +26.9 (c = 0.50, CHCl3). 
Additional analytical data match the racemic alcohol. 
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(S)-2-(3,5-Di-tert-butyl-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol 
((S)-2.50) 
 
The reaction was setup as described in the general procedure GP3 for the racemic silyl ethers. 
Deprotection of the analogous TBS ether (300 mg, 6.23 mmol) afforded the product (190 mg, 
5.17 mmol, 83%, 99.8% ee) as a colorless solid. 
C23H31NO2 (354.24 g/mol): 
[α]
20
D  = +19.2 (c = 0.39, CHCl3).  
Additional analytical data match the racemic alcohol 2.50. 
 
(S)-2-(3,4,5-Trimethoxyphenyl)-5,6,7,8-tetrahydroquinolin-8-ol ((S)-2.51) 
 
The reaction was setup as described in the general deprotection procedure GP3 of the racemic 
silyl ethers. Deprotection of analogous TBS ether (120 mg, 2.79 mmol) afforded the product 
(57.0 mg, 1.81 mmol, 65%, 99.8% ee) as a colorless solid.  
C18H21NO4 (315.37 g/mol): 
[α]
20
D  = +106.4 (c = 0.75, CHCl3). 
Additional analytical data match the racemic alcohol. 
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(S)-4-Methyl-2-(3,4,5-trimethoxyphenyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol ((S)-
2.52) 
 
The reaction was setup as described in the general procedure GP3 for the racemic silyl ethers. 
Deprotection of the analogous silyl ether (114 mg, 2.66 mmol) afforded the product (77.0 mg, 
2.44 mmol, 92%, 99.7% ee) as a colorless solid. 
C18H21NO4 (315.37 g/mol): 
[α]
20
D  = +14.9 (c = 0.75, CHCl3). 
Additional analytical data match the racemic alcohol ((S)-2.52).  
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8.2.2 Formation of N,P ligands followed by direct complexation 
 
General procedure: Synthesis of di-arylphosphinite based catalyst GP5 
 
Iridium complex ((S)-2.62) 
 
The pyridyl alcohol (S)-2.41 (60.0 mg, 163 mol, 1.00 eq.), 4-dimethylaminopyridine 
(23.9 mg, 196 mol, 1.20 eq.) and chloro-di-(2-methylphenyl)-phosphine (50.4 mg, 196 mol, 
1.20 eq.) were added into a dry Schlenk flask. This flask was evacuated and backfilled three 
times with argon. CH2Cl2 (1.4 mL) was added to obtain a colorless solution which was stirred 
for 7 h at room temperature. A second pre-dried Schlenk flask was filled with [Ir(COD)Cl]2 
(54.7 mg, 81.5 mol, 0.50 eq.), NaBArF (175 mg, 196 mol, 1.20 eq.) and equipped with a 
Schlenk frit. The frit was charged with basic aluminum oxide (d × h: 3 × 2 cm). The 
equipment was evaporated and backfilled with argon three times. 
The ligand containing solution was added onto the frit and eluated with CH2Cl2 (5 mL). The 
orange solution was stirred for 18 h at room temperature. The solvent was evaporated under 
reduced pressure and the crude iridium complex was concentrated and adsorbed onto silica 
(4 g). Column chromatography (SiO2, d × h: 3 × 20 cm, hexane:CH2Cl2 (1:1)) afforded the 
product (208 mg, 119 mol, 73%) as an orange solid. 
C78H70BF24IrNO2P (1743.39 g/mol): 
MP: 90-91 °C. 
TLC: Rf = 0.29 (SiO2, hexane:CH2Cl2 (1:1), UV). 
1
H NMR
 
(500 MHz, CDCl3): /ppm = 7.96 (dd, JHH = 18, 7 Hz, 1H, ar-H), 7.70 (s, 8H, BArF), 
7.61 (s, 2H, ar-H), 7.49 (s, 4H, BArF), 7.49-7.47 (m, 1H, ar-H), 7.36-7.32 (m, 3H, ar-H), 7.26-
7.22 (m, 2H, ar-H), 7.18 (t, JHH = 7.6 Hz, 1H, ar-H), 7.14 (dd, JHH = 7.3, 2.0 Hz, 1H, ar-H), 
6.92-6.89 (m, 1H, ar-H), 6.37-6.36 (m, 1H, HCOP), 5.02 (s br, 1H, CH COD), 3.96 (s br, 1H, 
CH COD), 3.82 (s, 3H, OCH3), 3.12-3.06 (m, 1H, CH COD), 2.85-2.75 (m, 2H, CH COD and 
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CH2), 2.70-2.63 (m, 2H, CH2), 2.36 (s, 3H, ar-CH3), 2.25-2.18 (m, 2H, CH2), 2.12-2.08 (m, 
2H, CH2 and CH2 COD), 2.05 (s, 3H, ar-CH3), 1.94-1.78 (m, 4H, CH2 COD), 1.53 (s, 18H, 2 
× C(CH3)3), 1.30-1.19 (m, 3H, CH2 COD).  
13
C{
1
H} NMR (126 MHz, CDCl3): ppm = 162.2 (s, ar-C), 161.9 (q, JBC = 50 Hz, BArF), 
161.7 (s, ar-C), 153.3 (d, JCP = 3 Hz, ar-C), 145.4 (s, ar-C), 142.6 (s, ar-C), 141.0 (s, ar-C), 
140.2 (d, JCP = 9 Hz, ar-C), 135.7 (s, ar-C), 135.3 (s, ar-C), 135.0 (s, BArF), 134.6 (s, ar-C), 
134.1 (s, ar-C), 133.8 (s, ar-C), 133.3 (d, JCP = 7 Hz, ar-C), 132.9 (s, ar-C), 132.2 (s, ar-C), 
132.1 (s, ar-C), 130.8 (d, JCP = 12 Hz, ar-C), 129.9 (s, ar-C), 129.1 (qq, JCF = 30 Hz, JCF = 
3 Hz, BArF), 127.1 (s, ar-C), 126.5 (d, JCP = 11 Hz, ar-C), 125.2 (d, JCP = 17 Hz, ar-C), 124.7 
(q, JCF = 273 Hz, BArF CF3), 117.6 (sept, JCF = 4 Hz, BArF), 97.6 (d, JCP = 8 Hz, CH COD), 
90.5 (d, JCP = 15 Hz, CH COD), 76.1 (s, COP), 69.2 (s, CH COD), 64.8 (s, OCH3), 64.0 (s, 
CH COD), 37.3 (d, JCP = 10 Hz, CH2), 36.5 (s, C(CH3)3), 33.9 (s, CH2 COD), 32.1 (s,  
2 × C(CH3)3), 30.5 (d, JCP = 10 Hz, CH2, COD), 28.6 (s, CH2 COD), 28.2 (s, CH2), 25.1 (s, 
CH2 COD), 22.0 (d, JCP = 5 Hz, ar-CH3), 21.4 (d, JCP = 3 Hz, ar-CH3), 17.3 (s, CH2). 
31
P{
1
H} NMR (161 MHz, CDCl3): ppm = 103.3 (s). 
19
F{
1
H} NMR (376 MHz, CDCl3): ppm = 62.7 (s). 
11
B{
1
H} NMR (160 MHz, CDCl3): ppm = 6.6 (s). 
IR (ATR): ṽ/cm-1 = 2961 (w), 2939 (w), 2889 (w), 2876 (w), 1609 (w), 1454 (w), 1353 (m), 
1273 (s), 1160 (m), 1117 (s), 1003 (m), 930 (m), 885 (m), 838 (m), 713 (m), 669 (m). 
MS (FAB NBA): m/z (%): 882.3 (13), 881.3 (49), 880.3 (100), 879.3 (31), 878.3 (60), 771.2 
(12), 770.1 (17), 769.1 (17), 768.2 (23), 767.1 (20), 766.1 (32), 765.1 (18), 764.1 (28), 763.1 
(11), 762.1 (18), 760.1 (10), 418.9 (12), 417.0 (11). 
EA (C78H20BF24IrNO2P): calc.: C 53.74, H 4.05, N 0.80; found: C 53.97, H 4.22, N 0.91.  
[α]
20
D  = +68.2 (c = 0.92, CHCl3). 
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Iridium complex ((S)-2.61) 
 
The reaction was set up as described in the general procedure GP5 except using the analogous 
(S)-pyridyl alcohol (40.0 mg, 109 mol, 1.00 eq.), 4-dimethylaminopyridine (17.0 mg, 
130 mol, 1.20 eq.) and chloro-di-(2-methylphenyl)-phosphine (34.0 mg, 130 mol, 1.20 eq.) 
in abs. CH2Cl2 (2 mL). This solution was filtered into [Ir(COD)Cl]2 (37.0 mg, 109 mol, 
1.00 eq.) and NaBArF (117 mg, 130 mol, 1.20 eq.). Column chromatography (SiO2, d × h: 3 
× 20 cm, hexane:CH2Cl2 (1:1)) afforded the product (130 mg, 74.6 mol, 68%) as an orange 
solid. 
C78H70BF24IrNO2P (1743.39 g/mol): 
MP: 96-99 °C. 
TLC: Rf = 0.58 (SiO2, hexane:CH2Cl2 (1:2), UV). 
1
H NMR
 
(500 MHz, CD2Cl2): /ppm = 8.32 (d, JHH = 14 Hz, 1H, ar-H), 7.75 (s, 8H, BArF), 
7.57 (s, 6H, BArF and ar-H), 7.45 (s, 2H, ar-H), 7.39-7.36 (m, 1H, ar-H), 7.33 (s, 2H, ar-H), 
7.23 (s, 1H, ar-H), 7.15-7.11 (m, 1H, ar-H), 6.69 (s, 1H, ar-H), 6.36 (s br, 1H, HCOP), 4.98 (s, 
1H, CH COD), 3.83 (s, 3H, OCH3), 3.80 (s, 1H, CH COD), 3.14-3.0 (m, 2H, CH COD and 
CH2), 2.95-2.85 (m, 2H, CH2), 2.67 (s, 1H, CH COD), 2.59 (s, 3H, CH3), 2.51-2.49 (m, 1H, 
CH2), 2.35 (s, 4H, CH3 and CH2 COD), 2.28-2.21 (m, 2H, CH2 COD), 2.11 (s, 3H, CH3), 
2.10-2.04 (m, 1H, CH2 COD), 1.89-1.83 (m, 1H, CH2 COD), 1.58 (s, 18H, 2 × C(CH3)3), 
1.45-1.30 (m, 3H, CH2 COD). 
13
C{
1
H} NMR (126 MHz, CD2Cl2): ppm = 162.8 (s, ar-C), 162.5 (s, ar-C), 162.3 (q, JCB = 
50 Hz, BArF), 159.3 (d, JCP = 5 Hz, ar-C), 150.1 (s, ar-C), 145.7 (s, ar-C), 143.3 (s, ar-C), 
141.4 (d, JCP = 8 Hz, ar-C), 138.9 (s, ar-C), 137.1 (d, JCP = 34 Hz, ar-C), 136.0 (s, ar-C), 
135.4 (s, 4H, BArF), 134.3 (s, ar-C), 133.6 (d, JCP = 8 Hz, ar-C), 133.3 (d, JCP = 1 Hz, ar-C), 
132.5 (d, JCP = 8 Hz, ar-C), 132.4 (d, JCP = 2 Hz, ar-C), 131.4 (d, JCP = 14 Hz, ar-C), 131.1 (s, 
ar-C), 129.5 (qq, JCF = 32, 4 Hz, BArF), 128.9 (s, ar-C), 128.2 (s, ar-C), 126.6 (d, JCP = 11 Hz, 
ar-C), 125.9 (d, JCP = 17 Hz, ar-C), 125.2 (q, JCF = 272 Hz, BArF CF3), 118.1 (sept, JCF = 
4 Hz, BArF), 100.0 (d, JCP = 10 Hz, CH COD), 94.0 (d, JCP = 14 Hz, CH COD), 84.5 (s, COP), 
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67.9 (s, CH COD), 65.4 (s, OCH3), 63.1 (s, CH COD), 37.8 (d, JCP = 3 Hz, CH2 COD), 36.8 
(s, C(CH3)3), 34.1 (s, CH2 COD), 32.5 (s, C(CH3)3), 29.9 (d, JCP = 10 Hz, CH2), 28.5 (s, CH2 
COD), 26.9 (s, CH2), 26.0 (s, CH2 COD), 23.0 (d, JCP = 4 Hz, CH3), 21.9 (d, JCP = 3 Hz, CH3), 
19.1 (s, CH3). 
31
P{
1
H} NMR (161 MHz, CD2Cl2): ppm = 111.1 (s). 
19
F{
1
H} NMR (376 MHz, CD2Cl2): ppm = 63.1 (s). 
11
B{
1
H} NMR (160 MHz, CD2Cl2): ppm = 5.7 (s). 
IR (ATR): ṽ/cm-1 = 2957 (w), 1611 (w), 1461 (w), 1352 (m), 1271 (m), 1115 (s), 1012 (w), 
959 (w), 886 (m), 824 (w), 719 (m), 670 (m). 
MS (FAB NBA): m/z (%): 882.3 (13), 881.3 (49), 880.3 (100), 879.3 (31), 878.3 (58), 771.2 
(12), 770.2 (24), 769.1 (20), 768.2 (31), 767.1 (25), 766.2 (38), 765.1 (21), 674.1 (28), 763.1 
(13), 762.1 (18), 760.1 (10), 419 (10), 350 (12). 
EA (C78H20BF24IrNO2P): calc.: C 53.74, H 4.05, N 0.80; found: C 53.80, H 4.14, N 0.95. 
[α]
20
D  = +63.3 (c = 0.94, CHCl3). 
 
Iridium complex ((S)-2.60) 
 
The reaction was set up as described in the general procedure GP5 except using the analogous 
(S)-pyridyl alcohol (35 mg, 95 mol, 1.00 eq.), 4-dimethylaminopyridine (14 mg, 114 mol, 
1.20 eq.) and chloro-di-phenyl-phosphine (21 L, 114 mol, 1.20 eq.) in CH2Cl2 (2 mL). This 
solution was filtered into [Ir(COD)Cl]2 (34 mg, 95 mol, 1.00 eq.) and NaBArF (104 mg, 
114 mol, 1.20 eq.). Column chromatography (SiO2, d × h: 3 × 20 cm, hexane:CH2Cl2 (1:1)) 
afforded the product (47 mg, 28 mol, 29%) as an orange solid. 
C76H66BF24IrNO2P (1715.33 g/mol): 
MP: 81-84 °C. 
TLC: Rf = 0.43 (SiO2, hexane:CH2Cl2 (1:1), UV). 
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1
H NMR
 
(500 MHz, CD2Cl2): /ppm = 7.75 (s, 8H, BArF), 7.57-7.54 (m, 9H, ar-H and BArF), 
7.46 (s, 1H, ar-H), 7.43-7.40 (m, 5H, ar-H), 7.35-7.32 (m, 2H, ar-H), 6.43-6.39 (m, 1H, 
HCOP), 4.65 (s br, 1H, CH COD), 4.21 (s br, 1H, CH COD), 3.77 (s, 3H, OCH3), 3.23-3.12 
(m, 3H, CH COD and CH2), 3.07-2.98 (m, 2H, CH2), 2.66-2.59 (m, 1H, CH2), 2.46 (s, 3H, 
CH3), 2.27-2.23 (m, 2H, CH2 COD), 2.17-2.08 (m, 1H, CH2 COD), 1.97-1.85 (m, 2H, CH2 
COD), 1.40 (s, 18H, 2 × C(CH3)3), 1.34-1.22 (m, 2H, CH2 COD), 0.90-0.83 (m, 1H, CH2 
COD). 
13
C{
1
H} NMR (126 MHz, CD2Cl2): ppm = 162.9 (s, ar-C), 162.4 (q, JCB = 50 Hz, BArF), 
162.4 (s, ar-C), 159.9 (d, JCP = 4 Hz, ar-C), 150.3 (s, ar-C), 146.2 (s, ar-C)), 138.6 (s, ar-C)), 
136.4 (d, JCP = 56 Hz, ar-C), 135.4 (s, BArF), 134.0 (s), 132.4 (d, JCP = 2 Hz, ar-C), 132.3 (d, 
JCP = 2 Hz, ar-C), 131.1 (d, JCP = 62 Hz, ar-C), 130.6 (d, JCP = 13 Hz, ar-C), 130.2 (d, JCP = 
11 Hz, ar-C), 129.9 (d, JCP = 7 Hz, ar-C), 129.9 (s, ar-C), 129.6 (d, JCP = 11 Hz, ar-C), 129.5 
(qq, JCF = 30, 3 Hz, BArF), 127.0 (s, ar-C), 125.2 (q, JCF = 272 Hz, BArF CF3), 118.1 (sept, 
JCF = 4 Hz, BArF), 100.3 (d, JCP = 10 Hz, CH COD), 92.8 (d, JCP = 14 Hz, CH COD), 85.6 (s, 
COP) 69.3 (s, CH COD), 65.3 (s, OCH3), 61.9 (s, CH COD), 37.1 (d, JCP = 3 Hz, CH2 COD), 
36.6 (s, C(CH3)3), 33.6 (s, CH2 COD), 32.3 (s, C(CH3)3), 30.2 (d, JCP = 3 Hz, CH2), 29.4 (s, 
CH2 COD), 27.1 (s, CH2), 25.9 (s, CH2 COD), 19.3 (s, CH3).  
31
P{
1
H} NMR (161 MHz, CD2Cl2): /ppm = 96.5 (s). 
19
F{
1
H} NMR (376 MHz, CD2Cl2): /ppm = 63.1 (s). 
11
B{
1
H} NMR (160 MHz, CD2Cl2): /ppm = 6.6 (s). 
IR (ATR): ṽ/cm-1 = 2962 (w), 1920 (w), 2851 (w), 1716 (m), 1597 (m), 1387 (m), 1352 (m), 
1278 (s), 1258 (m), 1163 (m), 1120 (s), 1024 (m), 894 (m), 678 (m). 
MS (FAB NBA): m/z (%): 854.3 (13), 853.3 (47), 852.3 (100), 851.3 (34), 850.2 (65), 740.1 
(10), 739.1 (12). 
EA (C76H66BF24IrNO2P): calc.: C 53.22, H 3.88, N 0.82; found: C 53.44, H 4.15, N 1.01. 
[α]
20
D  = +16.5 (c = 0.41, CHCl3). 
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Iridium complex ((S)-2.68)  
 
The reaction was set up as described in the general procedure GP5 except using the pyridyl 
alcohol (S)-2.57 (30 mg, 92 mol, 1.00 eq.), 4-dimethylaminopyridine (14 mg, 114 mol, 
1.20 eq.) and chloro-di-(2-methylphenyl)-phosphine (28 mg, 111 mol, 1.20 eq.) in CH2Cl2 
(0.8 mL). This solution was filtered into [Ir(COD)Cl]2 (31 mg, 46 mol, 0.50 eq.) and 
NaBArF (98 mg, 111 mol, 1.20 eq.). Column chromatography (SiO2, d × h: 3 × 20 cm, 
CH2Cl2) afforded the product (77 mg, 45 mol, 49%) as an orange solid. 
C77H56BF24IrNOP (1701.26 g/mol):  
MP: 105-106 °C. 
TLC: Rf = 0.85 (SiO2, CH2Cl2, UV). 
1
H NMR
 
(400 MHz, CD2Cl2): δ/ppm = 8.90 (d, J = 8.5 Hz, 1H), 8.88-8.84 (m, 1H), 8.26-8.19 
(m, 1H), 7.94-7.85 (m, 3H), 7.84-7.78 (m, 2H), 7.78-7.75 (m, 2H), 7.74 (s, 8H), 7.70-7.65 (m, 
1H), 7.60 (dd, J = 4.6, 2.8 Hz, 1H), 7.56 (s, 4H), 7.52 (s, 1H), 7.43-7.34 (m, 3H), 7.14-7.07 
(m, 1H), 6.58 (t, J = 10.5 Hz, 1H), 6.38-6.30 (m, 1H), 5.07-4.97 (m, 1H), 4.11-3.98 (m, 1H), 
3.22-3.14 (m, 1H), 3.10-3.03 (m, 1H), 3.03-2.88 (m, 2H), 2.81 (s, 3H), 2.64-2.50 (m, 2H), 
2.43 (s, 3H), 2.39-2.20 (m, 4H), 1.97-1.87 (m, 1H), 1.85-1.75 (m, 1H), 1.72-1.61 (m, 1H), 
1.16 (s, 2H), 1.01-0.85 (m, 1H), 0.35-0.23 (m, 1H). 
13
C{
1
H} NMR (101 MHz, CD2Cl2): ppm = 162.3 (q, JCB = 50 Hz, BArF), 160.4 (d, JCP = 
4 Hz, ar-C), 159.3 (s, ar-C), 149.4 (s, ar-C), 141.6 (d, JCP = 8 Hz, ar-C), 139.7 (s, ar-C), 135.9 
(s, ar-C), 135.7 (s, ar-C), 135.4 (s, BArF), 133.7 (d, JCP = 7 Hz, ar-C), 133.4 (s, ar-C), 132.6 (s, 
ar-C), 132.5 (d, JCP = 7 Hz, ar-C), 132.2 (s, ar-C), 131.6 (s, ar-C), 131.5 (d, JCP = 14 Hz, ar-C), 
131.1 (s, ar-C), 130.8 (s, ar-C), 130.5 (s, ar-C), 129.5 (s, ar-C), 129.4 (qq, JCF = 32, 3 Hz, 
BArF), 128.8 (s, ar-C), 128.8 (s, ar-C), 128.7 (s, ar-C), 128.6 (s, ar-C), 128.5 (s, ar-C), 126.7 
(d, JCP = 12 Hz, ar-C), 126.2 (s, ar-C), 125.2 (q, JCF = 273 Hz, BArF), 124.3 (s, ar-C), 123.9 (s, 
ar-C), 118.1 (sept, JCF = 4 Hz, BArF), 98.3-98.1 (m, CH COD), 89.0-88.7 (m, CH COD), 84.1 
(s, COP), 68.4 (s, CH COD), 66.2 (s, CH COD), 36.5 (d, JCP = 4 Hz, CH2 COD), 35.0 (s, 
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CH2), 29.8 (d, JCP = 10 Hz, CH2 COD), 28.3 (s, CH2 COD), 27.3 (s, CH2), 24.4 (d, JCP = 4 Hz, 
CH2 COD), 23.3 (d, JCP = 4 Hz, CH3), 22.9-22.8 (m, CH3), 19.3 (s, CH3). 
31
P{
1
H} NMR (202 MHz, CD2Cl2, 234 K): /ppm = 113.3 (s), 101.3 (s). 
19
F{
1
H} NMR (376 MHz, CD2Cl2): δ/ppm = 62.8 (s) 
IR (ATR): ṽ/cm-1 = 3060 (w), 3004 (w), 2880 (w), 2023 (w), 1967 (w), 1612 (w), 1566 (w), 
1354 (m), 1274 (s), 1118 (s), 1004 (w), 959 (w), 887 (m), 839 (m), 806 (w), 753 (m), 713 (m), 
679 (m), 619 (w). 
HRMS (ESI, 4500 V, 180 °C): (m/z) calc. for C45H44IrNOP
+
: 838.2787 [MBArF]
+
; found: 
838.2781. 
[α]
20
D  = +15.1 
(c = 0.20, CHCl3). 
 
Iridium complex ((S)-2.65) 
 
The reaction was set up as described in the general procedure GP5 except using the pyridyl 
alcohol (S)-2.54 (30 mg, 80 mol, 1.00 eq.), 4-dimethylaminopyridine (12 mg, 95 mol, 
1.20 eq.) and chloro-di-(2-methylphenyl)-phosphine (24 mg, 95 mol, 1.20eq.) in abs. CH2Cl2 
(0.6 mL). This solution was filtered into [Ir(COD)Cl]2 (27 mg, 40 mol, 0.50 eq.) and 
NaBArF (85 mg, 95 mol, 1.20 eq.). Column chromatography (SiO2, d × h: 3 × 20 cm, 
pentane:Et2O (1:1)  CH2Cl2) afforded the product (106 mg, 60 mol, 76%) as an orange 
solid. 
C81H60BF24IrNOP (1753.34 g/mol):  
MP: 103-104 °C. 
TLC: Rf = 0.89 (SiO2, CH2Cl2, UV). 
1
H NMR
 
(400 MHz, CD2Cl2): δ/ppm = 8.13-7.92 (m, 4H), 7.78-7.72 (m, 13H), 7.67-7.48 (m, 
10H), 7.45 (td, J = 7.5, 1.8 Hz, 1H), 7.40-7.30 (m, 2H), 7.28-7.15 (m, 2H), 7.10-7.03 (m, 1H), 
6.50 (dd, J = 13.5, 8.0 Hz, 1H), 6.39-6.32 (m, 1H), 4.94 (d, J = 8.0 Hz, 1H), 3.87 (t, J = 
6.0 Hz, 1H), 3.30-3.08 (m, 2H), 3.05-2.89 (m, 2H), 2.72 (s, 3H), 2.65 (dd, J = 14.6, 6.9 Hz, 
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1H), 2.54-2.45 (m, 1H), 2.44 (s, 3H), 2.37-2.19 (m, 1H), 2.12 (s, 3H), 2.07-1.77 (m, 4H), 
1.40-1.22 (m, 3H). 
13
C{
1
H} NMR (101 MHz, CD2Cl2): ppm = 162.3 (q, JCB = 50 Hz, BArF), 161.4 (s, ar-C), 
160.1 (d, JCP = 4 Hz, ar-C), 150.6 (s, ar-C), 144.0 (s, ar-C), 141.5 (d, JCP = 8 Hz, ar-C), 140.7 
(s, ar-C), 140.5 (s, ar-C), 139.3 (s, ar-C), 135.4 (d, JCP = 56 Hz, ar-C), 135.4 (s, BArF), 133.6 
(d, JCP = 7 Hz, ar-C), 133.1 (d, JCP = 2 Hz, ar-C), 132.6-132.4 (m, ar-C), 131.4 (d, JCP = 
14 Hz, ar-C), 130.2 (s, ar-C), 129.8 (s, ar-C), 129.8 (s, ar-C), 129.4 (qq, JCF = 32 Hz, 3 Hz, 
BArF), 129.1 (s, ar-C), 128.1 (s, ar-C), 126.8 (s, ar-C), 126.7 (d, JCP = 12 Hz), 126.2 (d, JCP = 
16 Hz, ar-C), 125.2 (q, JCF = 274 Hz, BArF), 118.1 (sept, JCF = 4 Hz, BArF), 99.6 (d, JCP = 
8 Hz, ar-C), 91.3 (d, JCP = 16 Hz, ar-C), 84.3 (s, COP), 68.6 (s, CH COD), 66.2-66.0 (m, CH 
COD), 37.2 (d, JCP = 3 Hz, CH2 COD), 34.6 (s, CH2), 30.0 (d, JCP = 10 Hz, CH2 COD), 28.4 
(d, JCP = 2 Hz, CH2 COD), 26.8 (s, CH2), 25.6 (d, JCP = 2 Hz, CH2 COD), 23.1 (d, JCP = 5 Hz, 
CH3), 22.5 (d, JCP = 3 Hz, CH3), 19.3 (s, CH3). 
31
P{
1
H} NMR (202 MHz, CD2Cl2, 234 K): /ppm = 113.3 (s), 100.8 (s). 
19
F{
1
H} NMR (376 MHz, CD2Cl2): δ/ppm = 62.8 (s). 
IR (ATR): ṽ/cm-1 = 2977 (w), 2888 (w), 1611 (w), 1455 (w), 1354 (m), 1274 (s), 1119 (s), 
966 (w), 886 (m), 839 (m), 821 (w), 757 (m), 712 (m), 679 (m). 
HRMS (ESI, 4500 V, 180 °C): (m/z) calc. for C49H48IrNOP
+
: 890.3101 [MBArF]
+
; found: 
890.3103. 
[α]
20
D  = +36.0 (c = 0.24, CHCl3). 
 
Iridium complex ((S)-2.66) 
 
The reaction was set up as described in the general procedure GP5 except using the pyridyl 
alcohol (S)-2.55 ((42 mg, 112 mol, 1.00 eq.), 4-dimethylaminopyridine (20 mg, 134 mol, 
1.20 eq.) and chloro-di-(2-methylphenyl)-phosphine (40 mg, 134 mol, 1.20 eq.) in abs. 
CH2Cl2 (3.4 mL). This solution was filtered into [Ir(COD)Cl]2 (44 mg, 56 mol, 0.50 eq.) and 
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NaBArF (137 mg, 134 mol, 1.20 eq.). Column chromatography (SiO2, d × h: 3 × 20 cm, 
pentane:Et2O (4:1)  Et2O  CH2Cl2) afforded the product (141 mg, 80.6 mol, 72%) as an 
orange solid. 
C81H60BF24IrNOP (1753.34 g/mol):  
MP: 107-108 °C. 
TLC: Rf = 0.32 (SiO2, pentane:Et2O (4:1), UV). 
1
H NMR
 
(400 MHz, CD2Cl2): /ppm = 7.98 (d, J = 1.8 Hz, 1H), 7.76 (s, 2H), 7.72-7.58 (m, 
12H), 7.52-7.47 (m, 8H), 7.45-7.40 (m, 2H), 7.37-7.32 (m, 1H), 7.31-7.23 (m, 2H), 7.16-7.13 
(m, 1H), 7.10-7.02 (m, 2H), 6.70-6.65 (m, 1H), 6.22-6.19 (m, 1H), 5.28-5.24 (m, 3H), 4.86 (s 
br, 1H), 4.08 (s br, 1H), 3.10-3.05 (m, 1H), 2.96-2.89 (m, 2H), 2.83-2.75 (m, 1H), 2.61 (s, 3H), 
2.56 (s, 1H), 2.30-2.19 (m, 2H), 1.99-1.64 (m, 9H), 1.26-1.06 (m, 3H).  
13
C{
1
H} NMR (126 MHz, CD2Cl2): ppm = 162.1 (q, JBC = 50 Hz, BArF), 160.8 (s, ar-C), 
154.3 (d, JCP = 2 Hz, ar-C), 144.0 (s, ar-C), 141.8 (d, JCP = 7 Hz, ar-C), 141.5 (s, ar-C), 141.3 
(d, JCP = 10 Hz, ar-C), 140.3 (s, ar-C), 140.2 (s, ar-C), 136.8 (s, ar-C), 135.2 (s, BArF), 134.7 
(s, ar-C), 134.2 (s, ar-C), 133.3 (d, JCP = 8 Hz, ar-C), 132.5 (d, JCP = 2 Hz, ar-C), 132.4-132.3 
(m, ar-C), 131.4 (d, JCP = 13 Hz, ar-C), 130.0 (s, ar-C), 129.7 (s, ar-C), 129.2 (qq, JCF = 31 Hz, 
JCF = 2.8 Hz, BArF), 129.0 (s, ar-C), 127.9 (s, ar-C), 127.6 (s, ar-C), 126.6 (d, JCP = 11 Hz, ar-
C), 126.3 (s, ar-C), 126.3 (d, JCP = 17 Hz, ar-C), 124.8 (q, JCF = 273 Hz, BArF CF3), 117.9 
(sept, JCF = 4 Hz, BArF), 95.9 (d, JCP = 7 Hz, CH COD), 85.3 (d, JCP = 17 Hz, CH COD), 76.2 
(s, COP), 69.8 (s, CH COD), 54.3 (s, OCH3), 54.0 (s, CH COD), 36.7 (d, JCP = 4 Hz, CH2), 
34.9 (s, CH2 COD), 30.9 (d, JCP = 10 Hz, CH2, COD), 29.1 (s, CH2 COD), 28.5 (s, CH2), 24.7 
(d, JCP = 3 Hz, CH2 COD), 22.4 (d, JCP = 5 Hz, ar-CH3), 22.2 (d, JCP = 6 Hz, ar-CH3), 16.3 (s, 
CH2). 
31
P{
1
H} NMR (162 MHz, CD2Cl2): ppm = 100.1 (s). 
IR (ATR): ṽ/cm-1 = 3059 (w), 2927 (w), 1593 (w), 1565 (w), 1498 (w), 1473 (w), 1454 (w), 
1353 (w), 1273 (s), 1117 (s), 1029 (s), 999 (m), 966 (m), 931 (m), 884 (m), 868 (m), 838 (m), 
806 (m), 755 (m), 711 (m), 697 (m), 681 (m), 669 (m), 613 (w), 599 (w), 569 (m), 534 (m), 
505 (w), 477 (m), 449 (m). 
HRMS (ESI, 4500 V, 180 °C): (m/z) calc. for C49H48IrNOP
+
: 890.3101 [MBArF]
+
; found: 
890.3101. 
[α]
20
D  = +42.0 (c = 0.46, CHCl3). 
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Iridium complex ((S)-2.71)  
 
The reaction was set up as described in the general procedure GP5 except using the pyridyl 
alcohol (S)-2.58 (60.0 mg, 230 mol, 1.00 eq.), 4-dimethylaminopyridine (35.0 mg, 276 mol, 
1.20 eq.) and chloro-di-(2-methylphenyl)-phosphine (70.0 mg, 276 mol, 1.20 eq.) in abs. 
CH2Cl2 (1.4 mL). This solution was filtered into [Ir(COD)Cl]2 (77.0 mg, 115 mol, 0.50 eq.) 
and NaBArF (246 mg, 276 mol, 1.20 eq.). Column chromatography (SiO2, d × h: 3 × 16 cm, 
pentane:Et2O (2:1)  CH2Cl2) afforded the product (154 mg, 128 mol, 56%) as an orange 
solid. 
C69H50BF26IrNOP (1637.12 g/mol):  
MP: 73-76 °C. 
TLC: Rf = 0.95 (SiO2, CH2Cl2, UV). 
1
H NMR
 
(400 MHz, CD2Cl2): δ/ppm = 7.67 (s, 1H, ar-H), 7.63 (s, 8H, ar-H), 7.52 (ddd, J = 
15.0, 8.6, 6.4 Hz, 1H, ar-H), 7.46 (s, 5H, ar-H), 7.31-7.21 (m, 4H, ar-H), 7.16-7.09 (m, 2H, ar-
H), 7.04 (q, J = 9.3 Hz, 3H, ar-H), 6.76-6.60 (m, 1H, ar-H), 6.33-6.13 (m, 1H, ar-H), 4.46-
4.29 (m, 1H), 3.35-3.17 (m, 1H), 2.97-2.72 (m, 3H), 2.66 (s, 3H), 2.61-2.49 (m, 1H), 2.36-
2.25 (m, 1H), 2.25-2.11 (s, 4H), 2.01-1.76 (m, 5H), 1.74-1.57 (m, 1H), 1.35-1.17 (m, 4H). 
13
C{
1
H} NMR (101 MHz, CD2Cl2): δ/ppm = 162.2 (q, J = 50 Hz, BArF), 155.9 (s, ar-C), 
150.0 (s, ar-C), 142.2-141.9 (m), 141.5 (s, ar-C), 141.4-141.1 (m, ar-C), 138.0 (s, BArF), 
135.2 (s, ar-C), 133.7 (t, J = 10 Hz, ar-C), 133.4 (s, ar-C), 132.9 (s, ar-C), 132.6-132.0 (m, ar-
C), 131.1 (d, J = 13.0 Hz), 131.1 (s, ar-C), 129.3 (qq, JCF = 33 Hz, 3 Hz, BArF), 126.8 (d, J = 
11 Hz), 126.3 (s, ar-C), 126.1 (s, ar-C), 123.6 (s, ar-C), 120.9 (s, ar-C), 117.8 (sept, JCF = 4 Hz, 
BArF), 112.9-112.0 (m), 97.4 (s, CH COD), 76.3 (s, COP), 68.2 (s, CH), 37.3 (d, J = 3 Hz, 
CH2 COD), 35.3 (s, CH2), 30.8 (d, J = 10 Hz, CH2 COD), 29.1 (s, CH2), 28.1 (s, CH2), 24.6 (d, 
J = 3 Hz, CH2 COD), 22.5 (d, J = 5 Hz, CH COD), 17.8 (s, CH2). 
31
P{
1
H} NMR (161 MHz, CD2Cl2): δ/ppm = 100.8 (br s). 
19
F{
1
H} NMR (376 MHz, CD2Cl2): δ/ppm = 62.8 (s), 108.5 (s), 114.6 (s). 
IR (ATR): ṽ/cm-1 = 2926 (w), 1628 (w), 1610 (w), 1469 (m), 1353 (m), 1272 (s), 1115 (s), 
1005 (m), 965 (w), 931 (w), 886 (w), 861 (w), 753 (m), 730 (m), 712 (m). 
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HRMS (ESI, 4500 V, 180 °C): (m/z) calc. for C37H38IrNOP
+
: 774.2285 [MBArF]
+
; found: 
774.2281. 
[α]
20
D  = +25.2 (c = 0.30, CHCl3). 
 
Iridium complex ((S)-2.67)  
 
The reaction was set up as described in the general procedure GP5 except using the pyridyl 
alcohol (S)-2.56 (30.0 mg, 100 mol, 1.00 eq.), 4-dimethylaminopyridine (12.5 mg, 
100 mmol, 1.20 eq.) and chloro-di-(2-methylphenyl)-phosphine (25.0 mg, 100 mol, 1.00 eq.) 
in abs. CH2Cl2 (1.4 mL). This solution was filtered into [Ir(COD)Cl]2 (27.5 mg, 50.0 mol, 
0.50 eq.) and NaBArF (246 mg, 276 mmol, 1.20 eq.). Column chromatography (SiO2, d × h: 3 
× 16 cm, CH2Cl2) afforded the product (111 mg, 65 mol, 65%) as an orange solid. 
C75H56BF24IrNOP (1677.24 g/mol). 
MP: 89-92 °C. 
TLC: Rf = 0.96 (SiO2, CH2Cl2, UV). 
1
H NMR (400 MHz, CD2Cl2) δ = 8.00-7.87 (m, 1H, ar-H), 7.83 (td, J = 7.6, 1.4 Hz, 1H, ar-H), 
7.79 (t, J = 2.9 Hz, 8H, BArF), 7.71 (t, J = 7.4 Hz, 1H, ar-H), 7.66 (dd, J = 7.8, 1.2 Hz, 1H, ar-
H), 7.61 (s, 4H, BArF), 7.48 (t, J = 4.8 Hz, 2H, ar-H), 7.42-7.36 (m, 2H, ar-H), 7.36-7.25 (m, 
5H, ar-H), 7.25-7.18 (m, 1H, ar-H), 7.10-7.02 (m, 2H, ar-H), 6.84 (s, 1H, ar-H), 6.76 (d, J = 
8.2 Hz, 1H, ar-H), 6.50 (ddd, J = 6.9, 4.5, 2.4 Hz, 1H, ar-H), 5.36 (t, J = 1.0 Hz, 2H), 5.26 (s, 
1H), 3.50 (q, J = 7.7 Hz, 1H), 3.09-2.90 (m, 4H), 2.90-2.77 (m, 1H, CH), 2.77-2.68 (m, 1H, 
CH), 2.70-2.45 (m, 4H, CH2), 2.43-2.29 (m, 1H, CH), 2.25-1.92 (m, 6H, CH3), 1.50-1.37 (m, 
1H, CH), 1.38-1.25 (m, 2H, CH2), 1.26-1.14 (m, 1H, CH). 
13
C{
1
H} NMR (101 MHz, CD2Cl2) δ (ppm) = 161.0 (q, J = 50.1 Hz, BArF), 158.5 (s, ar-C), 
153.0 (s, ar-C), 141.0-140.9 (m, ar-C), 139.3 (s, ar-C), 138.6 (s, ar-C), 137.9 (s, ar-C), 136.3 
(s, ar-C), 134.9 (s, BArF), 134.0 (s, ar-C), 133.3 (s, ar-C), 132.8 (s, ar-C), 131.8 (s, ar-C), 
131.3-131.6 (m, ar-C), 131.0 (s, ar-C), 130.9 (s, ar-C), 130.7 (s, ar-C), 128.3-128.2 (m, ar-C), 
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129.4 (s, ar-C), 128.7 (s, ar-C), 127.9 (s, ar-C), 127.6 (s, ar-C), 126.0 (s, ar-C), 125.5 (s, ar-C), 
126.1 (q, J = 272 Hz, BArF), 119.8 (s, ar-C), 116.7 (sept, J = 3 Hz, BArF), 75.4, 68.3, 53.1, 
53.0, 52.8, 52.6, 35.4, 33.8, 29.5 (d, JCP = 10 Hz), 27.7, 27.4 (s), 23.4 (d, JCP = 3 Hz), 21.2 (d, 
J = 5 Hz), 17.2. 
31
P{
1
H} NMR (161 MHz, CD2Cl2) δ/ppm = 98.7 (s). 
IR (ATR): ṽ/cm-1 = 2958 (w), 1352 (m), 1272 (s), 1116 (s), 860 (w), 744 (m), 711 (m), 701 
(m). 
HRMS (ESI, 4500 V, 180 °C): (m/z) calc. for C49H44IrNOP
+
: 814.2787 [MBArF]
+
; found: 
814.2794. 
[α]
20
D  = +45.0 (c = 0.17, CHCl3). 
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General procedure: Synthesis of di-tert-butyllphosphinite based catalyst 
GP6 
 
Iridium complex (R)-(2.63)  
 
The analogous (R)-pyridine alcohol (50 mg, 136 mol, 1.00 eq.) was added to a dry Young 
tube which was evacuated and backfilled with argon three times. KH (8.2 mg, 189 mol, 
1.50 eq.) and di-tert-butylchlorophosphine (24.5 mg, 136 mol, 1.00 eq.) were added and 
rinsed down with DMF (0.45 mL). The increasingly dark solution was stirred for 120 h at 
room temperature. DMF was completely evaporated in HV in a 60 °C hot water bath to assist 
complete removal of solvent. The brown residue was taken up in toluene (2 mL) and filtered 
through a plug of celite (2 × 2 cm). Toluene was evaporated in HV and the resulting violet 
residue was taken up in abs. CH2Cl2 (2 mL). [Ir(COD)Cl]2 (46 mg, 136 mol, 1.00 eq.) was 
added and the solution was stirred for 1 h at room temperature. NaBArF (142 mg, 163 mol, 
1.20 eq.) was added and the brownish solution was stirred for 14 h at room temperature. The 
solution was adsorbed and concentrated onto silica (2 g). Purification by column 
chromatography (SiO2, d × h: 3 × 20 cm, hexane:CH2Cl2 (1:1)) afforded the complex (117 mg, 
70 mol, 51%) as a red solid. 
C72H74BF24IrNO2P (1675.35 g/mol): 
MP: 142-143 °C. 
TLC: Rf = 0.39 (SiO2, hexane:CH2Cl2 (1:1), UV). 
1
H NMR
 
(500 MHz, CD2Cl2): /ppm = 7.71 (s, 8H, BArF), 7.66 (s, 2H, ar-H), 7.54 (s, 4H, 
BArF), 7.34 (s, 1H, ar-H), 5.70-5.60 (m, 1H, CH COD), 5.23-5.19 (m, 1H, HCOP), 4.67-4.75 
(m, 1H, CH COD), 4.05-4.00 (m, 1H, CH COD), 3.80 (s, 3H, OCH3), 3.06-3.00 (m, 1H, CH2), 
2.90-2.74 (m, 3H, CH COD and CH2), 2.38 (s, 3H, CH3), 2.38-2.32 (m, 1H, CH2 COD), 2.14-
1.93 (m, 3H, CH2 COD and CH2), 1.83 (dd, J = 15.0, 7.6 Hz, 1H, CH2 COD), 1.53–1.45 (m, 
1H, CH2 COD), 1.48 (s, 18H, 2 × C(CH3)3), 1.47 (d, JHP = 14.5 Hz, 9H, C(CH3)3), 1.29-1.21 
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(m, 1H, CH2 COD), 1.18-1.09 (m, 1H, CH2 COD), 1.10 (d, JHP = 14.5 Hz, 9H, C(CH3)3), 
0.95-89 (m, 1H, CH2 COD). 
13
C{
1
H} NMR (126 MHz, CD2Cl2): ppm = 162.3 (q, JBC = 50 Hz, BArF), 162.3 (s, ar-C), 
159.5 (d, JCP = 2 Hz, ar-C), 149.9 (s, ar-C), 145.6 (s, ar-C), 138.1 (s, ar-C), 135.4 (s, BArF), 
135.0 (s, ar-C), 132.0 (s, ar-C), 129.5 (qq, JCF = 32 Hz, JBC = 3 Hz, BArF), 127.5 (s, ar-C), 
127.5 (s, ar-C), 125.1 (q, JCF = 268 Hz, BArF CF3), 118.1 (sept, BArF), 91.1 (d, JCP = 5 Hz, 
CH COD), 85.2 (d, JCP = 2 Hz, COP), 78.6 (d, JCP = 19 Hz, CH COD), 75.1 (s, CH COD), 
64.9 (s, OCH3), 61.3 (s, CH COD), 41.7 (d, JCP = 19 Hz, C(CH3)3), 40.3 (d, JCP = 21 Hz, 
C(CH3)3), 38.4 (d, JCP = 4 Hz, CH2 COD), 36.8 (s, C(CH3)3), 35.6 (s, CH2 COD), 32.4 (s, 
C(CH3)3), 30.0 (d, JCP = 8 Hz, CH2), 29.1 (d, JCP = 7 Hz, C(CH3)3), 28.6 (s, CH2 COD), 26.9 
(s, CH2), 24.2 (d, JCP = 4 Hz, CH2 COD), 19.2 (s, CH3). 
31
P{
1
H} NMR (161 MHz, CDCl3): ppm = 143.7 (s). 
19
F{
1
H} NMR (376 MHz, CDCl3): ppm = 63.1 (s). 
11
B{
1
H} NMR (160 MHz, CDCl3): ppm = 5.6 (s). 
IR (ATR): ṽ/cm-1 = 2963 (m), 2881 (w), 1609 (w), 1458 (w), 1353 (m), 1273 (s), 1158 (m), 
1200 (s), 1007 (w), 885 (m), 836 (m), 809 (m), 712 (m), 671 (m). 
MS (FAB NBA): m/z (%): 812.4 (100), 698.3 (17), 350.2 (10). 
EA (C72H74BF24IrNO2P): calc.: C 51.62, H 4.45, N 0.84; found: C 51.67, H 4.46, N 1.00. 
[α]
20
D  = +10.5 (c = 0.53, CHCl3). 
 
Iridium complex (S)-2.78 
 
The reaction was set up as described in the general procedure GP6 except using the pyridyl 
alcohol (S)-2.50 (120 mg, 342 mol, 1.00 eq.), KH (20.6 mg, 512 mol, 1.50 eq.) and di-tert-
butylchlorophosphine (74.0 µL, 342 mol, 1.00 eq.) in DMF (0.5 mL). This solution was 
stirred for 14 h and filtered into [Ir(COD)Cl]2 (116 mg, 171 mol, 0.50 eq.) and NaBArF 
(357 mg, 365 mol, 1.20 eq.). Column chromatography (SiO2, d × h: 3.5 × 20 cm, 
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pentane:Et2O (3:1) → pentane:Et2O (1:1)) afforded the complex (370 mg, 223 μmol, 65%) as 
a red solid. 
C73H78BF24IrNO2P (1661.47 g/mol). 
MP: 186-190 °C. 
TLC: Rf = 0.15 (SiO2, pentane:CH2Cl2 (3:1), UV).  
1
H NMR (400 MHz, CD2Cl2) δ = 7.73 (d, J = 8.0 Hz, 1H, ar-H), 7.64 (s, 9H, BArF, ar-H), 
7.47 (s, 5H, BArF, ar-H), 7.45 (s, 1H, ar-H), 5.73-5.47 (m, 1H), 5.19 (t, J = 7.1, 1H, COH), 
4.65-4.52 (m, 1H), 4.08-3.90 (m, 1H), 3.73 (s, 3H, OCH3), 3.00-3.08 (m, 1H), 2.95-2.63 (m, 
3H), 2.36-2.22 (m, 1H), 2.12-1.86 (m, 3H), 1.85-1.73 (m, 1H), 1.47-1.32 (m, 27H), 1.29-1.14 
(m, 2H), 1.03 (d, J = 14.6 Hz, 9H), 0.93-0.84 (m, 1H), 0.84-0.80 (m, 1H). 
13
C{
1
H} NMR (101 MHz, CD2Cl2): ppm = 162.4 (q, J = 50 Hz, BArF), 162.4 (s, ar-C), 
162.2 (s, ar-C), 160.3 (s, ar-C), 145.6 (s, ar-C), 138.5 (s, ar-C), 137.1 (s, ar-C), 135.2 (s, 
BArF), 134.6 (s, ar-C), 131.2 (s, ar-C), 129.2 (qq, J = 32, 4 Hz, BArF), 124.5 (q, J = 279 Hz, 
BArF), 120.9 (s, ar-C), 117.8 (sept, JCF = 4 Hz, BArF), 91.0 (d, JCP = 5 Hz), 84.6 (d, JCP = 
2 Hz), 78.5 (d, JCP = 19 Hz), 75.5, 64.7, 61.5, 54.0, 53.7, 41.5 (d, JCP = 19 Hz), 40.2 (d, JCP = 
20 Hz), 38.2 (d, JCP = 4 Hz), 35.4, 32.2, 30.2 (d, JCP = 8 Hz), 28.9 (d, JCP = 7 Hz), 28.3 (d, JCP 
= 2 Hz), 27.9, 24.0 (d, JCP = 4 Hz). 
31
P{
1
H} NMR (161 MHz, CDCl3): ppm = 142.2 (s). 
IR (ATR): ṽ/cm-1 = 2964 (w), 1394 (m), 1307 (s), 1225 (s), 1158 (s), 924 (m), 696 (m), 682 
(m), 669 (m). 
HRMS (ESI, 4500 V, 180 °C):: (m/z) calc. for C39H60IrNO2P
+
: 798.3988 [MBArF]
+
; found: 
798.3997. 
[α]
20
D  = 13.2 (c = 0.54, CHCl3). 
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Iridium complex ((S)-2.64) 
 
The reaction was set up as described in the general procedure GP6 except using the analogous 
pyridyl alcohol (30 mg, 83.5 mol, 1.00 eq.), KH (5.0 mg, 125 mol, 1.50 eq.) and di-tert-
butylchlorophosphine (14.2 mg, 83.5 mol, 1.00 eq.) in DMF (0.45 mL). This solution was 
stirred for 120 h and filtered into [Ir(COD)2]BArF (105 mg, 83.5 mol, 1.20 eq.). Column 
chromatography (SiO2, d × h: 3 × 20 cm, hexane:CH2Cl2 (1:1)) and recrystallization from a 
mixture of Et2O and hexane afforded the complex (40 mg, 24 mol, 29%) in 95% purity 
determined by 
31
P NMR. 
C65H54BF30IrNOP (1669.11 g/mol). 
MP: 78-80 °C. 
TLC: Rf = 0.68 (SiO2, pentane:CH2Cl2 (1:1), UV). 
1
H NMR
 
(500 MHz, CDCl3): /ppm = 8.58 (s, 2H, ar-H), 8.21 (s, 1H, ar-H), 7.70 (s, 8H, 
BArF), 7.50 (s, 5H, ar-H and BArF), 5.73-568 (m, 1H, CH COD), 5.40-5.35 (m, 1H, CHOP), 
4.47 (s, 1H, CH COD), 4.16 (s, 1H, CH COD), 3.04-2.98 (m, 1H, CH2), 2.84-2.78 (m, 1H, 
CH2 COD), 2.43-2.31 (m, 2H, CH COD and CH2), 2.37 (s, 3H, CH3), 2.08-2.03 (m, 2H, CH2 
COD), 1.88-1.80 (m, 2H, CH2 COD), 1.49 (d, JHP = 13.8 Hz, 9H, C(CH3)3), 1.39-1.33 (m, 2H, 
CH2), 1.18-1.12 (s, 1H, CH2 COD), 1.08 (d, JHP = 14.7 Hz, 9H, C(CH3)3), 0.84-0.82 (m, 1H, 
CH2 COD).  
13
C{
1
H} NMR (126 MHz, CDCl3): ppm = 161.8 (q, JBC = 50 Hz, BArF), 160.9 (s, ar-C), 
156.7 (s, ar-C), 150.9 (s, ar-C), 141.0 (s, ar-C), 139.7 (s, ar-C), 134.9 (s, BArF), 133.1 (q, JCF 
= 33 Hz, ar-C), 130.7 (s, ar-C), 129.0 (qq, JCF = 31 Hz, JBC = 3 Hz, BArF), 127.6 (d, JCP = 
3 Hz), 124.7 (q, JCF = 273 Hz, BArF), 124.7 (sept, JCF = 4 Hz, ar-C), 124.7 (s, ar-C), 122.6 (q, 
JCF = 279 Hz, ar-C), 117.6 (sept, JCF = 4 Hz, BArF), 91.5 (d, JCP = 5 Hz, CH COD), 91.44 (s, 
CH COD), 84.8 (d, JCP = 2 Hz, CH COD), 78.9 (d, JCP = 2 Hz, CH COD), 76.3 (s, COP), 63.0 
(s, CH COD), 41.1 (d, JCP = 19 Hz, C(CH3)3), 40.1 (d, JCP = 21 Hz, C(CH3)3), 37.3 (d, JCP = 
3 Hz, CH2 COD), 31.7 (s, CH2 COD), 29.4 (d, JCP = 8 Hz, CH2 COD), 28.5 (s, C(CH3)3), 28.5 
(s, C(CH3)3), 27.9 (s, CH2), 26.3 (s, CH2), 23.9 (d, JCP = 8 Hz, CH2 COD), 18. (s, CH3). 
31
P{
1
H} NMR (161 MHz, CDCl3): ppm = 144.6 (s).
[I]
 
EXPERIMENTAL PART   CHAPTER 8  
268 
19
F{
1
H} NMR (376 MHz, CDCl3): ppm = 62.6 (s, 24F, BArF, CF3), 62.7 (s, 6F, CF3). 
11
B{
1
H} NMR (160 MHz, CDCl3): ppm = 5.6 (s). 
IR (ATR): ṽ/cm-1 = 2964 (w), 2930 (w), 2891 (w), 1609 (m), 1457 (w), 1394 (w), 1353 (s), 
1272 (s), 1114 (s), 882 (m), 838 (m), 710 (m). 
MS (FAB NBA): m/z (%): 806.2 (100) [M-BArF]
+
, 696.1 (17), 640.1 (33), 344.0 (12).  
EA (C65H54BF30IrNOP): calc.: C 46.78, H 3.26, N 0.84; found: C 46.22, H 3.45, N 0.90. 
[α]
20
D  = 39.1 (c = 0.32, CHCl3). 
[I] = Impurity at 131.6 ppm. 
 
Iridium complex ((S)-2.69) 
 
The reaction was set up as described in the general procedure GP6 except using the pyridyl 
alcohol (S)-2.57 (40 mg, 123 mol, 1.00 eq.), KH (7.4 mg, 123 mol, 1.50 eq.) and di-tert-
butylchlorophosphine (23.4 µL, 123 mol, 1.00 eq.) in DMF (0.4 mL). This solution stirred 
for 63 h and was filtered into [Ir(COD)Cl]2 (41 mg, 61 mol, 0.50 eq.) and NaBArF (131 mg, 
147 mol, 1.20 eq.). Column chromatography (SiO2, d × h: 3 × 25 cm, CH2Cl2) afforded the 
complex (20 mg, 12 mol, 10%) as a red solid. 
C71H60BF24IrNOP (1633.23 g/mol):  
MP: 192-193 °C. 
TLC: Rf = 0.78 (SiO2, CH2Cl2, UV). 
1
H NMR
 
(400 MHz, CD2Cl2): δ/ppm = 8.91 (d, J = 8.3 Hz, 1H), 8.86 (d, J = 8.3 Hz, 1H), 
8.73 (s, 1H), 7.99 (d, J = 7.8 Hz, 1H), 7.93-7.76 (m, 4H), 7.72 (s, 8H), 7.66 (s, 1H), 7.62 (s, 
1H), 7.56 (s, 4H), 5.68-5.62 (m, 1H), 5.16-5.10 (m, 1H), 4.81-4.74 (m, 1H), 4.10-4.01 (m, 
1H), 3.24-3.11 (m, 1H), 3.06-3.00 (m, 1H), 2.89-2.74 (m, 1H), 2.57-2.45 (m, 4H), 2.18-1.94 
(m, 3H), 1.53 (d, J = 13.7 Hz, 9H), 1.40 (q, J = 7.4 Hz, 1H), 1.18 (d, J = 14.4 Hz, 9H), 1.12-
1.05 (m, 1H), 1.04-0.97 (m, 1H), 0.78-0.62 (m, 2H), 0.02-0.15 (m, 1H). 
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13
C{
1
H} NMR (101 MHz, CD2Cl2): ppm = 162.3 (q, JCB = 50 Hz, BArF), 160.4 (d, JCP = 
3 Hz, ar-C), 157.9 (s, ar-C), 149.3 (s, ar-C), 139.3 (s, ar-C), 136.0 (s, ar-C), 135.3 (s, BArF), 
133.0 (s, ar-C), 131.6 (s, ar-C), 131.6 (s, ar-C), 130.9 (s, ar-C), 130.2 (s, ar-C), 129.5 (s, ar-C), 
129.4 (qq, JCF = 32 Hz, 3 Hz, BArF), 129.0 (s, ar-C), 128.8 (s, ar-C), 128.7 (s, ar-C), 128.6 (s, 
ar-C), 126.2 (s, ar-C), 126.0 (s, ar-C), 125.1 (q, JCF = 274 Hz, BArF), 124.2 (s, ar-C), 123.8 (s, 
ar-C), 118.0 (sept, JCF = 3 Hz, BArF), 89.0 (d, JCP = 5 Hz, CH COD), 85.2 (d, JCP = 2 Hz, CH 
COD), 76.9 (s, COP), 76.6 (d, JCP = 20 Hz, CH COD), 62.2 (s, CH COD), 42.0 (d, JCP = 18 
Hz, C(CH3)3), 40.2 (d, JCP = 21 Hz, C(CH3)3), 36.6 (d, JCP = 4 Hz, CH2 COD), 36.1 (s, CH2), 
29.8 (d, JCP = 8 Hz, CH2 COD), 29.2 (s, C(CH3)3), 29.1 (s, C(CH3)3), 28.4 (s, CH2 COD), 
27.7 (s, CH2), 23.3 (d, JCP = 4 Hz, CH2 COD), 19.4 (s, CH3). 
31
P{
1
H} NMR (161 MHz, CDCl3): ppm = 142.6 (s). 
19
F{
1
H} NMR (376 MHz, CDCl3): ppm = 62.9 (s). 
IR (ATR): ṽ/cm-1 = 2965 (w), 2931 (w), 2170 (w), 2055 (w), 1612 (w), 1470 (w), 1354 (s), 
1274 (s), 1118 (s), 1001 (w), 961 (w), 886 (m), 839 (m), 808 (w), 746 (w), 713 (m), 681 (m), 
616 (w). 
HRMS (ESI, 4500 V, 180 °C): (m/z) calc. for C39H48IrNOP
+
: 770.3099 [MBArF]
+
; found: 
707.3102. 
[α]
20
D  = 71 (c = 0.21, CHCl3). 
 
Iridium complex ((S)-2.70) 
  
The reaction was set up as described in the general procedure GP6 except using the pyridyl 
alcohol (S)-2.58 (40 mg, 123 mol, 1.00 eq.), KH (9.2 mg, 230 mol, 1.50 eq.) and di-tert-
butylchlorophosphine 30 µL, 153 mol, 1.00 eq.) in DMF (0.5 mL). This solution was stirred 
for 14 h, and filtered into [Ir(COD)Cl]2 (51 mg, 77 mol, 0.50 eq.) and NaBArF (163 mg, 
184 mol, 1.20 eq.). Column chromatography (SiO2, d × h: 3 × 16 cm, pentane:Et2O (2:1)  
CH2Cl2) afforded the complex (91 mg, 58 mol, 38%) as a red solid. 
C66H54BF26IrNOP (1569.26 g/mol):  
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MP: 177-178 °C. 
TLC: Rf = 0.89 (SiO2, CH2Cl2, UV). 
1
H NMR
 
(400 MHz, CD2Cl2): δ/ppm = 7.74 (s, 8H), 7.69-7.58 (m, 1H), 7.57 (s, 4H), 7.41 (s, 
1H), 7.21 (dt, J = 29.6, 9.0 Hz, 2H), 5.60 (ddd, J = 7.7, 5.4, 2.1 Hz, 1H), 5.52-5.43 (m, 1H), 
5.06-4.95 (m, 1H), 4.11 (tt, J = 8.4, 5.1 Hz, 1H), 3.12 (ddd, J = 16.3, 9.2, 6.6 Hz, 1H), 2.96 
(ddd, J = 17.4, 9.5, 3.6 Hz, 1H), 2.80-2.59 (m, 2H), 2.56-2.45 (m, 1H), 2.43 (s, 3H), 2.22-2.09 
(m, 1H), 2.09-1.93 (m, 2H), 1.86-1.75 (m, 1H), 1.51 (d, J = 13.6 Hz, 9H), 1.3-1.11 (m, 3H), 
0.91 (d, J = 14.7 Hz, 9H), 0.86-0.71 (m, 1H). 
13
C{
1
H} NMR (101 MHz, CD2Cl2): ppm = 162.4 (q, JCB = 50 Hz, BArF), 161.4 (d, JCP = 
3 Hz, ar-C), 150.4 (s, ar-C), 149.9 (s, ar-C), 140.3 (s, ar-C), 135.4 (s, BArF), 133.9 (s, ar-C), 
133.5 (t, JCF = 10 Hz, ar-C), 129.5 (qq, JCF = 32 Hz, 3 Hz, BArF), 125.2 (q, JCF = 274 Hz, 
BArF), 118.1 (sept, JCF = 4 Hz, BArF), 117.4 (t, JCF = 18 Hz, ar-C), 113.3-112.7 (m, ar-C), 
89.7 (d, JCP = 4 Hz, CH COD), 85.5 (d, JCP = 2 Hz, CH COD), 78.1 (s, COP), 74.7 (d, JCP = 
21 Hz, CH COD), 60.6 (s, CH COD), 41.5 (d, JCP = 17 Hz, C(CH3)3), 39.9 (d, JCP = 20 Hz, 
C(CH3)3), 38.2 (d, JCP = 5 Hz, CH2 COD), 36.6 (s, CH2), 29.8 (d, JCP = 8 Hz, CH2 COD), 
28.8 (s, C(CH3)3), 28.4-28.2 (m, C(CH3)3, CH2 COD), 27.7 (s, CH2), 24.5 (d, JCP = 4 Hz, CH 
COD), 19.2 (s, CH3). 
31
P{
1
H} NMR (161 MHz, CDCl3): ppm = 142.0 (s). 
19
F{
1
H} NMR (376 MHz, CDCl3): ppm = 62.8 (s), 105.0 (s), 109.4 (s). 
IR (ATR): ṽ/cm-1 = 2960 (w), 2031 (w), 1611 (w), 1568 (w), 1470 (w), 1354 (m), 1273 (s), 
1120 (s), 1048 (w), 1007 (m), 965 (w), 887 (m), 838 (m), 744 (w), 714 (m), 681 (m). 
HRMS (ESI, 4500 V, 180 °C): (m/z) calc. for C31H42F2IrNOP
+
: 706.2596 [MBArF]
+
; found: 
706.2592. 
[α]
20
D  = 27 (c = 0.20, CHCl3). 
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Iridium complex ((S)-2.79) 
 
The reaction was set up as described in the general procedure GP6 except using the analogous 
(S)-pyridyl alcohol (21 mg, 91 mol, 1.00 eq.), KH (5.5 mg, 137 mol, 1.50 eq.) and di-tert-
butylchlorophosphine (17 µL, 91 mol, 1.00 eq.) in DMF (0.3 mL). This solution was stirred 
for 14 h and was filtered into [Ir(COD)Cl]2 (31 mg, 46 mol, 0.50 eq.) and NaBArF (97 mg, 
109 mol, 1.20 eq.). Column chromatography (SiO2, d × h: 3 × 15 cm, CH2Cl2) afforded the 
complex (60 mg, 39 mol, 43%) as a red solid. 
C63H56BF24IrNOP (1533.11 g/mol):  
MP: 169-170 °C. 
TLC: Rf = 0.90 (SiO2, CH2Cl2, UV). 
1
H NMR
 
(400 MHz, CD2Cl2): δ/ppm = 8.26 (d, J = 7.1 Hz, 2H), 7.73 (s, 8H), 7.72-7.63 (m, 
3H), 7.59 (s, 1H), 7.56 (s, 4H), 5.75 (s, 1H), 4.58-4.48 (m, 1H), 4.16-4.05 (m, 1H), 3.14-3.02 
(m, 1H), 2.97-2.75 (m, 2H), 2.61-2.49 (m, 1H), 2.44 (s, 3H), 2.42-2.34 (m, 1H), 2.31-2.04 (m, 
3H), 1.91-1.80 (m, 1H), 1.74-1.65 (m, 1H), 1.51 (d, J = 13.2 Hz, 9H), 1.39-1.20 (m, 2H), 
1.20-1.00 (m, 1H), 1.06 (d, J = 14.4 Hz, 9H), 0.97-0.84 (m, 1H). 
13
C{
1
H} NMR (101 MHz, CD2Cl2): ppm = 162.3 (q, JCB = 50 Hz, BArF), 160.4 (d, JCP = 
2 Hz, ar-C), 160.0 (s, ar-C), 150.3 (s, ar-C), 139.3 (s, ar-C), 138.5 (s, ar-C), 135.4 (s, BArF), 
131.7 (s, ar-C), 130.4 (s, ar-C), 130.2 (s, ar-C), 129.4 (qq, JCF = 32 Hz, 3 Hz, BArF), 128.1 (s, 
ar-C), 125.1 (q, JCF = 273 Hz, BArF), 118.0 (sept, JCF = 4 Hz, BArF), 91.0 (d, JCP = 5 Hz, CH 
COD), 85.8 (d, JCP = 2 Hz, CH COD), 79.6 (d, JCP = 18 Hz, CH COD), 74.0 (s, COP), 63.3 (s, 
CH COD), 41.8 (d, JCP = 19 Hz, C(CH3)3), 40.3 (d, JCP = 22 Hz, C(CH3)3), 37.7 (d, JCP = 
4 Hz, CH2 COD), 35.7 (s, CH2), 29.9 (d, JCP = 8 Hz, CH2 COD), 28.9 (s, C(CH3)3), 28.8 (s, 
C(CH3)3), 28.3 (d, JCP = 1 Hz, CH2 COD), 27.1 (s, CH2), 24.3 (d, JCP = 3 Hz, CH2 COD), 
19.3 (s, CH3). 
31
P{
1
H} NMR (161 MHz, CDCl3): ppm = 142.1 (s). 
19
F{
1
H} NMR (376 MHz, CDCl3): ppm = 62.8 (s). 
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IR (ATR): ṽ/cm-1 = 2925 (w), 1723 (w), 1612 (w), 1464 (w), 1353 (m), 1272 (s), 1160 (m), 
1120 (s), 1048 (w), 964 (w), 926 (w), 886 (m), 838 (w), 807 (w), 774 (w), 745 (w), 714 (m), 
681 (m). 
[α]
20
D  = 40 (c = 0.18, CHCl3).  
 
Iridium complex ((S)-2.72) 
 
The reaction was set up as described in the general procedure GP6 except using the pyridyl 
alcohol (S)-2.59 (60.0 mg, 230 mol, 1.00 eq.), KH (13.9 mg, 344 mol, 1.50 eq.) and di-tert-
butylchlorophosphine in DMF:THF ((3:1), 3.0 mL). This solution was stirred for 14 h and 
filtered into a solution of [Ir(COD)Cl]2 (77.7 mg, 115 mol, 0.50 eq.) and NaBArF (257 mg, 
276 mol, 1.20 eq.) in CH2Cl2 (3 mL). Column chromatography (SiO2, d × h: 3 × 16 cm, 
pentane:Et2O (2:1)  CH2Cl2) afforded the complex (144 mg, 92 mol, 40%) as a red solid. 
C63H54BF26IrNOP (1569.09 g/mol):  
MP: 203-208 °C. 
TLC: Rf = 0.85 (SiO2, CH2Cl2, UV). 
1
H NMR
 
(400 MHz, CD2Cl2): δ/ppm = 7.67 (d, J = 8.3 Hz, 1H, ar-H), 7.64 (s, 8H, ar-H), 7.55 
(tt, J = 8.5, 6.3 Hz, 1H, ar-H), 7.47 (s, 4H, BArF), 7.36 (dd, J = 8.0, 2.1 Hz, 1H, ar-H), 7.13 
(dt, J = 24.0, 9.1 Hz, 2H, ar-H), 5.40 (dt, J = 8.8, 3.0 Hz, 1H), 5.38-5.29 (m, 1H), 5.24-5.20 
(m, 2H), 5.02-4.09 (m, 1H), 4.14-3.95 (m, 1H), 2.96-2.78 (m, 1H), 2.76-2.61 (m, 2H), 2.48-
2.37 (m, 1H), 2.01-1.89 (m, 3H), 1.89-1.82 (m, 2H), 1.79-1.62 (m, 1H), 1.61-1.50 (m, 1H), 
1.42 (d, J = 13.5 Hz, 9H, C(CH3)3), 1.37-1.29 (m, 1H), 1.15-0.97 (m, 2H), 0.79 (d, J = 14.7 
Hz, 9H, C(CH3)3). 
13
C{
1
H} NMR (101 MHz, CD2Cl2): δ/ppm = 162.7 (d, JCP = 5 Hz), 161.4 (q, JCB = 50 Hz), 
156.0, 150.2, 140.4, 138.0, 135.2, 133.3 (t, JCF = 10 Hz), 132.4, 129.2 (qq, JCF = 33, 3 Hz), 
125.3, 128.6, 120.9 (s, ar-C), 117.7 (sept, JCF = 4.1 Hz), 112.9 (tt, J = 26, 4 Hz), 89.7 (d, JCP = 
3.8 Hz), 78.2, 77.7, 74.9 (d, JCP = 22 Hz) 58.7, 41.1 (d, JCP = 17 Hz), 39.6 (d, JCP = 20 Hz), 
EXPERIMENTAL PART   CHAPTER 8  
273 
38.0 (d, JCP = 5 Hz), 36.2, 30.6 (d, JCP = 8 Hz), 28.9, 28.7-27.8 (m), 28.1, 27.8 (t, JCP = 7 Hz), 
24.2 (d, J = 4 Hz), 17.1. 
31
P{
1
H} NMR (161 MHz, CDCl3): ppm = 136.3 (s). 
19
F{
1
H} NMR (376 MHz, CD2Cl2): δ/ppm = 62.8 (s), 104.0 (s), 107.3 (s). 
IR (ATR): ṽ/cm-1 = 2923 (w), 1628 (w), 1610 (w), 1469 (m), 1352 (m), 1269 (s), 1161 (s), 
1019 (m), 1003 (m), 968 (w), 935 (w), 885 (w), 862 (w), 744 (m), 732 (m), 714 (m). 
EA (C63H54BF26IrNOP): calc.: C 48.22, H 3.47, N 0.89; found: C 48.54, H 3.55, N 1.26.  
[α]
20
D  = 24.9 (c = 0.43, CHCl3). 
 
8.2.3 Pyridine based catalyst with axial chiral backbone 
 
1-(Quinolin-8-yl)naphthalen-2-ol (2.80) 
 
 
A microwave vial was charged with 1-bromonaphthalen-2-ol (72.9 mg, 327 mol, 1.00 eq.), 
quinolin-8-ylboronic acid (100 mg, 392 mol, 1.20 eq.), allyl[1,3-bis(2,6-
diisopropylphenyl)imidazol-2-ylidene]chloropalladium(II) (15.3 mg, 3.0 mol%) and sealed. 
The vial was purged with argon for 15 min. Afterwards, degassed i-PrOH (3 mL) and 
degassed 4 M NaOH-solution (245 L) were added. The solution was stirred for 18 h at 50 °C. 
The reaction mixture was allowed to cool to room temperature, the resulting dark gel was 
dissolved in CH2Cl2 (30 mL) and H2O (10 mL) was added. The organic layer was separated 
and the aqueous layer was extracted with CH2Cl2 (2 × 30 mL). The combined organic layers 
were dried over MgSO4, filtered and the solvent was evaporated under reduced pressure. 
Purification by column chromatography (SiO2, d × h: 4 × 22 cm, pentane:Et2O (1:1)) afforded 
the product (35.2 mg, 131 mmol, 40%) as a colorless solid. 
C19H13NO (271.32 g/mol):  
MP: 183-184 °C. 
TLC: Rf = 0.23 (SiO2, pentane:Et2O (1:1), UV). 
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1
H NMR
 
(400 MHz, CDCl3): /ppm = 8.95 (dd, 
3
JHH = 4.2, 
4
JHH = 1.8 Hz, 1H, ar-H), 8.38 
(dd, 
3
JHH = 8.3 Hz, 
4
JHH = 1.8 Hz, 1H, ar-H), 8.02 (dd, 
3
JHH = 8.1 Hz, 
4
JHH = 1.5 Hz, 1H, ar-
H), 7.92 (d, 
3
JHH = 8.8 Hz, 1H, ar-H), 7.92-7.84 (m, 2H, ar-H), 7.76 (dd, 
3
JHH = 8.1 Hz, 
3
JHH = 
7.2 Hz, 1H, ar-H), 7.65 (s, 1H, OH), 7.53 (dd, 
3
JHH = 8.3 Hz, 
3
JHH = 4.2 Hz, 1H, ar-H), 7.50-
7.42 (m, 1H, ar-H), 7.42 (d, 
3
JHH = 8.9 Hz, 1H, ar-H), 7.38-7.29 (m, 2H, ar-H). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 151.7 (s, ar-qC), 150.9 (s, ar-C), 146.8 (s, ar-qC), 
137.9 (s, ar-C), 135.1 (s, ar-C), 134.7 (s, ar-qC), 134.4 (s, ar-qC), 130.2 (s, ar-C), 130.0 (s, ar-
qC), 129.2 (s, ar-qC), 128.6 (s, ar-C), 128.3 (s, ar-C), 126.8 (s, ar-C), 126.2 (s, ar-C), 125.3 (s, 
ar-C), 123.3 (s, ar-C), 121.5 (s, ar-C), 120.5 (s, ar-qC), 119.8 (s, ar-C). 
IR (ATR): ṽ/cm-1 = 3334 (m), 3050 (m), 2924 (m), 2641 (m), 1738 (w), 1622 (m), 1595 (m), 
1498 (s), 1435 (m), 1341 (m), 1271 (m), 1228 (m), 1132 (w), 1075 (w), 1027 (w), 860 (w), 
813 (s), 746 (s), 723 (w), 677 (m), 619 (m). 
HRMS (ESI, 4500 V, 180 °C): (m/z) calc. for C19H14NO
+
: 272.1070 [M+H]
+
; found: 
272.1072. 
HPLC: Daicel, Chiralpak IC (0.46 cm × 25 cm, heptane/iso-propanol = 80:20, 0.5 mL/min, 
20 °C, 220 nm): tR = 12.7 min and 19.5 min. 
 
Iridium 8-(naphthalen-1-yl)quinoline-di-o-tolylphosphinite based catalyst (2.83) 
 
The reaction was set up as described in the general procedure GP5 except using 1-(quinolin-
8-yl)naphthalen-2-ol (22.0 mg, 81.1 mol, 1.00 eq.), 4-dimethylaminopyridine (11.9 mg, 
97.3 mol, 1.20 eq.) and chloro-di-(2-methylphenyl)-phosphine (30.2 mg, 97.3 mol, 1.20 eq.) 
in abs. CH2Cl2 (1.5 mL). This solution was filtered into [Ir(COD)Cl]2 (27.2 mg, 40.5 mol, 
0.50 eq.) and NaBArF (79.0 mg, 89.2 mol, 1.10 eq.). Column chromatography (SiO2, d × h: 
3 × 12 cm, pentane:CH2Cl2 (4:1) → (1:1)) afforded the product (92.0 mg, 55.9 mol, 69%) as 
an orange solid. 
C73H50BF24IrNOP (1647.30 g/mol):  
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MP: >97 °C decomposition 
TLC: Rf = 0.69 (SiO2, pentane:CH2Cl2 (1:2), UV). 
NMRs: The collected NMR data revealed a complex spectra. In the 
31
P NMR two species 
were detected. The ration of this species changed by switching the solvent to toluene-d8. The 
structure could be approved by X-ray crystallography. Crystals suitable for X-ray diffraction 
were obtained by layering a solution of complex (30 mg) in CD2Cl2 (0.45 mL) with pentane 
(1.2 mL).  
31
P{
1
H} NMR (161 MHz, CD2Cl2): δ/ppm = 96.2 (s), 86.1 (s), ration (100:25). 
31
P{
1
H} NMR (161 MHz, toluene-d8): δ/ppm = 96.4 (s), 86.1 (s), ration (100:17). 
IR (ATR): ṽ/cm-1 = 1611 (w), 1509 (w), 1466 (w), 1354 (m), 1273 (s), 1116 (s), 973 (w), 949 
(w), 886 (m), 826 (m), 778 (w), 753 (m), 712 (m), 670 (m). 
HRMS (ESI, 4500 V, 180 °C): calc. for C41H38IrNOP
+
: 784.2317 [MBArF]
+
; found: 
784.2330. 
 
8.2.4 Derivatization for the selectivity determination of the hydrogenation of farnesol 
 
3,7,11-Trimethyldodecan-1-ol (P15)  
 
(2E,6E)-3,7,11-Trimethyldodeca-2,6,10-trien-1-ol (22.2 mg, 0.10 mmol, 1.00 eq.) was 
dissolved in abs. CH2Cl2 (0.5 mL) and the iridium complex (1.0 mol%) was added. The vial 
was charged with a magnetic stirrer, placed in an autoclave and sealed. The autoclave was 
pressurized to 50 bar with H2 and the solution was stirred at 800 rpm for 16 h. The hydrogen 
was released and the reaction mixture concentrated under reduced pressure. The residue was 
taken up in a mixture of hexane:Et2O (1:1, 0.4 mL) and filtered through a plug of SiO2 (d × h: 
0.5 × 2 cm, 5 mL eluent). Evaporation of the solvent afforded the analytically pure product as 
a colorless oil. 
C15H32O (228.42 g/mol): 
TLC: Rf = 0.30 (SiO2, hexane:ethyl acetate (5:1), KMnO4). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 3.73-3.62 (m, 2H, CH2OH), 1.65-1.47 (m, 3H, alkyl-
H), 1.41-1.02 (m, 14H, alkyl-H), 0.89 (d, JHH = 6.6 Hz, 3H, CH3), 0.86 (d, JHH = 6.6 Hz, 6H, 
CH3), 0.84 (d, JHH = 6.6 Hz, 3H, CH3). 
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13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 61.4 (s, CH2OH), 40.1 (s, alkyl-C), 39.5 (s, alkyl-
C), 37.6 (s, alkyl-C), 37.5 (s, alkyl-C), 37.4 (s, alkyl-C), 32.9 (s, alkyl-C), 29.7 (s, alkyl-C), 
28.1 (s, alkyl-C), 24.9 (s, alkyl-C), 24.5 (s, alkyl-C), 22.9 (s, alkyl-C), 22.8 (s, alkyl-C), 19.9 
(s, alkyl-C), 19.8 (s, alkyl-C). 
Obtained data are in accordance with literature data.
[53b]
 
 
3,7,11-Trimethyldodecanal  
 
3,7,11-Trimethyldodecan-1-ol (17.5 mg, 77 mol, 1.00 eq.) was dissolved in abs. CH2Cl2 
(0.5 mL) and trichloroisocyanuric acid (18.1 mg, 78 mol, 1.00 eq.) was added. The 
suspension was stirred for 15 min and cooled down to 0 °C. TEMPO (0.11 mg, 0.9 mol%) 
was added and the mixture was warmed up to room temperature. The suspension was stirred 
for 10 min and filtered through a plug of celite (d × h: 0.5 × 1 cm). The organic phase was 
extracted with sat. Na2CO3 solution (5 mL), 1 N HCl (5 mL) and brine (5 mL). The organic 
layer was dried over MgSO4 and the solvent evaporated in vacuum. The obtained oil was 
taken up in a mixture of hexane:ethyl acetate (5:1, 0.4 mL) and filtered through a plug of 
silica (d × h: 0.2 × 3 cm, 5 mL eluent) to obtain the product (17.0 mg, 74 mmol, 97%) as a 
colorless oil. 
C15H30O (226.40 g/mol): 
TLC: Rf = 0.75 (SiO2, hexane:ethyl acetate (5:1), KMnO4). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 9.76 (t, JHH = 2.3 Hz, 1H, CHO), 2.39 (ddd, JHH = 16.0, 
5.7, 1.9 Hz, 1H, CH2CHO), 2.22 (ddd, JHH = 16.0, 7.8, 2.6 Hz, 1H, CH2CHO), 2.09-2.01 (m, 
1H, alkyl-H), 1.55-1.48 (m, 1H, alkyl-H), 1.39-1.03 (m, 13H, alkyl-H), 0.97 (d, JHH = 6.7 Hz, 
3H, CH3), 0.86 (d, JHH = 6.6 Hz, 6H, 2 × CH3), 0.84 (d, JHH = 6.6 Hz, 3H, CH3).  
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 203.4 (s, CHO), 51.2 (s, CH2CHO), 39.5 (s, 
alkyl-C), 37.4 (s, alkyl-C), 37.4 (s, alkyl-C), 37.3 (s, alkyl-C), 32.9 (s, alkyl-C), 28.4 (s, alkyl-
C), 28.1 (s, alkyl-C), 24.9 (s, alkyl-C), 24.5 (s, alkyl-C), 22.9 (s, alkyl-C), 22.8 (s, alkyl-C), 
20.2 (s, alkyl-C), 19.9 (s, alkyl-C). 
Obtained data are in accordance with literature data.
[53b]
 
 
EXPERIMENTAL PART   CHAPTER 8  
277 
(4R,5R)-Di-iso-propyl 2-(2,6,10-trimethylundecyl)-1,3-dioxolane-4,5-dicarboxylate and 
(4S,5S)-di-iso-propyl 2-(2,6,10-trimethylundecyl)-1,3-dioxolane-4,5-dicarboxylate  
 
3,7,11-Trimethyldodecanal (20 mg, 8.8 mol, 1.00 eq.) was dissolved in abs. CH2Cl2 (1 mL). 
To one half of the above solution was added L-di-iso-propyltartrate (16 mg, 6.6 mol, 
0.75 eq.), to the other half, D-di-iso-propyltartrate (16 mg, 6.6 mol. 0.75 eq.) was added. 
Both solutions were cooled down to 78 °C and trimethylsilyl triflate (4 L, 22 mol, 
2.80 eq.) was added. The reaction mixture was stirred for 30 min at 78 °C and for 1.5 h at 
room temperature. Et3N (50 l) was added to quench the solution. The solvent was evaporated 
under reduced pressure and taken up in Et2O (0.4 mL). Filtration over SiO2 (0.2 × 1 cm, 3 mL 
eluent) and evaporation of the ether afforded the L- or the D-acetal as a colorless oil which 
was used without further purification for GC-analysis.  
C25H46O6 (442.64 g/mol): 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 5.30 (t, JHH = 5.1 Hz, 1H, O2CH), 5.16 (sept, JHH = 
6.0 Hz, 1H, CH(CH3)2), 5.10 (sept, JHH = 6.3 Hz, 1H, CH(CH3)2), 4.64 (d, JHH = 4.2 Hz, 1H, 
O2CCH), 4.47 (d, JHH = 4.2 Hz, 1H, O2CCH), 1.83-1.64 (m, 2H, alkyl-H), 1.28 (d, JHH = 
6.3 Hz, 12H, alkyl-H), 1.26-1.10 (m, 12H, alkyl-H), 0.95 (d, JHH = 6.5 Hz, 3H, alkyl-H), 0.85 
(d, JHH = 6.7 Hz, 6H, alkyl-H), 0.83 (d, JHH = 6.6 Hz, 6H, alkyl-H). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 171.3 (s, O2C), 169.7 and 169.0 (s, O2C), 107.1 
(s, OOC), 77.4 and 77.3 (s, O2CC), 72.2 (s, O2CC), 70.6 (s, CO2C), 69.8 (s, CO2C)), 40.8 (s, 
alkyl-C), 39.5 (s, alkyl-C), 37.8 (s, alkyl-C), 37.4 (s, alkyl-C), 37.4 (s, alkyl-C), 32.9 (s, alkyl-
C), 29.8 (s, alkyl-C), 29.3 (s, alkyl-C), 28.1 (s, alkyl-C), 24.9 (s, alkyl-C), 24.4 (s, alkyl-C), 
22.9 (s, alkyl-C), 22.8 (s, alkyl-C), 21.9 (s, alkyl-C), 21.8 (s, alkyl-C), 19.9 (s, alkyl-C), 19.9 
(s, alkyl-C). 
MS (FAB NBA): m/z (%): 443.3 (98), 401.3 (44), 359.2 (45), 245.0 (62), 227.2 (51), 69 (68), 
43 (100). 
GC (CP-Sil 88 (50 m × 0.25 mm × 0.25 m) 90 kPa H2 (110 °C – 0 min – 0.5 °C/min  
200 °C – 10 min): L-acetal tR = 144.8 min (3S,7R), 145.4 min [(3R,7S) + (3S,7S)], 146.4 min 
(3R,7R); D-acetal: tR = 144.8 min (3R,7S), 145.4 min [(3S,7R) + (3R,7R)], 146.4 min (3S,7S). 
Obtained data are in accordance with literature data.
[53b]
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8.3 Iridium N,P- ligand complexes in the asymmetric hydrogenation of α,β-
unsaturated carboxylic esters 
 
8.3.1 Synthesis of α,β-unsaturated carboxylic esters  
 
tert-Butyl (E)-2-methylpent-2-enoate (3.31) 
 
To a solution of trans-2-methyl-2-pentenoic acid (1.80 mL, 1.96 g, 15.4 mmol, 1.00 eq.) in 
CH2Cl2 (5 mL) oxalyl chloride (1.33 mL, 1.29 g, 15.5 mmol, 1.00 eq.) and DMF (25 L, 
0.02 mmol, 0.01 eq.) were added at 0 °C and the solution was stirred for 10 min at 0 °C. The 
solution was warmed up to room temperature and stirred overnight. The solution was 
quenched directly by adding tert-butanol (5.00 mL, 3.95 g, 53.3 mmol, 3.50 eq.) followed by 
Et3N (2.13 mL, 15.4 mmol, 1.00 eq.) dropwise at 0 °C. The resulting solution was stirred for 
5 h at room temperature. H2O (15 mL) was added and the mixture was extracted with CH2Cl2 
(3 × 15 mL). The combined organic layers were dried over MgSO4. Column chromatography 
(SiO2, d × h: 6 × 15 cm, cyclohexane:ehtyl acetate (10:1)) afforded the crude ester as pale 
brown liquid. Bulb-to-bulb distillation (150 °C, 60 bar) afforded the product (200 mg, 
1.18 mmol, 8%) as a colorless liquid. 
C10H18O2 (170.25 g/mol):  
TLC: Rf = 0.74 (SiO2, cyclohexane:ehtyl acetate (10:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm: 6.70 (tq, J = 7.4, 1.4 Hz, 1H, C=CH). 2.22 (m, 2H, CH2), 
1.80 (d, J = 1.4 Hz, CH3), 1.58 (s, 9H, C(CH3)3, 1.08 (t, J = 7.6 Hz, 3H, CH3). 
13
C NMR (101 MHz, CDCl3): ppm = 168.2 (s, C=O), 143.1 (s, CH=C), 128.7 (s, CH=C), 
80.1 (s, OC(CH3)3, 28.2 (s, OC(CH3)3), 22.2 (s, CH2), 13.1 (s, CH3), 12.3 (s, CH3). 
MS (EI, 70 eV, 50 °C) m/z (%): 114 (51), 69.1 (100), 68.1 (12), 67.1 (19), 55.1 (11), 53.1 (15), 
45.0 (15), 43.1 (22), 42.1 (13), 41.1 (99). 
GC (Chiraldex -cyclodextrin TFA G-TA (30 m × 0.25 mm × 0.12 m), 60 kPa H2 (45 °C – 
25 min – 20 °C/min – 160 °C – 5 min): tR = 30.4 min. 
Obtained data are in accordance with literature data.
[136]
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Ethyl (E)-2-methylpent-2-enoate (3.26) 
 
To a solution of trans-2-methyl-2-pentenoic acid (1.80 g, 2.00 mL, 15.4 mmol, 1.00 eq.) in 
CH2Cl2 (5 mL) oxalyl chloride (1.33 mL, 1.29 g, 15.5 mmol, 1.00 eq.) and DMF (25 L, 
0.02 mmol, 0.01 eq.) were added at 0 °C and the solution was stirred for 10 min at 0 °C. The 
solution was warmed up to room temperature and stirred overnight. The solution was 
quenched directly by adding ethanol (5.00 mL, 3.95 g, 85.9 mmol, 5.60 eq.) followed by Et3N 
(2.13 mL, 15.4 mmol, 1.00 eq.) dropwise at 0 °C. The resulting solution was stirred for 5 h at 
room temperature. H2O (15 mL) was added and the mixture was extracted with CH2Cl2 (3 × 
15 mL). The combined organic layers were dried over MgSO4. Column chromatography 
(SiO2, d × h: 5 × 16 cm, pentane:Et2O (40:1)) afforded the product (1.21 g, 8.52 mmol, 55%) 
as a colorless liquid. 
C8H14O2 (142.20 g/mol):  
TLC: Rf = 0.31 (SiO2, pentane:Et2O (30:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 6.72 (t, J = 6.8 Hz, 1H, C=CH), 4.19 (q, J = 6.7 Hz, 
2H, OCH2), 2.20 (m, 2H, CH2), 1.84 (s, 3H, CH3), 1.32 (t, J = 6.7 Hz, 3H, CH3), 1.08 (t, J = 
7.5 Hz, 3H, CH3).  
13
C NMR (101 MHz, CDCl3): ppm = 167.4 (s, CO2), 144.3 (s, CH=C), 127.8 (s, CH=C), 
59.6 (s, OCH2), 21.5 (s, CH2), 13.1 (s, CH3), 12.7 (s, CH3), 12.1 (s, CH3). 
MS (EI, 70 eV, 200 °C) m/z (%): 142.1 (25), 114.1 (22), 113.1 (19), 97.1 (42), 69.1 (100), 
67.1 (17), 43.1 (13), 41.1 (72). 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 15 min): 36.07 min.  
Obtained data are in accordance with literature data.
[137]
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(E)-Isopropyl 2-methylpent-2-enoate (3.27) 
 
To a solution of trans-2-methyl-2-pentenoic acid (1.80 g, 2.00 mL, 15.4 mmol, 1.00 eq.) in 
CH2Cl2 (5 mL) oxalyl chloride (1.33 mL, 1.29 g, 15.5 mmol, 1.00 eq.) and DMF (25 L, 
0.02 mmol, 0.01 eq.) were added at 0 °C and the solution was stirred for 10 min at 0 °C. The 
solution was warmed up to room temperature and stirred overnight. The solution was 
quenched directly by adding isopropanol (5.00 mL, 65.0 mmol, 4.02 eq.) followed by Et3N 
(2.13 mL, 15.4 mmol, 1.00 eq.) dropwise at 0 °C. The resulting solution was stirred for 5 h at 
room temperature. H2O (15 mL) was added and the mixture was extracted with CH2Cl2 (3 × 
15 mL). The combined organic layers were dried over MgSO4. Column chromatography 
(SiO2, d × h: 5 × 16 cm, pentane:Et2O (40:1)) afforded the product (1.50 g, 9.61 mmol, 62%) 
as a colorless liquid. 
C9H16O2 (156.22 g/mol):  
TLC: Rf = 0.41 (SiO2, pentane:Et2O (40:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 6.70 (t, 
3
JHH = 7.3 Hz, 1H, C=CH), 5.03 (sept, 
3
JHH = 
6.2 Hz, 1H, OCH(CH3)2), 2.19-2.12 (m, 2H, CH3CH2), 1.79 (s, 3H, C=CHCH3), 1.24 (d, 
3
JHH 
= 6.3 z, 6H, OCH(CH3)2), 1.03 (t, 
3
JHH = 7.6 Hz, 3H, CH3CH2).  
13
C NMR (101 MHz, CDCl3): ppm = 168.1 (s, CO2CH(CH3)2), 143.5 (s, C=CH), 127.8 (s, 
C=CH), 67.7 (s, CO2CH(CH3)2), 22.1 (s, CH3CH2), 22.1 (s, CO2CH(CH3)2), 13.2 (s, CH3), 
12.3 (s, CH3). 
IR (ATR): ṽ/cm-1 = 2975 (w), 2954 (w), 2876 (w), 1704 (s), 1646 (w), 1455 (w), 1386 (w), 
1372 (m), 1268 (m), 1243 (s), 1180 (w), 1165 (w), 1146 (m), 1111 (s), 1099 (s), 1087 (s), 
1035 (w), 929 (w), 898 (w), 844 (w), 741 (w). 
MS (EI, 70 eV, Inlet 150 °C) m/z (%): 156.1 (5), 127 (42), 115.0 (23), 114.0 (52), 97.0 (95), 
69 (100), 59.0 (13), 43 (44), 41 (55), 39 (11).  
EA (C9H16O2): calc.: C 69.19, H 10.32; found: C 68.94, H 10.18. 
GC (Chiraldex -cyclodextrin TFA G-TA (30 m × 0.25 mm × 0.12 m), 60 kPa H2 (45 °C – 
25 min – 20 °C/min – 160 °C – 5 min): tR = 28.4 min. 
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(E)-Heptyl 2-methyl-3-phenylacrylate (3.5) 
 
To a solution of α-methylcinnamic acid (1.50 g, 9.25 mmol, 1.00 eq.) in CH2Cl2 (10 mL) 
oxalyl chloride (1.56 mL, 2.34 g, 18.5 mmol, 2.00 eq.) and DMF (70 L, 0.09 mmol, 0.01 eq.) 
were added at 0 °C and the solution was stirred for 10 min at 0 °C. The solution was warmed 
up to room temperature and stirred overnight. All volatiles were evaporated in HV. The 
residue was dissolved in CH2Cl2 (10 mL) and heptanol (3.00 mL, 21.2 mmol, 2.20 eq.) 
followed by Et3N (1.50 mL, 10.8 mmol, 1.20 eq.) were added dropwise at 0 °C. The resulting 
solution was stirred for 16 h at room temperature. H2O (15 mL) was added and followed by 
extraction with CH2Cl2 (3 × 15 mL). The combined organic layers were dried over MgSO4. 
Column chromatography (SiO2, d × h: 5 × 12 cm, cyclohexane:ehtyl acetate (40:1)) afforded 
the crude ester. The ester was further purified via bulb-to-bulb distillation to afford the 
product (1.70 g, 6.53 mmol, 71%) as a colorless liquid. 
C17H24O2 (260.38 g/mol):  
BP: 155 °C (0.6 mbar).  
TLC: Rf = 0.56 (SiO2, cyclohexane:ehtyl acetate (40:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.69 (q, 
4
JHH = 1.4 Hz, C=CH, 1H), 7.42-7.37, (m, ar-
H, 4H), 7.35-7.30 (m, ar-H, 1H), 4.21 (t, 
3
JHH = 6.7 Hz, OCH2, 2H), 2.13 (d, 
4
JHH = 1.5 Hz, 
3H, CH=CCH3), 1.76-1.69 (m, 2H, OCH2CH2), 1.44-1.30 (m, 8H, alkyl-H), 0.90 (t, 
3
JHH = 
6.71 Hz, 3H, CH3).  
13
C NMR (101 MHz, CDCl3): ppm = 168.9 (s, COO), 138.8 (s, HC=C), 136.2 (s. ar-qC), 
129.8 (s, ar-C), 128.9 (s, HC=C), 128.5 (s, ar-C), 128.4 (s, ar-C), 65.3 (s, OCH2), 31.9 (s, 
CH2), 29.2 (s, CH2), 28.9 (s, CH2), 26.2 (s, CH2), 22.8 (s, CH2), 14.3 (s, CH3), 14.3 (s, CH3). 
IR (ATR): ṽ/cm-1 = 3027 (w), 2955 (m), 2926 (m), 1705 (s), 1636 (m), 1491 (m), 1448 (m), 
1356 (w), 1294 (w), 1245 (s), 1200 (m), 1111 (s), 1074 (w), 1030 (w), 1003 (m), 928 (m), 764 
(m), 738 (w). 
MS (EI, 70 eV, 50 °C) m/z (%): 260.2 (21), 163.1 (21), 162.1 (100), 161.1 (23), 145.1 (42), 
117.1 (44), 116.1 (37), 115.1 (26), 91.1 (11), 57.1 (13).  
EA (C17H24NO2): calc.: C 78.42, H 9.29; found: C 78.44, H 9.45. 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 15 min): 26.32 min.  
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HPLC: Daicel Chiralcel OJ (0.46 cm × 25 cm, heptane, 0.5 mL/min; T = 25 °C, 220 nm, tR = 
17.9 min. 
 
(E)-2,4,4-Trimethylpent-2-enoic acid 
 
A mixture of NaH (60% in mineral oil, 2.40 g, 60 mmol, 3.00 eq.) and diethyl phosphite 
(2.56 mL, 20.0 mmol, 1.00 eq.) in THF (50 mL) was treated with a solution of -
bromopropionic acid (1.79 mL, 20.0 mmol, 1.00 eq.) acid in THF (20 mL). After gas 
evolution had ceased, pivalaldehyde (2.17 mL, 20.0 mmol, 1.00 eq.) was added and the 
reaction mixture was stirred for 2 d at room temperature. Ethanol (5 mL) was added and the 
reaction mixture was poured into H2O (150 mL). The solution was washed with MTBE (50 
mL) and the aqueous phased acidified to a pH of 2-3 with 10% aqueous HCl. The mixture 
was extracted with MTBE (3 × 50 mL) and the combined organic layers were washed with 
brine (50 mL) and dried over MgSO4. The solvent was evaporated under reduced pressure and 
the crude product was purified by bulb-to-bulb distillation to afford the product (1.24 g, 
8.72 mmol, 44%) as a colorless solid. 
C8H14O2 (142.20 g/mol):  
BP: 182 °C (44 mbar).  
1
H NMR
 
(400 MHz, CDCl3): /ppm = 12.54 (s br, 1H, CO2H), 6.82 (m, 1H, C=CH), 1.84 (d, 
1.3 Hz, CH3), 1.18 (s, 1H, C(CH3)3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 176.1 (s, CO2H), 152.4 (s, CH=C), 126.2 (s, 
CH=C), 33.1 (s, C(CH3)3), 30.3 (s, C(CH3)3), 13.6 (s, CH=CCH3). 
Obtained data are in accordance with literature data.
[138]
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Isopropyl (E)-2,4,4-trimethylpent-2-enoate (3.32) 
 
 
To a solution of (E)-2,4,4-trimethylpent-2-enoic acid (700 mg, 4.92 mmol, 1.00 eq.) in 
CH2Cl2 (5 mL) oxalyl cloride (1.28 g, 840 L, 9.84 mmol, 2.00 eq.) and DMF (5 L) were 
added dropwise at 0 °C. The yellow reaction mixture was stirred for 16 h at room temperature 
followed by the addition of iso-propanol (1.56 g, 2.00 mL, 26.0 mmol, 11.1 eq.) and Et3N 
(365 mg, 500 L, 3.61 mmol, 1.60 eq.) at 0 °C. The solution was stirred for 4 h at room 
temperature and the solvent was evaporated under reduced pressure. Purification by column 
chromatography (SiO2, d × h: 3 × 25 cm, cyclohexane:ethyl acetate (25:1)) afforded the 
product as a colorless liquid (504 mg, 2.74 mmol, 57%). 
C11H20O2 (184.28 g/mol): 
TLC: Rf = 0.67 (SiO2, cyclohexane:ehtyl acetate (10:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 6.76 (q, J = 1.36 Hz, 1H, CH=C), 5.01 (sept, J = 
6.2 Hz, 1H, CH(CH3)2), 1.92 (d, J = 1.4 Hz, 3H, CH3), 1.24 (d, J = 6.3 Hz, 6H, CH(CH3)2), 
1.16 (s, 9H, C(CH3)3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 169.0 (s, CO2(C(CH3)3), 150.9 (s, CH=C), 127.2 
(s, CH=C), 67.9 (s, OC(CH3)3), 33.1 (s, C(CH3)3), 30.3 (s, C(CH3)3), 22.1 (s, CH(CH3)2), 13.4 
(s, CH=CCH3). 
IR (ATR): ṽ/cm-1 = 2961 (w), 2873 (w), 1733 (m), 1707 (m), 1640 (w), 1468 (m), 1367 (m), 
1251 (m), 1200 (m), 1181 (m), 1146 (m), 1102 (s), 1015 (w), 929 (w), 848 (w), 826 (w), 748 
(w), 671 (w). 
MS (EI, 70 eV, 50 °C) m/z (%): 184.1 (1), 142.1 (49), 127.1 (100), 125.1 (34), 109.1 (41), 
97.1 (16), 84.1 (18), 81.1 (25), 69.1 (10), 59.1 (31), 55.1 (23), 43.1 (28), 41.1 (31). 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 10 min): tR = 9.48 min. 
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Isobutyl (E)-2-methyl-3-phenylacrylate (3.8) 
 
To a solution of (E)-2-methyl-3-phenylacrylic acid (1.50 g 9.26 mmol, 1.00 eq.) in CH2Cl2 
(10 mL) oxalyl chloride (1.54 mL, 1.50 g, 18.0 mmol, 1.90 eq.) and DMF (10 L, 0.04 mmol, 
0.01 eq.) were added at 0 °C and the solution was stirred for 10 min at 0 °C. The solution was 
warmed up to room temperature and stirred overnight. All volatiles were evaporated in HV to 
afford the crude acid chloride which was used without further purification. The acid chloride 
was dissolved in CH2Cl2 (10 mL) and iso-butanol (1.60 g, 2.00 mL, 21.6 mmol, 2.30 eq.) and 
Et3N (1.09 g, 1.50 mL, 10.8 mmol, 1.20 eq.) were added dropwise at 0 °C. The solution was 
stirred for 6 h at room temperature and all volatiles were evaporated in HV. Purification by 
column chromatography (SiO2, d × h: 6 × 20 cm, cyclohexane:ethyl acetate (50:1→30:1)) 
afforded the product as a colorless liquid (1.68 g, 7.71mmol, 83%). 
C14H18O2 (218.30 g/mol):  
TLC: Rf = 0.28 (SiO2, cyclohexane:ehtyl acetate (50:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.71 (d, J = 1.3 Hz, 1H, CH=C), 7.46-7.36 (m, 4H, ar-
H), 7.35-7.27 (m, 1H, ar-H), 4.01 (d, J = 6.6 Hz, 2H, OCH2), 2.14 (d, J = 1.4 Hz, 3H, CH3), 
2.10-2.00 (m, 1H, OCH2CH(CH3)2), 1.01 (d, J = 6.7 Hz, 6H, OCH2CH(CH3)2). 
13
C NMR (101 MHz, CDCl3): ppm = 168.9 (s, CO2), 138.8 (s, CH=C), 136.1 (s, ar-qC), 
129.8 (s, ar-C), 128.8 (s, CH=C), 128.5 (s, ar-C), 128.4 (s, ar-C), 71.5 (s, OCH2), 28.0 (s, 
OCH2CH), 19.4 (s, CH3), 14.2 (s, CH3). 
IR (ATR): ṽ/cm-1 = 2961 (m), 2975 (w), 1707 (s), 1635 (w), 1470 (w), 1448 (w), 1376 (w), 
1248 (s), 1201 (m), 1114 (s), 929 (w), 765 (w), 704 (w), 634 (w). 
MS (EI, 70 eV, 200 °C) m/z (%): 218.1 (26), 163.1 (13), 162.1 (96), 161.1 (40), 146.1 (11), 
145.1 (89), 118.1 (13), 117.1 (100), 116.1 (84), 115.1 (76), 91.1 (25), 57.1 (13), 41.1 (17). 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 10 min): tR = 31.65 min. 
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2,4-Dimethylpentan-3-yl (E)-2-methyl-3-phenylacrylate 
 
To a solution of (E)-2-methyl-3-phenylacrylic acid (1.50 g 9.26 mmol, 1.00 eq.) in CH2Cl2 
(10 mL) oxalyl chloride (1.54 mL, 1.50 g, 18.0 mmol, 1.90 eq.) and DMF (10 L, 0.04 mmol, 
0.01 eq.) were added at 0 °C and the solution was stirred for 10 min at 0 °C. The solution was 
warmed up to room temperature and stirred overnight. All volatiles were evaporated in HV to 
afford the crude acid chloride which was used without further purification. The acid chloride 
was dissolved in CH2Cl2 (10 mL) and 2,4-dimethylpentan-3-ol (4.14 g, 5.00 mL, 35.7 mmol, 
11.0 eq.) and Et3N (1.41 g, 1.92 mL, 13.9 mmol, 1.60 eq.) were added dropwise at 0 °C. The 
solution was stirred for 6 h at room temperature and all volatiles were evaporated in HV. 
Purification by column chromatography (SiO2, d × h: 3 × 30 cm, cyclohexane:ethyl acetate 
(80:1)) afforded the product as a colorless liquid (2.09 g, 8.06 mmol, 87%). 
C17H24O2 (260.38 g/mol):  
TLC: Rf = 0.47 (SiO2, cyclohexane:ethyl acetate (50:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.71 (d, 
4
JHH = 1.1 Hz, 1H, C=CH), 7.43-7.37 (m, 4H, 
ar-H), 7.35-7.29 (m, 1H, ar-H), 4.75 (t, 
3
JHH = 6.1 Hz, 1H, OCH(CH(CH3)2)2), 2.14 (d, 
4
JHH = 
1.4 Hz, 3H C=CCH3), 2.03-1.95 (m, 2H, OCH(CH(CH3)2)2), 0.93 (d, 
3
JHH = 6.7 Hz, 12H 
OCH(CH(CH3)2)2). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 168.9 (s, C=O), 138.6 (s, HC=C), 136.2 (s, ar-
qC), 129.9 (s, ar-C), 129.0 (s, HC=C), 128.5 (s, ar-C), 128.4 (s, ar-C), 83.3 (s, 
OCH(CH(CH3)2)2), 29.8 (s, OCH(CH(CH3)2)2), 19.8 (s, OCH(CH(CH3)2)2), 17.6 (s, 
OCH(CH(CH3)2)2), 14.4 (s, CH3). 
IR (ATR): ṽ/cm-1 = 2965 (m), 2935 (w), 2876 (w), 1704 (s), 1636 (w), 1465 (w), 1388 (w), 
1369 (w), 1324 (w), 1248 (s), 1201 (m), 1112 (s), 1002 (w), 952 (m), 906 (w), 763 (w), 702 
(m), 625 (m). 
MS (EI, 70 eV, 200 °C) m/z (%): 260.1 (2), 162.1 (29), 146.1 (12), 117.1 (34), 116.1 (15), 
115.1 (29), 98.1 (19), 91.1 (10), 83.1 (16), 43.1 (10). 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 15 min): 22.90 min. 
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tert-Butyl (E)-2-methyl-3-phenylacrylate 
 
To a solution of (E)-2-methyl-3-phenylacrylic acid (1.50 g 9.26 mmol, 1.00 eq.) in CH2Cl2 
(10 mL) oxalyl chloride (1.54 mL, 1.50 g, 18.0 mmol, 1.90 eq.) and DMF (10 L, 0.04 mmol, 
0.01 eq.) were added at 0 °C and the solution was stirred for 10 min at 0 °C. The solution was 
warmed up to room temperature and stirred overnight. All volatiles were evaporated in HV to 
afford the crude acid chloride which was used without further purification. The acid chloride 
was dissolved in CH2Cl2 (10 mL) and 2,4-dimethylpentan-3-ol (2.64 g, 2.97 mL, 35.7 mmol, 
11.0 eq.) and Et3N (1.41 g, 1.92 mL, 13.9 mmol, 1.60 eq.) were added dropwise at 0 °C. The 
solution was stirred for 6 h at room temperature and all volatiles were evaporated in HV. 
Purification by column chromatography (SiO2, d × h: 3 × 30 cm, cyclohexane:ethyl acetate 
(80:1)) afforded the product as a colorless liquid (305 g, 1.40 mmol, 15%). 
C14H18O2 (218.30 g/mol): 
TLC: Rf = 0.72 (SiO2, cyclohexane:ethyl acetate (50:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.60 (s, 1H, CH=C), 7.38 (d, J = 4.4 Hz, 4H, ar-H), 
7.34-7.27 (m, 1H, ar-H), 2.07 (d, J = 1.4 Hz, 3H, CH3), 1.55 (s, 9H, C(CH3)3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 168.1 (s, CO2), 138.0 (s, CH=C), 136.4 (ar-qC), 
130.4 (s, C=CH), 129.7 (s, ar-C), 128.5 (s, ar-C), 128.2 (s, ar-C), 80.7 (s, OC(CH3)3), 28.3 (s, 
OC(CH3)3), 14.3 (s, CH3). 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 10 min): tR = 18.50 min. 
 
(E)-Isopropyl 2-benzylidenebutanoate (3.14) 
 
To a solution of (E)-2-benzylidenebutanoic acid (750 mg 4.26 mmol, 1.00 eq.), prepared 
according to literature know procedure
[72]
, in CH2Cl2 (5 mL) oxalyl chloride (0.73 mL, 0.71 g, 
8.52 mmol, 2.00 eq.) and DMF (30 L, 0.04 mmol, 0.01 eq.) were added at 0 °C and the 
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solution was stirred for 10 min at 0 °C. The solution was warmed up to room temperature and 
stirred overnight. All volatiles were evaporated in HV. The residue was dissolved in CH2Cl2 
(10 mL) and isopropanol (1.31 mL, 17.0 mmol, 4.00 eq.) and Et3N (0.59 mL, 4.26 mmol, 
1.00 eq.) were added dropwise at 0 °C. The reaction mixture was stirred for 5 h at room 
temperature. H2O (15 mL) was added and the mixture was extracted with CH2Cl2 (3 × 15 mL). 
The combined organic layers were dried over MgSO4. Purification by column 
chromatography (SiO2, d × h: 5 × 16 cm, pentane:Et2O (50:1)) followed by bulb-to-bulb 
distillation afforded the product (190 mg, 0.87 mmol, 20%) as a colorless liquid. 
C14H18O2 (218.30 g/mol):  
BP: 100 °C (0.6 mbar).  
TLC: Rf = 0.42 (SiO2, pentane:Et2O (50:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.63 (s, 1H, C=CH), 7.40–7.36 (m, 4H, ar-H), 7.33-
7.29 (m, 1H, ar-H), 5.16 (sept, 
3
JHH = 6.3 Hz, 1H, OCH(CH3)2), 2.54 (q, 
3
JHH = 7.4 Hz, 2H, 
CH2CH3), 1.33 (d, 
3
JHH = 6.3 Hz, 6H, OCH(CH3)2), 1.18 (t, 
3
JHH = 7.4 Hz, 3H, CH2CH3). 
13
C NMR (101 MHz, CDCl3): ppm = 168.0 (s, COOCH(CH3)2, 138.2 (s, CH=CCO2), 136.1 
(s, ar-C), 135.6 (s, ar-C), 129.3 (s, ar-C), 128.6 (s, ar-C), 128.3 (s, CH=CCO2), 68.2 (s, 
CH(CH3)2), 22.1 (s, CH(CH3)2), 21.0 (s, CH2CH3), 14.1 (s, CH2CH3).  
IR (ATR): ṽ/cm-1 = 3059 (w), 3024 (w), 2978 (m), 2935 (m), 1703 (s), 1632 (m), 1465 (w), 
1446 (w), 1373 (m), 1284 (w), 1236 (s), 1202 (m), 1180 (w), 1132 (m), 1106 (s), 1038 (w), 
966 (w), 928 (w), 766 (w), 700 (m). 
MS (EI, 70 eV, RT) m/z (%): 218.1 (55), 176.1 (49), 175.1 (25), 161.1 (11), 159.2 (56), 158.2 
(41.1), 132.1 (13), 131.1 (100), 130.1 (79), 117.0 (17), 116.0 (16), 115.0 (36), 91 (41), 43 (14).  
EA (C14H18O2) calc.: C 77.03, H 8.31; found: C 76.64, H 8.42. 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min –
250 °C – 15 min): 18.69 min.  
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(E)-tert-Butyl 2,3-diphenylacrylate (3.18) 
 
To a solution of (E)-2,3-diphenylacrylic acid (5.00 mg, 22.3 mmol, 1.00 eq.) in CH2Cl2 
(50 mL) oxalyl chloride (5.62 mg, 3.80 mL, 44.6 mmol, 2.00 eq.) and DMF (50 L) were 
added dropwise at 0 °C. The yellow reaction mixture was stirred for 16 h at room temperature 
and all volatiles were evaporated in HV to afford the acid chloride as a brownish solid which 
was used without further purification. The acid chloride was dissolved in CH2Cl2 (30 mL) and 
tert-butanol (5.53 g, 7.00 mL, 74.6 mmol, 11.1 eq.) and Et3N (3.65 g, 5.00 mL, 36.1 mmol, 
1.60 eq.) were added dropwise at 0 °C. The solution was stirred for 4 h at room temperature 
and all volatiles were evaporated in HV. Purification by column chromatography (SiO2, d × h: 
3 × 20 cm, cyclohexane:ethyl acetate (25:1)) afforded the product as a colorless solid (1.56 g, 
5.57 mmol, 25%). 
C19H20O2 (280.37 g/mol):  
MP: 70-71 °C. 
TLC: Rf = 0.43 (SiO2, cyclohexane:ethyl acetate (20:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.73 (s, 1H, C=CH), 7.37-7.31 (m, 3H, ar-H), 7.22-
7.12 (m, 5H, ar-H), 7.06-7.03 (m, 3H, ar-H), 1.51 (s, 9H, C(CH3)3). 
13
C{
1
H} NMR (100.6 MHz, CDCl3): ppm = 167.2 (s, COO), 139.2 (s, CH=C), 136.5, 135.2, 
134.6, 130.7, 130.0, 128.9, 128.6, 128.3, 127.7, 81.3 (s, OC(CH3)3, 28.3 (s, OC(CH3)3. 
IR (ATR): ṽ/cm-1 = 3057 (w), 2982 (w), 2928 (w), 1699 (s), 1621 (m), 1574 (w), 1493 (w), 
1446 (m), 1366 (m), 1246 (s), 1210 (w), 1149 (s), 1078 (w), 1032 (w), 995 (m), 947 (w), 882 
(w), 846 (w), 761 (m), 713 (m), 691 (s). 
MS (EI, 70 eV, 200 °C) m/z (%): 280.2 (26), 225.1 (16), 224.1 (91), 207.1 (12), 180.1 (18), 
179.1 (100), 178.1 (56), 152.1 (10), 118.1 (23), 57.1 (27). 
EA (C19H20O2): calc. C 81.40, H 7.19; found: C 81.33, H 7.16. 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min –
250 °C – 15 min): 25.90 min.  
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(E)-2,4-Dimethylpentan-3-yl 2,3-diphenylacrylate (3.19) 
 
To a solution of (E)-2,3-diphenylacrylic acid (750 mg, 3.25 mmol, 1.00 eq.) in CH2Cl2 
(20 mL) oxalyl chloride (390 mg, 260 L, 6.50 mmol, 2.00 eq.) and DMF (5 L) were added 
dropwise at 0 °C. The yellow reaction mixture was stirred for 6 h at room temperature and all 
volatiles were evaporated in HV to afford the acid chloride as a brownish solid which was 
used without further purification. The acid chloride was dissolved in CH2Cl2 (5 mL) and 2,4-
dimethylpentan-3-ol (2.90 g, 3.50 mL, 25.0 mmol, 7.70 eq.) and Et3N (548 mg, 750 L, 
5.42 mmol, 1.60 eq.) were added dropwise at 0 °C. The solution was stirred for 6 h at room 
temperature and all volatiles were evaporated in HV. Purification by column chromatography 
(SiO2, d × h: 3 × 30 cm, cyclohexane:ethyl acetate (30:1)) afforded the product as a colorless 
solid (805 mg, 2.50 mmol, 77%). 
C22H26O2 (322.45 g/mol): 
MP: 70-72 °C. 
TLC: Rf = 0.47 (SiO2, cyclohexane:ehtyl acetate (30:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.85 (s, 1H, CH=C), 7.39-7.31 (m, 3H, ar-H), 7.23-
7.06 (m, 7H, ar-H), 4.71 (t, JHH = 6.1 Hz, 1H, OCH(CH(CH3)2)2), 1.93-1.81 (m, 2H, 
OCH(CH(CH3)2)2), 0.89 (d, JHH = 6.8 Hz, 6H, OCH(CH(CH3)2)2), 0.80 (d, JHH = 6.7 Hz, 6H, 
OCH(CH(CH3)2)2). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 168.1 (s, PhCH=CPh-CO2), 140.0 (s, PhCH=C-
CO2), 136.6 (s, ar-qC), 135.0 (s, PhCH=CPh-COO), 133.4 (s, ar-qC), 130.8 (s, arC), 129.8 (s, 
ar-C), 129.1 (s, ar-C), 128.7 (s, ar-C), 128.4 (s, arC), 127.7 (s, ar-C), 83.7 (s, 
OCH(CH(CH3)2)2, 29.7 (s, OCH(CH(CH3)2)2), 19.8 (s, OCH(CH(CH3)2)2), 17.4 (s, 
OCH(CH(CH3)2)2). 
MS (EI, 70 eV, 50 °C) m/z (%): 322.2 (25), 225.1 (14), 224.1 (93), 207.1 (55), 180.1 (14), 
179.1 (100), 178.1 (46). 
EA (C22H26O2): calc. C 81.95, H 8.13; found: C 81.66, H 8.09. 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min –
250 °C – 10 min): tR = 31.65 min. 
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HPLC: Daicel Chiralpak AD-H (0.46 cm × 25 cm, heptane/iso-propanol 99:01, 0.5 mL/min; 
T = 20 °C, 220 nm, tR = 16.1 min. 
 
Isopropyl (E)-2,3-diphenylacrylate (3.17) 
 
To a solution of (E)-2,3-diphenylacrylic acid (500 mg, 2.23 mmol, 1.00 eq.) in CH2Cl2 (5 mL) 
oxalyl chloride (260 mg, 173 L, 4.46 mmol, 2.00 eq.) and DMF (5 L) were added dropwise 
at 0 °C. The yellow reaction mixture was stirred for 16 h at room temperature and all volatiles 
were evaporated in HV to afford the acid chloride as a brownish solid which was used without 
further purification. The acid chloride was dissolved in CH2Cl2 (5 mL) and iso-propanol 
(1.56 g, 2.00 mL, 26.0 mmol, 11.1 eq.) and Et3N (365 mg, 500 L, 3.61 mmol, 1.60 eq.) were 
added dropwise at 0 °C. The solution was stirred for 4 h at room temperature and all volatiles 
were evaporated in HV. Purification by column chromatography (SiO2, d × h: 3 × 20 cm, 
cyclohexane:ethyl acetate (20:1)) afforded the product as a colorless solid (404 mg, 
1.52 mmol, 68%). 
C18H18O2 (266.34 g/mol): 
MP: 65-66 °C. 
TLC: Rf = 0.33 (SiO2, cyclohexane:ethyl acetate (20:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.80 (s, 1H, C=CH), 7.38-7.33 (m, 3H, ar-H), 7.23-
7.13 (m, 5H, ar-H), 7.07-7.03 (m, 2H, ar-H), 5.14 (sept, 
3
JHH = 6.3 Hz, 1H, CH(CH3)2), 1.28 
(d, JHH = 6.3 Hz, 6H, CH(CH3)2). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 167.5, 139.9, 136.2, 135.0, 133.5, 130.7, 130.0, 
129.0, 128.7, 128.3, 127.9, 68.8, 22.1. 
MS (EI, 70 eV, 200 °C) m/z (%): 267.1 (16), 266.1 (80), 224.0 (16), 208.1 (17), 207.0 (12), 
180.1 (19), 179.1 (100), 178.1 (71), 177.1 (10), 176.1 (12), 152.1 (14), 118.1 (23), 107.1 (32), 
43.1 (14). 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min –
250 °C – 15 min): 25.64 min.  
Obtained data are in accordance with literature data.
[139]
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7-Methoxy-4-methyl-2H-chromen-2-one (3.37) 
 
A solution of 7-hydroxy-4-methyl-coumarin (1.00 g, 5.60 mmol, 1.00 eq.) in DMF (12 mL) 
was cooled to 0 °C and NaH (60% in mineral oil, 268 mg, 6.72 mmol, 1.20 eq.) was added in 
small portions. The reaction mixture was stirred for 30 min a room temperature followed by 
cooling to 0 °C. Methyliodide (0.42 mL, 953 mg, 6.72 mmol, 1.20 eq.) was added dropwise 
and the reaction mixture was stirred for 3 h at room temperature. All volatiles were 
evaporated in HV to afford a yellow residue. Purification by column chromatography (SiO2, d 
× h: 6 × 26 cm, cyclohexane:ethyl acetate (10:1→2:1)) afforded the product (1.02 g, 
5.32 mmol, 95%) as a colorless solid. 
C11H10O3 (190.20 g/mol):  
MP:156-157 °C. 
TLC: Rf = 0.15 (SiO2, cyclohexane:ehtyl acetate (7:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.48 (d, J = 8.8 Hz, 1H, ar-H), 6.85 (dd, J = 8.8 Hz, 
J = 2.5 Hz, 1H, ar-H), 6.79 (d, J = 2.5 Hz, 1H, ar-H), 6.11 (s, 1H, C=CH), 3.86 (s, 3H, OCH3), 
2.38 (s, 3H, CH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 162.8, 161.5, 155.5, 152.8, 125.7, 113.7, 112.4, 
112.1, 101.0, 55.9 (s, OCH3), 18.8 (s, CH3).  
MS (EI, 70 eV, 200 °C) m/z (%): 191.0 (10), 190.1 (81), 162.1 (81), 148.1 (10), 147.1 (100), 
91.1 (26), 77.1 (10), 65.1 (17). 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min –
250 °C – 15 min): 28.51 min.  
Obtained data are in accordance with literature data.
[140]
  
 
3-Phenyl-2H-chromen-2-one (3.36) 
 
A mixture of 2-hydroxybenzaldehyde (1.97 mL, 2.69 g, 22.0 mmol, 1.00 eq.), phenyl acetic 
acid (3.00 g, 22.0 mmol, 1.00 eq.), acetic anhydride (6.65 mL, 7.18 g, 70.3 mmol, 3.20 eq.) 
and Et3N (3.89 mL, 2.84 g, 28.1 mmol, 1.28 eq.) was stirred for 6 h at 80 °C. All volatiles 
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were evaporated in HV to afford an orange solid which was dissolved in CH2Cl2 (50 mL) and 
washed with H2O (3 × 30 mL). The organic layer was dried over MgSO4 followed by 
purification by column chromatography (SiO2, d × h: 6 × 30 cm, cyclohexane:ethyl acetate 
(8:1)) to afford the product (570 mg, 2.56 mmol, 12%) as a colorless solid. 
C15H10O2 (222.24 g/mol):  
MP: 134-137 °C. 
TLC: Rf = 0.31 (SiO2, cyclohexane:ethyl acetate (8:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.81 (s, 1H, C=CH), 7.74-7.68 (m, 3H, ar-H), 7.55-
7.51 (m, 2H, ar-H), 7.48-7.34 (m, 4H, ar-H), 7.32-7.28 (m, 1H, ar-H). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 160.8, 153.7, 140.1, 134.9, 131.6, 129.1, 128.7, 
128.7, 128.5, 128.1, 124.7, 119.9, 116.6. 
MS (EI, 70 eV, 200 °C) m/z (%): 223.0 (17), 222.0 (100), 195.1 (12), 194.1 (77), 166.1 (11), 
165.1 (72), 164.1 (11), 139.1 (12), 97.1 (12), 82.1 (20). 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min –
250 °C – 15 min): 36.07 min.  
HPLC: Daicel Chiralcel OD-H (0.46 cm × 25 cm, heptane/iso-propanol = 98:02, 0.5 mL/min; 
T = 20 °C, 208 nm, tR = 35.7 min. 
Obtained data are in accordance with literature data.
[141]
 
 
Isopropyl (2E,4E)-2,4-dimethylhexa-2,4-dienoate (3.49) 
 
To a solution of (2E,4E)-2,4-dimethylhexa-2,4-dienoic acid (300 mg, 2.14 mmol, 1.00 eq.) in 
CH2Cl2 (5 mL), oxalyl chloride (184 μL, 2.14 mmol, 1.00 eq.) and DMF (20 μL) were added 
dropwise in this order at 0 °C. The reaction mixture was stirred for 2 h at room temperature 
and isopropanol (1.3 mL, 21.4 mmol, 10.0 eq.) and triethylamine (600 μL, 4.28 mmol, 
2.00 eq.) were added to the mixture at 0 °C. The reaction mixture was stirred at room 
temperature overnight. H2O (10 mL) was added, the biphasic mixture was extracted with 
CH2Cl2 (3 × 10 mL) and dried over MgSO4. All volatiles were evaporated under reduced 
pressure and purification by a column chromatography (SiO2, d × h: 3.5 × 10 cm, 
pentane:Et2O (20:1)) afforded the product (218 mg, 1.18 mmol, 55%) as a colorless oil. 
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C11H18O2 (182.13 g/mol): 
TLC: Rf = 0.35 (SiO2, pentane:Et2O (20:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.03 (s, 1H, C=CH), 5.64 (q, J = 7.0 Hz, 1H, C=CH), 
4.99 (sept, J = 6.3 Hz, 1H, OCH), 1.92 (s, 3H, CH3), 1.77 (s, 3H, CH3), 1.68 (d, J = 7.0 Hz, 
3H, CH3), 1.20 (d, J = 6.3 Hz, 6H, CH3). 
13
C NMR (101 MHz, CDCl3): ppm = 168.8 (s, C=O), 142.6 (s, C=CH), 133.1 (s, C=CH), 
130.6 (s, C=CH), 125.3 (s, C=CH), 67.7 (s, OCH), 21.9 (s, CH3), 16.0 (s, CH3), 14.0 (s, CH3), 
14.0 (s, CH3). 
IR (ATR): ṽ/cm-1 = 2964 (w), 2934 (w), 1702 (s), 1352 (m), 1245 (s), 1181 (s), 820 (w), 744 
(w). 
MS (EI, 70 eV, 200 °C) m/z (%): 182.1 (6), 140.1 (37), 125-1 (100), 123.1 (18), 95.1 (33), 
79.1 (26), 67.0 (12), 55.0 (10), 43.0 (21), 41.0 (19). 
GC-MS (Restek Rtx-5MS (30 m × 0.25 mm × 0.25 m) 100 kPa He (50 °C – 2 min – 
30 °C/min – 250 °C –5 min): tR = 6.6 min. 
 
2,4-Dimethylpentan-3-yl (2E,4E)-2,4-dimethylhexa-2,4-dienoate (3.51) 
 
To a solution of (2E,4E)-2,4-dimethylhexa-2,4-dienoic acid (300 mg, 2.14 mmol, 1.00 eq.) in 
CH2Cl2 (5 mL), oxalyl chloride (184 μL, 2.14 mmol, 1.00 eq.) and DMF (20 μL) were added 
dropwise in this order at 0 °C. The reaction mixture was stirred for 2 h at room temperature 
and 2,4-dimethylpentan-3-ol (2.27 mL, 21.4 mmol, 10.0 eq.) and triethylamine (600 μL, 
4.28 mmol, 2.00 eq.) were added to the mixture at 0 °C. The reaction mixture was stirred at 
room temperature overnight. H2O (10 mL) was added, the biphasic mixture was extracted 
with CH2Cl2 (3 × 10 mL) and dried over MgSO4. All volatiles were evaporated under reduced 
pressure and purification by a column chromatography (SiO2, d × h: 3.5 × 10 cm, 
pentane:Et2O (100:1)) afforded the product (327 mg, 1.37 mmol, 64%) as a colorless oil. 
C15H26O2 (238.37 g/mol): 
TLC: Rf = 0.25 (SiO2, pentane:Et2O (100:1), UV).  
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.07 (s, 1H, C=CH), 5.66 (q, J = 7.0 Hz, 1H, C=CH), 
4.60 (t, J = 6.1 Hz, 1H, OCH), 1.95 (s, 3H, CH3), 1.93-1.81 (m, 2H, CH(CH(CH3)2)2), 1.78 (s, 
3H, CH3), 1.68 (d, J = 7.0 Hz, 3H, CH3), 0.82 (dd, J = 6.8, 3.2 Hz, 12H, CH3). 
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13
C NMR (101 MHz, CDCl3): ppm = 169.3 (s, C=O), 142.7 (s, C=CH), 133.2 (s, C=CH), 
130.8 (s, C=CH), 125.0 (s, C=CH), 82.6 (s, OCH), 29.6 (s, CH3), 19.6 (s, CH3), 17.3 (s, CH3), 
16.0 (s, CH), 14.1 (s, CH3), 14.0 (s, CH3). 
IR (ATR): ṽ/cm-1 = 2978 (w), 2924 (w), 1700 (s), 1356 (m), 1251 (s), 1143 (s), 828 (w), 704 
(w). 
MS (EI, 70 eV, 200 °C) m/z (%): 238.4 (6), 141.4 (11), 140.4 (90), 125.3 (100), 123.3 (89), 
95.2 (67), 83.2 (15), 79.2 (13), 67.1 (21), 57.1 (28), 55.0 (19), 43.0 (27), 41.0 (24). 
GC-MS (Restek Rtx-5MS (30 m × 0.25 mm × 0.25 m) 100 kPa He (50 °C – 2 min – 
30 °C/min – 250 °C –5 min): tR = 7.9 min. 
 
tert-Butyl (2E,4E)-2,4-dimethylhexa-2,4-dienoate (3.50) 
 
To a solution of (2E,4E)-2,4-dimethylhexa-2,4-dienoic acid (300 mg, 2.14 mmol, 1.00 eq.) in 
CH2Cl2 (5 mL), oxalyl chloride (184 μL, 2.14 mmol, 1.00 eq.) and DMF (20 μL) were added 
dropwise in this order at 0 °C. The reaction mixture was stirred for 2 h at room temperature 
and tert-butanol (1.70 mL, 21.4 mmol, 10.0 eq.) and triethylamine (600 μL, 4.28 mmol, 
2.00 eq.) were added to the mixture at 0 °C. The reaction mixture was stirred overnight at 
room temperature. H2O (10 mL) was added, the biphasic mixture was extracted with CH2Cl2 
(3 × 10 mL) and dried over MgSO4. All volatiles were evaporated under reduced pressure and 
purification by a column chromatography (SiO2, d × h: 3.5 × 10 cm, pentane:Et2O (50:1)) 
afforded the product (145 mg, 739 mol, 35%) as a colorless oil. 
C12H20O2 (196.29 g/mol): 
TLC: Rf = 0.65 (SiO2, pentane:Et2O (30:1), UV).  
1
H NMR
 
(400 MHz, CDCl3): /ppm = 6.96 (s, 1H, C=CH), 5.61 (q, J = 7.0 Hz, 1H, CH), 1.88 
(s, 3H, CH3), 1.76 (s, 3H, CH3), 1.67 (d, J = 7.0 Hz, 3H, CH3), 1.42 (s, 9H, C(CH3)3). 
13
C NMR (101 MHz, CDCl3): ppm = 168.6 (s, C=O), 142.1 (s, C=CH), 133.1 (s, C=CH), 
130.1 (s, C=CH), 126.5 (s, C=CH), 80.0 (s, OC(CH3)3), 28.1 (s, OC(CH3)3), 16.0 (s, CH3), 
14.0 (s, CH3), 14.0 (s, CH3). 
IR (ATR): ṽ/cm-1 = 2977 (w), 2929 (w), 1699 (s), 1330 (m), 1268 (s), 1252 (s), 1119 (s), 822 
(w), 701 (w). 
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MS (EI, 70 eV, 200 °C) m/z (%): 196.3 (6), 140.2 (37), 125.2 (100), 123.2 (19), 95.1 (31), 
79.0 (11), 67.0 (10), 57.0 (30), 41.0 (37). 
GC-MS (Restek Rtx-5MS (30 m × 0.25 mm × 0.25 m) 100 kPa He (50 °C – 2 min – 
30 °C/min – 250 °C –5 min): tR = 6.9 min. 
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8.3.2 Hydrogenation products of α,β-unsaturated carboxylic esters 
 
General procedure: Iridium-catalyzed hydrogenation GP7 
Typical procedure for Ir-catalyzed hydrogenation: Iridium catalyst (1.0 mol%) was added to a 
solution of substrate (0.10 mmol), in CH2Cl2 (0.5 mL). The reaction vial was equipped with a 
magnetic stir bar and placed in an autoclave that was pressurized to 50 bar with H2. The 
reaction mixture was stirred at 800 rpm for the given time, after this time, hydrogen was 
released and the solvent removed under reduced pressure. The mixture was filtered through a 
plug of silica gel (d × h: 0.5 × 2.0 cm) using a mixture of pentane:Et2O (1:1, 5.0 mL). 
Evaporation of the solvent afforded the analytically pure hydrogenation product. 
 
General procedure: Pd(OH)2/C catalyzed hydrogenation GP8 
Typical procedure for Pd(OH)2/C catalyzed hydrogenation: Pd(OH)2/C (15 mg, 20 wt%) was 
added to a solution of substrate (0.20 mmol), in CH2Cl2 (0.8 mL). The reaction vial was 
equipped with a magnetic stir bar and placed in an autoclave that was pressurized to 50 bar 
with H2. The reaction mixture was stirred at 800 rpm for 16 h, after this time, hydrogen was 
released and the reaction mixture was filtered through a syringe filter. Evaporation of the 
solvent afforded the analytically pure hydrogenation product. 
 
Heptyl 2-methyl-3-phenylpropanoate (3.9) 
 
 
The enantiomerically enriched product was obtained as a colorless liquid according to the 
standard hydrogenation protocol GP7 using iridium catalysts. The racemic sample was 
prepared according to general procedure GP8. 
C17H26O2 (262.39 g/mol): 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.31-7.23 (m, 2H, ar-H), 7.23-7.13 (m, 3H, ar-H), 4.02 
(t, 
3
JHH = 6.7 Hz, 2H, OCH2CH2), 3.02 (dd, 
2
JHH = 12.9 Hz, 
3
JHH = 6.5 Hz, 1H, ar-CH2), 2.79-
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2.62 (m, 2H, ar-CH2, ar-CH2CH), 1.61–1.48 (m, 2H, OCH2CH2), 1.35-1.21 (m, 8H, alkyl-H), 
1.15 (d, 
3
JHH = 6.7 Hz, 3H, CHCH3), 0.88 (t, 
3
JHH = 6.5 Hz, 3H, CH2CH3).  
13
C NMR (101 MHz, CDCl3): ppm = 176.4 (s, C=O), 139.6 (s, ar-C), 129.25 (s, ar-C), 
128.5 (s, ar-C), 126.45 (s, ar-C), 64.7 (s, OCH2), 41.7 (s, CH), 40.0 (CH2-ar), 31.9 (s, CH2), 
29.1 (s, CH2), 28. 8 (s, CH2), 26.0 (s, CH2), 22.8 (s, CH2), 17.0 (s, CH3), 14.3 (s, CH3).  
MS (EI, 70 eV, 200 °C) m/z (%): 262.2 (11), 164.2 (22), 119.1 (14), 118.1 (52), 91.0 (100), 
57.0 (16). 
IR (ATR): ṽ/cm-1 = 3028 (w), 2955 (m), 2928 (m), 2856 (m), 1731 (s), 1497 (w), 1454 (m), 
1200 (m), 1163 (s), 1117 (m), 1030 (m), 742 (m), 698 (s), 669 (m). 
EA (C17H26O2): calculated: C 77.82, H 9.99; found: C 77.95, H 9.90.  
GC: (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min –
250 °C – 10 min): tR = 23.56 min.  
HPLC: Daicel Chiralcel OJ (0.46 cm × 25 cm, heptane, 0.5 mL/min; T = 25 °C, 220 nm, tR = 
14.9 min (R) and 16.5 min (S). 
 
Isobutyl 2-methyl-3-phenylpropanoate (3.8) 
 
The enantiomerically enriched product was obtained as a colorless liquid according to the 
standard hydrogenation protocol GP7 using iridium catalysts. The racemic sample was 
prepared according to general procedure GP8. 
C14H20O2 (220.31 g/mol): 
TLC: Rf = 0.47 (SiO2, pentane:Et2O (50:1), UV).  
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.30-7.26 (m, 2H, ar-H), 7.22-7.16 (m, 3H, ar-H), 3.82 
(d, 
3
JHH = 6.6 Hz, 2H, OCH2CH(CH3)2), 3.04 (dd, 
2
JHH = 13.1 Hz, 
3
JHH = 6.8 Hz, 1H, 
arCH2CHCH3), 2.80-2.65 (m, 2H, arCH2CHCH3 and arCH2CHCH3), 1.92-1.82 (m, 1H, 
OCH2CH(CH3)2), 1.17 (t, 
3
JHH = 6.8 Hz, 3H, arCH2CHCH3), 0.88 (d, 
3
JHH = 6.7 Hz, 6H, 
OCH2CH(CH3)2).  
13
C NMR (101 MHz, CDCl3): ppm = 176.3 (s, C=O), 139.6 (s, ar-qC), 129.1 (s, ar-C), 
128.5 (s, ar-C), 126.4 (s, ar-C), 70.6 (s, OCH2CH(CH3)2), 41.8 (s, arCH2CHCH3), 40.0 (s, ar-
CH2), 27.9 (s, OCH2CH(CH3)2), 19.2 (s, OCH2CH(CH3)2), 17.0 (s, arCH2CHCH3).  
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IR (ATR): ṽ/cm-1 = 3028 (w), 2962 (m), 2937 (m), 1732 (s), 1497 (m), 1454 (m), 1394 (w), 
1379 (m), 1367 (m), 1356 (m), 1282 (m), 1202 (m), 1163 (s), 1117 (m), 1089 (m), 1040 (m), 
993 (m), 744 (m), 700 (s), 661 (m). 
MS (EI, 70 eV, RT) m/z (%): 220.2 (12), 164.1 (19), 147.1 (11), 119.1 (17), 118.1 (23), 91.1 
(100).  
EA (C14H20O2): calc.: C 76.33, H 9.15; found: C 76.32, H 9.18. 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 10 min): tR = 29.84 min. 
HPLC: Daicel Chiralpak AD-H (0.46 cm × 25 cm, heptane, 0.5 mL/min, 25 °C, 208 nm): tR 
= 27.9 min (S) and 29.8 min (R). 
 
Ethyl 2-methylpentanoate (3.29) 
 
The enantiomerically enriched product was obtained as a colorless liquid according to the 
standard hydrogenation protocol GP7 using iridium catalysts. The racemic sample was 
prepared according to general procedure GP8. 
C8H16O2 (144.21 g/mol): 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 4.05 (q, J = 7.1 Hz, 2H, OCH2), 2.40-2.31 (m, 1H, 
CH), 1.36-1.21 (m, 4H, 2 × CH2), 1.18 (t, J = 7.1 Hz, 3H, CH3), 1.07 (d, J = 7.0 Hz, 3H, CH3), 
0.83 (t, J = 7.2 Hz, 3H, CH3). 
13
C NMR (101 MHz, CDCl3): ppm = 177.1 (s, C=O), 60.2 (s, OCH2), 39.5 (s, CH), 36.1 (s, 
CH2), 20.5 (s, CH2), 17.2 (s, CH3), 14.4 (s, CH2), 14.1 (s, CH2). 
MS (EI, 70 eV, 200 °C) m/z (%): 115.1 (14), 102.1 (100), 99.1 (26), 87.1 (13), 74.1 (60), 73.1 
(12), 71.1 (61), 55.1 (12). 
GC (Chiraldex -cyclodextrin TFA G-TA (30 m × 0.25 mm × 0.12 m), 60 kPa H2 (30 °C – 
50 min – 10 °C/min – 160 °C – 10 min): tR = 41.0 min (), 43.6 (+) min. 
Compound available from different commercial sources (CAS: 39255-32-8). 
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Isopropyl 2-methylpentanoate (3.30) 
 
The enantiomerically enriched product was obtained as a colorless liquid according to the 
standard hydrogenation protocol GP7 using iridium catalysts. The racemic sample was 
prepared according to general procedure GP8. 
C9H18O2 (158.24 g/mol): 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 4.99 (sept, 
3
JHH = 6.2 Hz, 1H, CO2CH(CH3)2), 2.42-
2.30 (m, 1H, CHCH3), 1.62 (m, 1H, CHCH2), 1.41-1.24 (m, 3H, CHCH2 and CHCH2CH2), 
1.21 (d, 
3
JHH = 6.3 Hz, 6H, CO2CH(CH3)2), 1.10 (d, 
3
JHH = 7.0 Hz, 3H, CHCH3), 0.89 (t, 
3
JHH 
= 7.2 Hz, 3H, CH3CH2).  
13
C NMR (101 MHz, CDCl3): ppm = 176.7 (s, CO2CH(CH3)2), 67.3 (s, CO2CH(CH3)2), 
39.7 (s, CH), 36.2 (s, CH2CH), 22.0 (s, CO2CH(CH3)2), 22.0 (s, CO2CH(CH3)2), 20.6 (s, 
CH3CH2), 17.2 (s, CH3), 14.2 (s, CH3).  
IR (ATR): ṽ/cm-1 = 2975 (m), 2968 (m), 2934 (m), 2875 (w), 1728 (s), 1455 (m), 1374 (m), 
1273 (w), 1253 (w), 1235 (w), 1181 (s), 1152 (m), 1108 (s), 1083 (m), 950 (w), 918 (w), 667 
(s). 
MS (EI, 70 eV, Inlet 150 °C) m/z (%): 117.1 (12), 116.1 (20), 99.1 (25), 74.1 (40), 44.9 (45), 
43.1 (100), 41.0 (17).  
EA (C9H18O2): calc.: C 68.31, H 11.47; found: C 68.18, H 11.26. 
GC (Chiraldex -cyclodextrin TFA G-TA (30 m × 0.25 mm × 0.12 m), 60 kPa H2 (45 °C – 
25 min – 20 °C/min – 160 °C – 5 min): tR = 17.8 min (), 19.2 min (+). 
 
tert-Butyl 2-methylpentanoate (3.31) 
 
The enantiomerically enriched product was obtained as a colorless liquid according to the 
standard hydrogenation protocol GP7 using iridium catalysts. The racemic sample was 
prepared according to general procedure GP8. 
C10H20O2 (172.27 g/mol): 
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1
H NMR
 
(400 MHz, CDCl3): /ppm = 2.41-2.23 (m, 1H, CHCH3), 1.71-1.51 (m, 1H, 
CH2CH2CH3), 1.44 (s, 9H, CO2C(CH3)3), 1.39-1.23 (m, 3H, CH2CH2CH3 and CH2CH2CH3), 
1.09 (d, 
3
JHH = 7.0 Hz, 3H, CHCH3), 0.90 (t, 
3
JHH = 7.1 Hz, 3H, CH2CH2CH3).  
13
C NMR (101 MHz, CDCl3): /ppm = 176.6 (s, C=O), 79.9 (s, CO2C(CH3)3), 40.5 (s, CH), 
36.3 (s, CH2CH2CH3), 28.3 (s, CO2C(CH3)3), 20.6 (s, CH2CH2CH3), 17.4 (s, CH3), 14.3 (s, 
CH3). 
IR (ATR): ṽ/cm-1 = 2964 (m), 2908 (w), 2867 (m), 1728 (s), 1455 (m), 1391 (w), 1366 (m), 
1255 (m), 1143 (s), 1084 (m), 849 (m). 
MS (EI, 70 eV, Inlet 150 °C) m/z (%): 99.1 (18) [M-O(t-Bu)]
+
, 71.1 (26) [M-CO2(t-Bu]
+
, 57.1 
(100), 43.1 (11), 41.0 (17).  
EA (C10H20O2): calc.: C 69.72, H 11.70; found: C 69.77, H 11.49. 
GC (Chiraldex -cyclodextrin TFA G-TA (30 m × 0.25 mm × 0.12 m), 60 kPa H2 (45 °C – 
25 min – 20 °C/min – 160 °C – 5 min), tR = 16.8 min (+), 17.7 min (). 
 
Isopropyl 2-benzylbutanoate (3.15) 
 
The enantiomerically enriched product was obtained as a colorless liquid according to the 
standard hydrogenation protocol GP7 using iridium catalysts. The racemic sample was 
prepared according to procedure GP8. 
C14H20O2 (220.31 g/mol): 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.29-7.24 (m, 2H, ar-H), 7.20-7.16 (m, 3H, ar-H), 4.95 
(sept, 
3
JHH = 6.3 Hz, 1H, OCH(CH3)2), 2.90 (dd, 
2
JHH = 13.6 Hz, 
3
JHH = 8.7 Hz, 1H, ar-CH2), 
2.74 (dd, 
2
JHH = 13.6 Hz, 
3
JHH = 6.6 Hz, 1H, ar-CH2), 2.57-2.51 (m, 1H, CHCH2), 1.72-1.49 
(m, 2H, CHCH2), 1.17 (d, 
3
JHH = 6.3 Hz, 3H, OCH(CH3), 1.06 (d, 
3
JHH = 6.3 Hz, 3H, 
OCH(CH3), 0.92 (t, 
3
JHH = 7.4 Hz, 3H, CH2CH3).  
13
C NMR (101 MHz, CDCl3): ppm = 175.3 (s, C=O), 139.8 (s, ar-qC), 129.2 (s, ar-C), 
128.5 (s, ar-C), 126.4 (s, ar-C), 67.5 (s, OCH(CH3)2, 49.6 (s, CHCO), 38.5 (s, ar-CH2), 25.5 (s, 
CH2CH3), 22.1 (s, CH(CH3)2), 21.9 (s, CH(CH3)2), 11.9 (s, CH2CH3).  
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IR (ATR): ṽ/cm-1 = 3031 (w), 2968 (m), 2933 (m), 2876 (w), 1726 (s), 1494 (m), 1454 (m), 
1410 (m), 1371 (m), 1231 (w), 1200 (m), 1165 (m), 1143 (m), 1107 (s), 1074 (m), 1024 (w), 
1011 (m), 970 (m), 959 (m), 827 (m), 698 (s). 
MS (EI, 70 eV, RT) m/z (%): 220.1 (11), 178.1 (22), 133.1 (16), 132.1 (17), 131.1 (10), 92 
(11), 91 (100).  
EA (C14H20O2): calc.: C 76.33, H 9.15; found: C 75.98, H 9.20. 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 10 min): tR = 16.66 min. 
HPLC: Daicel Chiralcel OJ (0.46 cm × 25 cm, heptane, 0.5 mL/min, 25 °C, 208 nm): tR = 
15.6 min (), tR = 18.1 min (+). 
 
Isopropyl 2,3-diphenylpropanoate (3.21) 
 
The enantiomerically enriched product was obtained as a colorless liquid according to the 
standard hydrogenation protocol GP7 using iridium catalysts. The racemic sample was 
prepared according to general procedure GP8. 
C18H20O2 (268.36 g/mol): 
TLC: Rf = 0.50 (SiO2, pentane:Et2O (20:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.27–7.19 (m, 4H, ar-H), 7.19–7.12 (m, 3H, ar-H), 
7.11–7.03 (m, 3H, ar-H), 4.84 (sept, 3JHH = 6.3 Hz, 1H, OCH(CH3)2), 3.73 (dd, 
3
JHH = 9.2 Hz, 
3
JHH = 6.4 Hz, 1H, ar-CH), 3.31 (dd, 
2
JHH = 13.7 Hz, 
3
JHH = 9.3 Hz, 1H, ar-CH2), 2.93 (dd, 
2
JHH = 13.7 Hz, 
3
JHH = 6.4 Hz, 1H, ar-CH2), 0.99 (d, 
3
JHH = 6.3 Hz, 6H, CH(CH3)2).  
13
C NMR (101 MHz, CDCl3): /ppm = 173.0 (s, C=O), 139.3 (s, ar-C), 139.1 (s, ar-C), 129.2 
(s, ar-C), 128.7 (s, ar-C), 128.4 (s, ar-C), 128.1 (s, ar-C), 127.4 (s, ar-C), 126.5 (s, ar-C), 68.2 
(s, OCH(CH3)2), 54.0 (s, CH), 40.1 (s, CH2), 21.8 (s, OCH(CH3)2), 21.7 (s, OCH(CH3)2).  
IR (ATR): ṽ/cm-1 = 3028 (w), 2978 (w), 2965 (w), 2928 (w), 1724 (s), 1601 (w), 1495 (m), 
1453 (m), 1372 (m), 1212 (m), 1162 (m), 1104 (s), 1071 (m), 1030 (m), 745 (m), 696 (s). 
MS (EI, 70 eV, RT) m/z (%): 268.2 (23), 182.1 (11), 181.1 (76), 180.1 (10), 166.3 (13), 165.2 
(11), 103.1 (17), 91.1 (100), 77.1 (10), 43.1 (10).  
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EA (C18H20O2): calc.: C 80.56, H 7.51; found: C 80.41, H 7.76.  
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 10 min): tR = 24.49 min.  
HPLC: Daicel, Chiralpak IC (0.46 cm × 25 cm, heptane/iso-propanol = 98:02, 0.5 mL/min, 
25 °C, 220 nm): tR = 9.42 min (+) and 9.98 min (). 
 
tert-Butyl 2,3-diphenylpropanoate (3.22) 
 
 
The enantiomerically enriched product was obtained as a colorless solid according to the 
standard hydrogenation protocol GP7 using iridium catalysts. The racemic sample was 
prepared according to general procedure GP8. 
C19H22O2 (282.38 g/mol): 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.35-7.28 (m, 4H, ar-H), 7.28-7.22 (m, 3H, ar-H), 
7.20-7.13 (m, 3H, ar-H), 3.77 (ddd, J = 9.3, 6.4, 1.0 Hz, 1H, CH), 3.36 (dd, J = 13.7, 9.2 Hz, 
1H), 2.99 (dd, J = 13.7, 6.4 Hz, 1H, CH2), 1.32 (s, 9H, C(CH3)3). 
13
C NMR (101 MHz, CDCl3): /ppm = 172.7 (s, C=O), 139.5 (s, ar-qC), 139.4 (s, ar-qC), 
129.2 (s, ar-C), 128.6 (s, ar-C), 128.3 (s, ar-C), 128.0 (s, ar-C), 127.2 (s, ar-C), 126.4 (s, ar-C), 
80.9 (s, OC(CH3)3
)
, 54.6 (s, CH), 40.1 (s, CH2), 28.0 (s, CH3). 
IR (ATR): ṽ/cm-1 = 3031 (w), 2980 (w), 2928 (w), 2852 (w), 1716 (s), 1599 (w), 1494 (w), 
1454 (m), 1391 (m), 1367 (m), 1347 (m), 1235 (m), 1146 (s), 1079 (w), 843 (m), 745 (s), 697 
(s), 547 (s). 
MS (EI, 70 eV, RT) m/z (%): 282.2 (1), 227.1 (8), 226.1 (48), 182.1 (13), 181.1 (60), 166.1 
(12), 165.1 (11), 103.1 (17), 91.1 (50), 77.1 (13), 57.1 (100), 41.1 (19). 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 15 min): tR = 24.51 min.  
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2,4-Dimethylpentan-3-yl 2-methyl-3-phenylpropanoate 
 
The enantiomerically enriched product was obtained as a colorless liquid according to the 
standard hydrogenation protocol GP7 using iridium catalysts. The racemic sample was 
prepared according to general procedure GP8. 
C17H26O2 (262.39 g/mol): 
TLC: Rf = 0.44 (SiO2, cyclohexane:ethyl acetate (50:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.36-7.29 (m, 2H, ar-H), 7.28-7.21 (m, 2H, ar-H), 4.62 
(t, J = 6.1 Hz, 1H, CH(CH)2), 3.14 (dd, J = 13.5, 7.0 Hz, 1H, C6H5CH2), 2.89-2.80 (m, 1H, 
CH(CH)2), 2.70 (dd, J = 13.5, 8.0 Hz, 1H, C6H5CH2), 1.98-1.82 (m, 2H, CH(CH)2), 1.24 (d, J 
= 7.0 Hz, 3H, CHCH3), 0.90 (dd, J = 9.4, 6.8 Hz, 6H, CH(CH(CH3)2)2), 0.80 (dd, J = 10.8, 
6.8 Hz, 6H, CH(CH(CH3)2)2). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 176.2 (s, CO2), 139.7 (s, ar-C), 129.2 (s, ar-C), 
128.4 (s, ar-C), 126.3 (s, ar-C), 82.5 (s, CH(CH)2), 42.0 (s, CHCH2), 39 (s, CH2), 29.5 
CH(CH)2, 29.5 (s, CH(CH)2), 19.7 (s, CH3), 19.5 (s, CH3), 17.5 (s, CH3), 17.3 (s, CH3), 17.2 
(s, CH3). 
IR (ATR): ṽ/cm-1 = 3029 (w), 2967 (m), 2935 (m), 2877 (w), 1731 (s), 1496 (w), 1463 (m), 
1371 (m), 1339 (w), 1278 (w), 1249 (w), 1209 (m), 1168 (s), 1131 (m), 1098 (m), 1031 (m), 
999 (w), 964 (w), 902 (w), 774 (m), 699 (m). 
MS (EI, 70 eV, 200 °C) m/z (%): 164.1 (38), 147.1 (53), 119.1 (72), 118.1 (15), 99.1 (18), 
98.1 (19), 91.1 (100), 83.1 (12), 57.1 (73), 43.1 (17). 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 15 min): tR = 21.24 min.  
 
tert-Butyl 2-methyl-3-phenylpropanoate 
 
The enantiomerically enriched product was obtained as a colorless liquid according to the 
standard hydrogenation protocol GP7 using iridium catalysts. The racemic sample was 
prepared according to general procedure GP8. 
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C14H20O2 (220.31 g/mol): 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.31-7.23 (m, 2H, ar-H), 7.24-7.15 (m, 3H, ar-H), 
3.03-2.88 (m, 1H, CH), 2.66-2.56 (m, 2H, CH2), 1.38 (s, 9H, C(CH3)3), 1.12 (d, J = 6.5 Hz, 
3H, CH3). 
13
C NMR (101 MHz, CDCl3): ppm = 175.7 (s, C=O), 139.9 (s, ar-qC), 129.3 (s, ar-C), 
128.4 (s, ar-C), 126.3 (s, ar-C), 80.2 (s, OC(CH3)3), 42.5 (s, CH), 40.0 (s, CH2), 28.2 (s, 
OC(CH3)3), 17.2 (s, CH3). 
Obtained data are in accordance with literature data.
[142]
 
 
2,4-Dimethylpentan-3-yl 2,3-diphenylpropanoate (3.23) 
 
The enantiomerically enriched product was obtained as a colorless liquid according to the 
standard hydrogenation protocol GP7 using iridium catalysts. The racemic sample was 
prepared according to general procedure GP8. 
C22H28O2 (324.46 g/mol): 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.40-7.11 (m, 10H, ar-H), 4.49 (t, J = 6.1 Hz, 1H, 
CO2CH), 3.89 (dd, J = 9.2, 6.3 Hz, 1H, CH2), 3.46 (dd, J = 13.7, 9.3 Hz, 1H, CH2), 3.04 (dd, J 
= 13.7, 6.3 Hz, 1H, CH), 1.83-1.66 (m, J = 6.4 Hz, 2H, OC((CH)2CH3)2)2)), 0.66 (d, J = 
6.8 Hz, 3H, OC((CH)2CH3)2)2)), 0.65-0.54 (m, 9H, OC((CH)2CH3)2)2)). 
13
C NMR (101 MHz, CDCl3): ppm = 173.5 (s, CO2), 139.5 (s, ar-C), 139.3 (s, ar-C), 129.3 
(s, ar-C), 128.7 (s, ar-C), 128.5 (s, ar-C), 128.3 (s, ar-C), 127.5 (s, ar-C), 126.5 (s, ar-C), 83.2 
(s, OC((CH)2CH3)2)2), 54.1 (s, CH), 39.6 (s, CH2), 29.4 (s, CH), 29.1 (s, CH), 19.2 (s, CH3), 
19.3 (s, CH3), 17.4 (s, CH3), 16.9 (s, CH3). 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 10 min): tR = 29.84 min. 
HPLC: Daicel Chiralpak AD-H (0.46 cm × 25 cm, heptane/iso-propanol = 99:01, 0.5 mL/min; 
T = 20 °C, 208 nm, tR = 12.6 min and 13.9 min. 
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3-Phenylchroman-2-one 
 
The enantiomerically enriched product was obtained as a colorless liquid according to the 
standard hydrogenation protocol GP10 using iridium catalysts. The racemic sample was 
prepared according to general procedure GP8. 
C15H12O2 (224.26 g/mol): 
MP: 115-116 °C. 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.24-7.41 (m, 6H, ar-H), 7.20-7.26 (m, 1H, ar-H), 
7.09-7.18 (m, 2H, ar-H), 4.01 (dd, J = 11.2, 6.2 Hz, 1H, CH), 3.38 (dd, J = 15.6, 11.2 Hz, 1H, 
CH2), 3.25 (dd, J = 15.6, 6.2 Hz, 1H, CH2).  
13
C NMR (125 MHz, CDCl3): /ppm = 151.7 (s, CO2), 136.5 (s, ar-C), 128.9 (s, ar-C), 128.6 
(s, ar-C), 128.2 (s, ar-C), 128.0 (s, ar-C), 127.8 (s, ar-C), 124.6 (s, ar-C), 122.6 (s, ar-C), 116.8 
(s, ar-C), 45.6 (s, CH), 31.8 (s, CH2). 
MS (EI, 70 eV, 200 °C) m/z (%): 225.1 (17), 224.1 (100), 197.1 (14), 196.1 (93), 195.1 (62), 
181.1 (17), 179.1 (19), 178.1 (14), 177.1 (12), 167.1 (27), 165.1 (22), 152.1 (19), 118.1 (28), 
90.1 (23), 89.1 (26), 77.1 (12), 63.1 (10), 51.0 (11). 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 15 min): 29.94 min.  
HPLC: Daicel Chiralcel OD-H (0.46 cm × 25 cm, heptane/iso-propanol = 98:02, 0.5 mL/min; 
T = 20 °C, 208 nm, tR = 49.1 min and 57.7 min. 
Obtained data are in accordance with literature data.
[141]
 
 
7-Methoxy-4-methylchroman-2-one 
 
The enantiomerically enriched product was obtained as a colorless liquid according to the 
standard hydrogenation protocol GP10 using iridium catalysts. The racemic sample was 
prepared according to general procedure GP8. 
C11H12O3 (192.21 g/mol): 
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1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.10 (d, J = 8.4 Hz, 1H, ar-H), 6.66 (dd, J = 8.4, 
2.4 Hz, 1H, ar-H), 6.60 (d, J = 2.4 Hz, 1H, ar-H), 3.77 (s, 3H, OCH3), 3.16-3.05 (m, 1H, CH), 
2.81 (dd, J = 15.8, 5.3 Hz, 1H), 2.53 (dd, J = 15.8, 7.5 Hz, 1H, CH2), 1.29 (d, J = 7.0 Hz, 3H, 
CH3).  
13
C NMR (101 MHz, CDCl3): ppm = 168.1, 159.1, 151.6, 127.4, 120.1, 110.3, 102.1, 55.4, 
36.3, 27.9, 19.9. 
MS (EI, 70 eV, 200 °C) m/z (%): 192.1 (49), 178.1 (12), 177.1 (100), 150.1 (22), 149.1 (10), 
133.1 (18), 121.1 (24), 91.1 (10), 77.1 (14). 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 15 min): 22.98 min.  
HPLC: Daicel Chiralcel OD-H (0.46 cm × 25 cm, heptane/iso-propanol = 97:03, 0.5 mL/min; 
T = 25 °C, 208 nm, tR = 19.9 min and 23.9 min. 
Obtained data are in accordance with literature data.
[143]
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8.4 Hydrogenation of vitamin E side chain precursors 
 
8.4.1 Derivatization for the analysis of the hydrogenation products 
 
()-D-Diisopropyl-tartrade-acetal (D-4.18) and (+)-L-diisopropyl-tartrade-acetal (L-4.18) 
 
Both acetals were synthesized in accordance to literature-known procedures, by the use of 
trimethylsilyl triflate.
[88]
  
GC (CP-Sil 88 (50 m × 0.25 mm × 0.25 m) 90 kPa H2 (163 °C – 160 min – 5 °C/min – 
180 °C – 10 min): L-acetal tR = 148.5 min (3S,7R), 150.5 min [(3R,7S) + (3S,7S)], 154.5 min 
(3R,7R); D-acetal: tR = 148.5 min (3R,7S), 150.5 min [(3S,7R) + (3R,7R)], 154.5 min (3S,7S). 
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8.5 Hydrogenation of vinylbromides and chlorides 
 
8.5.1 Synthesis of vinyl bromides and chlorides 
 
4-Phenyl-2-bromobut-1-ene (5.8) 
 
4-Phenyl-1-butyne (1.80 g, 1.94 mL, 13.8 mmol, 1.00 eq.) was added dropwise to a 1 M 
solution of boron tribromide (6.91 mL, 6.91 mmol, 0.50 eq.) in CH2Cl2 at ‒78 °C. The 
solution was allowed to warm to room temperature over a period of 3 h. Glacial acetic acid 
(19.0 mL) was added to the reaction mixture and stirred for 1 h. The mixture was quenched 
with water (10 mL), extracted with pentane (3 × 20 mL) and the combined organic layers 
were washed with sat. NaHCO3 solution (~4 × 15 mL) until the pH of the water phase stays 
basic followed by water (15 mL) and brine (15 mL). After drying over MgSO4, the solvent 
was removed under reduced pressure. The crude product as diluted with pentane (1 mL) and 
purified over a plug of silica (d × h: 3 × 4 cm), followed by elution with pentane (300 mL). 
The solvent was removed under reduced pressure to obtain the crude vinylbromide as pale 
yellow liquid. The crude was purified by bulb-to-bulb distillation (20 mbar, 90 °C) to obtain 
the vinylbromide as pale yellow liquid which was filtered over a plug of silica (d × h: 3 × 
4 cm), followed by elution with pentane (300 mL). The solvent was removed under reduced 
pressure to obtain 4-phenyl-2-bromobut-1-ene (1.90 g, 9.00 mmol, 65%) as a colorless liquid 
in 95% purity. Final purification by semipreparative HPLC (OD-H, hexane, 8.0 mL/min, 
25 °C) afforded 4-phenyl-2-bromobut-1-ene (75% recovery) as a colorless liquid; purity 
>99.5% 
C10H11Br (211.10 g/mol):  
TLC: Rf = 0.56 (SiO2, pentane:Et2O (100:1), KMnO4). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.36-7.26 (m, 2H, ar-H), 7.25-7.20 (m, 3H, ar-H), 
5.56-5.50 (m, 1H, C=CH2), 5.41 (d, J = 1.7 Hz, 1H, C=CH2), 2.90 (dd, J = 8.8, 6.5 Hz, 2H, 
CH2), 2.77-2.71 (m, 2H, CH2). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 140.5 (s, ar-qC), 133.7 (s, C=CH2), 128.6 (s, ar-
C), 128.5 (s, ar-C), 126.3 (s, ar-C), 117.3 (s, C=CH2), 43.4 (s, CH2), 34.5 (s, CH2). 
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IR (ATR): ṽ/cm-1 = 3062 (w), 3027 (w), 2929 (w), 2859 (w), 1628 (m), 1496 (w), 1454 (m), 
1185 (m), 1115 (m), 1073 (m), 1030 (m), 886 (m), 838 (w), 748 (m), 698 (s), 628 (s). 
MS (EI, 70 eV, 200 °C) m/z (%): 212.0 (1), 210.0 (1), 131.1 (47), 91.1 (100), 65.1 (10). 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 10 min): tR = 13.52 min.  
HPLC: Daicel, Chiralcel OJ (0.46 cm × 25 cm, heptane, 0.3 mL/min, 25 °C, 217 nm): tR = 
28.9 min. 
Semipreparative HPLC: Daicel, Chiralcel OD (2 cm × 25 cm, heptane, 8.0 mL/min, 
208 nm): 16.8 min, 24.8 min (impurity). 
Obtained data are in accordance with literature data.
[144]
 
 
1-((2-Chloroallyl)oxy)-4-methoxybenzene (5.27) 
 
A 2-necked flasked equipped with a reflux condenser and a two-tap Schlenk adapter 
connected to a bubbler and an argon/vacuum manifold was charged with anhydrous potassium 
carbonate (4.98 g, 36.0 mmol, 2.00 eq.) and 4-methoxyphenol (2.28 g, 18.0 mmol, 1.00 eq.). 
The apparatus was flushed for 5 min with argon and acetone (75 mL) followed by 2,3-
dichloroprop-1-ene (3.00 g, 2.49 mL, 27.0 mmol, 1.50 eq.) were added. The reaction mixture 
was stirred for 18 h at reflux and potassium carbonate was filtered off. Evaporation of the 
solvent and purification by column chromatography (SiO2, d × h: 2 × 19 cm, pentane:Et2O 
(50:1)) afforded the product (2.26 g, 11.4 mmol, 63%) as a colorless liquid. 
C10H11ClO2 (198.65 g/mol):  
TLC: Rf = 0.43 (SiO2, pentane:Et2O (50:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 6.91-6.81 (m, 4H, ar-H), 5.55 (q, J = 1.6 Hz, 1H, 
C=CH2), 5.43 (q, J = 1.3 Hz, 1H, C=CH2), 4.54 (t, J = 1.3 Hz, 2H, CH2), 3.78 (s, 3H, OCH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 154.6 (s, ar-qC), 152.1 (s, ar-qC), 136.8 (s, 
C=CH2), 116.2 (s, ar-C), 114.8 (s, ar-C), 113.7 (s, C=CH2), 71.2 (s, OCH2), 55.8 (s, OCH3). 
IR (ATR): ṽ/cm-1 = 3001 (w), 2934 (w), 2835 (w), 1639 (w), 1507 (s), 1458 (w), 1389 (w), 
1229 (m), 1181 (w), 1108 (w), 1051 (m), 892 (w), 824 (m), 766 (w), 728 (w), 632 (s). 
MS (EI, 70 eV, 200 °C) m/z (%): 200.0 (5), 198.0 (15), 123.1 (100), 95.0 (13). 
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GC-MS (Restek Rtx-5MS (30 m × 0.25 mm × 0.25 m) 100 kPa He (50 °C – 2 min – 
30 °C/min – 250 °C –5 min): tR = 6.91 min (5.27+H2-Cl), 7.69 min (5.27), 8.18 min 
(5.27+H2). 
 
1-((2-Bromoallyl)oxy)-4-methoxybenzene (5.26) 
 
A 2-necked flasked equipped with a reflux condenser and a two-tap Schlenk adapter 
connected to a bubbler and an argon/vacuum manifold was charged with anhydrous potassium 
carbonate (4.98 g, 36.0 mmol, 2.00 eq.) and 4-methoxyphenol (2.28 g, 18.0 mmol, 1.00 eq.). 
The apparatus was flushed for 5 min with argon and acetone (75 mL) followed by 2,3-
dichloroprop-1-ene (6.75 g, 3.31 mL, 27.0 mmol, 1.50 eq.) were added. The reaction mixture 
was stirred for 16 h at reflux and potassium carbonate was filtered off. Evaporation of the 
solvent and purification by column chromatography (SiO2, d × h: 3 × 20 cm, pentane:Et2O 
(90:1)) afforded the product (3.27 g, 13.5 mmol, 75%) as a colorless liquid. 
C10H11BrO2 (243.10 g/mol):  
TLC: Rf = 0.24 (SiO2, pentane:Et2O (100:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 6.96-6.73 (m, 4H, ar-H), 5.99 (q, J = 1.8 Hz, 1H, 
C=CH2), 5.67 (dt, J = 2.3, 1.3 Hz, 1H, C=CH2), 4.60 (t, J = 1.5 Hz, 2H, CH2), 3.77 (s, 3H, 
OCH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 154.5 (s, ar-qC), 152.0 (s, ar-qC), 127.7 (s, 
C=CH2), 117.8 (s, C=CH2), 116.2, 114.8, 72.7 (OCH2), 55.8 (s, OCH3). 
MS (EI, 70 eV, 200 °C) m/z (%): 244.0 (10), 242.0 (11), 124.1 (10), 123.1 (100), 95.1 (15). 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 10 min): tR = 13.55 min. 
GC-MS (Restek Rtx-5MS (30 m × 0.25 mm × 0.25 m) 100 kPa He (50 °C – 2 min – 
30 °C/min – 250 °C –5 min): tR = 6.93 min (5.26+H2-Br), 8.15 min (5.26), 8.62 (5.26+H2). 
Obtained data are in accordance with literature data.
[145]
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(E)-1-(2-Bromoprop-1-en-1-yl)-4-methoxybenzene ((E)-5.29), (Z)-1-(2-bromoprop-1-en-
1-yl)-4-methoxybenzene ((Z)-5.30), 1-(2-bromoallyl)-4-methoxybenzene (5.31) 
 
A solution of triphenyl phosphite (3.00 g, 2.53 mL, 9.38 mmol, 1.00 eq.) in CH2Cl2 (25 mL) 
was cooled to 60 °C and bromine (1.63 g, 526 L, 10.2 mmol, 1.20 eq.) was added dropwise. 
Triethylamine (1.12 g, 1.56 mL, 11.1 mmol, 1.18 eq.) and 4-methoxyphenylacetone (1.40 g, 
1.31 mL, 8.53 mmol) were added to the pale orange solution. The reaction mixture was stirred 
for 18 h, while warming to room temperature, and stirred for further 2 h at reflux. All volatiles 
were evaporated under reduced pressure. The residue was filtered over a plug of silica (d × h: 
3 × 5 cm, pentane:Et2O (90:1)) to afford a mixture of E, Z and terminal vinyl bromide (1.35 g, 
5.94 mmol, 63%). The mixture of isomers was purified by semipreparative HPLC (OD-H, 
hexane, 8.0 mL/min, 25 °C) to afford the pure (E)-isomer and the terminal and the (Z)-isomer 
as a mixture. 
C10H11BrO (227.10 g/mol):  
1
H NMR
 
(400 MHz, CDCl3): 7.53 (d, J = 8.8 Hz, 2H, ar-H), 6.89 (d, J = 8.9 Hz, 2H, ar-H), 
6.66 (s, 1H, C=CH), 3.82 (s, 3H, OCH3), 2.47 (d, J = 1.4 Hz, 3H, CH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 159.0 (s, ar-qC), 130.2 (s, ar-C), 128.8 (s, ar-qC), 
127.5 (s, C=CH), 120.3 (s, C=CH), 113.6 (s, ar-C), 55.4 (s, OCH3), 30.8 (s, CH3). 
Semipreparative HPLC: Daicel, Chiralcel OD (2 cm × 25 cm, heptane, 8 mL/min, 220 nm): 
28.5 min (Z), 32.5 min (terminal), 39.5 min (E). 
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8.5.2 Hydrogenation products of vinyl bromides and chlorides 
(3-Bromobutyl)benzene (5.9) 
 
The enantiomerically enriched product was obtained as a colorless liquid according to the 
standard hydrogenation protocol GP7 using iridium catalysts. The racemic sample was 
prepared according to general procedure GP7 by the use of racemic catalyst 5.11. 
C10H13Br (213.13 g/mol):  
1
H NMR
 
(400 MHz, CDCl3): 7.37-7.24 (m, 5H, ar-H), 4.11 (m, 1H, CHBr), 2.89-275 (m, 2H, 
CH2Ph), 2.20-2.10 (m, 2H, CH2CH), 1.75 (d, J = 10.5 Hz, 3H, CH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): 140.8 (s, ar-C), 128.4 (s, ar-C), 128.5 (s, ar-C), 126.0 (s, 
ar-C), 50.8 (s, CHBr), 42.6 (s, CH2CH), 33.9 (s, CH2Ph), 26.5 (s, CH3) 
HPLC: Daicel, Chiralcel OJ (0.46 cm × 25 cm, heptane, 0.3 mL/min, 25 °C, 217 nm): tR = 
28.9 min, 33.4 min (overlay with substrate). 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 10 min): tR = 14.56 min, 7.61 min (5.9-Br). 
Obtained data are in accordance with literature data.
[146]
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8.6 Hydrogenation of α,β-unsaturated nitriles 
 
8.6.1 Synthesis of catalyst and characterization of intermediates 
 
Iridium tert-butyl PHOX para-nitro phenolate complex (6.106) 
 
A flame dried Schlenk flask was charged with [Ir(COD)Cl]2 (52.0 mg, 77.4 mmol, 0.50 eq.), 
sodium 2,6-di(tert-butyl)-4-nitrophenolate (46.6 mg, 170 mol, 1.10 eq.), (S)-4-tert-butyl-2-
[2-(diphenylphosphino)phenyl]-2-oxazoline (60.0 mg, 155 mol, 1.00 eq.) and CH2Cl2 (2 mL) 
was added. The reaction mixture was stirred for 4 h at room temperature. The solution was 
filtered through a plug of celite (d × h: 0.5 × 1 cm), eluted with CH2Cl2 (5 mL) and all 
volatiles were evaporated in HV. The residue was washed with Et2O (3 × 3 mL) to afford the 
product (121 mg, 129 mol, 83%) as a red solid. 
C47H58BF24IrN2O4P (938.18 g/mol):  
MP: 147-152 °C. 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 8.24-8.20 (m, 1H, ar-H), 7.95 (s, 2H, ar-H), 7.71-7.67 
(m, 1H, ar-H), 7.63-7.58 (m 1H, ar-H), 7.56-7.40 (m, 8H, ar-H), 7.29-7.25 (m, 1H, ar-H), 7.04 
(s, 2H, ar-H), 5.11 (s br, 1H, COD), 4.95 (s, br, 1H, COD), 4.58-4.55 (m, 2H, oxazoline), 
4.04-3.99 (m, 1H, oxazoline), 3.42-3.39 (m, 1H, oxazoline), 2.95 (s br, 1 H, COD), 2.55-2.37 
(m, 4H, COD), 2.04-1.92 (m, 2H, COD), 1.65-1.55 (m, 1H, COD), 1.44-1.35 (s br, 1H, COD), 
1.35 (s, 18H, 2 × C(CH3)3), 0.62 (s, 9H, C(CH3)3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 181.0 (s, ar-C counterion), 164.1, 164.1, 139.0 (s, 
ar-C counterion), 134.8, 134.8, 134.4, 134.4, 134.3, 134.2, 134.2, 133.4, 133.3, 132.8, 132.8, 
132.6, 132.6, 132.0, 132.0, 130.2, 129.8, 129.7, 129.5, 129.4, 128.9, 128.8, 127.7, 127.2, 
126.9, 123.1 (s, ar-C counterion), 123.0, 122.4, 98.9, 98.8, 94.0, 93.9, 77.4, 74.5, 70.4, 63.0, 
62.2, 37.0, 35.2, 34.5, 32.9, 29.9 (s, C(CH3)3, 28.3, 27.0, 25.8, 25.4. 
31
P{
1
H} NMR (162 MHz, CDCl3): ppm = 16.6 (s). 
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IR (ATR): ṽ/cm-1 = 3059 (w), 2948 (w), 2898 (w), 1589 (m), 1533 (w), 1481 (m), 1435 (w), 
1369 (m), 1239 (s), 1194 (m), 1135 (m), 1016 (w), 968 (w), 920 (m), 810 (w), 743 (m), 697 
(m). 
MS (ESI (+), 50 V, 200 °C, CH2Cl2) m/z (%): 690.2 (6), 689.2 (36), 688.2 (100), 687.3 (27), 
686.1 (60). 
MS (ESI (), 50 V, 200 °C, CH2Cl2) m/z (%): 250.1 (16), 248.9 (100). 
HRMS (ESI, 4500 V, 180 °C): (m/z) calc. for C33H38IrNOP
+
: 688.2316 [M4-NO2-2-5-di-
tert-butyl-phenolate]
+
; found: 688.2325. 
[α]
20
D  = 220 (c = 0.18, CHCl3). 
 
Iridium SerPHOX para-nitro phenolate complex (6.108) 
 
A flame dried Schlenk flask was charged with [Ir(COD)Cl]2 (52.0 mg, 77.4 mol, 0.50 eq.), 
sodium 2,6-di(tert-butyl)-4-nitrophenolate (46.6 mg, 170 mol, 1.10 eq.), (S)-4-(2-
((diphenylphosphanyl)oxy)-1,3-diphenylpropan-2-yl)-2-phenyl-4,5-dihydrooxazole (83.9 mg, 
155 mol, 1.00 eq.) and CH2Cl2 (2 mL) was added. The reaction mixture was stirred for 1 h at 
room temperature. The solution was filtered through a plug of celite (d × h: 0.5 × 1 cm), 
eluted with CH2Cl2 (5 mL) and all volatiles were evaporated in HV. The residue (150 mg) 
was dissolved in THF (1.00 mL) and hexane (10.0 mL) was added while stirring. The 
precipitate was filtered off and this procedure was repeated once to obtain the product 
(80.0 mg, 73.2 mol, 47%) as an orange solid. 
C58H64IrN2O5P (1092.35 g/mol):  
MP: 137 °C, decomposition. 
1
H NMR
 
(400 MHz, CD2Cl2): /ppm = 8.40 (d, J = 7.6 Hz, 2H, ar-H), 8.21-8.14 (m, 2H, ar-
H), 7.92-7.84 (m, 4H, ar-H), 7.72-7.68 (m, 4H, ar-H), 7.53-7.37 (m, 6H, ar-H), 7.19-7.06 (m, 
7H, ar-H), 6.77 (d, J = 7.3 Hz, 2H, ar-H), 5.11-5.05 (s br, 1H, COD), 5.03-4.97 (m, 2H, 
CH2O), 4.77-4.71 (m, 1H, CHN), 3.80-3.66 (m, 2H, COD), 3.05-2.88 (m, 3H, CH2Ph), 2.70 
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(d, J = 14.9 Hz, 1H, CH2Ph), 2.55-2.45 (m, 1H, COD), 2.42-2.34 (m, 1H, COD), 2.28-2.12 (m, 
3H, COD), 1.72-1.59 (m, 2H, COD), 1.55-1.48 (m, 1H, COD), 1.33 (s, 19H, C(CH3)3 and 
COD). 
13
C{
1
H} NMR (101 MHz, CD2Cl2): ppm = decomposition low sensitivity. 
31
P{
1
H} NMR (162 MHz, CD2Cl2): ppm = 99.5 (s). 
IR (ATR): ṽ/cm-1 = 2948 (w), 2913 (w), 1594 (w), 1481 (w), 1371 (w), 1382 (w), 1345 (m), 
1243 (s), 1197 (m), 1136 (m), 1102 (m), 1017 (m), 913 (m), 809 (w), 743 (m), 701 (m), 618 
(w). 
MS (ESI (+), 50 V, 200 °C, CH2Cl2) m/z (%): 844.5 (13), 843.5 (55), 842.6 (100), 841.7 (97), 
840.4 (71), 839.6 (32). 
MS (ESI (), 50 V, 200 °C, CH2Cl2) m/z (%): 250.1 (16), 248.9 (100). 
HRMS (ESI, 4500 V, 180 °C): (m/z) calc. for C44H44IrNO2P
+
: 842.2735 [M4-NO2-2-5-di-
tert-butyl-phenolate]
+
; found: 842.2736. 
[α]
20
D  = 17 (c = 0.09, CHCl3). 
 
(S)-SerPHOX PF6 iridium complex 
 
A flame dried Schlenk flask was charged with [Ir(COD)Cl]2 (48.5 mg, 72.3 mmol, 0.50 eq.), 
sodium AgPF6 (40.0 mg, 72.3 mol, 1.10 eq.), (S)-4-(2-((diphenylphosphanyl)oxy)-1,3-
diphenylpropan-2-yl)-2-phenyl-4,5-dihydrooxazole (78.3 mg, 144 mol, 1.00 eq.) and CH2Cl2 
(2 mL) was added. The reaction mixture was stirred for 4 h at room temperature. The solution 
was filtered through a plug of celite (d × h: 0.5 × 1 cm), eluted with CH2Cl2 (5 mL) and all 
volatiles were evaporated in HV. The residue was washed with Et2O (3 × 3 mL) to afford the 
product (121 mg, 129 mol, 83%) as a red solid. 
C44H44F6IrNO2P2 (987.00 g/mol):  
MP: 155-160 °C. 
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1
H NMR
 
(400 MHz, CD2Cl2): /ppm = 8.41 (d, J = 7.7 Hz, 1H, ar-H), 8.25-8.09 (m, 1H, ar-
H), 7.95-6.84 (m, 20H, ar-H), 6.85-6.70 (m, 1H, ar-H), 5.19-5.07 (m, 1H), 5.06-4.96 (m, 1H), 
4.81-4.67 (m, 1H), 3.87-3.70 (m, 1H), 3.08-2.84 (m, 3H), 2.72 (d, J = 14.8 Hz, 1H), 2.61-2.09 
(m, 5H), 1.72-1.63 (m, 2H), 1.60-1.50 (m, 2H), 1.48-1.32 (m, 2H). 
13
C{
1
H} NMR (101 MHz, CD2Cl2): ppm = 174.4 (s, C=N), 136.5, 136.1, 136.0, 135.2 (d, J 
= 15.5 Hz), 134.5, 134.3, 134.0 (d, J = 2.1 Hz), 132.2 (d, J = 11.7 Hz), 132.2 (d, J = 2.3 Hz), 
131.9, 131.0, 130.1 (d, J = 11.2 Hz), 129.8, 129.4, 128.8 (d, J = 11.1 Hz), 128.8, 128.3, 127.9, 
124.4, 104.5 (d, J = 11.4 Hz), 104.5 (d, J = 11.4 Hz), 96.5 (d, J = 13.7 Hz), 89.5 (d, J = 
7.2 Hz), 72.2 (d, J = 5.1 Hz), 70.8, 69.0, 65.6, 44.3 (d, J = 5.9 Hz), 41.5 (d, J = 1.6 Hz), 36.6 
(d, J = 3.6 Hz), 32.3 (d, J = 1.8 Hz), 29.2 (d, J = 1.6 Hz), 26.2. 
31
P{
1
H} NMR (162 MHz, CD2Cl2): ppm = 99.4 (s), 144.4 (sept, J = 711 Hz). 
IR (ATR): ṽ/cm-1 = 3061 (w), 2925 (w), 2028 (w), 1597 (w), 1495 (w), 1437 (w), 1253 (w), 
1101 (w), 831 (s), 740 (m), 696 (s), 555 (s). 
[α]
20
D  = 38 (c = 0.29, CHCl3). 
 
Iridium(III)–dihydride-species (6.13) 
 
To a solution of (E)-3-phenylbut-2-enenitrile (18.4 mg, 129 mol, 4.00 eq) in CH2Cl2 
(1.5 mL), diphenylphosphine-tert-butyl-iridium-PHOX (50.0 mg, 32 mol, 1.00 eq) was 
added. The reaction vial was equipped with a magnetic stir bar and placed in an autoclave that 
was pressurized to 70 bar with H2. The reaction mixture was stirred at 800 rpm for 2 h. After 
this time hydrogen was released and the solvent removed under reduced pressure in HV 
(0.05 mbar). The obtained yellow oil was washed with pentane (5 × 2 mL) and the residue 
dried in HV to afford a colorless foam (41.2 mg, 23.8 mol, 71%.) 
MP: 55°C, decomposition. 
1
H NMR
 
(500 MHz, CDCl3): /ppm = 8.35 (dd, J = 7.9 Hz, 3.8 Hz, 1H, ar-H), 7.77 (s, 8H, 
BArF), 7.66 – 7.37 (m, 28H, ar-H and BArF), 6.95 – 6.90 (m, 1H, ar-H), 6.02 (s, 1H, C=CH), 
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5.58 (br s, 1H, C=CH), 4.68 (dd, J = 9.4 Hz, 3.7 Hz, 1H, OCH2), 4.49 (t, J = 9.4 Hz, 1H, 
NCH), 4.26 (dd, J = 9.5 Hz, 3.6 Hz, 1H, OCH2), 2.61 (s, 3H, CH3), 1.99 (br s, 3H, CH3), 0.78 
(s, 9H, C(CH3)3), -20.37 – -20.58 (m, 2H, 2 × Ir-H). 
13
C{
1
H} NMR (101 MHz, CD2Cl2): ppm = 165.8 (d, JCP = 2 Hz), 165.6, 162.3 (q, JBC = 
50 Hz, BArF), 137.6, 135.4 (BArF), 134.8 (d, JCP = 12.0 Hz), 133.8, 132.6 (d, JCP = 11.3 Hz), 
133.3 (d, JCP = 7 Hz), 133.2 (d, JCP = 9 Hz), 133.0 (d, JCP = 2 Hz), 132.2 (d, JCP = 9 Hz), 
132.1, 132.1, 131.8 (d, JCP = 2 Hz), 129.6, (129.5 (qq, JCF = 30 Hz, JBC = 3 Hz, BArF), 129.4, 
129.4, 129.3, 129.2, 129.1 (d, JCP = 6 Hz), 126.4, 126.1, 125.2 (q, JCF = 272 Hz, BArF), 118.0 
(sept, JCF = 4 Hz, BArF), 93.8, 93.8, 76.9, 70.4, 35.8, 26.5, 21.3, 20.6. Quaternary carbons 
with 
1
JCP coupling were not detected. 
31
P{
1
H} NMR (161 MHz, CD2Cl2): ppm = 8.23.  
IR (ATR): ṽ/cm-1 = 3063 (w), 2966 (w), 1609 (m), 1576 (w), 1438 (m), 1353 (s), 1314 (w), 
1273 (s), 1242 (w), 1115 (s), 1020 (w), 1001 (w), 966 (w), 886 (m), 839 (m), 778 (w), 754 
(m), 712 (m), 692 (m), 681 (m), 670 (m). 
MS (ESI, 70 eV, 50 °C) m/z (%): 868.3 (11), 726.2 (37), 725.3 (100), 724.4 (31), 726.2 (57).
[I]
 
HRMS (ESI, 180 °C, 4500 V): (m/z) calc. for C25H28IrNOP: 582.1538 [M2×(E)-3-
phenylbut-2-enenitrile]
+
; found: 582.1533. 
  3.4320 D (c = 0.38, CHCl3). 
[I] = Ms was determined out of the reaction mixture before purification. This allowed 
detection of the mass of complex 4BArF. Determination of the mass of the isolated material 
gave predominantly [M2×(E)-3-phenylbut-2-enenitrile]+; and [M(E)-3-phenylbut-2-
enenitrile]
+
. 
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Ethyl (E)-3-(4-cyanophenyl)but-2-enoate (6.11) 
 
To a suspension of sodium hydride (60% in mineral oil, 484 mg, 12.1 mmol, 1.00 eq.) in THF 
(40 mL) was added ethyl diethylphosphonoacetate (2.71 g, 2.40 mL, 12.1 mmol, 1.00 eq.) 
dropwise at 0 °C and the mixture was stirred till gas evolution had ceased. 4-
Acetylbenzonitrile (1.75 g, 12.1 mmol, 1.00 eq.) was added in small portions and the solution 
was stirred for 16 h at room temperature. H2O (40 mL) was added followed by extraction with 
ethyl acetate (3 × 30 mL). The combined organic layers were dried over MgSO4 and the 
solvent was evaporated under reduced pressure. Purification by column chromatography 
(SiO2, d × h: 5 × 30 cm, cyclohexane:ethyl acetate (13:1)) afforded the product (900 mg, 
4.18 mmol, 35%) as a colorless solid and 1.05 g of a mixture of the (E/Z)-isomers. 
C13H13NO2 (215.25 g/mol): 
MP: 49-50 °C. 
TLC: Rf = 0.30 (SiO2, cyclohexane:ethyl acetate (15:1)). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.66 (d, 
3
JHH = 8.5 Hz, 2H, ar-H), 7.55 (d, 
3
JHH = 
8.4 Hz, 2H, ar-H), 6.14 (q, 
4
JHH = 1.4 Hz, 1H, C=CH), 4.22 (q, 
3
JHH = 7.1 Hz, 2H, OCH2), 
2.55 (d, 
4
JHH = 1.3 Hz, 3H, CH3), 1.31 (t, 
3
JHH = 7.1 Hz, 3H, CH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 166.3 (s, C=O), 153.1 (s, C=CH), 146.8 (s, ar-
qC), 132.4 (s, ar-C), 127.1 (s, ar-C), 119.8 (s, C=CH), 118.6 (s, C≡N), 112.6 (ar-qC), 60.3 (s, 
OCH2), 17.9 (s, CH3), 14.4 (s, CH3). 
MS (EI, 70 eV, 200 °C) m/z (%): 216.1 (10), 215.1 (67), 187.1 (30), 186.1 (72), 171.1 (14), 
170.1 (100), 169.1 (35), 143.1 (14), 142.1 (34), 141.1 (23), 140.1 (34), 116.1 (28), 115.1 (50). 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 10 min): tR = 25.14 min. 
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8.6.2 Synthesis of α,β-unsaturated nitriles and precursors 
 
General procedure: Horner–Wadsworth–Emmons reaction GP9  
 
(E)-3-Phenylbut-2-enenitrile (6.3)  
 
To a stirred suspension of NaH (1.85 g, 46.4 mmol, 1.50 eq., 60% in mineral oil) in THF 
(100 mL), diethyl cyanomethylphosphonate (6.57 g, 6.00 mL, 37.1 mmol, 1.20 eq.) was 
added dropwise at 0 °C. The solution was stirred at room temperature untill gas evolution had 
ceased. Acetophenone (3.71 g, 3.61 mL, 30.9 mmol, 1.00 eq.) was added dropwise and the 
reaction mixture was stirred for 14 h at room temperature. H2O (60 mL) was added and the 
reaction mixture was extracted with ethyl acetate (3 × 60 mL). The combined organic layers 
were dried over MgSO4. Purification by column chromatography (SiO2, d × h: 5 × 33 cm, 
pentane:Et2O (50:1)) afforded the product (3.79 g, 26.5 mmol, 86%) as a colorless liquid. 
C10H9N (143.19 g/mol):  
TLC: Rf = 0.26 (SiO2, pentane:Et2O (50:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.52-7.44 (m, 2H, ar-H), 7.44-7.37 (m, 3H, ar-H), 5.62 
(q, 
4
JHH = 1.1 Hz, 1H, C=CH), 2.47 (d, 
4
JHH = 1.1 Hz, 3H, CH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 159.6 (s, C=CH), 138.0 (s, ar-qC), 130.2 (s, ar-C), 
128.7 (s, ar-C), 125.8 (s, ar-C), 117.5 (s, C≡N), 95.4 (s, C=CH), 20.0 (s, CH3). 
MS (EI, 70 eV, 200 °C) m/z (%): 144.1 (12), 143.2 (100), 142.2 (12), 116.1 (34), 115.1 (35), 
103.1 (14), 78.1 (21), 77.1 (13). 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 10 min): tR = 15.42 min. 
HPLC: Daicel, Chiralcel OD-H (0.46 cm × 25 cm, heptane/iso-propanol = 95:05, 0.5 mL/min, 
25 °C, 208 nm): tR = 25.2 min. 
Obtained data are in accordance with literature data.
[110b]
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(Z)-3-Phenylbut-2-enenitrile (6.43) 
 
(Z)-3-phenylbut-2-enenitrile (252 mg, 1.76 mmol, 6%) was obtained as minor product in the 
Horner–Wadsworth–Emmons reaction of cyanomethylphosphonate with acetophenone as a 
colorless liquid. 
C10H9N (143.19 g/mol):  
TLC: Rf = 0.20 (SiO2, pentane:Et2O (40:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.59-7.49 (m, 2H, ar-H), 7.47-7.39 (m, 3H, ar-H), 5.40 
(q, 
4
JHH = 1.5 Hz, 1H, C=CH), 2.28 (d, 
4
JHH = 1.5 Hz, 3H, CH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 161.1 (s, C=CH), 138.0 (s, ar-qC), 129.9 (s, ar-
C), 128.7 (s, ar-C), 127.1 (s, ar-C), 117.6 (s, C≡N), 95.5 (s, C=CH), 24.7 (s, CH3). 
MS (EI, 70 eV, 200 °C) m/z (%): 144.1 (11), 143.1 (100), 142.1 (12), 116.1 (29), 115.1 (33), 
103.1 (13), 78.1 (18), 77.1 (11).  
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 10 min): tR = 16.6 min. 
HPLC: Daicel, Chiralcel OD-H (0.46 cm × 25 cm, heptane/iso-propanol = 95:05, 0.5 mL/min, 
25 °C, 208 nm): tR = 19.5 min. 
Obtained data are in accordance with literature data.
[110b]
  
 
(E)-3-(4-Methoxyphenyl)but-2-enenitrile (6.48) 
 
The -unsaturated nitrile was synthesized according to general procedure GP9 using NaH 
(927 mg, 23.2 mmol, 1.50 eq., 60% in mineral oil) in THF (50 mL), diethyl 
cyanomethylphosphonate (3.00 mL, 3.29 g, 18.5 mmol, 1.20 eq.) and 4’-
methoxyacetophenone (2.32 g, 15.5 mmol, 1.00 eq.). H2O (50 mL) was added and the mixture 
was extracted with EtOAC (3 × 50 mL). The combined organic layers were dried over MgSO4 
and the residue filtered over a plug of silica (d × h: 2 × 10 cm, pentane:Et2O (1:1)) to 
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obtainthe product as a (E/Z)-mixture (2.40 g). The residue was dissolved in a mixture of 
pentane:Et2O ((2:3), 50 mL) and stored for 12 h at 25 °C. The resulting crystals were filtered 
off and washed with pentane (3 × 5 mL) to afford the pure (E)-isomer (1.56 g, 9.01 mmol, 
58%) as colorless crystals. 
C11H11NO (173.21 g/mol):  
MP: 61-62 °C.
 
TLC: Rf = 0.15 (SiO2, pentane:Et2O (10:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.43 (d, 
3
JHH = 8.9 Hz, 2H, ar-H), 6.91 (d, 
3
JHH = 
8.9 Hz, 2H, ar-H), 5.54 (s, 1H, C=CH), 3.84 (s, 3H, OCH3), 2.43 (s, 3H, CH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 161.5 (s, ar-qC), 158.9 (s, C=CH), 130.5 (ar-qC), 
127.5 (s, ar-C), 118.3 (s, C≡N), 114.3 (s, ar-C), 93.3 (s, C=CH), 55.6 (s, OCH3), 20.1 (s, CH3). 
MS (EI, 70 eV, 200 °C) m/z (%): 174.1 (10), 173.1 (100), 172.1 (13), 158.1 (34), 143.1 (16), 
130.1 (18), 103.1 (31), 77.1 (18). 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 10 min): tR = 20.56 min. 
HPLC: Daicel, Chiralcel OD-H (0.46 cm × 25 cm, heptane/iso-propanol = 95:05, 0.5 mL/min, 
25 °C, 208 nm): tR = 19.4 min. 
Obtained data are in accordance with literature data.
[147]
 
 
(E)-3-Phenylpent-2-enenitrile (6.54) 
 
The -unsaturated nitrile was synthesized according to general procedure GP9 using NaH 
(927 mg, 23.2 mmol, 1.50 eq., 60% in mineral oil) in THF (40 mL), diethyl 
cyanomethylphosphonate (3.00 mL, 3.29 g, 18.5 mmol, 1.20 eq.) and propiophenone (2.07 g, 
15.5 mmol, 1.00 eq.). Purification by column chromatography (SiO2, d × h: 5 × 25 cm, 
pentane:Et2O (25:1)) afforded the product (1.95 g, 12.3 mmol, 80%) as a colorless liquid.  
C11H11N (157.22 g/mol):  
TLC: Rf = 0.54 (SiO2, pentane:Et2O (10:1), UV). 
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1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.43-7.37 (m, 5H, ar-H), 5.49 (s, 1H, C=CH), 2.90 (q, 
3
JHH = 7.6 Hz, 2H, CH2), 1.13 (t, 
3
JHH = 7.6 Hz, 3H, CH3). 
13
C{
1
H}c NMR (101 MHz, CDCl3): ppm = 166.6 (s, ar-qC), 137.5 (s, C=CH), 130.2 (s, ar-
C), 129.1 (s, ar-C), 126.5 (s, ar-C), 117.5 (s, C≡N), 95.2 (s, C=CH), 27.4 (s, CH2), 13.5 (s, 
CH3). 
MS (EI, 70 eV, 200 °C) m/z (%): 158.1 (13), 157.1 (100), 156.2 (71), 142.1 (64), 140.1 (10), 
130.1 (18), 129.1 (32), 128.1 (16), 117.1 (14), 116.1 (17), 115.1 (67), 102.1 (10), 91.1 (11), 
78.1 (15), 77.1 (16). 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 10 min): tR = 17.17 min. 
HPLC: Daicel, Chiralcel OD-H (0.46 cm × 25 cm, heptane/iso-propanol = 95:05, 0.5 mL/min, 
25 °C, 215 nm): tR = 14.8 min. 
Obtained data are in accordance with literature data.
[110b]
  
 
(E)-3-(4-Fluorophenyl)but-2-enenitrile (6.57) 
 
The -unsaturated nitrile was synthesized according to general procedure GP9 using NaH 
(584 mg, 14.6 mmol, 1.50 eq., 60% in mineral oil) in THF (40 mL), diethyl 
cyanomethylphosphonate (1.89 mL, 2.07 g, 11.7 mmol, 1.20 eq.) and 4’-fluoroacetophenone 
(1.34 g, 1.18 mL 9.73 mmol, 1.00 eq.). Purification by column chromatography (SiO2, d × h: 
5 × 20 cm, pentane:Et2O (40:1)) afforded the product (900 mg, 5.89 mmol, 61%) as a 
colorless solid. 
C10H8FN (161.18 g/mol): 
MP: 48-50 °C. 
TLC: Rf = 0.28 (SiO2, pentane:Et2O (10:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.53-7.38 (m, 2H, ar-H), 7.17-6.98 (m, 2H, ar-H), 
5.64-5.46 (m, 1H, C=CH), 2.45 (d, J = 0.9 Hz, 3H, CH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 164.1 (d, 
1
JCF = 251 Hz, ar-qC), 158.6 (s, C=CH), 
134.5 (d, 
4
JCF = 3 Hz, ar-qC), 128.0 (d, 
3
JCF = 9 Hz, ar-C), 117.6 (s, C≡N), 116.0 (d, 
2
JCF = 
22 Hz, ar-C), 95.6 (d, 
6
JCF = 2 Hz, C=CH), 20.4 (s, CH3). 
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19
F{
1
H} NMR (376 MHz, CDCl3): ppm = 110.1. 
IR (ATR): ṽ/cm-1 = 3068 (w), 2928 (w), 2210 (s), 1927 (w), 1904 (w), 1877 (w), 1656 (w), 
1598 (s), 1512 (s), 1444 (s), 1412 (m), 1224 (s), 1212 (m), 1112 (m), 941 (w), 829 (s), 795 (s), 
746 (m). 
MS (EI, 70 eV, 200 °C) m/z (%): 162.1 (11), 161.1 (100), 160.1 (10), 146.1 (16), 134.1 (37), 
133.1 (42), 126.1 (13), 121.1 (13), 101.1 (11), 96.1 (31), 75.0 (10). 
EA (C10H8FN): calc.: C 74.52, H 5.00, N 8.69; found: C 74.52, H 5.07, N 8.88. 
GC (Chiraldex -cyclodextrin TFA G-TA (30 m × 0.25 mm × 0.12 m), 60 kPa H2 (50 °C – 
0 min – 10 °C/min – 100 °C – 0 min – 2 °C/min – 140 °C – 10 °C/min – 160 °C – 5 min): tR = 
22.49 min. 
 
(E)-3-Phenylhex-2-enenitrile (6.55) 
 
The -unsaturated nitrile was synthesized according to general procedure GP9 using NaH 
(584 mg, 14.6 mmol, 1.50 eq., 60% in mineral oil) in THF (40 mL), diethyl 
cyanomethylphosphonate (1.89 mL, 2.07 g, 11.7 mmol, 1.20 eq.) and butyrophenone (1.44 g, 
1.41 mL 9.73 mmol, 1.00 eq.). Purification by column chromatography (SiO2, d × h: 5 × 
20 cm, pentane:Et2O (20:1)) afforded the product (1.15 g, 6.72 mmol, 69%) as a colorless 
liquid. 
C12H13N (143.19 g/mol):  
TLC: Rf = 0.48 (SiO2, pentane:Et2O (10:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.44-7.38 (m, 5H, ar-H), 5.51 (s, 1H, C=CH), 2.89-
2.86 (m, 2H, CH2), 1.59-1.43 (m, 2H, CH2), 0.95 (t, J = 7.4 Hz, 3H, CH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 165.1 (s, ar-qC), 137.8 (s, C=CH), 130.2 (s, ar-C), 
129.3 (s, ar-C), 126.5 (s, ar-C), 117.6 (s, C≡N), 96.0 (s, C=CH), 35.9 (s, CH2), 21.9 (s, CH2), 
13.7 (s, CH3). 
IR (ATR): ṽ/cm-1 = 3061 (w), 2963 (m), 2873 (w), 2214 (s), 1603 (m), 1574 (m), 1495 (w), 
1458 (m), 1381 (w), 1336 (w), 1256 (w), 1081 (w), 830 (w), 758 (s), 696 (s), 632 (s). 
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MS (EI, 70 eV, 200 °C) m/z (%): 171.1 (45), 156.1 (13), 144.1 (20), 143.1 (100), 142.1 (32), 
131.1 (12), 129.1 (48), 128.1 (14), 116.1 (16), 115.1 (47), 103.1 (24), 102.1 (13), 78.1 (13), 
77.1 (13),  
EA (C12H13N): calc.: C 84.17, H 7.65, N 8.18; found: C 83.79, H 7.50, N 8.46. 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 10 min): tR = 18.59 min. 
HPLC: Daicel, Chiralcel OD-H (0.46 cm × 25 cm, heptane/iso-propanol = 98:02, 0.5 mL/min, 
25 °C, 208 nm): tR = 17.0 min. 
 
(E)-3-(p-Tolyl)but-2-enenitrile (6.46) 
 
The -unsaturated nitrile was synthesized according to general procedure GP9 using NaH 
(927 mg, 23.2 mmol, 1.50 eq., 60% in mineral oil) in THF (60 mL), diethyl 
cyanomethylphosphonate (3.28 mL, 3.00 g, 18.5 mmol, 1.20 eq.) and 4′-methylacetophenone 
(2.07 mL, 2.08 g, 15.5 mmol, 1.00 eq.). Purification by column chromatography (SiO2, d × h: 
5 × 25 cm, pentane:Et2O (30:1)) afforded the product (1.83 g, 11.6 mmol, 75%) as a colorless 
solid.  
C11H11N (157.22 g/mol):  
MP: 36-37 °C. 
TLC: Rf = 0.41 (SiO2, pentane:Et2O (10:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.37 (d, 
3
JHH = 8.2 Hz, 2H, ar-H), 7.21 (d, 
3
JHH = 
8.2 Hz, 2H, ar-H), 5.60 (q, 
4
JHH = 1.0 Hz, 1H, C=CH), 2.45 (d, 
4
JHH = 1.0 Hz, 3H, CH3), 2.38 
(s, 3H, CH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 159.7 (s, C=CH), 140.9 (s, ar-qC), 135.5 (s, ar-
qC), 129.7 (s, ar-C), 126.0 (s, ar-C), 118.1 (s, C≡N), 94.7 (s, C=CH), 21.5 (s, CH3), 20.3 (s, 
CH3). 
MS (EI, 70 eV, 200 °C) m/z (%): 58.1 (11), 157.1 (100), 156.1 (54), 142.1 (34), 140.1 (11), 
130.1 (15), 129.1 (26), 128.1 (11), 116.1 (10), 115.1 (34), 91.1 (20), 65.1 (10). 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 10 min): tR = 18.62 min. 
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HPLC: Daicel, Chiralcel OD-H (0.46 cm × 25 cm, heptane/iso-propanol = 96:04, 0.5 mL/min, 
25 °C, 208 nm): tR = 15.5 min. 
Obtained data are in accordance with literature data.
[110b]
  
 
(E)-4-(1-Cyanoprop-1-en-2-yl)benzonitrile (6.61)  
 
The -unsaturated nitrile was synthesized according to general procedure GP9 using NaH 
(926 mg, 23.2 mmol, 1.50 eq., 60% in mineral oil) in THF (60 mL), diethyl 
cyanomethylphosphonate (3.00 mL, 3.28 g, 18.5 mmol, 1.20 eq.) and 4-acetylbenzonitrile 
(2.24 g, 15.4 mmol, 1.00 eq.). Purification by column chromatography (SiO2, d × h: 5 × 
25 cm, pentane:Et2O (3:1)) afforded the product (180 mg, 1.07 mmol, 7%) as a colorless solid. 
C11H8N2 (168.20 g/mol): 
MP: 134-136 °C. 
TLC: Rf = 0.47 (SiO2, pentane:Et2O (1:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.70 (d, 
3
JHH = 8.6, 2H, ar-H), 7.56 (d, 
3
JHH = 8.5 Hz, 
2H, ar-H), 5.68 (q, 
4
JHH = 1.0 Hz, 1H, C=CH), 2.48 (d, 
4
JHH = 1.1 Hz, 3H, CH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 157.9 (s, ar-qC), 142.6 (s, C=CH), 132.8 (s, ar-C), 
126.8 (s, ar-C), 118.2 (s, C≡N), 116.8 (s, C≡N), 114.0 (s, ar-qC), 98.8 (s, C=CH), 20.3 (s, 
CH3). 
IR (ATR): ṽ/cm-1 = 3070 (w), 2931 (w), 2214 (s), 1929 (w), 1674 (w), 1609 (m), 1504 (w), 
1411 (m), 1336 (m), 1261 (w), 1183 (w), 1134 (w), 1080 (w), 1014 (w), 968 (w), 922 (w), 
815 (s), 721 (w). 
MS (EI, 70 eV, 200 °C) m/z (%): 169.1 (13), 168.1 (100), 167.1 (12), 141.1 (37), 140.1 (33), 
128.1 (26), 114.1 (15), 103.1 (16). 
EA (C11H8N2): calc.: C 78.55, H 4.79, N 16.66; found: C 78.66, H 5.06, N 16.45. 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 10 min): tR = 25.53 min. 
HPLC: Daicel, Chiralpak AS-H (0.46 cm × 25 cm, heptane/iso-propanol = 60:40, 
0.5 mL/min, 25 °C, 208 nm): tR = 24.7 min. 
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(E)-3-(4-Chlorophenyl)but-2-enenitrile (6.50) 
 
The -unsaturated nitrile was synthesized according to general procedure GP9 using NaH 
(927 mg, 24.7 mmol, 1.50 eq., 60% in mineral oil) in THF (60 mL), diethyl 
cyanomethylphosphonate (3.00 mL, 3.29 g, 18.5 mmol, 1.20 eq.) and 4′-chloroacetophenone 
(2.01 mL. 2.49 g, 15.5 mmol, 1.00 eq.). Purification by column chromatography (SiO2, d × h: 
5 × 25 cm, pentane:Et2O (30:1)) afforded the product (2.20 g, 12.4 mmol, 80%) as a colorless 
solid. 
C10H8ClN (177.63 g/mol):  
MP: 54-55 °C. 
TLC: Rf = 0.39 (SiO2, pentane:Et2O (10:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.43-7.34 (m, 4H, ar-H), 5.60 (q, 
4
JHH = 1.2 Hz, 1H, 
C=CH), 2.45 (d, 
4
JHH = 1.2 Hz, 3H, CH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 158.5 (s, C=CH), 136.7 (s, ar-qC), 136.5 (s, ar-
qC), 129.2 (s, ar-C), 127.3 (s, ar-C), 117.4 (s, C≡N), 96.2 (s, C=CH), 20.3 (s, CH3). 
MS (EI, 70 eV, 200 °C) m/z (%): 179.0 (32), 177.0 (100), 142.1 (51), 137.1 (11), 127.1 (14), 
116.1 (12), 115.1 (73), 142.1 (51), 140.1 (15), 137.1 (11), 127.1 (14), 116.1 (12), 115.1 (73), 
114.1 (14), 112.0 (23), 75.0 (15). 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 10 min): tR = 20.73 min. 
HPLC: Daicel, Chiralcel OD-H (0.46 cm × 25 cm, heptane/iso-propanol = 96:04, 0.5 mL/min, 
25 °C, 220 nm): tR = 19.2 min. 
Obtained data are in accordance with literature data.
[110b]
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(E)-3-(4-Bromophenyl)but-2-enenitrile (6.58) 
 
The -unsaturated nitrile was synthesized according to general procedure GP9 using NaH 
(926 mg, 23.1 mmol, 1.50 eq., 60% in mineral oil) in THF (60 mL), diethyl 
cyanomethylphosphonate (3.00 mL, 3.29 g, 18.5 mmol, 1.20 eq.) and 4'-bromoacetophenone 
(3.07 g, 15.4 mmol, 1.00 eq.). Purification by column chromatography (SiO2, d × h: 5 × 
18 cm, pentane:Et2O (20:1)) afforded the product (1.08 g, 4.86 mmol, 32%) as a colorless 
solid. 
C10H8BrN (222.08 g/mol):  
MP: 54-55 °C.
 
TLC: Rf = 0.29 (SiO2, pentane:Et2O (10:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.53 (d, 
3
JHH = 8.5 Hz, 2H, ar-H), 7.33 (d, 
3
JHH = 
8.5 Hz, 2H, ar-H), 5.61 (d, 
4
JHH = 0.4 Hz, 1H, C=CH), 2.45 (d, 
4
JHH = 0.4 Hz, 3H, CH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 158.6 (s, C=CH), 137.3 (s, ar-qC), 132.2 (s, ar-C), 
127.6 (s, ar-C), 124.9 (s, ar-qC), 117.5 (s, C≡N), 96.3 (s, C=CH), 20.3 (s, CH3). 
IR (ATR): ṽ/cm-1 = 3058 (w), 2994 (w), 2964 (w), 2111 (m), 1914 (w), 1602 (m), 1484 (m), 
1436 (m), 1400 (m), 1326 (m), 1257 (w), 1083 (m), 1007 (m), 922 (w), 803 (s), 671 (w). 
MS (EI, 70 eV, 200 °C) m/z (%): 223.0 (74), 221.0 (75), 142.1 (53), 140.1 (18), 127.1 (22), 
116.1 (21), 115.1 (100), 102.1 (15), 77.1 (10), 75.1 (11), 70.6 (10), 50.0 (10).  
EA (C10H8BrN): calc.: C 54.08, H 3.63, N 6.31; found: C 54.30, H 3.68, N 6.40. 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 10 min): tR = 22.71 min. 
HPLC: Daicel, Chiralpak AS-H (0.46 cm × 25 cm, heptane/iso-propanol = 97:03, 
0.5 mL/min, 25 °C, 220 nm): tR = 36.5 min. 
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(E)-5-Methyl-3-phenylhex-2-enenitrile (6.56) 
 
The -unsaturated nitrile was synthesized according to general procedure GP9 using NaH 
(584 mg, 14.6 mmol, 1.50 eq., 60% in mineral oil) in THF (40 mL), diethyl 
cyanomethylphosphonate (1.89 mL, 2.07 g, 11.7 mmol, 1.20 eq.) and 3-methyl-1-
phenylbutan-1-one (1.66 mL, 1.58 g, 9.74 mmol, 1.00 eq.). Purification by column 
chromatography (SiO2, d × h: 5 × 25 cm, pentane:Et2O (80:1)) afforded the product (720 mg, 
3.89 mmol, 40%) as a colorless liquid. 
C13H15N (185.27 g/mol):  
TLC: Rf = 0.56 (SiO2, pentane:Et2O (80:1)). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.43-7.36 (m, 5H, ar-H), 5.52 (s, 1H, C=CH), 2.78 (d, 
3
JHH = 7.3 Hz, 2H, CH2), 1.79-1.65 (m, 1H, CH), 0.93 (d, 
3
JHH = 6.7 Hz, 6H, CH(CH3)2). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 164.5 (s, C=CH), 138.1 (s, ar-qC), 130.1 (s, ar-C), 
129.0 (s, ar-C), 126.5 (s, ar-C), 117.7 (s, C≡N), 96.7 (C=CH), 42.9 (s, CH2), 27.7 (s, CH), 
22.3 (s, CH3). 
IR (ATR): ṽ/cm-1 = 3062 (w), 2958 (m), 2870 (w), 2214 (s), 1604 (m), 1573 (w), 1494 (w), 
1465 (m), 1387 (w), 1369 (w), 1219 (w), 1167 (w), 1080 (w), 927 (w), 828 (m), 801 (m), 774 
(m), 756 (s), 695 (s). 
MS (EI, 70 eV, 200 °C) m/z (%): 185.1 (16), 143.1 (100), 143.1 (100), 115.1 (11). 
HRMS (EI): (m/z) calc. for C13H15N
+
: 185.1199 [M]
+
; found: 185.1199. 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 10 min): tR = 19.25 min.  
HPLC: Daicel, Chiralcel OD-H (0.46 cm × 25 cm, heptane/iso-propanol = 96:04, 0.5 mL/min, 
25 °C, 212 nm): tR = 13.9 min. 
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(E)-Methyl 4-(1-cyanoprop-1-en-2-yl)benzoate (6.60) 
 
The -unsaturated nitrile was synthesized according to general procedure GP9 using NaH 
(600 mg, 15.0 mmol, 1.50 eq., 60% in mineral oil) in THF (40 mL), diethyl 
cyanomethylphosphonate (1.94 mL, 2.13 g, 12.0 mmol, 1.20 eq.) and methyl 4-acetylbenzoate 
(1.78 g, 10.0 mmol, 1.00 eq.). The residue was filtered over a plug of silica (SiO2, d × h: 5 × 
5 cm, pentane:Et2O (1:1)), all volatiles evaporated under reduced pressure and the residue 
recrystallized from a mixture of pentane:Et2O ((1:1), 80 mL, 1.50 g) at 25 °C. Impurity of 
the corresponding ethylester was detected. The obtained crystals were dissolved in MeOH 
(35 mL) and DMAP (10 mg) was added. The solution was stirred for 2 h at reflux. The 
solvent was evaporated and the residue filtered over a plug of silica (d × h: 2 × 2 cm, 
pentane:Et2O (1:1)) to afford the product (710 mg, 3.53 mmol, 35%) as a colorless solid. 
C12H11NO2 (201.22 g/mol):  
MP: 102-104 °C. 
TLC: Rf = 0.29 (SiO2, pentane:Et2O (1:10), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 8.05 (d, 
3
JHH = 8.6 Hz, 2H, ar-H), 7.51 (d, 
3
JHH = 
8.5 Hz, 2H, ar-H), 5.68 (s, 1H, C=CH), 3.92 (s, 3H, OCH3), 2.48 (s, 3H, CH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 168.5 (s, C=O), 158.7 (s, C=CH), 139.9 (s, ar-
qC), 133.6 (s, ar-qC), 126.7 (s, ar-C), 119.5 (s, ar-C), 117.8 (s, C≡N), 94.4 (s, C=CH), 24.7 (s, 
CH3), 20.0 (s, CH3). 
IR (ATR): ṽ/cm-1 = 3078 (w), 3001 (w), 2956 (w), 2207 (m), 1934 (w), 1795 (w), 1709 (s), 
1608 (m), 1567 (m), 1435 (m), 1376 (w), 1339 (w), 1281 (s), 1192 (m), 1110 (m), 1014 (w), 
962 (w), 829 (m), 763 (s), 693 (m). 
MS (EI, 70 eV, 200 °C) m/z (%): 201.1 (40), 171.1 (13), 170.1 (100), 142.1 (26), 116.0 (10), 
115.1 (24). 
EA (C12H11NO2): calc.: C 71.63, H 5.51, N 6.96; found: C 71.64, H 5.51, N 7.08. 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 10 min): tR = 25.22 min.  
HPLC: Daicel, Chiralcel OD-H (0.46 cm × 25 cm, heptane/iso-propanol = 96:04, 0.5 mL/min, 
25 °C, 233 nm): tR = 30.3 min. 
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(E)-3-Methyl-5-phenylpent-2-enenitrile ((E)-6.68) and (Z)-3-methyl-5-phenylpent-2-
enenitrile ((Z)-6.69) 
 
The -unsaturated nitriles were synthesized according to general procedure GP9 using NaH 
(584 mg, 14.6 mmol, 1.50 eq., 60% in mineral oil) in THF (40 mL), diethyl 
cyanomethylphosphonate (1.89 mL, 2.07 g, 11.7 mmol, 1.20 eq.), benzylacetone (1.44 g, 
1.46 mL, 9.74 mmol, 1.00 eq.). Filtration over a plug of silica (SiO2, d × h: 5 × 5 cm, 
pentane:Et2O (10:1)) afforded a mixture of (E/Z)-isomers (1.53 mg, 8.93 mmol, 92%, ratio 
(2:1)) as a colorless liquid. The isomers (1.35 g) were separated using semipreparative HPLC 
(OD, hexane:iso-proponal (94:6), 25 °C, 8 mL/min, 220 nm, 150 mg/injection) to afford the 
products ((E), 550 mg, 3.18 mmol, 33%) and ((Z), 400 mg, 2.34 mmol, 24%) both as a 
colorless liquids. 
(E)-3-Methyl-5-phenylpent-2-enenitrile 
C12H13N (171.24 g/mol): 
TLC: Rf = 0.32 (SiO2, cyclohexane:Et2O (10:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.34-7.26 (m, 2H, ar-H), 7.25-7.18 (m, 1H, ar-H), 
7.17-7.12 (m, 2H, ar-H), 5.08-5.06 (m, 1H, C=CH), 2.77 (t, 
3
JHH = 8.2 Hz, 2H, CH2), 2.48 (t, 
3
JHH = 8.2 Hz, 2H, CH2), 2.07 (d, 
4
JHH = 1.2 Hz, 3H, CH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 164.2 (s, C=CH), 140.2 (s, ar-qC), 128.6 (s, ar-
C), 128.2 (s, ar-C), 126.5 (s, ar-C), 117.1 (s, C≡N), 95.8 (s, C=CH), 40.2 (s, CH2), 33.5 (s, 
CH2), 21.2 (s, CH3). 
MS (EI, 70 eV, 200 °C) m/z (%): 171.1 (13), 91.1 (100), 65.1 (10). 
Chiral GC (-Cyclodextrin, DEtTButSil (Brechbühler, SE54), (25 m × 0.25 mm × 0.25 μm) 
60 kPa He (50 °C – 0 min – 20 °C/min 108 °C – 60 min  5 °C/min  180 °C – 5 min): tR = 
69.0 min. 
semi-preparative HPLC: (Daicel Chiralcel OD, hexane/i-PrOH = 94:6, 8.0 mL/min, 25 °C, 
300 mL, 450 mg/mL): tR = 51 min. 
Obtained data are in accordance with literature data.
[66]
  
EXPERIMENTAL PART   CHAPTER 8  
331 
(Z)-3-Methyl-5-phenylpent-2-enenitrile 
C12H13N (171.24 g/mol): 
TLC: Rf = 0.32 (SiO2, cyclohexane:Et2O (10:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.35-7.28 (m, 2H, ar-H), 7.26-7.18 (m, 3H, ar-H), 5.10 
(d, 
4
JHH = 1.6 Hz, 1H, C=CH), 2.85-2.80 (m, 2H, CH2), 2.75-2.66 (m, 2H, CH2), 1.90 (d, 
4
JHH 
= 1.6 Hz, 3H, CH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 164.2 (s, C=CH), 140.2 (s, ar-qC), 128.6 (s, ar-
C), 128.2 (s, ar-C), 126.5 (s, ar-C), 117.1 (s, C≡N), 95.8 (s, C=CH), 40.2 (s, CH2), 33.5 (s, 
CH2), 21.2 (s, CH3). 
MS (EI, 70 eV, 200 °C) m/z (%): 171.1 (11), 91.1 (100), 65.1 (10). 
Chiral GC (-Cyclodextrin, DEtTButSil (Brechbühler, SE54), (25 m × 0.25 mm × 0.25 μm) 
60 kPa He (50 °C – 0 min – 20 °C/min 108 °C – 60 min  5 °C/min  180 °C – 5 min): tR = 
44.2 min. 
semi-preparative HPLC: (Daicel Chiralcel OD, hexane/i-PrOH = 94:6, 8.0 mL/min, 25 °C, 
300 mL, 450 mg/mL): tR = 26 min. 
Obtained data are in accordance with literature data.
[66]
  
 
(E)-3-(o-Tolyl)but-2-enenitrile (6.44)  
 
The -unsaturated nitrile was synthesized according to general procedure GP9 using NaH 
(893 mg, 22.3 mmol, 1.50 eq., 60% in mineral oil) in THF (60 mL), diethyl 
cyanomethylphosphonate (2.89 mL, 3.16 g, 17.9 mmol, 1.20 eq.) and 2′-methylacetophenone 
(1.95 mL, 2.00 g, 14.9 mmol, 1.00 eq.). The reaction mixture was stirred for 3 h after the 
addition of the ketone. Purification by column chromatography (SiO2, d × h: 5 × 22 cm, 
pentane:Et2O (30:1)) afforded the product (1.21 g, 7.70 mmol, 52%) as a colorless liquid. 
C11H11N (157.22 g/mol):  
TLC: Rf = 0.53 (SiO2, pentane:Et2O (10:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.28-7.08 (m, 3H, ar-H), 7.01-6.93 (m, 1H, ar-H), 5.22 
(q, 
4
JHH = 1.2 Hz, 1H, C=CH), 2.36 (d, 
4
JHH = 1.2 Hz, 3H, CH3), 2.29 (s, 3H, CH3). 
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13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 163.4 (s, C=CH), 140.5 (s, ar-qC), 134.0 (s, ar-
qC), 130.8 (s, ar-C), 128.7 (s, ar-C), 127.0 (s, ar-C), 126.0 (s, ar-C), 116.8 (s, C≡N), 99.1 (s, 
C=CH), 23.0 (s, CH3), 19.8 (s, CH3). 
MS (EI, 70 eV, 200 °C) m/z (%): 158.1 (11), 157.1 (92), 156.1 (34), 140.1 (10), 131.1 (12), 
130.1 (100), 129.1 (82), 128.1 (17), 127.1 (10), 116.1 (17), 115.1 (84), 91.1 (14).  
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 10 min): tR = 16.15 min.  
HPLC: Daicel, Chiralcel OD-H (0.46 cm × 25 cm, heptane/iso-propanol = 92:08, 0.5 mL/min, 
25 °C, 208 nm): tR = 12.9 min. 
Obtained data are in accordance with literature data.
[110b]
 
 
(E)-3-(3-Nitrophenyl)but-2-enenitrile (6.63) 
 
The -unsaturated nitrile was synthesized according to general procedure GP9 using NaH 
(927 mg, 23.2 mmol, 1.50 eq., 60% in mineral oil) in THF (60 mL), diethyl 
cyanomethylphosphonate (3.00 mL, 3.28 g, 18.5 mmol, 1.20 eq.) and 3′-nitroacetophenone 
(2.63 g, 15.5 mmol, 1.00 eq.). Purification by column chromatography (SiO2, d × h: 5 × 
26 cm, cyclohexane:ethyl acetate (1:1)) afforded the product (950 mg, 13.4 mmol, 33%) as a 
colorless solid. 
C10H8N2O2 (188.19 g/mol): 
MP: 88-90 °C. 
TLC: Rf = 0.34 (SiO2, cyclohexane:ethyl acetate (5:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 8.34-8.22 (m, 2H, ar-H), 7.79 (d, 
3
JHH = 7.9 Hz, 1H, 
ar-H), 7.62 (“t”, 3JHH = 8.0 Hz, 1H, ar-H), 5.74 (s, 1H, C=CH), 2.54 (s, 3H, CH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 157.3 (s, C=CH), 148.8 (s, ar-qC), 140.1 (s, ar-
qC), 131.8 (s, ar-C), 130.3 (s, ar-C), 124.9 (s, ar-C), 121.1 (s, ar-C), 116.8 (s, C≡N), 98.6 (s, 
C=CH), 20.5 (s, CH3). 
IR (ATR): ṽ/cm-1 = 3092 (w), 2985 (w), 2867 (w), 2214 (m), 2214 (m), 1611 (w), 1517 (s), 
1433 (w), 1354 (s), 1114 (w), 1020 (w), 949 (w), 904 (w), 872 (m), 834 (m), 736 (m), 678 (m). 
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MS (EI, 70 eV, 200 °C) m/z (%): 189.1 (12), 188.1 (100), 158.2 (15), 143.1 (13), 142.1 (12), 
141.1 (12), 140.1 (29), 130.1 (20), 116.1 (35), 115.1 (80), 103.1 (20), 89.1 (19), 63.1 (14), 
51.0 (10). 
EA (C10H8N2O2): calc.: C 63.82, H 4.28, N 14.89; found: C 63.71, H 4.34, N 15.10. 
GC-MS (Restek Rtx-5MS (30 m × 0.25 mm × 0.25 m) 100 kPa He (50 °C – 2 min – 
30 °C/min – 250 °C –5 min): tR = 9.11 min.  
HPLC: Daicel, Chiralcel OD-H (0.46 cm × 25 cm, heptane/iso-propanol = 94:06, 0.5 mL/min, 
25 °C, 220 nm): tR = 45.9 min. 
 
(E)-3-(m-Tolyl)but-2-enenitrile (6.47) 
 
The -unsaturated nitrile was synthesized according to general procedure GP9 using NaH 
(927 mg, 23.2 mmol, 1.50 eq., 60% in mineral oil) in THF (60 mL), diethyl 
cyanomethylphosphonate (3.00 mL, 3.28 g, 18.5 mmol, 1.20 eq.) and 3′-methylacetophenone 
(2.14 g, 2.17 mL, 15.5 mmol, 1.00 eq.). Purification by column chromatography (SiO2, d × h: 
5 × 24 cm, pentane:Et2O (50:1)) afforded the product (2.11 g, 13.4 mmol, 87%) as a colorless 
liquid. 
C11H11N (157.22 g/mol):  
TLC: Rf = 0.41 (SiO2, pentane:Et2O (50:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.37-7.13 (m, 4H, ar-H), 5.74-5.43 (m, 1H, C=CH), 
2.45 (d, 
4
JHH = 1.1 Hz, 3H, CH3), 2.38 (s, 3H, CH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 160.0 (s, C=CH), 138.6 (s, ar-qC), 138.3 (s, ar-
qC), 131.1 (s, ar-C), 128.8 (s, ar-C), 126.6 (s, ar-C), 123.1 (s, ar-C), 117.8 (s, C≡N), 95.4 (s, 
C=CH), 21.5 (s, CH3), 20.3 (s, CH3). 
IR (ATR): ṽ/cm-1 = 3047 (w), 2958 (w), 2923 (w), 2213 (s), 1602 (m), 1582 (m), 1441 (m), 
1380 (w), 1329 (w), 1278 (w), 1196 (w), 1103 (w), 1041 (w), 881 (w), 826 (w), 781 (s), 695 
(s), 634 (s). 
MS (EI, 70 eV, 200 °C) m/z (%): 158.1 (13), 157.1 (100), 156.1 (84), 143.1 (10), 140.1 (12), 
130.1 (17), 129.1 (39), 128.1 (18), 116.1 (11), 115.1 (42), 92.1 (11), 91.1 (21), 65.1 (10). 
HRMS (EI): (m/z) calc. for C11H11N
+
: 157.0886 [M]
+
; found: 157.0884. 
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GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min –
250 °C – 10 min): tR = 18.27 min.  
HPLC: Daicel, Chiralcel OD-H (0.46 cm × 25 cm, heptane/iso-propanol = 96:04, 0.5 mL/min, 
25 °C, 220 nm): tR = 15.5 min. 
 
(E)-3-(Naphthalen-2-yl)but-2-enenitrile (6.62) 
 
The -unsaturated nitrile was synthesized according to general procedure GP9 using NaH 
(930 mg, 23.3 mmol, 1.50 eq., 60% in mineral oil) in THF (60 mL), diethyl 
cyanomethylphosphonate (3.01 mL, 3.29 g, 18.6 mmol, 1.20 eq.) and 2-acetonaphthone 
(2.66 g, 15.5 mmol, 1.00 eq.). Purification by column chromatography (SiO2, d × h: 5 × 25 
cm, pentane:Et2O (20:1)) afforded the product (1.72 g, 8.90 mmol, 58%) as a colorless solid. 
C14H11N (193.25 g/mol): 
MP: 60-61 °C. 
TLC: Rf = 0.27 (SiO2, pentane:Et2O (20:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.93 (s br, 1H, ar-H), 7.90-7.82 (m, 3H, ar-H), 7.58-
7.52 (m, 3H, ar-H), 5.76 (q, 
4
JHH = 1.1 Hz, 1H, C=CH), 2.58 (d, 
4
JHH = 1.1 Hz, 3H, CH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 159.4 (s, C=CH), 135.4 (s, ar-qC), 134.1 (s, ar-
qC), 133.0 (s, ar-qC), 128.8 (s, ar-C), 128.7 (s, ar-C), 127.8 (s, ar-C), 127.5 (s, ar-C), 127.1 (s, 
ar-C), 126.2 (s, ar-C), 122.9 (s, ar-C), 117.8 (s, C≡N), 95.9 (s, C=CH), 20.3 (s, CH3). 
MS (EI, 70 eV, 200 °C) m/z (%): 194.1 (16), 193.1 (100), 192.1 (16), 165.1 (17), 151.1 (10), 
128.1 (26). 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 10 min): tR = 28.36 min. 
HPLC: Daicel, Chiralcel OD-H (0.46 cm × 25 cm, heptane/iso-propanol = 92:08, 0.5 mL/min, 
25 °C, 276 nm): tR = 24.7 min. 
Obtained data are in accordance with literature data.
[148]
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(E)-3-(3-Methoxyphenyl)but-2-enenitrile (6.49) 
 
The -unsaturated nitrile was synthesized according to general procedure GP9 using NaH 
(930 mg, 23.3 mmol, 1.50 eq., 60% in mineral oil) in THF (60 mL), diethyl 
cyanomethylphosphonate (3.01 mL, 3.29 g, 18.6 mmol, 1.20 eq.) and 3′-
methoxyacetophenone (2.33 g, 2.14 mL, 15.5 mmol, 1.00 eq.). Purification by column 
chromatography (SiO2, d × h: 5 × 25 cm, pentane:Et2O (20:1)) afforded the product (1.95 g, 
11.3 mmol, 73%) as a colorless liquid. 
C11H11NO (173.21 g/mol): 
TLC: Rf = 0.21 (SiO2, pentane:Et2O (20:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.37-7.27 (m, 1H, ar-H), 7.07-7.00 (m, 1H, ar-H), 
7.00-6.91 (m, 2H, ar-H), 5.60 (s, 1H, C=CH), 3.83 (s, 3H, OCH3), 2.44 (s, 3H, CH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 159.8 (s, ar-qC), 159.7 (s, C=CH), 139.7 (s, ar-
qC), 129.9 (s, ar-C), 118.3 (s, ar-C), 117.6 (s, C≡N), 115.3 (s, ar-C), 111.9 (s, ar-C), 95.8 (s, 
C=CH), 55.4 (s, OCH3), 20.3 (s, CH3). 
IR (ATR): ṽ/cm-1 = 3069 (w), 2961 (w), 2838 (w), 2213 (s), 1614 (m), 1577 (s), 1487 (m), 
1430 (m), 1381 (w), 1328 (m), 1288 (s), 1216 (s), 1043 (s), 824 (w), 779 (s), 691 (m), 629 (s). 
MS (EI, 70 eV, 200 °C) m/z (%): 174.1 (12), 173.1 (100), 172.1 (10), 158.1 (17), 145.1 (22), 
144.1 (26), 143.1 (14), 130.1 (13), 116.1 (16), 115.1 (18), 108.1 (20), 103.1 (25), 78.1 (11), 
77.1 (19). 
EA (C11H11N): calc.: C 76.28, H 6.40, N 8.09; found: C 76.11, H 6.33, N 8.31. 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min –
250 °C – 10 min): tR = 21.30 min.  
HPLC: Daicel, Chiralcel OD-H (0.46 cm × 25 cm, heptane/iso-propanol = 92:08, 0.5 mL/min, 
25 °C, 217 nm): tR = 39.4 min (overlay with first enantiomers of the hydrogenation product). 
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(E)-3-(3-Chlorophenyl)but-2-enenitrile (6.51) 
 
The -unsaturated nitrile was synthesized according to general procedure GP9 using NaH 
(970 mg, 24.3 mmol, 1.50 eq., 60% in mineral oil) in THF (50 mL), diethyl 
cyanomethylphosphonate (3.14 mL, 3.44 g, 19.4 mmol, 1.20 eq.) and 3’-chloroacetophenone 
(2.50 g, 2.10 mL, 16.2 mmol, 1.00 eq.). Purification by column chromatography (SiO2, d × h: 
5 × 25 cm, pentane:Et2O (40:1)) afforded the product (900 mg, 5.07 mmol, 31%) as a 
colorless solid. 
C10H8ClN (177.63 g/mol): 
MP: 29-30 °C. 
TLC: Rf = 0.45 (SiO2, pentane:Et2O (10:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.46-7.30 (m, 4H, ar-H), 5.62 (s, 1H, C=CH), 2.45 (s, 
3H, CH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 158.4 (s, C=CH), 140.1 (s, ar-qC), 135.1 (s, ar-
qC), 130.3 (s, ar-C), 130.2 (s, ar-C), 126.2 (s, ar-C), 124.1 (s, ar-C), 117.2 (s, C≡N), 97.0 (s, 
C=CH), 20.3 (s, CH3). 
IR (ATR): ṽ/cm-1 = 3064 (w), 2994 (w), 2213 (s), 1994 (w), 1870 (w), 1794 (w), 1682 (w), 
1605 (m), 1563 (m), 1420 (s), 1381 (m), 1324 (w), 1089 (m), 1013 (w), 937 (w), 896 (w), 833 
(s), 771 (s), 700 (s). 
MS (EI, 70 eV, 200 °C) m/z (%): 179.0 (32), 178.1 (12), 177.0 (100), 142.1 (58), 140.1 (19), 
137.1 (13), 116.1 (13), 115.1 (75), 114.1 (19), 112.0 (32), 102.1 (11), 75.0 (15). 
EA (C10H8ClN): calc.: C 67.62, H 4.54, N 7.89; found: C 67.65, H 4.58, N 7.94. 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 10 min): tR = 20.26 min.  
HPLC: Daicel, Chiralcel OD-H (0.46 cm × 25 cm, heptane/iso-propanol = 96:04, 0.5 mL/min, 
25 °C, 220 nm): tR = 24.0 min. 
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(2E,4E)-3-Methyl-5-phenylpenta-2,4-dienenitrile (6.67) 
 
The -unsaturated nitrile was synthesized according to general procedure GP9 using NaH 
(927 mg, 23.2 mmol, 1.50 eq., 60% in mineral oil) in THF (60 mL), diethyl 
cyanomethylphosphonate (3.00 mL, 3.28 g, 18.5 mmol 1.20 eq.) and (E)-4-phenylbut-3-en-2-
one (2.62 g, 15.5 mmol, 1.00 eq.). Purification by column chromatography (SiO2, d × h: 5 × 
25 cm, pentane:Et2O (25:1)) afforded the product as (E/Z)-mixture (4:1) (704 mg, 4.16 mmol, 
27%) as a colorless solid. Double recrystallization from pentane:Et2O afforded the pure (E) 
isomere (180 mg, 1.06 mmol, 7%). 
C12H11N (169.23 g/mol):  
MP: 65-66 °C.
 
TLC: Rf = 0.35 (SiO2, pentane:Et2O (10:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.51-7.44 (m, 2H, ar-H), 7.43-7.29 (m, 3H, ar-H), 6.91 
(d, 
3
JHH = 16.1 Hz, 1H, HC=CH), 6.82 (d, 
3
JHH = 16.0 Hz, 1H, HC=CH), 5.32 (s, 1H, C=CH), 
2.27 (s, 3H, CH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 156.8 (s, C=CH), 136.0 (s, ar-qC), 135.7 (s, 
C6H5HC=CH), 129.4 (s, ar-C), 129.0 (s, ar-C), 128.4 (s, C6H5HC=CH), 127.4 (s, ar-C), 117.9 
(s, C≡N), 98.2 (s, CHC≡N), 16.8 (s, CH3). 
IR (ATR): ṽ/cm-1 = 3259 (w), 3080 (w), 3016 (w), 2206 (m), 1990 (w), 1915 (w), 1823 (w), 
1722 (w), 1677 (w), 1617 (m), 1582 (m), 1492 (m), 1434 (m), 1331 (m), 1195 (m), 1029 (w), 
962 (s), 846 (m), 804 (s), 752 (s), 693 (s). 
MS (EI, 70 eV, 200 °C) m/z (%): 169.1 (48), 168.1 (15), 155.1 (12), 154.1 (100), 153.1 (14), 
141.1 (13), 127.1 (33). 
EA (C12H11N): calc.: C 85.17, H 6.55, N 8.28; found: C 85.30, H 6.71, N 8.32. 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 10 min): tR = 22.89 min. 
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(E)-3-(Naphthalen-1-yl)but-2-enenitrile (6.45) 
 
The -unsaturated nitrile was synthesized according to general procedure GP9 using NaH 
(927 mg, 23.3 mmol, 1.50 eq., 60% in mineral oil) in THF (60 mL), diethyl 
cyanomethylphosphonate (3.00 mL, 3.29 g, 18.5 mmol, 1.20 eq.) and 1-acetonaphthone 
(2.77 g, 2.47 mL, 15.5 mmol, 1.00 eq.). Purification by column chromatography (SiO2, d × h: 
5 × 20 cm, pentane:Et2O (20:1)) afforded the product (1.63 g, 8.43 mmol, 55%) as a colorless 
solid. 
C14H11N (193.25 g/mol): 
MP: 51-52 °C. 
TLC: Rf = 0.34 (SiO2, pentane:Et2O (17:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.93-7.81 (m, 3H, ar-H), 7.58-7.51 (m, 2H, ar-H), 7.47 
(dd, 
3
JHH = 8.3 Hz, 
3
JHH = 7.0 Hz, 1H, ar-H), 7.29 (dd, J = 7.1, 1.3 Hz, 1H, ar-H), 5.46 (d, 
3
JHH = 1.3 Hz, 1H, C=CH), 2.56 (d, 
3
JHH = 1.3 Hz, 3H, CH3).
  
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 162.3 (s, C=CH), 138.6 (s, ar-qC), 133.7 (s, ar-
qC), 129.8 (s, ar-qC), 129.3 8 (s, ar-C), 128.7 (s, ar-C), 126.9 (s, ar-C), 126.4 (s, ar-C), 125.1 (s, 
ar-C), 124.7 (s, ar-C), 124.4 (s, ar-C), 116.8 (s, C≡N), 100.2 (s, C=CH), 23.8 (s, CH3). 
IR (ATR): ṽ/cm-1 = 3058 (w), 3043 (w), 2981 (w), 2218 (m), 1624 (w), 1589 (w), 1508 (w), 
1431 (m), 1395 (m), 1373 (w), 1316 (w), 1248 (w), 1207 (w), 1068 (w), 1029 (w), 846 (m), 
830 (w), 804 (s), 774 (s), 744 (w). 
MS (EI, 70 eV, 200 °C) m/z (%): 194.1 (17), 193.1 (100), 192.1 (16), 165.1 (18), 151.1 (11), 
128.1 (29). 
EA (C14H11N): calc.: C 87.01, H 5.74, N 7.25; found: C 86.77, H 5.81, N 7.35. 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 10 min): tR = 24.88 min. 
 
EXPERIMENTAL PART   CHAPTER 8  
339 
(E)-3-(4-Aminophenyl)but-2-enenitrile (6.66) 
 
The -unsaturated nitrile was synthesized according to general procedure GP9 using NaH 
(988 mg, 24.7 mmol, 1.50 eq., 60% in mineral oil) in THF (60 mL), diethyl 
cyanomethylphosphonate (3.20 mL, 3.50 g, 19.8 mmol, 1.20 eq.) and 4'-aminoacetophenon 
(2.27 g, 16.5 mmol, 1.00 eq.). Purification by column chromatography (SiO2, d × h: 5 × 5 cm, 
cychlohexane:ethyl acetate (1:1)) afforded the product as (E/Z)-mixture (2.08 g). 
Recrystallization from chloroform:hexane (1:1) afforded the (E)-product (1.32 g, 8.32 mmol, 
51%) as a colorless solid. 
C10H10N2 (158.20 g/mol):  
MP: 109-110 °C.
 
TLC: Rf = 0.29 (SiO2, pentane:Et2O (1:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.31 (d, 
3
JHH = 8.6 Hz, 2H, ar-H), 6.65 (d, 
3
JHH = 
8.6 Hz, 2H, ar-H), 5.49 (s, 1H, C=CH), 3.98 (s, 2H, NH2), 2.40 (s, 3H, CH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 159.1 (s, C=CH), 148.9 (s, ar-qC), 127.7 (s, ar-C), 
127.5 (s ar-qC), 118.9 (s, C≡N), 114.7 (s, ar-C), 91.3 (s, C=CH), 19.9 (s, CH3). 
IR (ATR): ṽ/cm-1 = 3450 (m), 3365 (m), 2198 (s), 1900 (w), 1624 (m), 1576 (s), 1434 (m), 
1382 (w), 1259 (m), 1172 (m), 1144 (w), 1048 (w), 827 (s), 796 (s). 
MS (EI, 70 eV, 200 °C) m/z (%): 159.1 (12), 158.1 (100), 143.1 (58), 131.1 (11), 130.1 (11), 
116.1 (18), 93.1 (10). 
EA (C10H10N2): calc.: C 75.92, H 6.37, N 17.71; found: C 76.04, H 6.42, N 18.11. 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 10 min): tR = 26.73 min. 
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(E)-3-(4-Nitrophenyl)but-2-enenitrile (6.64) 
 
The -unsaturated nitrile was synthesized according to general procedure GP9 using NaH 
(927 mg, 23.2 mmol, 1.50 eq., 60% in mineral oil) in THF (60 mL), diethyl 
cyanomethylphosphonate (3.28 mL, 3.00 g, 18.5 mmol, 1.20 eq.) and 4'-nitroacetophenone 
(2.55 g, 15.5 mmol, 1.00 eq.). Extraction and filtration over a plug of silica (d × h: 2 × 5 cm, 
pentane:Et2O (1:1)) afforded the product as (E/Z)-mixture (1.85 g) as a brown solid. 
Recrystalization from hexane:ethyl acetate (5:1) afforded the pure (E)-product (1.47 g, 
7.81 mmol, 51%) as a pale yellow solid. 
C10H8N2O2 (188.19 g/mol):  
MP: 117-119 °C.
 
TLC: Rf = 0.64 (SiO2, pentane:Et2O (1:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 8.26 (d, 
3
JHH = 8.9 Hz, 2H, ar-H), 7.62 (d, 
3
JHH = 
8.9 Hz, 2H, ar-H), 5.72 (q, 
4
JHH = 1.0 Hz, 1H, C=CH), 2.48 (d, 
4
JHH = 1.0 Hz, 3H, CH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 157.6 (s, C=CH), 148.8 (s, ar-C), 144.5 (s, ar-C), 
127.1 (s, ar-C), 124.2 (s, ar-C), 116.7 (s, C≡N), 99.4 (s, C=CH), 20.5 (s, CH3). 
IR (ATR): ṽ/cm-1 = 3078 (w), 2988 (w), 2847 (w), 2452 (w), 2215 (m), 1933 (w), 1796 (w), 
1594 (m), 1512 (s), 1441 (w), 1338 (s), 1195 (w), 1111 (m), 1010 (w), 856 (s), 822 (s), 748 
(s), 688 (m). 
MS (EI, 70 eV, 200 °C) m/z (%): 189.1 (11), 188.1 (100), 158.1 (26), 142.1 (41), 141.1 (10). 
140.1 (26), 130.1 (18), 116.1 (32), 115.1 (70), 103.1 (41), 89.1 (18), 77.1 (14), 63.1 (14), 51.1 
(10). 
EA (C10H8N2): calc.: C 63.82, H 4.28, N 14.89; found: C 64.06, H 4.30, N 15.21. 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 10 min): tR = 27.70 min. 
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(E)-3-(Pyridin-2-yl)but-2-enenitrile (6.65) 
 
The -unsaturated nitrile was synthesized according to general procedure GP9 using NaH 
(773 mg, 19.3 mmol, 1.50 eq., 60% in mineral oil) in THF (60 mL), diethyl 
cyanomethylphosphonate (2.50 mL, 2.74 g, 15.5 mmol, 1.20 eq.) and 2-acetylpyridine 
(1.44 mL, 1.56 g, 12.9 mmol, 1.00 eq.). Purification by column chromatography (SiO2, d × h: 
5 × 20 cm, cyclohexane:ethyl acetate (1:1)) afforded the product (196 mg, 1.36 mmol, 11%) 
as a colorless solid. 
C9H8N2 (144.18 g/mol):  
TLC: Rf = 0.55 (SiO2, ethyl acetate:cyclohexane (20:1), UV). 
MP: 31-32 °C. 
1
H-NMR
 
(400 MHz, CDCl3): /ppm = 8.62 (ddd, J = 4.8, 1.8, 0.9 Hz, 1H, ar-H), 7.75 (td, J = 
7.8,1.9 Hz, 1H, ar-H), 7.51 (dt, J = 8.0, 1.0 Hz, 1H, ar-H), 7.31 (ddd, J = 7.7, 4.7, 1.1 Hz, 1H, 
ar-H), 6.56 (q, J = 1.0 Hz, 1H, C=CH), 2.49 (d, J = 1.0 Hz, 3H, CH3). 
13
C{
1
H}-NMR (101 MHz, CDCl3): ppm = 157.2 (s, C=CH), 154.1 (s, ar-qC)149.8 (s, ar-C), 
137.2 (s, ar-C), 124.8 (s, ar-C), 120.8 (s, ar-C), 117.9 (s, C≡N), 98.7 (s, C=CH), 18.6 (s, CH3). 
MS (EI, 70 eV, 200 °C) m/z (%): 145.1 (10), 144.1 (100), 143.1 (49), 129.1 (14), 188.1 (15), 
177.1 (25), 104.1 (33), 93.1 (12), 79.0 (36), 78.0 (18). 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 10 min): tR = 17.75 min. 
Obtained data are in accordance with literature data.
[110b]
 
 
(E)-4-Methyl-3-phenylpent-2-enenitrile (6.52) and (Z)-4-methyl-3-phenylpent-2-
enenitrile (6.53) 
 
The -unsaturated nitriles were synthesized according to general procedure GP9 using NaH 
(927 mg, 23.2 mmol, 1.50 eq., 60% in mineral oil) in THF (40 mL), diethyl 
cyanomethylphosphonate (3.00 mL, 3.29 g, 18.5 mmol, 1.20 eq.) and 2-methyl-1-
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phenylpropan-1-one (2.36 g, 15.5 mmol, 1.00 eq.). Purification by column chromatography 
(SiO2, d × h: 5 × 25 cm, pentane:Et2O (50:1)) afforded the (E)-product (902 mg, 5.55 mmol, 
34%) and the (Z)-product (500 mg, 2.92 mmol, 19%) both as a colorless liquid. 
C12H13N (171.24 g/mol):  
(E)-4-Methyl-3-phenylpent-2-enenitrile: 
TLC: Rf = 0.50 (SiO2, pentane:Et2O (10:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.41-7.32 (m, 3H, ar-H), 7.26-7.20 (m, 2H, ar-H), 5.26 
(s, 1H, C=CH), 3.33 (sept, 
3
JHH = 7.0 Hz, 1H, CH(CH3)2), 1.25 (d, 
3
JHH = 7.0 Hz, 6H, 
CH(CH3)2). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 172.2 (s, C=CH), 138.9 (s, ar-qC), 129.0 (s, ar-C), 
128.4 (s, ar-C), 127.2 (s, ar-C), 116.9 (s, C≡N), 96.6 (s, C=CH), 34.6 (s, CH(CH3)2), 21.3 (s, 
CH(CH3)2). 
MS (EI, 70 eV, 200 °C) m/z (%): 171.1 (55), 170.2 (17), 157.1 (10), 156.1 (72), 129.1 (100), 
128.1 (26), 127.1 (12), 116.1 (11), 155.1 (17), 102.1 (16), 91.1 (10), 78.1 (14), 77.1 (16), 51.0 
(11). 
(Z)-4-Methyl-3-phenylpent-2-enenitrile: 
TLC: Rf = 0.47 (SiO2, pentane:Et2O (10:1), UV). 
1
H NMR
 
(500 MHz, CDCl3): /ppm = 7.45-7.38 (m, 2H, ar-H), 7.36-7.32 (m, 2H, ar-H), 5.35 
(d, J = 1.4 Hz, 1H, C=CH), 2.85 (sept, J = 6.8, 1.4 Hz, 1H, CH(CH3)2), 1.10 (d, J = 7.0 Hz, 
6H, CH(CH3)2). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 172.4 (s, C=CH), 138.3 (s, ar-qC), 129.3 (s, ar-C), 
128.6 (s, ar-C), 127.4 (s, ar-C), 117.7 (s, C≡N), 94.4 (s, C=CH), 35.8 (s, CH), 21.2 (s, CH3). 
MS (EI, 70 eV, 200 °C) m/z (%): 171.2 (52), 170.1 (17), 156.1 (74), 130.1 (20), 129.1 (100), 
128.1 (27), 127.1 (12), 116.1 (11), 115.1 (17), 102.1 (17), 91.1 (10), 78.1 (14), 77.1 (16). 
Obtained data are in accordance with the literature data obtained by Maisey et al.
[119]
 Data is 
not in accordance with literature data in which the (E)-isomer is assigned as (Z)-isomer.
[110b]
 
The assignment of the configuration was confirmed by NOESY experiments. 
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(E)-3-(o-Tolyl)but-2-enenitrile (6.44) and (Z)-3-(o-tolyl)but-2-enenitrile 
 
The -unsaturated nitriles were synthesized according to general procedure GP9 using NaH 
(893 mg, 22.3 mmol, 1.50 eq., 60% in mineral oil) in THF (60 mL), diethyl 
cyanomethylphosphonate (2.89 mL, 3.16 g, 17.9 mmol, 1.20 eq.) and 2′-methylacetophenone 
(1.95 mL, 2.00 g, 14.9 mmol, 1.00 eq.). The reaction mixture was stirred for 3 h after the 
addition of the ketone. Purification by column chromatography (SiO2, d × h: 5 × 22 cm, 
pentane:Et2O (30:1)) afforded the (E)-isomer (1.21 g, 7.70 mmol, 52%) and (Z)-isomer 
(640 mg, 4.01 mmol, 27%) as colorless liquids. 
C11H11N (157.22 g/mol):  
(E)-3-(o-Tolyl)but-2-enenitrile: 
TLC: Rf = 0.53 (SiO2, pentane:Et2O (10:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.28-7.08 (m, 3H, ar-H), 7.01-6.93 (m, 1H, ar-H), 5.22 
(q, 
4
JHH = 1.2 Hz, 1H, C=CH), 2.36 (d, 
4
JHH = 1.2 Hz, 3H, CH3), 2.29 (s, 3H, CH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 163.4 (s, C=CH), 140.5 (s, ar-qC), 134.0 (s, ar-
qC), 130.8 (s, ar-C), 128.7 (s, ar-C), 127.0 (s, ar-C), 126.0 (s, ar-C), 116.8 (s, C≡N), 99.1 (s, 
C=CH), 23.0 (s, CH3), 19.8 (s, CH3). 
MS (EI, 70 eV, 200 °C) m/z (%): 158.1 (11), 157.1 (92), 156.1 (34), 140.1 (10), 131.1 (12), 
130.1 (100), 129.1 (82), 128.1 (17), 127.1 (10), 116.1 (17), 115.1 (84), 91.1 (14).  
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 10 min): tR = 16.15 min. 
Obtained data are in accordance with literature data.
[110b]
 
(Z)-3-(o-Tolyl)but-2-enenitrile: 
TLC: Rf = 0.35 (SiO2, pentane:Et2O (10:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.24-7.12 (m, 3H, ar-H), 7.08-6.96 (m, 1H, ar-H), 5.42 
(q, 
4
JHH = 1.6 Hz, 1H, C=CH), 2.23 (s, 3H, CH3), 2.11 (d, 
4
JHH = 1.6 Hz, 3H, CH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 163.8 (s, C=CH), 138.9 (s, ar-qC), 134.0 (s, ar-
qC), 130.8 (s, ar-C), 128.8 (s, ar-C), 126.8 (s, ar-C), 126.2 (s, ar-C), 116.7 (s, C≡N), 98.7 (s, 
C=CH), 25.7 (s, CH3), 19.3 (s, CH3). 
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MS (EI, 70 eV, 200 °C) m/z (%): 158.1 (12), 157.1 (91), 156.1 (34), 140.1 (10), 131.1 (12), 
131.1 (12), 130.1 (100), 129.1 (81), 128.1 (17), 127.1 (10), 116.1 (16), 115.1 (84), 91.1 (13), 
77.1 (10). 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min –
250 °C – 10 min): tR = 16.64 min.  
Obtained data are in accordance with literature data.
[119]
 
 
Diethyl (1-cyanoethyl)phosphonate 
 
n-BuLi (2.5 M, 50.4 mL, 8.07 g, 126 mmol, 2.10 eq.) and THF (80 mL) were placed in a two-
neck round bottom flask and cooled to 78 °C. Diisopropylamine (17.9 mL, 12.9 g, 128 mmol, 
2.10 eq.) in THF (60 mL) was added dropwise to the stirred solution via a dropping funnel 
and stirring was maintained for 10 min at 78 °C. Then propionitrile (4.34 mL, 3.30 g, 
60.0 mmol, 1.00 eq.) in THF (60 mL) was added dropwise at the same temperature. After 
30 min diethyl chlorophosphate (9.50 mL, 10.7 g, 62.0 mmol, 1.00 eq.) in THF (60 mL) was 
added at 78 °C via a dropping funnel and stirring was maintained at 78 °C for 15 min. 
Afterwards, the reaction mixture was allowed to warm to room temperature and poured into a 
stirred mixture of HCl (3 M, 100 mL), CH2Cl2 (100 mL) and ice (60 g). The organic layer was 
separated and the aqueous layer was extracted with CH2Cl2 (3 × 60 mL). The combined 
organic layers were washed with H2O (50 mL), dried over MgSO4, filtered and all volatiles 
were evaporated under reduced pressure to afford a yellowish liquid (6.96 g, 36.4 mmol, 61%) 
which showed sufficient purity for the next step. 
C7H14NO3P (143.19 g/mol):  
1
H NMR
 
(250 MHz, CDCl3): /ppm = 4.03 (s br, 4H, OCH2), 2.87 (m, 1H, CH), 1.34 (s br, 
3H, CH3), 1.18 (s br, 6H, CH2CH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 117.1 (d, J = 9.4 Hz, C≡N), 64.1 (d, J = 7.0 Hz, 
OCH2), 63.8 (d, J = 6.9 Hz, OCH2), 23.8 (d, J = 146 Hz, CH), 16.4 (d, J = 2.0 Hz, CH2CH3), 
16.4 (d, J = 2.0 Hz, CH2CH3), 12.7 (d, J = 5.9 Hz, CHCH3). 
31
P{
1
H} NMR (162 MHz, CD2Cl2): ppm = 18.7 (s). 
Obtained data are in accordance with literature data.
[149]
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(E)-2-Methyl-3-phenylacrylonitrile ((E)-6.72) and (Z)-2-methyl-3-phenylacrylonitrile 
((Z)-6.73) 
 
 
NaH (60%, 780 mg, 19.5 mmol, 1.50 eq.) in THF (70 mL) was placed in a dried two-neck 
round bottom flask, cooled to 0 °C and diethyl cyanoethylphophonate (2.74 mL, 2.98 g, 
15.6 mmol, 1.20 eq.) was added dropwise to the stirred solution. Afterwards, the reaction 
mixture was allowed to warm to room temperature and stirring was maintained until gas 
evolution had ceased. Benzaldehyde (1.31 mL, 1.38 g, 13.0 mmol, 1.00 eq.) was added 
dropwise to the yellow mixture maintaining the internal temperature below 25 °C. After the 
addition of benzaldehyde the reaction mixture was stirred at room temperature for 17 h. 
EtOAc (40 mL) and H2O (80 mL) were added, the organic layer was separated and the 
aqueous layer was extracted with EtOAc (3 × 60 mL). The combined organic layers were 
washed with brine (50 mL), dried over Na2SO4, filtered and the solvent evaporated under 
reduced pressure to afford a yellow liquid. The crude product was purified by column 
chromatography (SiO2, d × h: 5 × 15 cm, pentane:Et2O (45:1)) to obtain trans-2-methyl-3-
phenylprop-2-enonitrile (0.57 g, 3.98 mmol, 31%) and cis-2-methyl-3-phenylprop-2-
enonitrile (0.35 g, 2.45 mmol, 19%) both as a pale yellow liquid.  
C10H9N (143.19 g/mol):  
(E)-2-Methyl-3-phenylacrylonitrile: 
TLC: Rf = 0.26 (SiO2, pentane:Et2O (45:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.38 (m, 5H, ar-H), 7.21 (q, 
4
JHH = 1.5 Hz, 1H, C=CH), 
2.15 (d, 
4
JHH = 1.5 Hz, 3H, CH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 144.6 (s, CH=C), 134.3 (s, ar-qC), 129.5 (s, ar-C), 
129.5 (s, ar-C), 128.9 (s, ar-C), 121.4 (s, C≡N), 109.8 (s, CH=C), 17.0 (s, CH3). 
(Z)-2-Methyl-3-phenylacrylonitrile: 
TLC: Rf = 0.29 (SiO2, pentane:Et2O (45:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.93-7.55 (m, 2H, ar-H), 7.39 (m, 3H, ar-H), 6.94 (q, 
4
JHH = 1.6 Hz, 1H, CH=C), 2.16 (d, 
4
JHH = 1.6 Hz, 3H, CH3). 
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13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 144.2 (s, CH=C), 134.0 (s, ar-qC), 130.0 (s, ar-C), 
129.0 (s, ar-C), 128.6 (s, ar-C), 119.4 (s, C≡N), 106.3 (s, CH=C), 22.4 (s, CH3). 
Obtained data are in accordance with literature data.
[150]
 
 
(E)-2-Methyl-3-phenylbut-2-enenitrile (6.75) 
 
The -unsaturated nitrile was synthesized according to general procedure GP9 using NaH 
(780 mg, 19.5 mmol, 1.50 eq., 60% in mineral oil) in THF (70 mL), diethyl (1-
cyanoethyl)phosphonate (2.74 mL, 2.97 g, 15.6 mmol, 1.20 eq.) and acetophenone (1.52 mL, 
1.56 g, 13.0 mmol, 1.00 eq.). Purification by column chromatography (SiO2, d × h: 5 × 15 cm, 
pentane:Et2O (15:1)) afforded the product (830 mg, 5.28 mmol, 41%) as a colorless liquid. 
C11H11N (157.22 g/mol):  
TLC: Rf = 0.15 (SiO2, pentane:Et2O (15:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.36 (m, 3H, ar-H), 7.15 (m, 2H, ar-H), 2.36 (q, 
5
JHH = 
1.6 Hz, 3H, CH3), 1.84 (q, 
5
JHH = 1.5 Hz, 3H, CH3).  
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 154.4 (s, ar-C=C), 139.4 (s, ar-qC), 128.7 (s, ar-
C), 128.5 (s, ar-C), 127.3 (s, ar-C), 120.0 (s, C≡N), 105.9 (s, ar-C=C), 24.9 (s, CH3), 17.8 (s, 
CH3). 
MS (EI, 70 eV, 200 °C) m/z (%):158.1 (12), 157.1 (100), 156.1 (72), 142.1 (36), 140.1 (11), 
130.1 (25), 129.1 (39), 128.1 (13), 116.1 (14), 115.1 (57), 103.1 (19), 78.0 (16), 77.1 (17), 
51.0 (15). 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 10 min): tR = 15.34 min. 
Obtained data are in accordance with literature data.
[151]
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(E)-N-(4-(1-Cyanoprop-1-en-2-yl)phenyl)acetamide (6.59) 
 
To a solution of (E)-3-(4-aminophenyl) but-2-enenitrile (200 mg, 1.26 mmol, 1.00 eq.) in 
CH2Cl2 (5 mL) was added acetic anhydride (125 L, 1.33 mmol, 1.05 eq.) and N,N-
diisopropylethylamine (209 L, 1.26 mmol, 1.00 eq.). The reaction mixture was stirred for 2 h 
at room temperature and CH2Cl2 (30 mL) was added. The reaction mixture was washed with a 
saturated NaHCO3 solution (3 × 10 mL) and the organic layer was dried over MgSO4. 
Filtration and evaporation of all volatiles afforded the product (240 mg, 1.20 mmol, 95%) as a 
pale yellow solid. 
C12H12N2O (200.24 g/mol):  
MP: 171-172 °C. 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.57 (d, 
3
JHH = 8.8 Hz, 2H, ar-H), 7.56 (s br, 1H, NH), 
7.43 (d, 
3
JHH = 8.7 Hz, 2H, ar-H), 5.58 (d, 
4
JHH = 1.0 Hz, 1H, C=CH), 2.44 (d, 
4
JHH= 0.9 Hz, 
3H, CH3), 2.20 (s, 3H, CH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 168.5 (s, C=O), 158.7 (s, C=CH), 139.9 (s, ar-
qC), 133.6 (s, ar-qC), 126.7 (s, ar-C), 119.5 (s, ar-C), 117.8 (s, C≡N), 94.4 (s, C=CH), 24.7 (s, 
CH3), 20.0 (s, CH3). 
IR (ATR): ṽ/cm-1 = 3317 (m), 3189 (w), 3107 (w), 3045 (m), 2854 (w), 2210 (m), 1684 (s), 
1586 (s), 1530 (s), 1412 (m), 1370 (m), 1324 (m), 1270 (s), 1191 (m), 1016 (w), 814 (s), 728 
(m). 
MS (EI, 70 eV, 200 °C) m/z (%): 200.1 (36), 159.1 (12), 158.1 (100), 143.1 (30), 43 (21). 
EA (C12H12N2O): calc.: C 71.98, H 6.04, N 13.99; found: C 71.68, H 6.05, N 19.87. 
GC (Optima 5 (30 m × 0.25 mm × 0.5 m) 60 kPa He (150 °C – 0 min – 10 °C/min – 
250 °C – 20 min)): tR = 21.94 min.  
HPLC: Daicel, Chiralpak IC (0.46 cm × 25 cm, heptane/iso-propanol = 80:20, 0.5 mL/min, 
25 °C, 246 nm): tR = 51.6 min. 
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(Z)-2,3-Diphenylacrylonitrile (6.2)  
 
A mixture of benzaldehyde (1.11 mL, 1.17 g, 11.0 mmol, 1.00 eq.), phenylacetonitrile 
(11.0 mmol, 1.00 eq.), and K2CO3 (1.69 g, 13.2 mmol, 1.20 eq.) in MeOH (50 mL) was 
stirred for 4 h at reflux under an argon atmosphere. The reaction mixture was cooled to 0 °C, 
the precipitate was collected by filtration, washed with H2O (25 mL) and pentane (25 mL). 
Drying in HV afforded (Z)-2,3-diphenylacrylonitrile (1.62 g, 7.91 mmol, 72%) as a colorless 
solid. 
C15H11N (143.19 g/mol):  
MP: 84-85 °C. 
TLC: Rf = 0.19 (SiO2, pentane:Et2O (35:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.91-7.89 (m, 2H, ar-H), 7.70-7.67 (m, 2H, ar-H), 7.55 
(s, 1H, C=CH), 7.51-7.35 (m, 6H, ar-H). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 142.5 (s, C=CH), 134.7 (s, ar-qC), 133.9 (s, ar-
qC), 130.7 (s, ar-C), 129.5 (s, ar-C), 129.4 (s, ar-C), 129.3 (s, ar-C), 129.2 (s, ar-C), 126.2 (s, 
ar-C), 118.2 (s, C≡N), 111.9 (s, C=CH). 
MS (EI, 70 eV, 200 °C) m/z (%): 206.1 (15), 205.0 (100), 204.0 (80), 203.0 (21), 190.0 (42), 
178.1 (17), 177.0 (20), 176.0 (16), 102.1 (10), 89.1 (20), 88.1 (14), 76.0 (11). 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 10 min): tR = 27.80 min. 
HPLC: Daicel, Chiralcel OD-H (0.46 cm × 25 cm, heptane/iso-propanol = 98:02, 0.5 mL/min, 
20 °C, 220nm): tR = 16.2 min. 
Obtained data are in accordance with literature data.
[152]
 
 
(E)-3-(4-Methoxyphenyl)-2-methylacrylonitrile (6.1) 
 
A mixture of 4-methoxybenzenediazonium tetrafluoroborate (1.00 g, 4.51 mmol, 1.00 eq.), 
methyl acrylonitrile (300 mg, 373 L, 4.51 mmol, 1.00 eq.), palladium diacetate (20 mg, 
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2 mol%) and CaCO3 (451 mg, 4.51 mmol, 1.00 eq.) in MeOH (15 mL) was stirred for 16 h at 
room temperature. The solvent was evaporated under reduced pressure and the residue was 
purified by column chromatogarphie (SiO2, d × h: 3 × 20 cm, pentane:Et2O (10:1)) to afford 
the product as a colorless solid (275 mg, 1.59 mmol, 35%). 
C11H11NO (173.21 g/mol):  
MP: 35-36 °C. 
TLC: Rf = 0.28 (SiO2, pentane:Et2O (10:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.68 (d, 
3
JHH = 8.8 Hz, 2H, ar-H), 6.92 (d, 
3
JHH = 
8.8 Hz, 2H, ar-H), 6.85 (s, 1H, C=CH), 3.84 (s, 3H, OCH3), 2.12 (s, 3H, CH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 160.8 (s, ar-qC), 143.7 (s, C=CH), 130.0 (s, ar-C), 
126.7 (s, ar-qC), 119.8 (s, C≡N), 114.2 (s, ar-C), 103.0 (s, C=CH), 55.4 (s, OCH3), 22.1 (s, 
CH3). 
IR (ATR): ṽ/cm-1 = 3027 (w), 2970 (w), 2840 (w), 2205 (s), 2043 (w), 1900 (w), 1602 (s), 
1510 (s), 1441 (m), 1368 (w), 1303 (m), 1255 (s), 1217 (w), 1184 (s), 1155 (w), 1114 (w), 
1030 (s), 1016 (m), 903 (s), 826 (s), 781 (w), 623 (m). 
MS (EI, 70 eV, 200 °C) m/z (%): 174.1 (12), 173.1 (100), 172.1 (13), 158.1 (21), 13.1 (30), 
121.1 (16), 115.1 (11), 103.1 (41), 77.1 (21). 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 10 min): tR = 21.16 min. 
 
(Z)-3-bromo-3-phenylacrylonitrile (6.77) 
 
A two-necked round bottom flask was charged with benzoylacetonitrile (0.50 g, 3.44 mmol, 
1.00 eq.), PBr3 (10.1 mL, 29.0 g, 107 mmol, 31.1 eq.) and the resulting mixture was stirred for 
48 h at 160 °C. The reaction mixture was cooled to room temperature and poured onto 
crushed ice (50 g). After the addition of CHCl3 (30 mL), the mixture was stirred for 1 h at 
room temperature. The organic layer was separated and aqueous layer was extracted with 
CHCl3 (3 × 20 mL). The combined organic layers were washed with saturated NaHCO3 (2 × 
20 mL) and brine (25 mL) and dried over MgSO4. The solvent was evaporated under reduced 
pressure to obtain a black oil. The residue was purified by column chromatography (SiO2, d × 
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h: 5 × 10 cm, pentane:Et2O (10:1)) to afford the product as brown oil (55.3 mg, 0.27 mmol, 
8%). 
C9H6BrN (208.06 g/mol):  
TLC: Rf = 0.34 (SiO2, pentane:Et2O (10:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.63-7.61 (m, 2H, ar-H), 7.49-7.41 (m, 3H, ar-H), 6.23 
(s, 1H, C=CH). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 145.7 (s, C-Br), 136.1 (s, ar-qC), 131.8 (s, ar-C), 
128.9 (s, ar-C), 127.8 (s, ar-C), 116.7 (s, C≡N), 100.7 (s, C=CH). 
Obtained data are in accordance with literature data.
[153]
 
 
Allyl 4-acetylbenzoate 
 
A 2 necked flask was charged with NaH (60 in mineral oil, 205 mg, 5.14 mmol, 1.10 eq.) 
under an argon atmosphere. A solution of 4-acetylbenzoic acid (767 mg, 4.67 mmol, 1.00 eq.) 
in DMF (20 mL) was added dropwise and the reaction mixture was stirred until gas evolution 
had ceased. Allyl bromide (592 mg, 427 L, 4.90 mmol, 1.05 eq.) was added and the reaction 
was stirred for 16 h at room temperature. H2O (100 mL) was added followed by extraction 
with Et2O (3 × 100 mL). The combined organic layers were dried over MgSO4 and the 
solvent was evaporated under reduced pressure. Purification by column chromatography 
(SiO2, d × h: 10 × 5 cm, (pentane:Et2O (10:1)) afforded the product (620 mg, 3.04 mmol, 65%) 
as a colorless liquid. 
C12H12O3 (204.23 g/mol): 
TLC: Rf = 0.32 (pentane:Et2O (10:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 8.17-8.07 (m, 2H, ar-H), 8.01-7.96 (m, 2H, ar-H), 
6.11-5.92 (m, 1H, CH=CH2), 5.46-5.39 (m, 1H, CH=CH2), 5.34-5.24 (m, 1H, CH=CH2), 
4.92-4.79 (m, 2H, OCH2), 2.63 (s, 3H, CH3). 
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13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 197.6 (s, C=O), 165.5 (s, CO2), 140.4 (s, ar-qC), 
134.0 (s, ar-qC), 132.0 (s, C=CH2), 130.0 (s, ar-C), 128.3 (s, ar-C), 118.8 (s, C=CH2), 66.1 (s, 
OCH2), 27.0 (s, CH3). 
Obtained data are in accordance with literature data.
[154]
 
 
(E)-Allyl 4-(1-cyanoprop-1-en-2-yl)benzoate 
 
The -unsaturated nitrile was synthesized according to general procedure GP9 using NaH 
(411 mg, 10.3 mmol, 1.50 eq., 60% in mineral oil) in THF (35 mL), diethyl 
cyanomethylphosphonate (1.33 mL, 1.46 g, 8.23 mmol, 1.20 eq.) and allyl 4-acetylbenzoate 
(1.40 g, 6.86 mmol, 1.00 eq.). Purification by column chromatography (SiO2, d × h: 5 × 
20 cm, pentane:Et2O (10:1)) afforded the crude product containig 10% ethyl ester impurity 
(790 mg). The crude was dissolved in allylic alcohol (10 mL) followed by the addition of 
DBU (262 mg, 257 L, 1.72 mmol) and LiBr (1.49 g, 17.2 mmol). The reaction mixture was 
stirred at room temperature for 4 h. All volatiles were evaporated in vacuum and saturated 
NH4Cl solution (20 mL) was added. The mixture was extracted with Et2O (3 × 30 mL) and 
the combined organic layers were dried over MgSO4. Purification by column chromatography 
(SiO2, d × h: 2 × 10 cm, pentane:Et2O (10:1)) afforded the product (782 mg, 3.42 mmol, 50%) 
as a colorless solid. 
C14H13NO2 (227.26 g/mol): 
MP: 31-32 °C. 
TLC: Rf = 0.23 (pentane:Et2O (1:10), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 8.08 (d, 
3
JHH = 8.5 Hz, 2H, ar-H), 7.52 (d, 
3
JHH = 
8.5 Hz, 2H, ar-H), 6.04 (ddt, J = 17.3, 10.4, 5.7 Hz, 1H, CH2=CHCH2), 5.69 (q, 
4
JHH = 1.1 Hz, 
1H, C=CH), 5.46-5.36 (m, 1H, CH2=CH), 5.33-5.25 (m, 1H, CH2=CH), 4.85-4.82 (m, 2H, 
OCH2), 2.49 (d, 
4
JHH = 1.1 Hz, 3H, CH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 165.6 (s, C=O), 158.9 (s, C=CH), 142.7 (s, ar-
qC), 132.2 (s, CH2=CH), 131.8 (s, ar-qC), 130.3 (s, ar-C), 126.1 (s, ar-C), 118.8 (s, CH2=CH), 
117.3 (s, C≡N), 97.8 (s, C=CH), 66.1 (s, CH2), 20.4 (s, CH3). 
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IR (ATR): ṽ/cm-1 = 3067 (w), 2961 (w), 2888 (w), 2211 (s), 1706 (s), 1606 (m), 1568 (w), 
1459 (w), 1411 (m), 1362 (m), 1270 (s), 1186 (m), 1003 (m), 972 (m), 940 (s), 859 (m), 824 
(m), 764 (s), 693 (m), 650 (w). 
MS (EI, 70 eV, 200 °C) m/z (%): 227.1 (11), 171.1 (33), 170.1 (100), 143.1 (22), 142.1 (22), 
115.1 (20). 
EA (C14H13NO2): calc.: C 73.99, H 5.77 N 6.16; found: C 74.28, H 5.78, N 6.33. 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 10 min): tR = 28.24 min. 
 
2-(4-Bromophenyl)-2-methyl-1,3-dioxolane (6.90) 
 
To a solution of 4'-bromoacetophenone (8.50 g, 41.7 mmol, 1.00 eq.) in toluene (70 mL) 
ethylene glycol (3.88 mL, 3.48 g, 62.5 mol, 1.50 eq.) and para-toluenesulfonic acid 
monohydrate (396 mg, 2.08 mmol, 0.05 eq.) were added. A dean stark apparatus was attached 
and the solution was stirred for 16 h at reflux. The reaction mixture was washed with 
NaHCO3 (3 × 30 mL), the organic layer was dried over MgSO4 and the solvent was 
evaporated under reduced pressure. Purification by bulb-to-bulb distillation (150 °C/0.1 bar) 
afforded the product (9.80 g, 40.3 mmol, 97%) as a colorless solid. 
C10H11BrO2 (243.10 g/mol):  
MP: 43 °C. 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.39-7.32 (m, 2H, ar-H), 7.28-7.23 (m, 2H, ar-H), 
3.97-3.89 (m, 2H, CH2), 3.68-3.61 (m, 2H, CH2), 1.53 (s, 3H, CH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 142.6, 131.5, 127.3, 122.0, 108.6, 64.6, 27.7. 
MS (EI, 70 eV, 200 °C) m/z (%): 230.0 (10), 229.0 (97), 228.0 (10), 227.0 (100), 185.0 (44), 
183.0 (47), 157.0 (10), 155.0 (11), 103.1 (11), 87.1 (32), 77.0 (11), 76.1 (13), 75.0 (12), 43.0 
(73). 
Obtained data are in accordance with literature data.
[155]
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1-(4-(2-Hydroxypropan-2-yl)phenyl)ethan-1-one (6.91) 
 
Magnesia swarf (286 g, 11.8 mmol, 1.05 eq.) was layered with Et2O (5 mL) and 2-(4-
bromophenyl)-2-methyl-1,3-dioxolane (146 mg, 0.56 mmol, 0.05 eq.) was added. After 
starting of the reaction a solution of 2-(4-bromophenyl)-2-methyl-1,3-dioxolane (2.58 g, 
10.6 mmol, 0.95 eq.) in Et2O (35 mL) was added and the reaction mixture was stirred for 16 h 
at room temperature. H2O (30 mL) was added and the reaction mixture was extracted with 
EtOAc (3× 30 mL). The combined organic layers were dried over MgSO4 and the solvent was 
evaporated under reduced pressure. The crude acetal was dissolved in a dioxane:H2O mixture 
(1:1, 100 mL), 3 M HCl (25 mL) was added and the mixture was stirred for 30 min at room 
temperature. The reaction mixture was extracted with CH2Cl2 (3 × 100 mL) and the combined 
organic layers were dried over MgSO4. Purification by column chromatography (SiO2, d × h: 
3 × 20 cm, cyclohexane:EtOAc (2:1)) afforded the product (1.78 g, 9.99 mol, 89%) as a 
colorless solid.  
C11H14O2 (178.23 g/mol):  
MP: 78-80 °C. 
TLC: Rf = 0.21 (SiO2, cyclohexane:ethyl acetate (5:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.90 (d, 
3
JHH = 8.5 Hz, 2H, ar-H), 7.57 (d, 
3
JHH = 
8.5 Hz, 2H, ar-H), 2.57 (s, 3H, CH3), 2.20 (s, 1H, OH), 1.58 (s, 6H, C(CH3)2). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 198.2 (s, C=O), 154.8 (s, ar-qC), 135.8 (s, ar-qC), 
128.6 (s, ar-C), 124.9 (s, ar-C), 72.7 (s, COH), 31.9 (s, CH3), 26.8 (s, CH3). 
MS (EI, 70 eV, 200 °C) m/z (%): 164.1 (10), 163.1 (88), 121.1 (22), 43 (100). 
Obtained data are in accordance with literature data.
[156]
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1-(4-(Prop-1-en-2-yl)phenyl)ethan-1-one (6.92) 
 
A round bottomed flask was charged with 1-(4-(2-hydroxypropan-2-yl)phenyl)ethan-1-one 
(1.39 g, 7.80 mmol, 1.00 eq.) and potassium disulfate (604 mg, 2.34 mmol, 0.30 eq.). The 
reaction mixture was stirred for 90 min at 190 °C. Purification by column chromatography 
(SiO2, d × h: 2 × 20 cm, pentane:Et2O (2:1)) afforded the product (1.11 g, 6.91 mmol, 89%) as 
a colorless solid. 
C11H12O (160.22 g/mol): 
MP: 51-52 °C. 
TLC: Rf = 0.73 (SiO2, pentane:Et2O (9:1), UV). 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.91 (d, 
3
JHH = 8.5 Hz, 2H, ar-H), 7.53 (d, 
3
JHH = 
8.5 Hz, 2H, ar-H), 5.47 (s, 1H, C=CH2), 5.21-5.19 (m, 1H, C=CH2), 2.59 (s, 3H, CH3), 2.17 (s, 
3H, CH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 197.7 (s, C=O), 145.9 (s, ar-qC), 142.5 (s, 
C=CH2), 136.1 (s, ar-qC), 128.5 (s, ar-C), 125.7 (s, ar-C), 114.9 (s, C=CH2), 26.7 (s, CH3), 
21.7 (s, CH3). 
IR (ATR): ṽ/cm-1 = 3004 (w), 2977 (w), 2947 (w), 1915 (w, 1837 (w), 1669 (s), 1624 (w), 
1602 (m), 1557 (m), 1463 (w), 1401 (m), 1356 (m), 1310 (w), 1268 (m), 1190 (m), 1120 (m), 
1013 (m), 956 (m), 916 (m), 839 (s), 683 (w), 646 (m). 
MS (EI, 70 eV, 200 °C) m/z (%): 160.1 (41), 146.1 (14), 145.1 (100), 117.1 (16), 115.1 (41), 
91.1 (15). 
Obtained data are in accordance with literature data.
[157]
 
 
(E)-3-(4-(Prop-1-en-2-yl)phenyl)but-2-enenitrile (6.94) 
 
The -unsaturated nitrile was synthesized according to general procedure GP9 using NaH 
(374 mg, 9.36 mmol, 1.50 eq., 60% in mineral oil) in THF (35 mL), diethyl 
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cyanomethylphosphonate (1.21 mL, 1.33 g, 7.49 mmol, 1.20 eq.), 1-(4-(prop-1-en-2-
yl)phenyl)ethanone (1.00 g, 6.24 mmol, 1.00 eq.). Purification by column chromatography 
(SiO2, d × h: 5 × 24 cm, pentane:Et2O (45:1)) afforded the product (910 mg, 4.97 mmol, 80%) 
as a colorless solid. 
C13H13N (183.25 g/mol):  
MP: 62-63 °C. 
TLC: Rf = 0.51 (SiO2, pentane:Et2O (30:1), UV).  
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.50 (d, 
3
JHH = 8.6 Hz, 2H, ar-H), 7.44 (d, 
3
JHH = 
8.5 Hz, 2H, ar-H), 5.64 (q, 
4
JHH = 1.2 Hz, 1H, C=CH), 5.44 (s, 1H, C=H2), 5.17 (m, 
4
JHH = 
1.5 Hz, 1H, C=H2), 2.47 (d, 
4
JHH = 1.1 Hz, 3H, CH3), 2.16 (s, 3H, CH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 159.2 (s, C=CH), 143.2, 142.3, 137.1 (s, ar-qC), 
126.0 (s, ar-C), 125.9 (s, ar-C), 117.8 (s, C≡N), 114.0 (s, C=CH2), 95.2 (s, C=CH), 21.7 (s, 
CH3), 20.1 (s, CH3).  
IR (ATR): ṽ/cm-1 = 3064 (w), 2987 (w), 2944 (w), 2211 (s), 1917 (w), 1832 (w), 1593 (s), 
1508 (w), 1440 (m), 1379 (m), 1257 (m), 1120 (w), 1010 (w), 914 (s), 810 (s), 753 (m). 
MS (EI, 70 eV, 200 °C) m/z (%): 184.1 (14), 183.1 (100), 182.1 (18), 168.1 (43), 167.1 (20), 
153.1 (11), 143.1 (27), 141.1 (15), 128.1 (11), 115.1 (22). 
EA (C13H13N): calc.: C 85.21, H 7.15, N 7.64; found: C 84.94, H 7.14, N 7.71. 
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8.6.3 Hydrogenation products of α,β-unsaturated nitriles  
General procedure: Iridium-catalyzed hydrogenation with DIPEA as 
additive GP10 
 
Typical procedure for Ir-catalyzed hydrogenation with DIPEA as additive: The iridium 
catalyst (1.0 mol%) was added to a solution of substrate (0.10 mmol) and DIPEA (74.4 L, 
0.45 mmol, 4.50 eq.) in MeOH (0.5 mL). The reaction vial was equipped with a magnetic stir 
bar and placed in an autoclave that was pressurized to 100 bar with H2. The reaction mixture 
was stirred at 800 rpm for 4 h and, after this time, hydrogen was released and the solvent 
removed under reduced pressure. The mixture was filtered through a plug of silica gel (d × h: 
0.5 × 2.0 cm) using a mixture of pentane:Et2O (1:1, 5.0 mL). After evaporation of the solvent, 
the analytically pure hydrogenation product was obtained. 
 
3-Phenylbutanenitrile (6.17) 
 
The enantiomerically enriched product was obtained as a colorless liquid according to the 
standard hydrogenation protocol GP10 using iridium catalysts. The racemic sample was 
prepared according to general procedure GP8. 
C10H11N (145.20 g/mol):  
1
H NMR
 
(400 MHz, CD2Cl2): /ppm = 7.40-7.32 (m, 2H, ar-H), 7.30-7.23 (m, 3H, ar-H), 
3.23-3.08 (m, 1H, CH), 2.68-2.50 (m, 2H, CH2), 1.42 (d, J = 7.0 Hz, 3H, CH3). 
13
C{
1
H} NMR (101 MHz, CD2Cl2): ppm = 144.0 (s, ar-qC), 129.3 (s, ar-C), 127.7 (s, ar-C), 
127.1 (s, ar-C), 119.1 (s, C≡N), 37.1 (s, CH), 26.7 (s, CH2), 21.1 (s, CH3). 
MS (EI, 70 eV, 200 °C) m/z (%): 145.1 (17), 105.1 (100), 130.1 (12), 79.1 (11), 77.1 (13). 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 10 min): tR = 15.30 min. 
HPLC: Daicel, Chiralcel OD-H (0.46 cm × 25 cm, heptane/iso-propanol = 98:02, 0.5 mL/min, 
20 °C, 208 nm): tR = 32.0 min (), 39.4 min (). 
Obtained data are in accordance with literature data.
[110b]
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3-Phenylpentanenitrile  
 
The enantiomerically enriched product was obtained as a colorless liquid according to the 
standard hydrogenation protocol GP10 using iridium catalysts. The racemic sample was 
prepared according to general procedure GP8. 
C11H13N (159.23 g/mol):  
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.40-7.29 (m, 2H, ar-H), 7.29-7.23 (m, 1H, ar-H), 
7.22-7.13 (m, 2H, ar-H), 2.89-2.78 (m, 1H, CH), 2.60-2.56 (m, 2H, CH2), 1.96-1.83 (m, 1H, 
CH2), 1.80-1.61 (m, 1H, CH2), 0.84 (t, 
3
JHH = 7.4 Hz, 3H, CH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 141.7 (s, ar-qC), 128.9 (s, ar-C), 127.4 (s, ar-C), 
127.3 (s, ar-C), 118.8 (s, C≡N), 43.9 (s, CH), 28.0 (s, CH2), 24.8 (s, CH2), 11.9 (s, CH3). 
MS (EI, 70 eV, 200 °C) m/z (%): 159.1 (24), 130.1 (26), 119.1 (50), 103.1 (18), 91.1 (100), 
77.1 (14). 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 10 min): tR = 16.74 min. 
HPLC: Daicel, Chiralcel OD-H (0.46 cm × 25 cm, heptane/iso-propanol = 95:05, 0.5 mL/min, 
25 °C, 215 nm): tR = 19.6 min (), 25.2 min (). 
[α]
20
D  = 17.9 (c = 0.90, CHCl3) for ee = 98%. 
Obtained data are in accordance with literature data.
[110b]
  
 
3-Phenylhexanenitrile 
 
The enantiomerically enriched product was obtained as a colorless liquid according to the 
standard hydrogenation protocol GP10 using iridium catalysts. The racemic sample was 
prepared according to general procedure GP8. 
C12H15N (173.26 g/mol):  
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1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.38-7.33 (m, 2H, ar-H), 7.31-7.25 (m, 1H, ar-H), 
7.25-7.19 (m, 2H, ar-H), 3.00-2.93 (m, 1H, CH), 2.60 (d, J = 6.9 Hz, 2H, CH2), 1.90-1.67 (m, 
2H, CH2), 1.34-1.16 (m, 2H, CH2), 0.91 (t, J = 7.3 Hz, 3H, CH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 142.1 (s, ar-qC), 129.1 (s, ar-C), 127.5 (s, ar-C), 
127.4 (s, ar-C), 118.9 (s, C≡N), 42.2 (s, CH), 37.3 (s, CH2), 25.3 (s, CH2), 20.6 (s, CH2), 14.0 
(s, CH3). 
IR (ATR): ṽ/cm-1 = 3030 (w), 2959 (m), 2931 (m), 2872 (w), 2246 (w), 1603 (w), 1494 (w), 
1454 (m), 1380 (m), 1331 (w), 1108 (w), 1073 (w), 1030 (w), 761 (m), 701 (s), 666 (m), 627 
(m). 
MS (EI, 70 eV, 200 °C) m/z (%): 173.1 (14), 133.1 (27), 130.1 (16), 104.1 (13), 103.1 (12), 
92.1 (10), 91.1 (100). 
HRMS (EI): (m/z) calc. for C12H15N
+
: 173.1199 [M]
+
; found: 173.1198. 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 10 min): tR = 18.26 min. 
HPLC: Daicel, Chiralcel OD-H (0.46 cm × 25 cm, heptane/iso-propanol = 98:02, 0.5 mL/min, 
25 °C, 215 nm): tR = 25.3 min (), 33.7 min (). 
[α]
20
D  = 13.9 (c = 1.2 CHCl3) for ee = 98%.  
 
5-Methyl-3-phenylhexanenitrile  
 
The enantiomerically enriched product was obtained as a colorless liquid according to the 
standard hydrogenation protocol GP10 using iridium catalysts. The racemic sample was 
prepared according to general procedure GP8. 
C13H17N (187.29 g/mol):  
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.38-7.32 (m, 2H, ar-H), 7.30-7.20 (m, 3H, ar-H), 
3.10-2.98 (m, 1H, CH), 2.56 (d, J = 6.9 Hz, 2H, CH2), 1.79-1.71 (m, 1H, CH2), 1.67-1.51 (m, 
1H, CH2), 1.47-1.32 (m, 1H, CH(CH3)), 0.89 (m, 6H, CH(CH3)2). 
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13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 141.9 (s, ar-qC), 129.0 (s, ar-C), 127.4 (s, ar-C), 
127.3 (s, ar-C), 118.7 (s, C≡N), 44.1 (s, CH2), 40.1 (s, CH), 25.7 (s, CH2), 25.4 (s, CH), 23.3 
(s, CH3), 21.7 (s, CH3). 
IR (ATR): ṽ/cm-1 = 2957 (m), 2928 (w), 2870 (w), 14945 (w), 1468 (w), 1368 (w), 892 (w), 
761 (w), 702 (m), 632 (s). 
MS (EI, 70 eV, 200 °C) m/z (%): 187.1 (18), 147.2 (23), 131.1 (11), 130.1 (19), 105.1 (45), 
104.1 (48), 103.1 (14), 91.1 (100), 77 (11). 
HRMS (EI): (m/z) calc. for C13H17N
+
: 187.1356 [M]
+
; found: 187.1353. 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 10 min): tR = 18.96 min.  
HPLC: Daicel, Chiralcel OD-H (0.46 cm × 25 cm, heptane/iso-propanol = 96:04, 0.5 mL/min, 
25 °C, 212 nm): tR = 19.7 min (), 23.3 min (+). 
[α]
20
D  = +19.5 (c = 0.81, CHCl3) for ee = 98%. 
 
3-(m-Tolyl)butanenitrile 
 
The enantiomerically enriched product was obtained as a colorless liquid according to the 
standard hydrogenation protocol GP10 using iridium catalysts. The racemic sample was 
prepared according to general procedure GP8. 
C11H13N (159.23 g/mol): 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.29-7.16 (m, 1H, ar-H), 7.13-6.97 (m, 3H, ar-H), 
3.18-3.02 (m, 1H, CH), 2.62-2.42 (m, 2H, CH2), 2.35 (d, 
4
JHH = 0.9 Hz, 3H, CH3), 1.43 (d, 
3
JHH = 7.0 Hz, 3H, CH3).
 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 143.2 (s, ar-qC), 138.5 (s, ar-qC), 128.1 (s, ar-C), 
128.1 (s, ar-C), 127.4 (s, ar-C), 123.6 (s, ar-C), 118.7 (s, C≡N), 36.6 (s, CH), 26.4 (s, CH2), 
21.5 (s, CH3), 20.8 (s, CH3). 
IR (ATR): ṽ/cm-1 = 3025 (w), 2967 (w), 2924 (w), 2247 (w), 1608 (w), 1491 (m), 1458 (m), 
1381 (m), 1345 (w), 1164 (w), 883 (w), 786 (m), 704 (s), 665 (m), 630 (s). 
MS (EI, 70 eV, 200 °C) m/z (%): 159.1 (22), 120.1 (11), 119.1 (100), 117.1 (13), 91.1 (18). 
HRMS (EI): (m/z) calc. for C11H13N
+
: 159.1043 [M]
+
; found: 159.1037. 
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GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 10 min): tR = 16.86 min.  
HPLC: Daicel, Chiralcel OD-H (0.46 cm × 25 cm, heptane/iso-propanol = 96:04, 0.5 mL/min, 
25 °C, 220 nm): tR = 17.9 min (+), 21.2 min (). 
[α]
20
D  = +0.3 (c = 1.06, CHCl3) for ee = 96%. 
 
3-(p-Tolyl)butanenitrile 
 
The enantiomerically enriched product was obtained as a colorless liquid according to the 
standard hydrogenation protocol GP10 using iridium catalysts. The racemic sample was 
prepared according to general procedure GP8. 
C11H13N (159.23 g/mol): 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.23-7.02 (m, 4H, ar-H), 3.20-3.07 (m, 1H, CH), 2.60 
(dd, 
2
JHH = 16.7 Hz, 
3
JHH = 6.5 Hz, 1H, CH2), 2.53 (dd, 
2
JHH = 16.7 Hz, 
3
JHH = 7.5 Hz, 1H, 
CH2), 2.35 (s, 3H, CH3), 1.44 (d, 
3
JHH = 7.0 Hz, 3H, CH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 140.4 (s, ar-qC), 137.1 (s, ar-qC), 129.7 (s, ar-C), 
126.6 (s, ar-C), 118.9 (s, C≡N), 36.3 (s, CH), 26.6 (s, CH2), 21.2 (s, CH3), 20.9 (s, CH3). 
MS (EI, 70 eV, 200 °C) m/z (%): 159.1 (17), 120.1 (10), 119.1 (100), 117.1 (13), 91.1 (18). 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 10 min): tR = 17.10 min. 
HPLC: Daicel, Chiralcel OD-H (0.46 cm × 25 cm, heptane/iso-propanol = 96:04, 0.5 mL/min, 
25 °C, 208 nm): tR = 19.6 min (S), 23.0 min (R). 
[α]
20
D  = 2.0 (c = 0.61, CHCl3) for ee = 92% (R). 
Obtained data are in accordance with literature data.
[110b]
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3-(o-Tolyl)butanenitrile 
 
The enantiomerically enriched product was obtained as a colorless liquid according to the 
standard hydrogenation protocol GP10 using iridium catalysts. The racemic sample was 
prepared according to general procedure GP8. 
C11H13N (159.23 g/mol): 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.25-7.02 (m, 4H, ar-H), 3.52-3.35 (m, 1H, CH), 2.66-
2.44 (m, 2H, CH2), 2.37 (s, 3H, CH3), 1.44 (d, 
3
JHH = 7.0 Hz, 3H, CH3). 
13
C{
1
H}NMR (101 MHz, CDCl3): ppm = 141.4 (s, ar-qC), 135.2 (s, ar-C), 130.9 (s, ar-qC), 
127.1 (s, ar-C), 126.8 (s, ar-C), 124.8 (s, ar-C), 118.8 (s, C≡N), 31.8 (s, CH), 25.4 (s, CH2), 
20.5 (s, CH3), 19.5 (s, CH3). 
MS (EI, 70 eV, 200 °C) m/z (%): 159.1 (29), 119.1 (100), 117.1 (15), 91.1 (19). 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 10 min): tR = 17.26 min. 
HPLC: Daicel, Chiralcel OD-H (0.46 cm × 25 cm, heptane/iso-propanol = 92:08, 0.5 mL/min, 
25 °C, 208 nm): tR = 18.5 min, 31.0 min. 
Obtained data are in accordance with literature data.
[110b]
 
 
4-Methyl-3-phenylpentanenitrile 
 
The enantiomerically enriched product was obtained as a colorless liquid according to the 
standard hydrogenation protocol GP10 using iridium catalysts. The racemic sample was 
prepared according to general procedure GP8. 
C12H15N (173.26 g/mol):  
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.40-7.30 (m, 2H, ar-H), 7.30-7.23 (m, 1H, ar-H), 
7.20-7.18 (m, 2H, ar-H), 2.76-2.55 (m, 3H, CH2 and CH), 2.16-1.97 (m, 1H, CH), 1.02 (d, 
3
JHH = 6.7 Hz, 3H, CH3), 0.77 (d, 
3
JHH = 6.7 Hz, 3H, CH3). 
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13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 141.3 (s, ar-qC), 128.8 (s, ar-C), 128.0 (s, ar-C), 
127.4 (s, ar-C), 119.1 (s, C≡N), 49.3 (s, CH), 32.2 (s, CH), 22.6 (s, CH2), 20.9 (s, CH3), 20.5 
(s, CH3).  
MS (EI, 70 eV, 200 °C) m/z (%): 173.1 (23), 133.2 (12), 131.1 (18), 130.1 (21), 105.1 (17), 
104.2 (100), 103.1 (16), 91.1 (32), 77.1 (11). 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 10 min): 18.00 min. 
HPLC: Daicel, Chiralcel OD-H (0.46 cm × 25 cm, heptane/iso-propanol = 95:05, 0.5 mL/min, 
25 °C, 208 nm) tR = 17.7 min (), 27.8 min (+). 
[α]
20
D  = 12.6 (c = 0.96, CHCl3) for ee = 62%.  
Obtained data are in accordance with literature data.
[110b]
 
 
3-(4-Methoxyphenyl)butanenitrile 
 
The enantiomerically enriched product was obtained as a colorless liquid according to the 
standard hydrogenation protocol GP10 using iridium catalysts. The racemic sample was 
prepared according to general procedure GP8. 
C11H13NO (175.23 g/mol):  
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.17 (d, J = 8.7 Hz, 2H, ar-H), 6.88 (d, J = 8.7 Hz, 2H, 
ar-H), 3.80 (s, 3H, OCH3), 3.17-3.07 (m, 1H, CH), 2.61-2.47 (m, 2H, CH2), 1.43 (d, J = 
7.0 Hz, 3H, CH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 158.9 (s, ar-qC), 135.4 (s, ar-qC), 127.7 (s, ar-C), 
118.9 (s, ar-C), 114.4 (s, C≡N), 55.4 (s, OCH3), 35.9 (s, CH), 26.8 (s, CH2), 21.0 (s, CH3). 
IR (ATR): ṽ/cm-1 = 2965 (m), 2935 (w), 2838 (w), 2246 (w), 1613 (m), 1584 (w), 1515 (s), 
1460 (m), 1424 (w), 1298 (m), 1250 (s), 1181 (m), 1350 (m), 831 (m), 633 (s). 
MS (EI, 70 eV, 200 °C) m/z (%): 175.1 (15), 136.1 (11), 135.1 (100), 105.1 (16). 
EA (C11H13NO): calc.: C 75.40, H 7.48, N 7.99; found: C 75.11, H 7.39, N 7.95. 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 10 min): tR = 22.45 min. 
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HPLC: Daicel, Chiralcel OD-H (0.46 cm × 25 cm, heptane/iso-propanol = 95:05, 0.5 mL/min, 
25 °C, 208 nm): tR = 24.1 min (), 28.2 min (). 
[α]
20
D  = +9.6 (c = 0.96, CHCl3) for ee = 92%.  
 
3-(3-Methoxyphenyl)butanenitrile 
 
The enantiomerically enriched product was obtained as a colorless liquid according to the 
standard hydrogenation protocol GP10 using iridium catalysts. The racemic sample was 
prepared according to general procedure GP8. 
C11H13NO (175.23 g/mol):  
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.29-7.25 (m, 1H, ar-H), 6.85-6.76 (m, 3H, ar-H), 3.81 
(s, 3H, OCH3), 3.13 (m, 1H, CH), 2.66-2.46 (m, 2H, CH2), 1.44 (d, 
3
JHH = 7.0 Hz, 3H, CH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 160.0 (s, ar-qC), 144.9 (s, ar-qC), 130.0 (s, ar-C), 
118.9 (s, ar-C), 118.7 (s, C≡N), 112.8 (s, ar-C), 112.4 (s, ar-C), 55.3 (s, OCH3), 36.7 (s, CH), 
26.3 (s, CH2), 20.7 (s, CH3). 
IR (ATR): ṽ/cm-1 = 2966 (s), 2939 (m), 2837 (m), 2247 (w), 1602 (s), 1571 (s), 1489 (s), 
1455 (m), 1381 (w), 1347 (w), 1318 (w), 1294 (m), 1262 (s), 1160 (m), 1045 (m), 880 (m), 
787 (w), 701 (m), 633 (s). 
MS (EI, 70 eV, 200 °C) m/z (%): 175.1 (28), 136.1 (11), 135.1 (100), 105.1 (20), 103.5 (10). 
HRMS (EI): (m/z) calc. for C11H13NO
+
: 175.0992 [M]
+
; found: 175.0990. 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 10 min): tR = 20.18 min. 
HPLC: Daicel, Chiralcel OD-H (0.46 cm × 25 cm, heptane/iso-propanol = 92:08, 0.5 mL/min, 
25 °C, 217 nm): tR = 38.0 min (+), 56.2 min (). (Due to overlay with starting material full 
conversion is necessary to determine the ee of this hydrogenation). 
[α]
20
D  = +1.5 (c = 0.92, CHCl3) for ee = 97%. 
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3-(4-Chlorophenyl)butanenitrile 
 
The enantiomerically enriched product was obtained as a colorless liquid according to the 
standard hydrogenation protocol GP10 using iridium catalysts. The racemic sample was 
prepared according to general procedure GP10 by the use of Crabtree’s catalyst. 
C10H10ClN (179.65 g/mol):  
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.36-7.28 (m, 2H, ar-H), 7.22-7.11 (m, 2H, ar-H), 
3.23-3.05 (m, 1H, CH), 2.68-2.40 (m, 2H, CH2), 1.43 (d, 
3
JHH = 7.0 Hz, 3H, CH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 141.6 (s, ar-qC), 133.2 (s, ar-qC), 129.1 (s, ar-C), 
128.1 (s, ar-C), 118.3 (s, C≡N), 36.1 (s, CH), 26.4 (s, CH2), 20.7 (s, CH3). 
MS (EI, 70 eV, 200 °C) m/z (%): 179.1 (14), 141.1 (31), 139.1 (100), 103.1 (45), 77.1 (16). 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 10 min): tR = 20.04 min. 
HPLC: Daicel, Chiralcel OD-H (0.46 cm × 25 cm, heptane/iso-propanol = 96:04, 0.5 mL/min, 
25 °C, 220 nm): tR = 24.8 min (+), 27.1 min (). 
[α]
20
D  = 3.9 (c = 0.49, CHCl3) for ee = 97%. 
Obtained data are in accordance with literature data.
[110b]
  
 
3-(3-Chlorophenyl)butanenitrile 
 
The enantiomerically enriched product was obtained as a colorless liquid according to the 
standard hydrogenation protocol GP10 using iridium catalysts. The racemic sample was 
prepared according to to general procedure GP10 by the use of Crabtree’s catalyst. 
C10H10ClN (179.65 g/mol):  
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.31-7.19 (m, 3H, ar-H), 7.15-7.12 (m, 1H, ar-H), 
3.13-3.10 (m, 1H, CH), 2.66-2.47 (m, 2H, CH2), 1.44 (d, J = 7.0 Hz, 3H, CH3). 
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13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 145.2 (s, ar-qC), 134.8 (s, ar-qC), 130.3 (s, ar-C), 
127.7 (s, ar-C), 127.0 (s, ar-C), 125.0 (s, ar-C), 118.3 (s, C≡N), 36.5 (s, CH), 26.3 (s, CH2), 
20.7 (s, CH3). 
IR (ATR): ṽ/cm-1 = 3068 (w), 2970 (m), 2933 (w), 2249 (w), 1597 (m), 1273 (m), 1478 (m), 
1432 (m), 1382 (w), 1341 (w), 1198 (w), 1084 (m), 882 (w), 698 (s), 632 (s). 
MS (EI, 70 eV, 200 °C) m/z (%): 179.1 (21), 141.1 (31), 140.1 (10), 139.1 (100), 103.1 (44), 
77.0 (14). 
HRMS (EI): (m/z) calc. for C10H10ClN
+
: 179.0497 [M]
+
; found: 179.0499. 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 10 min): tR = 19.85 min.  
HPLC: Daicel, Chiralcel OD-H (0.46 cm × 25 cm, heptane/iso-propanol = 96:04, 0.5 mL/min, 
25 °C, 220 nm): tR = 27.7 min (+), 36.9 min (). 
[α]
20
D  = +1.7 (c = 1.09, CHCl3) for ee = 97%. 
 
3-(4-Fluorophenyl)butanenitrile 
 
The enantiomerically enriched product was obtained as a colorless liquid according to the 
standard hydrogenation protocol GP10 using iridium catalysts. The racemic sample was 
prepared according to general procedure GP8. 
C10H10FN (163.20 g/mol):  
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.25-7.17 (m, 2H, ar-H), 7.08-6.99 (m, 2H, ar-H), 
3.20-3.12 (m, 1H, CH), 2.63-2.49 (m, 2H, CH2), 1.43 (d, 
3
JHH = 7.0 Hz, 3H, CH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 162.1 (d, 
1
JCF = 246 Hz, ar-qC), 139.0 (d, 
4
JCF = 
3 Hz, ar-qC), 128.3 (d, 
3
JCF = 8 Hz, ar-C), 118.5 (s, C≡N), 115.9 (d, 
2
JCF = 21 Hz, ar-C), 36.0 
(s, CH), 26.7 (s, CH2), 20.9 (s, CH3). 
19
F{
1
H} NMR (376 MHz, CDCl3): ppm = 115.1 (s). 
IR (ATR): ṽ/cm-1 = 3044 (w), 2970 (w), 2248 (w), 1605 (m), 1511 (s), 1459 (m), 1422 (m), 
1383 (w), 1343 (w), 1224 (s), 1161 (m), 1094 (w), 1015 (m), 833 (s), 670 (m), 627 (m). 
MS (EI, 70 eV, 200 °C) m/z (%): 163.1 (14), 123.1 (100), 103.5 (36). 
HRMS (EI): (m/z) calc. for C10H10FN
+
: 163.0792 [M]
+
; found: 163.0793. 
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GC (Chiraldex -cyclodextrin TFA G-TA (30 m × 0.25 mm × 0.12 m), 60 kPa H2 (50 °C – 
0 min – 10 °C/min – 100 °C – 0 min – 2 °C/min – 140 °C – 10 °C/min – 160 °C – 5 min), tR = 
19.47 min (+), 19.87 min (). 
[α]
20
D  = +0.5 (c = 0.46, CHCl3) for ee = 90%. 
 
3-(4-Bromophenyl)butanenitrile 
 
The enantiomerically enriched product was obtained as a colorless liquid according to the 
standard hydrogenation protocol GP10 using iridium catalysts. The racemic sample was 
prepared according to general procedure GP10 by the use of Crabtree’s catalyst. 
C10H10BrN (224.10 g/mol):  
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.47 (d, 
3
JHH = 8.4 Hz, 2H, ar-H), 7.13 (d, 
3
JHH = 
8.4 Hz, 2H, ar-H), 3.20-3.05 (m, 1H, CH), 2.65-2.48 (m, 2H, CH2), 1.43 (d, 
3
JHH = 7.1 Hz, 3H, 
CH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 142.2 (s, ar-qC), 132.1 (s, ar-C), 128.5 (s, ar-C), 
121.3 (s, ar-qC), 118.3 (s, C≡N), 36.2 (s, CH), 26.4 (s, CH2), 20.7 (s, CH3). 
IR (ATR): ṽ/cm-1 = 2969 (m), 2929 (w), 2247 (m), 1901 (w), 1593 (w), 1489 (s), 1422 (m), 
1334 (w), 1010 (s), 902 (w), 822 (s), 629 (w). 
MS (EI, 70 eV, 200 °C) m/z (%): 225.0 (24), 223.0 (24), 185.0 (88), 183.0 (88), 105.1 (10), 
104.1 (100), 103.1 (23), 102.1 (11), 78.1 (11), 77.1 (19), 51.1 (10). 
HRMS (EI): (m/z) calc. for C10H10BrN
+
: 222.9992 [M]
+
; found: 222.9990. 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 10 min): tR = 21.98 min. 
HPLC: Daicel, Chiralpak AS-H (0.46 cm × 25 cm, heptane/iso-propanol = 97:03, 
0.5 mL/min, 25 °C, 220 nm): tR = 29.8 min (), 34.3 min (+). 
[α]
20
D  = +2.8 (c = 1.55, CHCl3) for ee = 97%. 
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N-(4-(1-Cyanopropan-2-yl)phenyl)acetamide 
 
The enantiomerically enriched product was obtained as a colorless liquid according to the 
standard hydrogenation protocol GP10 using iridium catalysts. MeOH was used as eluent. 
The racemic sample was prepared according to general procedure GP8. 
C12H14N2O (143.19 g/mol): 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.47 (d, J = 8.5 Hz, 2H, ar-H), 7.39 (s br, 1H, NH), 
7.19 (d, J = 8.5 Hz, 2H, ar-H), 3.20-3.06 (m, 1H, CH), 2.66-2.42 (m, 2H, CH2), 2.16 (s, 3H, 
CH3), 1.42 (d, J = 7.0 Hz, 3H, CH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 168.5 (s, C=O), 139.1 (s, ar-qC), 137.2 (s, ar-qC), 
127.3 (s, ar-C), 120.5 (s, ar-C), 118.7 (s, C≡N), 36.1 (s, CH), 26.6 (s, CH2), 24.7 (s, CH3), 
20.8 (s, CH3). 
IR (ATR): ṽ/cm-1 = 3310 (m), 3191 (w), 3123 (w), 3062 (w), 2967 (w), 1665 (s), 1601 (s), 
1522 (s), 1458 (w), 1414 (s), 1371 (m), 1317 (s), 1363 (m), 1014 (m), 965 (w), 833 (m), 631 
(s). 
MS (EI, 70 eV, 200 °C) m/z (%): 202.1 (18), 162.1 (33), 121.1 (12), 120.1 (100), 43.0 (13). 
HRMS (EI): (m/z) calc. for C12H14N2O
+
: 202.1101 [M]
+
; found: 202.1102. 
GC (Optima 5 (30 m × 0.25 mm × 0.5 m) 60 kPa He (150 °C – 0 min – 10 °C/min – 
250 °C – 20 min)): tR = 18.87 min. 
HPLC: Daicel, Chiralpak IC (0.46 cm × 25 cm, heptane/iso-propanol = 80:20, 0.5 mL/min, 
25 °C, 246 nm):tR = 61.0 min (), 66.3 min (+). 
[α]
20
D  = +6.4 (c = 0.59, CHCl3) for ee = 96%. 
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Methyl 4-(1-cyanopropan-2-yl)benzoate 
 
The enantiomerically enriched product was obtained as a colorless liquid according to the 
standard hydrogenation protocol GP10 using iridium catalysts. The racemic sample was 
prepared according to general procedure GP8. 
C12H13NO2 (203.24 g/mol): 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 8.00 (d, 
3
JHH = 8.3 Hz, 2H, ar-H), 7.31 (d, 
3
JHH = 
8.3 Hz, 2H, ar-H), 3.90 (s, 3H, OCH3), 3.26-3.17 (m, 1H, CH), 2.73-2.35 (m, 2H, CH2), 1.45 
(d, 
3
JHH = 7.0 Hz, 3H, CH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 166.9 (s, C=O), 148.4 (s, ar-qC), 130.4 (s, ar-C), 
129.5 (s, ar-qC), 126.9 (s, ar-C), 118.3 (s, C≡N), 52.3 (s, OCH3), 36.7 (s, CH), 26.2 (s, CH2), 
20.7 (s, CH3). 
IR (ATR): ṽ/cm-1 = 3067 (w), 2961 (w), 2888 (w), 2211 (s), 1706 (s), 1606 (m), 1568 (w), 
1459 (w), 1411 (m), 1362 (m), 1270 (s), 1186 (m), 1003 (m), 972 (m), 940 (s), 859 (m), 824 
(m), 764 (s), 693 (m), 650 (w). 
MS (EI, 70 eV, 200 °C) m/z (%): 203.1 (20), 172.1 (20), 164.1 (12), 163.1 (100), 132.1 (15), 
131.1 (17), 104.1 (13), 103.1 (14), 91.1 (13). 
HRMS (EI): (m/z) calc. for C12H13NO2
+
: 203.0941 [M]
+
; found: 203.0944. 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 10 min): tR = 25.00 min.  
HPLC: Daicel, Chiralcel OD-H (0.46 cm × 25 cm, heptane/iso-propanol = 96:04, 0.5 mL/min, 
25 °C, 233 nm): tR = 42.3 min (+), 47.6 min (). 
[α]
20
D  = 5.9 (c = 0.66, CHCl3) for ee = 98%. 
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4-(1-Cyanopropan-2-yl)benzonitrile 
 
The enantiomerically enriched product was obtained as a colorless solid according to the 
standard hydrogenation protocol GP10 using iridium catalysts. The racemic sample was 
prepared according to general procedure GP8. 
C11H10N2 (170.22 g/mol):  
MP: 47-48 °C. 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.66 (d, 
3
JHH = 8.4 Hz, 2H, ar-H), 7.38 (d, 
3
JHH = 8.3 Hz, 2H, ar-H), 3.22 (m, 1H, CH), 2.62-2.60 (m, 2H, CH2), 1.47 (d, 
3
JHH = 7.0 Hz, 
3H, CH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 148.4 (s, ar-qC), 132.9 (s, ar-C), 127.7 (s, ar-C), 
118.7 (s, C≡N), 117.8 (s, C≡N), 111.7 (s, ar-qC), 36.8 (s, CH), 26.1 (s, CH2), 20.5 (s, CH3). 
MS (EI, 70 eV, 200 °C) m/z (%): 170.1 (10), 131.1 (10), 130.1 (100), 103.1 (23). 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 10 min): tR = 25.53 min. 
HPLC: Daicel, Chiralpak AS-H (0.46 cm × 25 cm, heptane/iso-propanol = 60:40, 
0.5 mL/min, 25 °C, 220 nm): tR = 18.7 min (), 20.5 min (+). 
[α]
20
D  = +5.5 (c = 0.96, CHCl3) for ee = 93%. 
Obtained data are in accordance with literature data.
[158]
 
 
3-(Naphthalen-2-yl)butanenitrile 
 
The enantiomerically enriched product was obtained as a colorless solid according to the 
standard hydrogenation protocol GP10 using iridium catalysts. The racemic sample was 
prepared according to general procedure GP8. 
C14H13N (195.26 g/mol):  
MP: 54-57 °C.
 [66][63]
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1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.89-7.78 (m, 3H, ar-H), 7.71-7.67 (m, 1H, ar-H), 
7.53-7.44 (m, 2H, ar-H), 7.37 (dd, 
3
JHH = 8.5 Hz, 
4
JHH = 1.9 Hz, 1H, ar-H), 3.38-3.30 (m, 1H, 
CH), 2.78-2.57 (m, 2H, CH2), 1.55 (d, 
3
JHH = 7.0 Hz, 3H, CH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 140.6 (s, ar-qC), 133.6 (s, ar-qC), 132.8 (s, ar-qC), 
128.8 (s, ar-C), 127.9 (s, ar-C), 127.8 (s, ar-C), 126.5 (s, ar-C), 126.1 (s, ar-C), 125.3 (s, ar-C), 
124.9 (s, ar-C), 118.7 (s, C≡N), 36.8 (s, CH), 26.4 (s, CH2), 20.9 (s, CH3). 
MS (EI, 70 eV, 200 °C) m/z (%): 195.1 (23), 156.1 (13), 155.1 (100), 153.1 (16), 152.1 (10). 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 10 min): tR = 26.78 min. 
HPLC: Daicel, Chiralcel OD-H (0.46 cm × 25 cm, heptane/iso-propanol = 92:08, 0.5 mL/min, 
25 °C, 276 nm): tR = 34.9 min (+), 69.8 min (). 
[α]
20
D  = +7.5 (c = 1.47, CHCl3) for ee = 98%.  
Obtained data are in accordance with literature data.
[159]
 
 
3-(3-Nitrophenyl)butanenitrile 
 
The enantiomerically enriched product was obtained as a colorless liquid according to the 
standard hydrogenation protocol GP10 using iridium catalysts. The racemic sample was 
prepared according to general procedure GP10 by the use of Crabtree’s catalyst. 
C10H10N2O2 (190.20 g/mol): 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 8.24-8.05 (m, 2H, ar-H), 7.66-7.59 (m, 1H, ar-H), 
7.59-7.50 (m, 1H, ar-H), 3.38-3.24 (m, 1H, CH), 2.66 (dd, 
3
JHH = 6.9 Hz, 
4
JHH = 0.6 Hz, 2H, 
CH2), 1.51 (d, 
3
JHH = 7.0 Hz, 3H, CH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 148.7 (s, ar-qC), 145.1 (s, ar-qC), 133.2, (s, ar-C), 
130.1 (s, ar-C), 122.7 (s, ar-C), 121.8 (s, ar-C), 117.9 (s, C≡N), 36.5 (s, CH), 26.2 (s, CH2), 
20.6 (s, CH3). 
IR (ATR): ṽ/cm-1 = 2972 (w), 2932 (w), 2878 (w), 2250 (w), 1527 (s), 1459 (w), 1423 (w), 
1349 (s), 1102 (w), 894 (w), 810 (w), 739 (m), 689 (m), 631 (m). 
MS (EI, 70 eV, 200 °C) m/z (%): 190.1 (9), 150.1 (100), 120.1 (19), 104.1 (30), 103.1 (21), 
78.0 (10), 77.1 (14). 
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HRMS (EI): (m/z) calc. for C13H17N2O2
+
: 190.0737 [M]
+
; found: 190.0733. 
GC-MS (Restek Rtx-5MS (30 m × 0.25 mm × 0.25 m) 100 kPa He (50 °C – 2 min – 
30 °C/min – 250 °C –5 min): tR = 8.96 min.  
HPLC: Daicel, Chiralcel OD-H (0.46 cm × 25 cm, heptane/iso-propanol = 94:06, 0.5 mL/min, 
25 °C, 220 nm): tR = 51.6 min (), 56.5 min (+). 
[α]
20
D  = 0.8 (c = 0.45, CHCl3) for ee = 93%. 
 
3-Methyl-5-phenylpentanenitrile 
 
The enantiomerically enriched product was obtained as a colorless liquid according to the 
standard hydrogenation protocol GP10 using iridium catalysts. The racemic sample was 
prepared according to general procedure GP8. 
C12H15N (173.26 g/mol):  
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.33-7.24 (m, 2H, ar-H), 7.23-7.14 (m, 3H, ar-H), 
2.69-2.60 (m, 2H, alkyl-H), 2.38-2.22 (m, 2H, alkyl-H), 1.88 (m, 1H, alkyl-H), 1.77 (ddt, J = 
13.6, 9.5, 6.3 Hz, 1H, alkyl-H), 1.64 (m, 1H, alkyl-H), 1.13 (d, 
3
JHH = 6.7 Hz, 3H, CH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 141.6 (s, ar-qC), 128.6 (s, ar-C), 128.4 (s, ar-C), 
126.2 (s, ar-C), 118.8 (s, C≡N), 37.6 (s, alkyl–C), 33.2 (s, alkyl–C), 30.0 (s, alkyl–C), 24.6 (s, 
alkyl–C), 19.5 (s, CH3). 
MS (EI, 70 eV, 200 °C) m/z (%): 173.2 (13), 158.2 (35), 92.1 (30), 91.1 (100), 65.1 (11). 
Chiral GC (-Cyclodextrin, DEtTButSil (Brechbühler, SE54), (25 m × 0.25 mm × 0.25 μm) 
60 kPa He (50 °C – 0 min – 20 °C/min 108 °C – 60 min  5 °C/min  180 °C – 5 min): tR = 
55.8 min (+), 56.3 min (). 
Obtained data are in accordance with literature data.
[66]
 
 
EXPERIMENTAL PART   CHAPTER 8  
372 
3-(4-Aminophenyl)butanenitrile 
 
The enantiomerically enriched product was obtained as a pale yellow solid according to the 
standard hydrogenation GP10 protocol using iridium catalysts. The racemic sample was 
prepared according to general procedure GP8. 
C10H12N2 (160.22 g/mol):  
MP: 38-40 °C. 
1
H NMR
 
(400 MHz, CDCl3): /ppm = 7.03 (d, 
3
JHH = 8.3 Hz, 2H, ar-H), 6.75-6.54 (m, 2H, 
ar-H), 3.63 (s, 2H, NH2), 3.10-3.01 (m, 1H, CH), 2.58-2.45 (m, 2H, CH2), 1.40 (d, 
3
JHH = 
7.0 Hz, 3H, CH3). 
13
C{
1
H} NMR (101 MHz, CDCl3): ppm = 145.7 (s, ar-C), 133.2 (s, ar-C), 127.5 (s, ar-C), 
119.0 (s, C≡N), 115.5 (s, ar-C), 35.9 (s, CH), 26.8 (s, CH2), 20.9 (s, CH3). 
IR (ATR): ṽ/cm-1 = 3463 (s), 3372 (s), 3219 (w), 3033 (w), 2960 (w), 2931 (w), 2248 (m), 
1627 (s), 1518 (s), 1459 (m), 1440 (w), 1383 (w), 1294 (s), 1184 (m), 1130 (w), 1022 (w), 
948 (w), 884 (w), 824 (s). 
MS (EI, 70 eV, 200 °C) m/z (%): 160.1 (18), 121.1 (10), 120.1 (100). 
EA (C10H12N2): calc.: C 74.97, H 7.55, N 17.48; found: C 74.95, H 7.51, N 17.67. 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 10 min): tR = 23.13 min.  
 
Analytical conditions for (E)-3-(4-(Prop-1-en-2-yl)phenyl)but-2-enenitrile. 
 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 2 min – 7 °C/min – 
250 °C – 10 min): tR = 21.37 min (6.95), 22.60 min (6.94), 19.59 min (6.97), 22.25 min (6.96). 
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HPLC: Daicel, Chiralcel OD-H (0.46 cm × 25 cm, heptane/iso-propanol = 95:5, 0.5 mL/min, 
25 °C, 213 nm) tR = 16.5 (6.95), 20.0 min (6.95), 14.1 min (6.94), 14.1 min (6.97), 14.6 min 
(6.97). 
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8.7 Recovery of iridium based catalysts for after the hydrogenation 
 
8.7.1 Reisolation of catalysts and catalyst synthesis 
 
(R)-()-[1,5-Cycloocatdien-2-phenyl-8-(5,6,7,8-tetrahydrochinolinyl)-
di(2’methylphenyl)-phosphinit-iridium(I)]-hexafluorophosphate (7.7) 
 
 
A pre-dried Schlenk flask was charged with (R)-2-phenyl-5,6,7,8-tetrahydroquinolin-8-ol 
(250 mg, 1.11 mmol, 1.00 eq.), 4-dimethylaminopyridine (163 mg, 1.33 mmol, 1.20 eq.) and 
chloro-di-(2-methylphenyl)phosphine (330 mg, 1.33 mmol, 1.20 eq.). The Schlenk flask was 
evacuated three times and each time backfilled with argon. The mixture was dissolved in 
CH2Cl2 (7.5 mL) and stirred for 1 h at room temperature. A second preheated Schlenk flask 
was charged with [Ir(COD)Cl]2 (410 mg, 0.611 mmol, 0.50 eq.) and assembled with a 
preheated Schlenk frit. The Schlenk frit was charged with basic aluminium oxide (d  h: 1  
3 cm). The equipment was evacuated three times and each time backfilled with argon.  
The ligand containing solution was filtered through the aluminium oxide layer and rinsed with 
CH2Cl2 (4  5 mL). The new obtained reaction mixture was stirred for 2 h at room 
temperature. The solution was treated with NH4PF6 (2  20 mL), washed with H2O (2  
20 mL) and the combined organic phases were dried over Na2SO4. The solvent was 
evaporated under reduced pressure to afford a crude, red solid.  
The crude was dissolved in CH2Cl2 (10 mL) and Et2O (17.5 mL) was added. The slightly 
turbid solution was filtrated and the filtrate cooled down to 24 °C and stored for 2 h at this 
temperature. Crystallization overnight afforded the product as red crystals (750 mg, 849 µmol, 
77%).  
C37H40F6IrNOP2 (882.89 g/mol):  
MP: 170-172 °C. 
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1
H NMR
 
(400 MHz, CD2Cl2): /ppm = 7.82 (d, J = 8.1 Hz, 1H, ar-H), 7.77-7.66 (m, 3H, ar-
H), 7.65-7.60 (m, 2H, ar-H), 7.59-7.51 (s, 1H, ar-H), 7.50 (1H, d, J = 8.1 Hz, ar-H), 7.46-7.40 
(m, 2H, ar-H), 7.39-7.32 (m, 2H, ar-H), 7.30-7.22 (m, 1H, ar-H), 7.21-7.16 (m, 1H, ar-H), 
6.89 (dd, J = 12.5, 7.9 Hz, 1H, ar-H), 6.31-6.24 (m, 1H, CHOP), 4.78-4.70 (m, 1H, 
CH(COD)), 4.51-4.42 (m, 1H, CH(COD)), 3.28-3.14 (s, 1H, CH(COD)), 3.08-3.00 (m, 1H, 
CH2), 2.98-2.86 (m, 4H, CH3, CH2), 2.85-2.78 (m, 1H, CH(COD)), 2.66-2.57 (m, 1H, CH2), 
2.55-2.35 (m, 5H, CH3, CH2, CH2(COD)), 2.14-1.96 (m, 3H, CH2, CH2(COD)), 1.95-1.79 (m, 
3H, CH2(COD)), 1.42-1.30 (m, 1H, CH2(COD)), 1.30-1.18 (m, 1H, CH2(COD)), 1.15-1.04 (m, 
1H, CH2(COD)). 
13
C{
1
H} NMR (101 MHz, CD2Cl2): ppm = 160.4 (s, ar-C), 154.4 (s, ar-C), 141.9 (d, J = 
9.7 Hz, ar-C), 141.5 (s, ar-C), 139.5 (s, ar-C), 136.6 (s, ar-C), 134.8 (s, ar-C), 134.3 (s, ar-C), 
132.8 (d, J = 8.0 Hz, ar-C), 132.6 (s, ar-C), 132.5 (d, J = 2.2 Hz, ar-C), 132.5 (s, ar-C), 132.4 
(d, J = 1.9 Hz, ar-C), 131.9 (s, ar-C), 131.8 (s, ar-C), 131.7 (s, ar-C, 130.2 (s, ar-C), 128.1 (s, 
ar-C), 126.7 (d, J = 10.6 Hz, ar-C), 126.5 (d, J = 11.5 Hz, ar-C), 126.3 (s, ar-C), 95.0 (d, J = 
7.5 Hz, CH(COD)), 83.0 (d, J = 20.5 Hz, CH(COD)), 76.7 (s, CH(COD)), 70.0 (s, 
CH(COD)), 69.8 (s, CHOP), 36.3 (d, J = 3.5 Hz, CH2), 35.0 (s, CH2), 30.9 (d, J = 9.8 Hz, 
CH2), 29.1 (s, CH2), 28.9 (s, CH2), 24.2 (s, CH2), 23.2 (d, J = 5.9 Hz, CH3), 22.4 (d, J = 
5.5 Hz, CH3), 18.9 (s, CH2). 
31
P{
1
H} NMR (162 MHz, CD2Cl2): ppm = 98.1 (s), 144.5 (sept). 
IR (ATR): ṽ/cm-1 = 1466 (w), 1450 (w), 1206 (w), 1073 (w), 965 (w), 929 (w), 833 (s), 760 
(m), 671 (w), 556 (s). 
HRMS (ESI, 4500 V, 180 °C): (m/z) calc. for C37H40IrNOP
+
: 738.2485 [MPF6]
+
; found: 
738.2473. 
[α]
20
D  = +20.6 (c = 0.45, CHCl3). 
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General procedure: Recovery [Ir(L)COD)]BArF catalysts GP11 
 
A glass inlet of an autoclave was charged with the respective iridium catalyst (1% mol) and 
the substrate dissolved in CH2Cl2 (0.2 M) was added. The glass inlet was placed in an 
autoclave that was pressurized to 50 bar with H2. The reaction mixture was stirred for 2 h at 
700 rpm. The autoclave was opened under normal atmosphere and the reaction mixture was 
transferred to a round bottom flask, which was previously purged with argon for 5 min. 1,5-
Cyclooctadiene (0.10 eq.) was added and the reaction mixture was stirred for 1 h at room 
temperature. All volatiles were evaporated under reduced pressure. Purification of the residue 
by column chromatography (SiO2) afforded by the use of the first eluent mixture the 
hydrogenated substrate and by the second eluent mixture the catalyst. 
 
Recovery of diphenylphosphine tert-butyl PHOX catalyst 7.11 
 
The reaction was set up according to general procedure GP11 using 30.4 mg catalyst and 
trans-methyl stilbene as substrate. Purification by column chromatography (SiO2, d × h: 2 × 
5 cm, 1. pentane:Et2O (1:1, 100 mL), 2. CH2Cl2 (30 mL)) afforded the complex (20.2 mg, 
13 mol, 66%) as a red solid. 
Analytical data of the substrate
[160]
 are in accordance with literature data. The recovered 
catalyst matches the data of the applied catalyst. 
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Recovery of pyridine based catalyst 7.10 
 
The reaction was set up according to general procedure GP11 using 30.0 mg catalyst and 
trans-methyl stilbene as substrate. Purification by column chromatography (SiO2, d × h: 2 × 
5 cm, 1. pentane:Et2O (100 mL), 2. CH2Cl2 (40 mL)) afforded the complex (18.1 mg, 12 mol, 
60%) as an orange solid. 
Analytical data of the substrate
[160]
 and the recovered catalyst
[52b]
 are in accordance with 
literature data. 
 
Recovery of pyridine based catalyst 7.5 
 
The reaction was set up according to general procedure GP11 using (40.0 mg, 25.0 µmol, 
1.0 mol%) catalyst and (5E,9E)-farnesylacetone (656 mg, 2.50 mmol), in CH2Cl2 (12.5 mL). 
Purification by column chromatography (SiO2, d × h: 2  10 cm) afforded the product 
(663 mg, 2.47 mmol, 99%) with (Pentan:Et2O, (1:1)) followed by eluting the catalyst 
(27.9 mg, 17.4 µmol, 70%) with CH2Cl2. 
Analytical data of the substrate
[161]
 and the recovered catalyst
[52b]
 are in accordance with 
literature data. 
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8.8 Analytical Data for the Model Substrates 
 
(E)-Prop-1-ene-1,2-diyldibenzene (S1) 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 
2 min – 7 °C/min – 250 °C – 10 min): tR = 18.3 min (P1), 21.4 min (S1). 
HPLC: Daicel, Chiracel OJ (0.46 cm × 25 cm, heptane/iso-propanol = 
99:01, 0.5 mL/min, 25 °C, 220 nm): tR = 15.6 min ((R)-S1), 23.8 min 
((S)-S1). 
(E)-2-(4-Methoxyphenyl)-2-butene (S2) 
GC (Chiraldex -cyclodextrin TFA G-TA (30 m × 0.25 mm × 0.12 m), 
60 kPa H2 (60 °C – 30 min – 5 °C/min – 100 °C – 0 min – 10 °C/min – 
160 °C – 10 ° min), tR = 38.4 min ((S)-P2), 38.6 min ((R)-P2), 41.2 min 
(S2). 
(Z)-2-(4-Methoxyphenyl)-2-butene (S3) 
GC (Chiraldex -cyclodextrin TFA G-TA (30 m × 0.25 mm × 0.12 m), 
60 kPa H2 (60 °C – 30 min – 5 °C/min – 100 °C – 0 min – 10 °C/min – 
160 °C – 10 ° min), tR = 38.4 min ((S)-P2), 38.6 min ((R)-P2), 39.3 min 
(S3). 
2-(4-Methoxyphenyl)-1-butene (S4) 
GC (Chiraldex -cyclodextrin TFA G-TA (30 m × 0.25 mm × 0.12 m), 
60 kPa H2 (60 °C – 30 min – 5 °C/min – 100 °C – 0 min – 10 °C/min – 
160 °C – 10 ° min), tR = 38.4 min ((S)-P2), 38.6 min ((R)-P2), 40.3 min 
(S4). 
7-Methoxy-1,2-dihydro-naphthalene (S5) 
 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 
2 min – 7 °C/min – 250 °C – 10 min): tR = 15.0 min (P5), 17.6 min (S5), 
19.8 min (naphtalene deivative). HPLC: Daicel, Chiracel OD-H 
(0.46 cm × 25 cm, heptane, 0.75 mL/min, 25 °C, 220 nm): tR = 20.4 min 
((R)-P5), 27.0 min ((S)-P5).  
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4-Isopropyl-7-methoxy-1,2-dihydronaphthalene (S6) 
GC (chiral, -Cyclodextrin, DEtTButSil (Brechbühler, SE54 (25 m × 
0.25 mm × 0.25 m) 60 kPa H2 (100 °C – 2 min – 7 °C/min – 250 °C – 
10 min): tR = 10.8 min ((S)-P6a), tR = 11.3 min ((R)- P6a), tR = 12.5 min 
(S6), tR = 15.0 min (P6b). 
4-(tert-Butyl)-7-methoxy-1,2-dihydronaphthalene (S7) 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 
2 min – 7 °C/min – 250 °C – 10 min): 20.82 min (P7a), 21.46 min (S7), 
23.39 min (P7b)  
HPLC: Daicel, Chiracel OD-H (0.46 cm × 25 cm, heptane, 1.00 mL/min, 
25 °C, 220 nm): tR = 6.4 min (P7a), tR = 8.7 min (P7a), tR = 14.7 min 
(S7), tR = 10.8 min (P7b) 
(E)-2-Methyl-3-phenylprop-2-en-1-ol (S8) 
 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 
2 min – 7 °C/min – 250 °C – 10 min): tR = 14.6 min (P8), 16.5 min (S8). 
HPLC: Daicel, Chiracel OD-H (0.46 cm × 25 cm, heptane/iso-propanol 
= 95:05, 0.5 mL/min, 40 °C, 220 nm): tR = 15.3 min ((R)-P8), 17.5 min 
((S)-P8), 19.6 min (S8). 
 
(E)-Ethyl 3-phenylbut-2-enoate (S9) 
 
GC (Chiraldex -cyclodextrin TFA G-TA (30 m × 0.25 mm × 0.12 m), 
60 kPa H2 (60 °C – 30 min – 5 °C/min – 100 °C – 0 min – 10 °C/min – 
160 °C – 10 ° min), tR = 42.9 min ((R)-P9), 44.9 min ((S)-P9), 57.0 min 
(S9). 
Ehyl (E)-2-methyl-3-phenylacrylate (S10) 
 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 
2 min – 7 °C/min – 250 °C – 10 min): tR = 14.5 min (P10), 17.2 min 
(S10). HPLC: Daicel, Chiracel OB-H (0.46 cm × 25 cm, heptanes, 
0.5 mL/min, 20 °C, 220 nm): tR = 22.7 min ((R)-P10), 25.3min ((S)-P10). 
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(E)-4-Phenylpent-3-en-2-one (S12) 
 
GC (Restek Rtx-1701 (30 m × 0.25 mm × 0.25 m) 60 kPa He (100 °C – 
2 min – 7 °C/min – 250 °C – 10 min): tR = 13.9 min (P12), 16.0 min 
(S12). HPLC: Daicel, Chiracel AS-H (0.46 cm × 25 cm, heptane/iso-
propanol = 99.3:0.7, 0.5 mL/min, 20 °C, 220 nm): tR = 20.5min ((S)- 
P12), 24.7min ((R)-P12). 
 
(E)-N-(1-phenylethylidene)aniline (S14) 
 
GC (Optima 5 (30 m × 0.25 mm × 0.5 m) 60 kPa He (150 °C – 0 min – 
7 °C/min – 250 °C – 10 min)): tR = 12.6 min (P14), 12.9 min (S14), 
4.9 min acetophenone, 5.4 min aniline. HPLC: Daicel, Chiracel OD-H 
(0.46 cm × 25 cm, heptane/iso-propanol = 99:01, 0.5 mL/min, 25 °C, 
220 nm): tR = 24.6 min ((S)-P14), 33.0 min ((R)- P14). 
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9 Appendix 
 
9.1 Crystallographic data 
Compound 2.83 (R)-2.63 
formula C74H52BCl2F24IrNOP C72H74BF24IrNO2P 
Mr [g × mol
-1
] 1732.09 1675.34 
shape plate block 
color red orange 
space group P-1 C 2 
crystal size 0.02 × 0.15 × 0.18 mm
3
 0.09 × 0.19 × 0.23 mm
3
 
a [Å] 15.8491(11) 44.280(2) 
b [Å] 15.8906(11) 12.7293(6) 
c [Å] 16.253(2) 25.6592(11) 
[°] 96.195(3) 90 
[°] 105.164(3) 95.409(4) 
[°] 115.839(2) 90 
V [Å
3
] 3437.8(6) 14398.4(11) 
Z 2 8 
F(000) 1716 6736 
range of data detection [°] 3.196-68.417 1.665-30.522 
calc [g × cm-3] 1.673 1.546 
absorption coeff.  [mm-1] 5.697 1.984 
measured reflections 47103 135833 
independent reflections 12256 (merging r = 0.047) 42181 (merging r = 0.065) 
used reflections 12256 28295 
parameters refined 1020 1866 
R 0.0351 0.0442 
Rw 0.0415 0.0667 
Goodness of fit 1.0847 0.9750 
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Compound (S)-2.77 (S)-2.72 
formula C69H52BF24IrNOP C63H54B1F26IrNOP 
Mr [g × mol
-1
] 1601.13 1569.08 
shape plate needle 
color orange orange 
space group P 21 21 21 P 21 21 21 
crystal size 0.03 × 0.09 × 0.21 mm
3
 0.02 × 0.05 × 0.23 mm
3
 
a [Å] 13.0563(3) 13.7895(7) 
b [Å] 13.1861(3) 17.2803(8) 
c [Å] 36.8217(8) 26.5684(13) 
[°] 90 90 
[°] 90 90 
[°] 90 90 
V [Å
3
] 6339.3(2) 6330.9(5) 
Z 4 4 
F(000) 3176 3112 
range of data detection [°] 1.640-30.036 3.051-68.215 
calc [g × cm-3] 1.678 1.646 
absorption coeff.  [mm-1] 2.248 5.399 
measured reflections 116807 52927 
independent reflections 18534 (merging r = 0.050) 11246 (merging r = 0.038) 
used reflections 16162 10454 
parameters refined 884 959 
R 0.0253 0.0249 
Rw 0.0259 0.0306 
Goodness of fit 1.1083 1.1417 
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Compound (S)-2.78 
formula C71H72BF24IrNO2P 
Mr [g × mol
-1
] 1661.32 
shape block 
color orange 
space group P 1 
crystal size 0.060 × 0.16 × 0.19 mm
3
 
a [Å] 13.5575(7) 
b [Å] 15.0582(8) 
c [Å] 18.9181(9) 
[°] 90.286(2) 
[°] 90.286(2) 
[°] 101.754(2) 
V [Å
3
] 3576.7(3) 
Z 2 
F(000) 1668.000 
range of data detection [°] 3.006-68.206 
calc [g × cm-3] 1.542 
absorption coeff.  [mm-1] 4.780 
measured reflections 49427 
independent reflections 22908 (merging r = 0.027) 
used reflections
[a]
 21661 
parameters refined 1968 
R 0.0237 
Rw 0.0280 
Goodness of fit 1.1035 
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9.2 List of Abbreviations 
 
Å Angstrom (1 Å = 10
-10
m) 
Ac acetyl 
Ant anthracenyl 
Ar aryl 
BArF tetrakis[3,5-bis(trifluoro-methyl)phenyl]borate 
BINAP 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl 
Bn benzyl 
BPPM butoxycarbonyl-4-diphenylphosphino-2-
diphenylphosphinomethyl-pyrrolidin 
br broad 
Bu butyl 
°C Grad Celsius 
c concentration 
CAL-B Candida Antartica Lipase B 
calc.  calculated 
cat. catalyst 
COD cycloocta-1,5-diene 
conv. conversion 
COSY correlation spectroscopy 
Cy cyclohexyl 
d day(s) or doublet (NMR) 
D  sodium D line 
d (NMR) chemical shift 
DCE 1,2-dichloroethane 
DCM dichloromethane 
DIPEA N,N-diisopropylethylamine 
DMAP N,N-4-(dimethylamino)pyridine 
DMF dimethylformamide 
DMSO dimethyl sulfoxide 
dppf 1,1’-bis(diphenyl-phosphino)ferrocene 
E opposite 
EA elemental analysis 
ee enantiomeric axcess 
EI Electron-imp 
eq. equivalent(s) 
ESI electrospray ionization 
Et ethyl 
EtOH ethanol 
FAB fast atom bomardement 
GC gas chromatography 
h hour(s) 
hmbc heteronuclear multiple bond coherence 
hmqc heteronuclear multiple bond coherence 
HPLC high performance liquid chromatography 
Hz Hertz 
i-Pr 2-propyl 
J coupling constante 
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K Kelvin 
LDA lithium diisopropylamide 
M molar [mol/L] 
m meta 
m multiplet (NMR) or medium (IR) 
MP melting point 
m/z mass-to-charge ratio 
MALDI matrix assisted laser desorption ionization 
MCPBA 3-chloroperoxybenzoic acid 
Me methyl 
MeOH methanol 
Mes mesityl 
min minute(s) 
mL milliliter 
MS mass spectrometry or molecular sieves 
n normal 
n.d. not determined 
n.o. not observed 
NBA 3-nitrobenzyl aclohol 
nbd norbornadiene 
n-BuLi 1-butyl lithium 
NMR nuclear magnetic resonance 
NOESY nuclear Overhauser enhancement spectroscopy 
o ortho 
o-Tol ortho-toly 
p para 
Ph phenyl 
PHIM phosphino-imidazoline 
PHOX phosphino-oxazoline 
pin pinacolborane 
ppm parts per million 
q (NMR) quartet 
quint (NMR) quintet 
rac. racemic 
Rf retention factor 
RT room temperature 
s singlet (NMR) or strong (IR) 
sat. saturated 
sec second(s) 
T time 
t (NMR) triplet 
t or tert tertiary 
TBAI tetrabutylammonium iodide 
TBAF tetrabutylammonium fluoride 
TBME tert-butyl methyl ether 
TBS tert-butyldimethylsilyl 
t-Bu tert-butyl 
t-BuLi tert-butyl lithium 
TEA triethylamine 
THF tetrahydrofurane 
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The objective of this thesis was the synthesis and further development of different iridium N,P 
ligand complexes as well as the evaluation and application of different challenging substrate 
classes in the asymmetric hydrogenation using iridium-based catalysts. 
The first chapter of this thesis deals with the further development of bicyclic pyridine-based 
ligands. A late stage SuzukiMiyaura cross-coupling allowed for the synthesis of a large 
variety of different ligands for which a phenyl group was exchanged with more sterically 
demanding aryl-group. Iridium complexes of these new ligandss emerged as efficient 
catalysts for the asymmetric hydrogenation of different functionalized and unfunctionalized 
olefins. For several substrate classes superior results were achieved compared to the original 
catalysts (scheme 11.1). 
 
Scheme 11.1: Bicyclic pyridine-based iridium complexes with sterically demanding aryl groups as efficient 
catalysts in the hydrogenation of different substrates. 
 
Significant improvements were achieved with α,β-unsaturated esters which were 
hydrogenated with high conversion and excellent enantioselectivity (scheme 11.2). 
 
 
Scheme 11.2: α,β-Unsaturated esters as substrates in the hydrogenation with iridium-based catalysts. 
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In cooperation with DSM Nutritional Products different tocopherol side chain precursors were 
investigated as substrates for the asymmetric hydrogenation using these new catalysts. 
Hydrogenations of (5E,9E)-farnesylacetone in trifluoroethanol resulted in the reduction of 
three C=C bonds, the introduction of two new stereogenic centers and the almost exclusive 
formation of the desired stereoisomers in combination with high catalyst reactivity (Scheme 
11.3). 
 
 
Scheme 11.3: Iridium N,P ligand complexes emerged as efficient catalysts for the hydrogenation of tocopherol 
side chain precursors. 
 
Another substrate class which was investigated in the course of this PhD thesis are vinyl 
bromides. Established iridium-based catalysts turned out to be extremely unreactive in the 
hydrogenation of this substrate class. Only terminal vinyl bromides revealed a certain 
reactivity. As best results, up to >99% conversion with 72% enantiomeric excess was 
observed (scheme 11.4). 
 
 
Scheme 11.4: Vinyl bromides as substrates in the asymmetric hydrogenation with iridium-based catalysts.  
 
The sixth chapter of this thesis addressed the hydrogenation of α,β-unsaturated nitriles using 
iridium-based catalysts. Although, first experiments revealed that iridium-based catalysts 
were inhibited by α,β-unsaturated nitriles it was found that they become highly active 
SUMMARY  CHAPTER 11 
394 
catalysts upon addition of N,N-diisopropylethylamine. The base-activated catalysts enable 
conjugate reduction of α,β-unsaturated nitriles with H2 at low catalyst loadings, affording the 
corresponding saturated nitriles with high conversion and excellent enantioselectivity. In 
contrast, alkenes lacking a conjugated cyano group do not react under these conditions, 
making it possible to selectively reduce the conjugated C=C bond of an α,β-unsaturated nitrile, 
while leaving other types of C=C bonds in the molecule intact (scheme 11.5). 
 
 
Scheme 11.5: Base-promoted asymmetric hydrogenation of α,β-unsaturated nitriles with iridium-based catalysts. 
 
In the last chapter of the thesis new experimental data gained on the behavior of iridium N,P 
ligand complexes in the absence of substrate were used to develop an efficient protocol for the 
recovery of N,P ligand complexes. Upon addition of COD after the hydrogenation reaction it 
was possible to recover up to 70% of the catalyst. The recovered catalysts gave similar 
conversions and the same enantiomeric excesses as the original catalysts (scheme 11.6). 
 
 
Scheme 11.6: Schematic diagram of the protocol applied for the recovery of the catalyst from the reaction 
mixture.
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